#!/usr/bin/env python3
"""Apply zh-Hans, zh-Hant and es translations to a Localizable.xcstrings catalog.

Chinese lives in `T` below (English -> (Simplified, Traditional)); Spanish lives in
`localization/es_translations.py` (English -> Spanish) and is applied to every
catalog key it covers by the same pass.
"""

import json
import subprocess
import sys
import tempfile
from pathlib import Path

# Translations: English -> (Simplified, Traditional)
T = {
    "Limitations": ("局限性", "局限性"),
    # Settings → substance names in the app language, or English
    "English Substance Names": ("英文物质名称", "英文物質名稱"),
    "Show substances by their English names instead of the names used in your language. Search finds both.": (
        "以英文名称显示物质，而非你所用语言中的名称。两种名称都能搜索到。",
        "以英文名稱顯示物質，而非你所用語言中的名稱。兩種名稱都能搜尋到。",
    ),
    # Substance color system (class colors, Oklch picker, update notice)
    "Class color": ("类别颜色", "類別顏色"),
    "Custom color": ("自定义颜色", "自訂顏色"),
    "Use Class Color": ("使用类别颜色", "使用類別顏色"),
    "Lightness": ("明度", "明度"),
    "Chroma": ("彩度", "彩度"),
    "Hue": ("色相", "色相"),
    "Search Colors": ("搜索颜色", "搜尋顏色"),
    "Reset All": ("全部重置", "全部重置"),
    "Reset every substance to its class color?": (
        "将所有物质重置为类别颜色？",
        "將所有物質重置為類別顏色？",
    ),
    "Colors you picked yourself are replaced.": (
        "你自己挑选的颜色将被替换。",
        "你自己挑選的顏色將被取代。",
    ),
    "Colors now follow class": ("颜色现在跟随类别", "顏色現在跟隨類別"),
    "Every substance now gets a color from its class — stimulants share one family, psychedelics another — so a timeline reads at a glance. You can still give any substance a color of your own.": (
        "现在每种物质都会从所属类别获得颜色——兴奋剂属于一个色系，迷幻剂属于另一个——时间线一眼就能看懂。你仍然可以为任何物质自选颜色。",
        "現在每種物質都會從所屬類別獲得顏色——興奮劑屬於一個色系，迷幻劑屬於另一個——時間軸一眼就能看懂。你仍然可以為任何物質自選顏色。",
    ),
    "You have %lld substances with colors from before. Move them to class colors, or keep them exactly as they are.": (
        "你有 %lld 种物质沿用着之前的颜色。可以将它们改为类别颜色，也可以原样保留。",
        "你有 %lld 種物質沿用著之前的顏色。可以將它們改為類別顏色，也可以原樣保留。",
    ),
    "Use Class Colors": ("使用类别颜色", "使用類別顏色"),
    "Keep My Colors": ("保留我的颜色", "保留我的顏色"),
    # The move to the new app identity: the legacy build's notice and the
    # successor's confirmation (LegacyHandoff).
    "Piru has moved": ("Piru 搬家了", "Piru 搬家了"),
    "Piru now lives in a new app. Install it on this device and the first time you open it, your journal, meds and settings come across on their own. Nothing here is deleted.": (
        "Piru 现在是一个新的 App。在这台设备上安装它，第一次打开时，你的日记、用药和设置会自动搬过去。这里的内容不会被删除。",
        "Piru 現在是一個新的 App。在這台裝置上安裝它，第一次打開時，你的日記、用藥和設定會自動搬過去。這裡的內容不會被刪除。",
    ),
    "Your journal has moved": ("你的日记已经搬走了", "你的日記已經搬走了"),
    "The new Piru app already has your journal. Entries you add here stay in this app and won't follow, so the new one is the place to log from now on.": (
        "新的 Piru App 已经有你的日记了。在这里添加的记录只会留在这个 App 里，不会同步过去，所以从现在起，新 App 才是记录的地方。",
        "新的 Piru App 已經有你的日記了。在這裡新增的紀錄只會留在這個 App 裡，不會同步過去，所以從現在起，新 App 才是記錄的地方。",
    ),
    "Open in TestFlight": ("在 TestFlight 中打开", "在 TestFlight 中打開"),
    "Your journal came with you": ("你的日记跟着你过来了", "你的日記跟著你過來了"),
    "Everything from the old Piru app is here: your journal, meds and settings. Once you've looked it over, you can delete the old app.": (
        "旧版 Piru App 里的一切都在这里：你的日记、用药和设置。确认无误后，就可以删除旧 App 了。",
        "舊版 Piru App 裡的一切都在這裡：你的日記、用藥和設定。確認無誤後，就可以刪除舊 App 了。",
    ),
    # The check-in schedule section on the session screen, the sociability
    # scale, and the per-class reassurance added with the split lens sets.
    "Sociability": ("社交欲", "社交慾"),
    "Alone": ("独处", "獨處"),
    "Passed": ("已过", "已過"),
    "%lld earlier": ("更早的 %lld 条", "更早的 %lld 條"),
    "Quiet hours": ("勿扰时段", "勿擾時段"),
    "Edit times": ("编辑时间", "編輯時間"),
    "No times on this schedule yet.": ("这份计划里还没有时间。", "這份計劃裡還沒有時間。"),
    "All of these have passed. Times are measured from your latest dose.": (
        "这些都已经过去了。时间是从你最近一次剂量算起的。",
        "這些都已經過去了。時間是從你最近一次劑量算起的。",
    ),
    "Times are measured from your latest dose, so logging another moves them.": (
        "时间是从你最近一次剂量算起的，所以再记录一次就会把它们往后推。",
        "時間是從你最近一次劑量算起的，所以再記錄一次就會把它們往後推。",
    ),
    "Check-in notifications are off in Settings, so none of these will arrive.": (
        "状态确认通知在设置里是关闭的，所以这些都不会送达。",
        "狀態確認通知在設定裡是關閉的，所以這些都不會送達。",
    ),
    "This class stops memories forming while it is active, so the blanks stay blank. What you write down now is the record.": (
        "这一类药在起效期间会阻止记忆形成，所以空白就是空白。你现在写下的就是记录。",
        "這一類藥在起效期間會阻止記憶形成，所以空白就是空白。你現在寫下的就是記錄。",
    ),
    "Coordination can be impaired before you notice it. This increases the risk of accidents on stairs and in the kitchen.": (
        "协调性可能在你察觉之前就已受损。这会增加在楼梯上和厨房里发生意外的风险。",
        "協調性可能在你察覺之前就已受損。這會增加在樓梯上和廚房裡發生意外的風險。",
    ),
    "Vision softening at this dose is usual, and it clears as the dose does.": (
        "这个剂量下视觉发虚很常见，会随着剂量一起消退。",
        "這個劑量下視覺發虛很常見，會隨著劑量一起消退。",
    ),
    "What you are seeing is not there, however solid it looks. It goes as the dose does.": (
        "你看到的东西并不存在，不管它看起来多真实。它会随着剂量一起消失。",
        "你看到的東西並不存在，不管它看起來多真實。它會隨著劑量一起消失。",
    ),
    "This class blocks the signal to the bladder. If it has not eased once the dose has, get seen.": (
        "这一类药会阻断通往膀胱的信号。如果剂量过去了还没缓解，去看医生。",
        "這一類藥會阻斷通往膀胱的信號。如果劑量過去了還沒緩解，去看醫生。",
    ),
    "Feeling bad here is the drug's character rather than a sign something has gone wrong.": (
        "这里感觉糟糕是这个药的性格，而不是出了什么问题的信号。",
        "這裡感覺糟糕是這個藥的性格，而不是出了什麼問題的信號。",
    ),
    # Check-in lenses, the derived ladder, and the "did it work?" scale
    # (Specs/adhd-audience-fit-v2.md §5).
    "Did it work?": ("起效了吗？", "起效了嗎？"),
    "Is it working?": ("现在起效了吗？", "現在起效了嗎？"),
    "Less than usual": ("比平时弱", "比平時弱"),
    "About right": ("和平时差不多", "和平時差不多"),
    "More than usual": ("比平时强", "比平時強"),
    "Less": ("偏弱", "偏弱"),
    "One tap records how this dose is going — less than usual, about right, or more.": (
        "一次轻点就能记下这次剂量的表现——比平时弱、和平时差不多，还是比平时强。",
        "一次輕點就能記下這次劑量的表現——比平時弱、和平時差不多，還是比平時強。",
    ),
    "Noticing": ("正注意到", "正注意到"),
    "Any side effects?": ("有副作用吗？", "有副作用嗎？"),
    "Optional — leave them where they are to record nothing.": (
        "都是可选的——不动它们就等于什么都不记。",
        "都是可選的——不動它們就等於什麼都不記。",
    ),
    "Opens how this compares with your other days": (
        "打开它与你其他日子的对照",
        "打開它與你其他日子的對照",
    ),
    "Use these times": ("就用这些时间", "就用這些時間"),
    "Up to %lld prompts, from %lld minutes to 24 hours after the dose. The suggested times come from the modeled phases of what you logged. Each one opens a timestamped note; none of them is required.": (
        "最多 %lld 条提示，落在服用后 %lld 分钟到 24 小时之间。建议的时间来自你所记录物质的各阶段模型。每条都会打开一则带时间戳的笔记；没有一条是必须的。",
        "最多 %lld 條提示，落在服用後 %lld 分鐘到 24 小時之間。建議的時間來自你所記錄物質的各階段模型。每條都會打開一則帶時間戳的筆記；沒有一條是必須的。",
    ),
    # Side-effect reassurance — the comedown guide's register, in one line each.
    "This is the drug, not you. It eases as the dose wears off.": (
        "这是药物，不是你。随着剂量消退它会缓下来。",
        "這是藥物，不是你。隨著劑量消退它會緩下來。",
    ),
    "Common here. Moving a little settles it better than sitting still.": (
        "这里很常见。稍微动一动比坐着不动更能安定下来。",
        "這裡很常見。稍微動一動比坐著不動更能安定下來。",
    ),
    "Jaw clenching is typical. Magnesium and something to chew help.": (
        "咬紧下颌是典型反应。镁和一点能嚼的东西会有帮助。",
        "咬緊下頜是典型反應。鎂和一點能嚼的東西會有幫助。",
    ),
    "Appetite comes back as it wears off. Something small now still counts.": (
        "食欲会随着消退回来。现在吃一点小东西也算数。",
        "食慾會隨著消退回來。現在吃一點小東西也算數。",
    ),
    "Expected while it's still active — the curve says until when.": (
        "只要还在起效就是预料之中的——曲线会告诉你到什么时候。",
        "只要還在起效就是預料之中的——曲線會告訴你到什麼時候。",
    ),
    "A faster heart is common at this dose. If it stays hard or hurts, get it looked at.": (
        "这个剂量下心跳变快很常见。如果一直很重或者疼，去看一下。",
        "這個劑量下心跳變快很常見。如果一直很重或者疼，去看一下。",
    ),
    "Chemical, not character. It lifts as levels drop.": (
        "这是化学作用，不是性格。随着浓度下降它会散去。",
        "這是化學作用，不是性格。隨著濃度下降它會散去。",
    ),
    "Hands shake at this dose and stop on the way down.": (
        "这个剂量下手会抖，下行时就会停。",
        "這個劑量下手會抖，下行時就會停。",
    ),
    "Usually passes in the first hour. Small sips rather than gulps.": (
        "通常第一个小时内就过去了。小口喝，别大口灌。",
        "通常第一個小時內就過去了。小口喝，別大口灌。",
    ),
    "Once it settles, sip water — small and often.": (
        "等它平息下来，小口喝水——少量多次。",
        "等它平息下來，小口喝水——少量多次。",
    ),
    "It's the drug talking. It fades with the peak.": (
        "是药物在说话。它会随着峰值一起淡去。",
        "是藥物在說話。它會隨著峰值一起淡去。",
    ),
    "Thinking gets loose here and comes back. Nothing to fix.": (
        "思路在这里会松散，之后会回来。不用去修它。",
        "思路在這裡會鬆散，之後會回來。不用去修它。",
    ),
    "Sit down until it passes. It usually goes with the peak.": (
        "坐下来等它过去。通常会随峰值一起走。",
        "坐下來等它過去。通常會隨峰值一起走。",
    ),
    "Gaps here are normal, and the memory comes back after.": (
        "这里出现断片是正常的，记忆之后会回来。",
        "這裡出現斷片是正常的，記憶之後會回來。",
    ),
    "Opioids release histamine — the itch is that, not an allergy.": (
        "阿片类会释放组胺——痒是因为这个，不是过敏。",
        "鴉片類會釋放組織胺——癢是因為這個，不是過敏。",
    ),
    "Running hot and cold is part of it. Cool down, and sip steadily rather than a lot at once.": (
        "忽冷忽热是其中的一部分。降降温，稳着小口喝，别一次喝太多。",
        "忽冷忽熱是其中的一部分。降降溫，穩著小口喝，別一次喝太多。",
    ),
    # The felt-patterns insight.
    "Compare your rated days": (
        "比较你评过分的日子",
        "比較你評過分的日子",
    ),
    'Each comparison cuts your rated days on one thing at a time and counts how often the dose read "about right" or better.': (
        "每一组对照每次只按一件事切分你打过分的日子，数一数其中有多少次读作“和平时差不多”或更好。",
        "每一組對照每次只按一件事切分你打過分的日子，數一數其中有多少次讀作「和平時差不多」或更好。",
    ),
    "Nothing rated yet": ("还没有打过分", "還沒有打過分"),
    "A check-in asks whether a dose worked the way it usually does. After rating a few days, you can compare your answers by dose, time of day, weekday, and prior caffeine use.": (
        "状态确认会问这次剂量是不是像平时那样起效。评过几天的分后，你就可以按剂量、服用时段、星期几和之前是否摄入咖啡因来比较答案。",
        "狀態確認會問這次劑量是不是像平時那樣起效。評過幾天的分後，你就可以按劑量、服用時段、星期幾和之前是否攝取咖啡因來比較答案。",
    ),
    "Days rated": ("已打分的天数", "已打分的天數"),
    "Not enough rated days yet. A comparison needs at least %lld rated days in each group. With fewer days, one bad week can skew the results.": (
        "评分天数还不够。一组对照需要每组至少 %lld 个评过分的日子。天数太少时，一个状态不佳的星期就可能影响结果。",
        "評分天數還不夠。一組對照需要每組至少 %lld 個評過分的日子。天數太少時，一個狀態不佳的星期就可能影響結果。",
    ),
    "These comparisons use only your own recorded days, with no control group. A difference does not establish a cause.": (
        "这些对照只使用你自己记录的日子，没有对照组。有差异不代表存在因果关系。",
        "這些對照只使用你自己記錄的日子，沒有對照組。有差異不代表存在因果關係。",
    ),
    "Both groups have similar ratings.": (
        "两组评分相近。",
        "兩組評分相近。",
    ),
    "%lld of %lld days about right or better": (
        "%lld / %lld 天和平时差不多或更好",
        "%lld / %lld 天和平時差不多或更好",
    ),
    "Time of day": ("一天中的时间", "一天中的時間"),
    "Caffeine before it": ("之前的咖啡因", "之前的咖啡因"),
    "Before %@": ("%@ 之前", "%@ 之前"),
    "%@ or later": ("%@ 或更晚", "%@ 或更晚"),
    "Under %@": ("低于 %@", "低於 %@"),
    "%@ or more": ("%@ 或更多", "%@ 或更多"),
    "Weekdays": ("工作日", "工作日"),
    "Weekends": ("周末", "週末"),
    "No caffeine first": ("之前没有咖啡因", "之前沒有咖啡因"),
    "Caffeine within the hour": ("一小时内有咖啡因", "一小時內有咖啡因"),
    'Compare your "did it work?" answers': (
        "比较你的“起效了吗？”答案",
        "比較你的「起效了嗎？」答案",
    ),
    "Compare your dose ratings": (
        "比较你的剂量评分",
        "比較你的劑量評分",
    ),
    # Custom check-in schedule — the editor sheet, the offer banner, the menu.
    "Custom…": ("自定…", "自訂…"),
    "Pick my own times": ("自己挑选时间", "自己挑選時間"),
    "A quiet prompt at a few points in the session, each opening a timestamped note. Off unless you turn it on, and you pick the times.": (
        "在场次中的几个时间点上安静地提示一下，每次都会打开一条带时间戳的笔记。默认关闭，时间由你来定。",
        "在場次中的幾個時間點上安靜地提示一下，每次都會打開一條帶時間戳的筆記。預設關閉，時間由你來定。",
    ),
    "Check-in times": (
        "状态确认时间",
        "狀態確認時間",
    ),
    "After your latest dose": ("在你最近一次剂量之后", "在你最近一次劑量之後"),
    "No times yet. Add one below and the prompts start from your latest dose.": (
        "还没有设定时间。在下方添加一个，提示就会从你最近一次剂量开始计算。",
        "還沒有設定時間。在下方新增一個，提示就會從你最近一次劑量開始計算。",
    ),
    "Add a time": ("添加一个时间", "新增一個時間"),
    "%@ is already on the list.": ("%@ 已经在列表里了。", "%@ 已經在列表裡了。"),
    "You've reached the limit for check-in times in this session. Remove one to add another.": (
        "这个场次的状态确认时间已达上限。先移除一个，再添加另一个。",
        "這個場次的狀態確認時間已達上限。先移除一個，再新增另一個。",
    ),
    "The first prompt arrives at least %lld minutes after the dose.": (
        "第一条提示至少落在服用后 %lld 分钟。",
        "第一條提示至少落在服用後 %lld 分鐘。",
    ),
    "%lld m": ("%lld 分钟", "%lld 分鐘"),
    "%lld day streak": ("连续 %lld 天", "連續 %lld 天"),
    # Injection Levels v3 / Hormone Levels — the testosterone esters, the
    # companion series, and the calibration copy.
    "%@ %@ on %@": ("%@ %@（%@）", "%@ %@（%@）"),
    "%lld %@ injections logged. No serum curve is drawn for it — no validated release data.": (
        "已记录 %lld 次 %@ 注射。不为其绘制血清曲线——没有经过验证的释放数据。",
        "已記錄 %lld 次 %@ 注射。不為其繪製血清曲線——沒有經過驗證的釋放資料。",
    ),
    "A level only means something with its draw time: for cypionate and enanthate, measure midway between injections; for undecanoate, measure at trough, just before the next dose.": (
        "一个数值只有配上采血时间才有意义：环戊丙酸酯和庚酸酯在两次注射的中点测量；十一酸酯在谷值测量，即下一次给药之前。",
        "一個數值只有配上採血時間才有意義：環戊丙酸酯和庚酸酯在兩次注射的中點測量；十一酸酯在谷值測量，即下一次給藥之前。",
    ),
    "About %lld to %lld %@ across the cycle": (
        "整个周期内约 %lld 至 %lld %@",
        "整個週期內約 %lld 至 %lld %@",
    ),
    "Add %@": ("添加%@", "新增%@"),
    "An injected ester releases slowly from the oil depot, splits into the free hormone, and clears. This curve sums your logged esters into the serum level a blood test would read.": (
        "注射的酯从油性储库中缓慢释放，分解为游离激素，然后被清除。这条曲线把你记录的各种酯汇总为一次血检会读到的血清水平。",
        "注射的酯從油性貯庫中緩慢釋放，分解為游離激素，然後被清除。這條曲線把你記錄的各種酯彙總為一次血檢會讀到的血清水平。",
    ),
    "Aromatized estradiol": ("芳香化生成的雌二醇", "芳香化生成的雌二醇"),
    "Assumed depot levels": ("假定的储库水平", "假定的貯庫水平"),
    "Decreased": ("下降", "下降"),
    "Each ester's own release, before they sum to the serum estimate above.": (
        "每种酯各自的释放，在汇总为上方的血清估计值之前。",
        "每種酯各自的釋放，在彙總為上方的血清估計值之前。",
    ),
    "Estimated %@ level over time": ("%@ 水平随时间的估计", "%@ 水平隨時間的估計"),
    "Estimated serum estradiol": ("估计的血清雌二醇", "估計的血清雌二醇"),
    "Estimated serum estradiol or testosterone from your logged esters": (
        "根据你记录的酯估计的血清雌二醇或睾酮",
        "根據你記錄的酯估計的血清雌二醇或睪固酮",
    ),
    "Estimated serum testosterone": ("估计的血清睾酮", "估計的血清睪固酮"),
    "Hematocrit": ("血细胞比容", "血球容積比"),
    "Hemoglobin": ("血红蛋白", "血紅素"),
    "Hormone Levels": ("激素水平", "荷爾蒙水平"),
    "Increased": ("上升", "上升"),
    "It estimates a level. It never suggests a dose or a target. Lab results calibrate it to you, and the reference lines are your own.": (
        "它估计一个水平，从不建议剂量或目标。化验结果能让它按你的情况校准，参考线是你自己的。",
        "它估計一個水平，從不建議劑量或目標。化驗結果能讓它按你的情況校準，參考線是你自己的。",
    ),
    "Levels vary a lot between people, so an uncalibrated curve is a starting point, not a reading. Retest after any change in dose, ester, interval, or site.": (
        "不同人之间水平差异很大，所以未校准的曲线是一个起点，不是一次读数。剂量、酯、间隔或注射部位有任何变化后都要重新检测。",
        "不同人之間水平差異很大，所以未校準的曲線是一個起點，不是一次讀數。劑量、酯、間隔或注射部位有任何變化後都要重新檢測。",
    ),
    "Log an injectable estradiol or testosterone ester to see your estimated hormone levels here.": (
        "记录一次可注射的雌二醇或睾酮酯，就能在这里看到你的激素水平估计。",
        "記錄一次可注射的雌二醇或睪固酮酯，就能在這裡看到你的荷爾蒙水平估計。",
    ),
    "Monitored alongside hematocrit on T. Your measured points, plotted.": (
        "用 T 期间与血细胞比容一同监测。这是你实测数据点的绘图。",
        "用 T 期間與血球容積比一同監測。這是你實測資料點的繪圖。",
    ),
    "Note the time since your last injection when you draw — a peak and a trough tell different stories, and the curve reads both against your dose times.": (
        "采血时记下距上次注射过了多久——峰值和谷值说的是两回事，曲线会把两者都对照你的给药时间来读。",
        "採血時記下距上次注射過了多久——峰值和谷值說的是兩回事，曲線會把兩者都對照你的給藥時間來讀。",
    ),
    "Shaded: the 300–1000 ng/dL male reference range (FDA label; Wang 2010). A reference, not a target.": (
        "阴影部分：300–1000 ng/dL 的男性参考范围（FDA 说明书；Wang 2010）。这是参考，不是目标。",
        "陰影部分：300–1000 ng/dL 的男性參考範圍（FDA 說明書；Wang 2010）。這是參考，不是目標。",
    ),
    "Testosterone (suppression)": ("睾酮（抑制）", "睪固酮（抑制）"),
    "Testosterone aromatizes to estradiol, so E2 often rises on T. Piru plots your measured points — the conversion is person-specific, not modeled.": (
        "睾酮会芳香化为雌二醇，所以用 T 期间 E2 常会上升。Piru 绘制你的实测点——这种转化因人而异，未被建模。",
        "睪固酮會芳香化為雌二醇，所以用 T 期間 E2 常會上升。Piru 繪製你的實測點——這種轉化因人而異，未被建模。",
    ),
    "Testosterone ester curves are fit from label and primary-literature half-lives — there is no community PK simulator for them, so the band stays wide until your lab results calibrate the model.": (
        "睾酮酯曲线根据说明书和原始文献中的半衰期拟合而成。由于没有适用的社区药代动力学模拟器，在用你的化验结果校准模型前，误差带会较宽。",
        "睪固酮酯曲線根據說明書和原始文獻中的半衰期擬合而成。由於沒有適用的社群藥物動力學模擬器，在用你的檢驗結果校準模型前，誤差帶會較寬。",
    ),
    "Testosterone raises red-cell production, so hematocrit is monitored on T (largest rise in the first year). These are your measured points, plotted, not a prediction.": (
        "睾酮会提高红细胞生成，所以用 T 期间要监测血细胞比容（第一年升幅最大）。这些是你实测点的绘图，不是预测。",
        "睪固酮會提高紅血球生成，所以用 T 期間要監測血球容積比（第一年升幅最大）。這些是你實測點的繪圖，不是預測。",
    ),
    "The Endocrine Society / WPATH SOC8 monitoring goal. Tapping sets it as your own reference lines — Piru still sets no target.": (
        "内分泌学会 / WPATH SOC8 的监测目标。点按会把它设为你自己的参考线——Piru 仍然不设定目标。",
        "內分泌學會 / WPATH SOC8 的監測目標。點按會把它設為你自己的參考線——Piru 仍然不設定目標。",
    ),
    "Use the common clinical goal (%lld–%lld %@)": (
        "使用常见临床目标（%lld–%lld %@）",
        "使用常見臨床目標（%lld–%lld %@）",
    ),
    "Your measured testosterone. On estradiol, T usually falls; Piru plots your points rather than modeling suppression.": (
        "你实测的睾酮。用雌二醇期间 T 通常会下降；Piru 绘制你的数据点，而不是对抑制建模。",
        "你實測的睪固酮。用雌二醇期間 T 通常會下降；Piru 繪製你的資料點，而不是對抑制建模。",
    ),
    # ADHD audience fit v2 — curve milestones, word-state glance, the late-dose
    # sleep clause, and the de-shamed adherence surfaces.
    "Kicks in": ("开始起效", "開始起效"),
    "Begins to wear off": ("开始消退", "開始消退"),
    "around %@": ("约 %@", "約 %@"),
    "Coming up": (
        "上升中",
        "上升中",
    ),
    "Wearing off": ("消退中", "消退中"),
    "%@ active until ~%@": ("%@ 预计持续到约 %@", "%@ 預計持續到約 %@"),
    "%lld of %lld scheduled doses": ("%lld / %lld 次计划剂量", "%lld / %lld 次計劃劑量"),
    "Which days you took your meds": ("哪些天服了药", "哪些天服了藥"),
    "Morning dose not logged": ("早间剂量未记录", "早間劑量未記錄"),
    "Evening dose not logged": ("晚间剂量未记录", "晚間劑量未記錄"),
    # SubstanceCategory.classSummary — category descriptions shown atop each
    # browse list; LocalizedStringResource literals the extractor misses, inserted
    # via NEW_KEYS and persistent because they carry a translation.
    "Agonists at the 5-HT2A receptor. That single action reshapes perception, thought and the sense of self; the family splits by chemistry — phenethylamines, tryptamines, and the ergolines LSD belongs to.": (
        "5-HT2A 受体的激动剂。这一个作用便重塑了知觉、思维和自我感；这一族按化学结构分为苯乙胺类、色胺类，以及 LSD 所属的麦角灵类。",
        "5-HT2A 受體的促效劑。這一個作用便重塑了知覺、思維和自我感；這一族按化學結構分為苯乙胺類、色胺類，以及 LSD 所屬的麥角靈類。",
    ),
    "Block the NMDA glutamate receptor, uncoupling perception from the body that reports it. The effect scales sharply with dose, from analgesia through anesthesia.": (
        "阻断 NMDA 谷氨酸受体，使知觉与报告它的身体脱离。效应随剂量急剧变化，从镇痛直至麻醉。",
        "阻斷 NMDA 麩胺酸受體，使知覺與回報它的身體脫離。效應隨劑量急劇變化，從鎮痛直至麻醉。",
    ),
    "Act at the κ-opioid receptor rather than 5-HT2A, which is why the experience is nothing like a classical psychedelic — dysphoric, disorienting, and usually brief.": (
        "作用于 κ-阿片受体而非 5-HT2A，因此体验与经典迷幻剂截然不同——烦躁不安、方向迷失，且通常短暂。",
        "作用於 κ-鴉片受體而非 5-HT2A，因此體驗與經典迷幻劑截然不同——煩躁不安、方向迷失，且通常短暫。",
    ),
    "Block muscarinic acetylcholine receptors. Unlike psychedelics they produce true hallucinations — things that are not there and are not recognized as unreal — alongside amnesia and a narrow margin to toxicity.": (
        "阻断毒蕈碱型乙酰胆碱受体。与迷幻剂不同，它们产生真正的幻觉——并不存在、且不被察觉为虚假的事物——并伴随健忘和狭窄的中毒安全边际。",
        "阻斷蕈毒鹼型乙醯膽鹼受體。與迷幻劑不同，它們產生真正的幻覺——並不存在、且不被察覺為虛假的事物——並伴隨健忘和狹窄的中毒安全邊際。",
    ),
    "Agonists at the µ-opioid receptor: analgesia, warmth and sedation, and depressed breathing by the same mechanism. Tolerance to the first outpaces tolerance to the last, which is what makes the margin narrow.": (
        "μ-阿片受体的激动剂：镇痛、温暖与镇静，以及由同一机制导致的呼吸抑制。对前者的耐受快于对后者的耐受，这正是安全边际狭窄的原因。",
        "μ-鴉片受體的促效劑：鎮痛、溫暖與鎮靜，以及由同一機制導致的呼吸抑制。對前者的耐受快於對後者的耐受，這正是安全邊際狹窄的原因。",
    ),
    "Positive allosteric modulators at GABA-A — they amplify the brain's own inhibitory signal rather than acting on their own. That ceiling is why they are relatively safe alone and dangerous with anything else that sedates.": (
        "GABA-A 的正向别构调节剂——它们放大大脑自身的抑制信号，而非独立起作用。这一上限使它们单独使用时相对安全，却与任何其他镇静物质同用时危险。",
        "GABA-A 的正向異位調節劑——它們放大大腦自身的抑制訊號，而非獨立起作用。這一上限使它們單獨使用時相對安全，卻與任何其他鎮靜物質同用時危險。",
    ),
    "Bind the α2δ subunit of voltage-gated calcium channels, reducing excitatory transmitter release. Not GABAergic despite the name.": (
        "结合电压门控钙通道的 α2δ 亚基，减少兴奋性递质释放。名称虽如此，但并非 GABA 能药物。",
        "結合電壓閘控鈣通道的 α2δ 次單元，減少興奮性遞質釋放。名稱雖如此，但並非 GABA 能藥物。",
    ),
    "Release serotonin, along with dopamine and noradrenaline — warmth, closeness and emotional openness rather than the perceptual change of a psychedelic. Most are amphetamines with a methylenedioxy ring.": (
        "释放血清素，以及多巴胺和去甲肾上腺素——带来温暖、亲近和情感开放，而非迷幻剂的知觉改变。多数是带有亚甲二氧基环的苯丙胺。",
        "釋放血清素，以及多巴胺和正腎上腺素——帶來溫暖、親近和情感開放，而非迷幻劑的知覺改變。多數是帶有亞甲二氧基環的安非他命。",
    ),
    "Act at the CB1 receptor. The phytocannabinoids are partial agonists with a natural ceiling; the synthetic ones are full agonists without it, which is the whole of the difference in risk.": (
        "作用于 CB1 受体。植物大麻素是有天然上限的部分激动剂；合成大麻素则是没有上限的完全激动剂，风险的差异全在于此。",
        "作用於 CB1 受體。植物大麻素是有天然上限的部分促效劑；合成大麻素則是沒有上限的完全促效劑，風險的差異全在於此。",
    ),
    "A functional grouping rather than a mechanistic one: compounds taken for cognition, with radically different pharmacology and, mostly, thin human evidence.": (
        "这是按功能而非机制划分的一类：为改善认知而服用的化合物，药理各不相同，且大多缺乏充分的人体证据。",
        "這是按功能而非機制劃分的一類：為改善認知而服用的化合物，藥理各不相同，且大多缺乏充分的人體證據。",
    ),
    "Positive allosteric modulators of the AMPA glutamate receptor. The high-impact ones carry convulsant liability; the low-impact ones are safer and weaker.": (
        "AMPA 谷氨酸受体的正向别构调节剂。作用强的有致惊厥风险；作用弱的更安全，也更弱。",
        "AMPA 麩胺酸受體的正向異位調節劑。作用強的有致驚厥風險；作用弱的更安全，也更弱。",
    ),
    "Promote wakefulness without the dopaminergic surge of a classical stimulant. Mechanism is still argued over; the effect is alertness without much euphoria.": (
        "在没有经典兴奋剂那种多巴胺激增的情况下促进清醒。机制仍有争议；效果是警觉，而少有欣快。",
        "在沒有經典興奮劑那種多巴胺激增的情況下促進清醒。機制仍有爭議；效果是警覺，而少有欣快。",
    ),
    "Slow central nervous system activity, mostly through GABA. Their doses add up with each other in a way that is easy to underestimate.": (
        "减缓中枢神经系统活动，主要通过 GABA。它们的剂量彼此叠加，其程度容易被低估。",
        "減緩中樞神經系統活動，主要透過 GABA。它們的劑量彼此疊加，其程度容易被低估。",
    ),
    "Block the orexin receptors that hold wakefulness in place, rather than enhancing GABA. They add next-day sedation with other depressants but not brainstem respiratory depression.": (
        "阻断维持清醒的食欲素受体，而非增强 GABA。与其他抑制剂同用会叠加次日镇静，但不会导致脑干性呼吸抑制。",
        "阻斷維持清醒的食慾素受體，而非增強 GABA。與其他抑制劑同用會疊加次日鎮靜，但不會導致腦幹性呼吸抑制。",
    ),
    "Raise serotonin, noradrenaline or dopamine signalling over weeks rather than hours. The class matters here mostly for what it blocks or stacks with.": (
        "在数周而非数小时内提升血清素、去甲肾上腺素或多巴胺信号。这一类在此主要因其阻断或叠加的对象而重要。",
        "在數週而非數小時內提升血清素、正腎上腺素或多巴胺訊號。這一類在此主要因其阻斷或疊加的對象而重要。",
    ),
    "Block dopamine D2 receptors, and usually several serotonin receptors alongside. Sedating, and a common blunting agent for other substances.": (
        "阻断多巴胺 D2 受体，通常同时阻断数种血清素受体。具镇静作用，也是常见的钝化其他物质效果的药物。",
        "阻斷多巴胺 D2 受體，通常同時阻斷數種血清素受體。具鎮靜作用，也是常見的鈍化其他物質效果的藥物。",
    ),
    "Block histamine H1 receptors. The first-generation ones cross into the brain and are strongly anticholinergic, which is why they sedate — and, in quantity, deliriate.": (
        "阻断组胺 H1 受体。第一代药物能进入大脑且抗胆碱能作用强，因此会镇静——而大剂量下会致谵妄。",
        "阻斷組織胺 H1 受體。第一代藥物能進入大腦且抗膽鹼能作用強，因此會鎮靜——而大劑量下會致譫妄。",
    ),
    "Vitamins, minerals, amino acids and plant preparations. Pharmacologically a mixed bag, and the place where interactions are most often assumed to be absent.": (
        "维生素、矿物质、氨基酸和植物制剂。药理上参差不齐，也是人们最常想当然地以为不存在相互作用的一类。",
        "維生素、礦物質、胺基酸和植物製劑。藥理上參差不齊，也是人們最常想當然地以為不存在交互作用的一類。",
    ),
    "Short chains of amino acids acting at hormone or growth-factor receptors. Almost all are injected, and almost none have long-term human data.": (
        "作用于激素或生长因子受体的短链氨基酸。几乎全为注射给药，也几乎都没有长期人体数据。",
        "作用於激素或生長因子受體的短鏈胺基酸。幾乎全為注射給藥，也幾乎都沒有長期人體資料。",
    ),
    "Damp excessive neuronal firing, by sodium-channel block, GABA enhancement or SV2A binding depending on the drug.": (
        "抑制过度的神经元放电，视药物不同，通过阻断钠通道、增强 GABA 或结合 SV2A 实现。",
        "抑制過度的神經元放電，視藥物不同，透過阻斷鈉通道、增強 GABA 或結合 SV2A 實現。",
    ),
    # Skins (Settings → Appearance)
    "Piru": ("Piru", "Piru"),
    "Soft pink, hot pink, liquid glass": ("柔粉、亮粉、液态玻璃", "柔粉、亮粉、液態玻璃"),
    "ely.pink": ("ely.pink", "ely.pink"),
    "Night and pink, stickers and pixels": ("夜色与粉色，贴纸与像素", "夜色與粉色，貼紙與像素"),
    "Tsuki": ("Tsuki", "Tsuki"),
    "Deep purple night, a sleeping moon": ("深紫夜色，一轮睡着的月亮", "深紫夜色，一輪睡著的月亮"),
    "Starfield": ("星野", "星野"),
    "Steel blue and gold under a thousand stars": ("千星之下的钢蓝与金", "千星之下的鋼藍與金"),
    "Jellyfish": ("水母", "水母"),
    "Deep water, bioluminescence, jellyfish": ("深水、生物荧光、水母", "深水、生物螢光、水母"),
    "Graphite": ("石墨", "石墨"),
    "Neutral grays, nothing moving": ("中性灰，静止不动", "中性灰，靜止不動"),
    "Linen": ("亚麻", "亞麻"),
    "Warm paper and charcoal, quiet": ("暖纸与炭色，安静", "暖紙與炭色，安靜"),
    "Slate": ("板岩", "板岩"),
    "Cool blue-gray, quiet": ("冷蓝灰，安静", "冷藍灰，安靜"),
    "Paper Garden": ("纸庭", "紙庭"),
    "Washi, raked sand, sakura": ("和纸、枯山水、樱花", "和紙、枯山水、櫻花"),
    # The skin's picker name is Aurora; the case and raw value stay `hotaru`.
    "Aurora": ("极光", "極光"),
    "Fireflies over a dark meadow": ("暗色草原上的萤火虫", "暗色草原上的螢火蟲"),
    "Yuki": ("Yuki", "Yuki"),
    "Periwinkle, snow and frost": ("长春花蓝、雪与霜", "長春花藍、雪與霜"),
    "Hebi Arcade": ("Hebi 街机", "Hebi 街機"),
    "Neon City on a CRT": ("CRT 上的霓虹城", "CRT 上的霓虹城"),
    # Romanised Japanese app names stay as they are, like Tsuki / Yuki / Kumo.
    "Hanabi": ("Hanabi", "Hanabi"),
    "Selenia": ("Selenia", "Selenia"),
    "Engraved gold, a plum night, a turning wheel": (
        "镌刻的金色、梅紫夜空、缓缓旋转的星盘",
        "鐫刻的金色、梅紫夜空、緩緩旋轉的星盤",
    ),
    "A night sky, five suits, fireworks": ("夜空、五种花色、烟花", "夜空、五種花色、煙火"),
    "Kumo": ("Kumo", "Kumo"),
    "A sky that follows the day": ("随一天变化的天空", "隨一天變化的天空"),
    "dose.wiki": ("dose.wiki", "dose.wiki"),
    "Plum and fuchsia, from the open encyclopedia": (
        "梅紫与紫红，来自开放百科",
        "梅紫與紫紅，來自開放百科",
    ),
    "In partnership with dose.wiki ↗": ("与 dose.wiki 合作 ↗", "與 dose.wiki 合作 ↗"),
    "A skin changes the app's colors, cards, and type. Your substance colors, the timeline, and every chart stay exactly as they are.": (
        "皮肤会改变应用的颜色、卡片和字体。你的物质颜色、时间轴和所有图表都保持原样。",
        "皮膚會改變應用程式的顏色、卡片和字體。你的物質顏色、時間軸和所有圖表都保持原樣。",
    ),
    "Follow System": ("跟随系统", "跟隨系統"),
    "Light Mode": ("浅色模式", "淺色模式"),
    "Dark Mode": ("深色模式", "深色模式"),
    "Decorations": ("装饰", "裝飾"),
    "Stars, hearts, and stickers behind everything. Off automatically with Reduce Motion.": (
        "背后的星星、爱心和贴纸。开启“减弱动态效果”时会自动关闭。",
        "背後的星星、愛心和貼紙。開啟「減少動態效果」時會自動關閉。",
    ),
    "Every skin has a light and a dark side. Follow System switches with iOS.": (
        "每个皮肤都有浅色和深色两面。跟随系统会随 iOS 切换。",
        "每個皮膚都有淺色和深色兩面。跟隨系統會隨 iOS 切換。",
    ),
    # Quick-log Edit sheet (2026-09-04)
    "New Drink…": ("新增饮品…", "新增飲品…"),
    "Add Favorite…": ("添加收藏…", "新增收藏…"),
    "Add Favorite": ("添加收藏", "新增收藏"),
    "Add Preset…": ("添加预设…", "新增預設…"),
    "Star a substance to keep it in your quick-log favorites.": (
        "给物质加星，即可保留在快捷记录的收藏中。",
        "為物質加星，即可保留在快捷記錄的收藏中。",
    ),
    # Brand picker IR/XR grouping (2026-09-04)
    "Unbranded": ("无品牌", "無品牌"),
    "Immediate-release": ("速释", "速釋"),
    # Branded formulations section on substance detail (2026-09-12)
    "Branded formulations": ("品牌制剂", "品牌製劑"),
    "Substance default": ("物质默认", "物質預設"),
    "Doses stay the substance's own — only the duration curve changes.": (
        "剂量仍为该物质本身的剂量——只有作用时长曲线会改变。",
        "劑量仍為該物質本身的劑量——只有作用時長曲線會改變。",
    ),
    # Injection Levels tool (2026-09-04)
    "Injection Levels": (
        "注射后血药水平",
        "注射後血藥水平",
    ),
    "Project hormone levels from injectable esters": (
        "根据注射用酯类推算激素水平",
        "根據注射用酯類推算激素水平",
    ),
    "Hormone": ("激素", "激素"),
    "Ester": ("酯类", "酯類"),
    "No specific ester": ("不指定酯类", "不指定酯類"),
    "From your log": ("来自你的记录", "來自你的記錄"),
    # Injection Levels copy trim + app-wide missing translations (2026-09-07)
    "%lld mL injections converted at this strength": (
        "已按此浓度换算 %lld 次 mL 注射",
        "已按此濃度換算 %lld 次 mL 注射",
    ),
    "%lld injections are in mL. Enter the vial strength to include them.": (
        "%lld 次注射以 mL 记录。输入药瓶浓度以纳入。",
        "%lld 次注射以 mL 記錄。輸入藥瓶濃度以納入。",
    ),
    "Start from your log": ("从记录开始", "從記錄開始"),
    "Starts at today's level from your log. Next dose one interval after your last.": (
        "从记录中今天的水平开始。下一剂在上一剂后一个间隔。",
        "從記錄中今天的水平開始。下一劑在上一劑後一個間隔。",
    ),
    "Starting level": ("起始水平", "起始水平"),
    "The level in your body today, if any. First dose today.": (
        "今天体内已有的水平（如有）。第一剂在今天。",
        "今天體內已有的水平（如有）。第一劑在今天。",
    ),
    "An injected ester releases slowly from the oil depot, splits into the free hormone, and clears. The curve models that from your doses.": (
        "注射的酯从油性储库缓慢释放，分解为游离激素，再被清除。曲线据你的剂量模拟这一过程。",
        "注射的酯從油性儲庫緩慢釋放，分解為游離激素，再被清除。曲線據你的劑量模擬這一過程。",
    ),
    "No injectable ester data in this build.": (
        "此版本没有注射用酯数据。",
        "此版本沒有注射用酯資料。",
    ),
    "Lab calibration": ("化验校准", "化驗校準"),
    "Add a blood test to fit the curve to you. The band narrows.": (
        "添加一次验血，让曲线贴合你。范围带会收窄。",
        "新增一次驗血，讓曲線貼合你。範圍帶會收窄。",
    ),
    "Use my lab results": ("使用我的化验结果", "使用我的化驗結果"),
    "Height and shape fit to your results. Terminal release %@.": (
        "高度和形状已贴合你的结果。末端释放%@。",
        "高度和形狀已貼合你的結果。末端釋放%@。",
    ),
    "Height fit to your result. A second test on another day fits the shape too.": (
        "高度已贴合你的结果。另一天再测一次，形状也会贴合。",
        "高度已貼合你的結果。另一天再測一次，形狀也會貼合。",
    ),
    "Fit shape as well as height": ("同时拟合形状与高度", "同時擬合形狀與高度"),
    "Adjust if you run higher or lower than average. A blood test replaces this with a fit.": (
        "若你的水平高于或低于平均，可在此调整。验血后将由拟合取代。",
        "若你的水平高於或低於平均，可在此調整。驗血後將由擬合取代。",
    ),
    "%@× faster than average": (
        "快于平均（%@×）",
        "快於平均（%@×）",
    ),
    "%@× slower than average": (
        "慢于平均（%@×）",
        "慢於平均（%@×）",
    ),
    "Your own lines. Piru sets no target.": (
        "你自己的参考线。Piru 不设目标。",
        "你自己的參考線。Piru 不設目標。",
    ),
    "Older studies used radioimmunoassay; modern LC-MS/MS reads lower. Calibrating to your own results absorbs the difference.": (
        "早期研究使用放射免疫法，现代 LC-MS/MS 读数偏低。按你的结果校准可消除差异。",
        "早期研究使用放射免疫法，現代 LC-MS/MS 讀數偏低。按你的結果校準可消除差異。",
    ),
    "Subcutaneous and intramuscular reach similar levels (196 vs 190 pg/mL head-to-head), so one curve serves both (Herndon 2023; Misakian 2025).": (
        "皮下与肌肉注射水平相近（直接对比 196 对 190 pg/mL），因此共用一条曲线（Herndon 2023；Misakian 2025）。",
        "皮下與肌肉注射水平相近（直接對比 196 對 190 pg/mL），因此共用一條曲線（Herndon 2023；Misakian 2025）。",
    ),
    "Parameters from estrannaise.js (MIT), checked against the literature": (
        "参数来自 estrannaise.js（MIT），已对照文献核查",
        "參數來自 estrannaise.js（MIT），已對照文獻核查",
    ),
    "Enter it in your lab's unit. Stored in %@.": (
        "按化验单的单位输入。以 %@ 保存。",
        "按化驗單的單位輸入。以 %@ 儲存。",
    ),
    "fl oz": ("液量盎司", "液量盎司"),
    "Caffeine": ("咖啡因", "咖啡因"),
    "Nicotine": ("尼古丁", "尼古丁"),
    "Cannabis": ("大麻", "大麻"),
    "Ethylphenidate": ("乙苯哌酯", "乙苯哌酯"),
    "Tramadol → O-DSMT": ("曲马多 → O-DSMT", "曲馬多 → O-DSMT"),
    "Dose · %@": ("剂量 · %@", "劑量 · %@"),
    "By dose · %@": ("按剂量 · %@", "按劑量 · %@"),
    "/day": ("/天", "/天"),
    "": ("", ""),
    "—": ("—", "—"),
    "— %@": ("— %@", "— %@"),
    "“%@”": (
        "“%@”",
        "「%@」",
    ),
    "%@ · %@": ("%@ · %@", "%@ · %@"),
    "%@ mg": ("%@ mg", "%@ mg"),
    "%@–%@ %@": ("%@–%@ %@", "%@–%@ %@"),
    "%@%%": ("%@%%", "%@%%"),
    "%lld×": ("%lld×", "%lld×"),
    "DAT:SERT %@": ("DAT:SERT %@", "DAT:SERT %@"),
    "LogP": ("LogP", "LogP"),
    "SMILES": ("SMILES", "SMILES"),
    "TPSA": ("TPSA", "TPSA"),
    "mL": ("mL", "mL"),
    "%@ + %@ active together ~%lldh (%@ + %@).": (
        "%@ 与 %@ 同时活跃约 %lld 小时（%@ + %@）。",
        "%@ 與 %@ 同時活躍約 %lld 小時（%@ + %@）。",
    ),
    "%@ and %@, %@: %@": ("%@ 与 %@，%@：%@", "%@ 與 %@，%@：%@"),
    "%@ blocks the %@ that %@ needs to work.": (
        "%1$@ 会阻断 %3$@ 起效所需的 %2$@。",
        "%1$@ 會阻斷 %3$@ 起效所需的 %2$@。",
    ),
    "%@ dose rising, +%lld%% over the reporting period (%@ → %@ %@).": (
        "%@ 剂量上升，报告期内 +%lld%%（%@ → %@ %@）。",
        "%@ 劑量上升，報告期內 +%lld%%（%@ → %@ %@）。",
    ),
    "%lld reports": ("%lld 份报告", "%lld 份報告"),
    "%lld selected": ("已选 %lld 项", "已選 %lld 項"),
    "%lld%% load": ("负荷 %lld%%", "負荷 %lld%%"),
    "%lld%% remaining": ("剩余 %lld%%", "剩餘 %lld%%"),
    "≈ %@ %@ %@ at %@ kg": ("≈ %@ %@ %@（按 %@ kg）", "≈ %@ %@ %@（按 %@ kg）"),
    "About monoamine profile": ("关于单胺特征", "關於單胺特徵"),
    "Alcohol dehydrogenase saturates at about one drink, so clearance runs at a fixed rate and each extra drink stacks on the last. Chronic heavy drinking speeds clearance somewhat (CYP2E1 induction); the ALDH2 “flush” variant slows acetaldehyde clearance.": (
        "乙醇脱氢酶在约一杯酒时饱和，此后以固定速率清除，每多一杯都叠加在上一杯之上。长期大量饮酒会略微加快清除（CYP2E1 诱导）；ALDH2“脸红”变异会减慢乙醛清除。",
        "乙醇脫氫酶在約一杯酒時飽和，此後以固定速率清除，每多一杯都疊加在上一杯之上。長期大量飲酒會略微加快清除（CYP2E1 誘導）；ALDH2「臉紅」變異會減慢乙醛清除。",
    ),
    "Alerts": ("提醒", "提醒"),
    "An existing iCloud backup was found": ("发现已有的 iCloud 备份", "發現已有的 iCloud 備份"),
    "An existing iCloud backup was found. Merge it with your current data to restore it, or remove it to start fresh.": (
        "发现已有的 iCloud 备份。与当前数据合并以恢复，或删除它重新开始。",
        "發現已有的 iCloud 備份。與目前資料合併以還原，或刪除它重新開始。",
    ),
    "Backup Merged": ("备份已合并", "備份已合併"),
    "Backup Removed": ("备份已删除", "備份已刪除"),
    "Benzodiazepine effect kinetics: Vinkers & Olivier 2012; Piot & Jovanovic 2026.": (
        "苯二氮䓬效应动力学：Vinkers & Olivier 2012；Piot & Jovanovic 2026。",
        "苯二氮平效應動力學：Vinkers & Olivier 2012；Piot & Jovanovic 2026。",
    ),
    "Beta-blockers": ("β 受体阻滞剂", "β 受體阻斷劑"),
    "Beta-blockers (propranolol)": ("β 受体阻滞剂（普萘洛尔）", "β 受體阻斷劑（普萘洛爾）"),
    "Bioavailability": ("生物利用度", "生物利用度"),
    "Body content": ("体内含量", "體內含量"),
    "Body load": ("身体负荷", "身體負荷"),
    "Both active %@–%@ (%@ overlap)": (
        "两者在 %@–%@ 同时活跃（重叠 %@）",
        "兩者在 %@–%@ 同時活躍（重疊 %@）",
    ),
    "By dose": ("按剂量", "按劑量"),
    'Cocaethylene adds extra strain on the heart and liver beyond cocaine alone, so this combination is harder on your body. (The widely-repeated "18–25× sudden death" figure is not supported by the evidence — but the added cardiac and liver strain is real.)': (
        "可卡乙烯对心脏和肝脏的负担超过单用可卡因，因此这一组合对身体负担更重。（广为流传的“猝死风险 18–25 倍”没有证据支持，但额外的心脏与肝脏负担是真实的。）",
        "古柯乙烯對心臟和肝臟的負擔超過單用古柯鹼，因此這一組合對身體負擔更重。（廣為流傳的「猝死風險 18–25 倍」沒有證據支持，但額外的心臟與肝臟負擔是真實的。）",
    ),
    "Codeine works through CYP2D6 conversion to morphine, and most people's enzyme caps how much they make: past ~60 mg the pain relief plateaus while side effects keep climbing. Ultra-rapid metabolizers have no cap and can reach dangerous levels at ordinary doses; poor metabolizers get little relief.": (
        "可待因需经 CYP2D6 转化为吗啡才起效，多数人的酶有上限：超过约 60 mg 后镇痛不再增强，副作用却继续上升。超快代谢者没有上限，常规剂量即可达到危险水平；慢代谢者几乎没有镇痛效果。",
        "可待因需經 CYP2D6 轉化為嗎啡才起效，多數人的酶有上限：超過約 60 mg 後鎮痛不再增強，副作用卻繼續上升。超快代謝者沒有上限，常規劑量即可達到危險水平；慢代謝者幾乎沒有鎮痛效果。",
    ),
    "Combined depression peaks around %@": (
        "合并抑制作用约在 %@ 达到峰值",
        "合併抑制作用約在 %@ 達到峰值",
    ),
    "Conditioned tolerance: Siegel 1976; Siegel, Hinson, Krank & McCully 1982; Weise-Kelly & Siegel 2001; Carlton & Wolgin 1971.": (
        "条件性耐受：Siegel 1976；Siegel, Hinson, Krank & McCully 1982；Weise-Kelly & Siegel 2001；Carlton & Wolgin 1971。",
        "條件性耐受：Siegel 1976；Siegel, Hinson, Krank & McCully 1982；Weise-Kelly & Siegel 2001；Carlton & Wolgin 1971。",
    ),
    "Copies set aside automatically (after an upgrade hiccup) or before a restore appear here, ready to restore.": (
        "自动保存的副本（升级出错后）或恢复前的副本会显示在这里，可随时恢复。",
        "自動儲存的副本（升級出錯後）或還原前的副本會顯示在這裡，可隨時還原。",
    ),
    "Day": ("天", "天"),
    "Dissociatives": ("解离剂", "解離劑"),
    "Dose intensity": ("剂量强度", "劑量強度"),
    "Dosed in low milligrams — use a milligram scale (0.001 g). Can't be measured by eye or kitchen scale.": (
        "剂量仅几毫克，请用毫克秤（0.001 g）。无法目测或用厨房秤称量。",
        "劑量僅幾毫克，請用毫克秤（0.001 g）。無法目測或用廚房秤稱量。",
    ),
    "Drug": ("药物", "藥物"),
    "Each line as a share of its own peak": (
        "每条线按自身峰值的比例显示",
        "每條線按自身峰值的比例顯示",
    ),
    "Effects can outlast the duration above — %@ is still present when %@'s listed duration ends.": (
        "效应可能超过上述时长：%2$@ 的标注时长结束时，%1$@ 仍在体内。",
        "效應可能超過上述時長：%2$@ 的標註時長結束時，%1$@ 仍在體內。",
    ),
    "Emerges at %@": ("%@ 时出现", "%@ 時出現"),
    "Emotional": ("情绪", "情緒"),
    "Entries from the backup will be added to your current data. Duplicates are skipped. Automatic backups will be turned on.": (
        "备份中的记录将添加到当前数据。重复项会跳过。自动备份将开启。",
        "備份中的記錄將加入目前資料。重複項會跳過。自動備份將開啟。",
    ),
    "Estimate only": ("仅为估算", "僅為估算"),
    "Faint": ("微弱", "微弱"),
    "Favorites, colors, units, and the substances you added.": (
        "收藏、颜色、单位和你添加的物质。",
        "收藏、顏色、單位和你新增的物質。",
    ),
    "Fires when the model's next dose window opens after a logged dose. Estimate only.": (
        "记录剂量后，模型的下一剂时段开启时提醒。仅为估算。",
        "記錄劑量後，模型的下一劑時段開啟時提醒。僅為估算。",
    ),
    "First-hand reports. Opens in your browser.": (
        "第一手报告。在浏览器中打开。",
        "第一手報告。在瀏覽器中開啟。",
    ),
    "For most substances, twice the dose is roughly twice the exposure. For these, an enzyme or carrier runs out of capacity: exposure climbs faster than the dose, or an effect stops climbing. Estimates only.": (
        "多数物质剂量加倍，暴露量也大致加倍。而这些物质的酶或转运体会饱和：暴露量的增长快于剂量，或效应不再增强。仅为估算。",
        "多數物質劑量加倍，暴露量也大致加倍。而這些物質的酶或轉運體會飽和：暴露量的增長快於劑量，或效應不再增強。僅為估算。",
    ),
    "GHB's clearing pathway saturates at moderate recreational doses: 25 → 35 mg/kg gave ~40% more exposure, and doubling the regulated product's dose raises exposure ~3.8×. Other depressants, especially alcohol, compound it. No reliable human Km/Vmax exists, so there is no curve.": (
        "GHB 的清除通路在中等娱乐剂量下即饱和：25 → 35 mg/kg 使暴露量增加约 40%，处方制剂剂量加倍则暴露量增至约 3.8 倍。其他中枢抑制药（尤其是酒精）会加重这一效应。目前没有可靠的人体 Km/Vmax 数据，因此没有曲线。",
        "GHB 的清除通路在中等娛樂劑量下即飽和：25 → 35 mg/kg 使暴露量增加約 40%，處方製劑劑量加倍則暴露量增至約 3.8 倍。其他中樞抑制藥（尤其是酒精）會加重這一效應。目前沒有可靠的人體 Km/Vmax 資料，因此沒有曲線。",
    ),
    "Grouped under Supplements, off the timeline graphs. Reminders are silent.": (
        "归入补充剂，不显示在时间线图表上。提醒为静音。",
        "歸入補充劑，不顯示在時間線圖表上。提醒為靜音。",
    ),
    "How much of a dose becomes its active form is partly genetic — the same dose can produce noticeably more effect in some people than in others.": (
        "一剂中有多少转化为活性形式部分取决于基因。同样的剂量在某些人身上效应明显更强。",
        "一劑中有多少轉化為活性形式部分取決於基因。同樣的劑量在某些人身上效應明顯更強。",
    ),
    "In your body": ("体内", "體內"),
    "Injection": ("注射", "注射"),
    "Intensity spectrum": ("强度谱", "強度譜"),
    "Keep Order": ("保持顺序", "保持順序"),
    "Level over time": ("水平随时间变化", "水平隨時間變化"),
    "Load": ("负荷", "負荷"),
    "Low Stock": ("库存不足", "庫存不足"),
    "Lower is better. Load on the body.": ("越低越好。身体的负荷。", "越低越好。身體的負荷。"),
    "Measure": ("测量", "測量"),
    "Merge Backup": ("合并备份", "合併備份"),
    "Merge Failed": ("合并失败", "合併失敗"),
    "Methylphenidate and alcohol together form ethylphenidate — an active stimulant your body makes only while both are present. It leans more on dopamine and lingers a little longer than methylphenidate, so the stimulant effect is drawn out.": (
        "哌甲酯与酒精同用会生成乙苯哌酯，一种只在两者同时存在时体内才产生的活性兴奋剂。它更偏向多巴胺，且比哌甲酯稍持久，因此兴奋效应被拉长。",
        "哌甲酯與酒精同用會生成乙苯哌酯，一種只在兩者同時存在時體內才產生的活性興奮劑。它更偏向多巴胺，且比哌甲酯稍持久，因此興奮效應被拉長。",
    ),
    "Mild": ("轻微", "輕微"),
    "Model a fixed dose schedule's plateau": (
        "模拟固定给药方案的平台期",
        "模擬固定給藥方案的平台期",
    ),
    "MOST REPORTED AT THIS DOSE": ("此剂量下最常报告", "此劑量下最常報告"),
    "Never marked missed. A daily limit feeds the cumulative dose warnings.": (
        "不会标记为漏服。每日上限用于累计剂量警告。",
        "不會標記為漏服。每日上限用於累計劑量警告。",
    ),
    "No active overlap at this timing": ("此时间安排下没有活跃重叠", "此時間安排下沒有活躍重疊"),
    "Notifications are turned off in Settings. Alerts below can't be delivered until they're allowed again.": (
        "通知已在“设置”中关闭。重新允许前，以下提醒无法送达。",
        "通知已在「設定」中關閉。重新允許前，以下提醒無法送達。",
    ),
    "Nudges and re-asks stay silent during quiet hours. Scheduled reminders and safety warnings still come through.": (
        "静音时段内不会推送提示和再次询问。定时提醒和安全警告仍会送达。",
        "靜音時段內不會推送提示和再次詢問。定時提醒和安全警告仍會送達。",
    ),
    "On a fixed schedule doses overlap and the level climbs until intake and clearance balance: steady state.": (
        "固定方案下各剂量相互重叠，水平持续上升，直到摄入与清除平衡：稳态。",
        "固定方案下各劑量相互重疊，水平持續上升，直到攝入與清除平衡：穩態。",
    ),
    "Overdose": ("过量", "過量"),
    "Peak opioid load %lld MME/day — above the CDC 90 MME reference.": (
        "阿片负荷峰值 %lld MME/天，高于 CDC 90 MME 参考值。",
        "鴉片類負荷峰值 %lld MME/天，高於 CDC 90 MME 參考值。",
    ),
    "Peak opioid load %lld MME/day — at or above the CDC 50 MME reference.": (
        "阿片负荷峰值 %lld MME/天，达到或高于 CDC 50 MME 参考值。",
        "鴉片類負荷峰值 %lld MME/天，達到或高於 CDC 50 MME 參考值。",
    ),
    "Phenotype": ("表型", "表型"),
    "Piru asks the system once. You choose exactly what it sends below.": (
        "Piru 只向系统请求一次。要发送哪些内容，由你在下方逐项决定。",
        "Piru 只向系統請求一次。要傳送哪些內容，由你在下方逐項決定。",
    ),
    "Population-average half-lives in a one-compartment model.": (
        "单室模型中的群体平均半衰期。",
        "單室模型中的群體平均半衰期。",
    ),
    "Projected Steady State": ("预计稳态", "預計穩態"),
    "Psychedelics": (
        "迷幻剂",
        "迷幻劑",
    ),
    "Pull": ("拉动", "拉動"),
    "Raise dopamine and noradrenaline signalling, which raises drive, attention and wakefulness — and heart rate and temperature with them. They differ mostly in how they do it: releasing the neurotransmitter, or blocking its reuptake.": (
        "增强多巴胺和去甲肾上腺素信号，从而提升动力、注意力和清醒度，心率和体温也随之升高。它们的差异主要在于方式：促进神经递质释放，或阻断其再摄取。",
        "增強多巴胺和正腎上腺素訊號，從而提升動力、注意力和清醒度，心率和體溫也隨之升高。它們的差異主要在於方式：促進神經傳導物質釋放，或阻斷其再攝取。",
    ),
    "Range": ("范围", "範圍"),
    "Read experience reports on FreeODWiki": (
        "在 FreeODWiki 阅读体验报告",
        "在 FreeODWiki 閱讀體驗報告",
    ),
    "Reduced effect (~%@)": ("效应减弱（约 %@）", "效應減弱（約 %@）"),
    "Reference high": ("参考上限", "參考上限"),
    "Reference low": ("参考下限", "參考下限"),
    "Relative to your recent baseline": ("相对于你近期的基线", "相對於你近期的基線"),
    "Removal Failed": ("删除失败", "刪除失敗"),
    "Remove Backup?": ("删除备份？", "刪除備份？"),
    "Remove Existing Backup": ("删除已有备份", "刪除已有備份"),
    "Restore from Backup": ("从备份恢复", "從備份還原"),
    "Restoring…": ("正在恢复…", "正在還原…"),
    "Save it as a screenshot, a PDF report, or a Markdown summary.": (
        "保存为截图、PDF 报告或 Markdown 摘要。",
        "儲存為截圖、PDF 報告或 Markdown 摘要。",
    ),
    "Sealed with AES-256-GCM. Tampering is detected and refused.": (
        "以 AES-256-GCM 加密封存。篡改会被检测并拒绝。",
        "以 AES-256-GCM 加密封存。竄改會被偵測並拒絕。",
    ),
    "Sedatives": ("镇静剂", "鎮靜劑"),
    "Serotonin releasers": ("血清素释放剂", "血清素釋放劑"),
    "Share Substance": ("分享物质", "分享物質"),
    "Share this session": (
        "分享本场",
        "分享本場",
    ),
    "Showing the first 60 days.": ("显示前 60 天。", "顯示前 60 天。"),
    "Slide to move, pinch to zoom, and hold to inspect a moment.": (
        "滑动移动，捏合缩放，长按查看某一时刻。",
        "滑動移動，捏合縮放，長按查看某一時刻。",
    ),
    "Social": ("社交", "社交"),
    "Substance Info": ("物质信息", "物質資訊"),
    "Swipe up or down to change the dose": ("上下滑动调整剂量", "上下滑動調整劑量"),
    "Tap to view": ("轻点查看", "輕點查看"),
    "The existing iCloud backup was removed.": (
        "已删除已有的 iCloud 备份。",
        "已刪除已有的 iCloud 備份。",
    ),
    "The existing iCloud backup will be permanently deleted. This cannot be undone.": (
        "已有的 iCloud 备份将被永久删除。此操作无法撤销。",
        "已有的 iCloud 備份將被永久刪除。此操作無法復原。",
    ),
    "The iCloud backup was merged with your data. Automatic backups are now on.": (
        "iCloud 备份已与你的数据合并。自动备份已开启。",
        "iCloud 備份已與你的資料合併。自動備份已開啟。",
    ),
    "The intestinal carrier (system-L / LAT1) saturates, so the fraction absorbed falls from ~60% at 900 mg/day to ~27% at 4800 mg/day.": (
        "肠道转运体（system-L / LAT1）会饱和，吸收比例从 900 mg/天时的约 60% 降至 4800 mg/天时的约 27%。",
        "腸道轉運體（system-L / LAT1）會飽和，吸收比例從 900 mg/天時的約 60% 降至 4800 mg/天時的約 27%。",
    ),
    "The mix adds cardiovascular strain beyond either alone, and the ethylphenidate it forms outlasts the methylphenidate itself, so the load on your heart is stretched out rather than added up.": (
        "这一组合对心血管的负担超过单用任一者，且生成的乙苯哌酯比哌甲酯本身更持久，因此心脏负荷被拉长而非简单叠加。",
        "這一組合對心血管的負擔超過單用任一者，且生成的乙苯哌酯比哌甲酯本身更持久，因此心臟負荷被拉長而非簡單疊加。",
    ),
    "Tramadol becomes a strong opioid only after CYP2D6 converts it to O-DSMT, so the ceiling depends on your genes: most people plateau, ultra-rapid metabolizers don't. Repeated dosing raises tramadol's own absorption (~75% → 90–100%), and CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) mute the opioid effect while leaving the parent's serotonergic and seizure risk.": (
        "曲马多只有经 CYP2D6 转化为 O-DSMT 后才成为强效阿片类药物，因此上限取决于基因：多数人会达到平台期，超快代谢者则不会。重复给药会提高曲马多自身的吸收（约 75% → 90–100%），而 CYP2D6 抑制剂（帕罗西汀、氟西汀、安非他酮）会减弱阿片类效应，但母体的血清素能和癫痫风险不变。",
        "曲馬多只有經 CYP2D6 轉化為 O-DSMT 後才成為強效鴉片類，因此上限取決於基因：多數人會達到平台期，超快代謝者則不會。重複給藥會提高曲馬多自身的吸收（約 75% → 90–100%），而 CYP2D6 抑制劑（帕羅西汀、氟西汀、安非他酮）會減弱鴉片效應，但母體的血清素能和癲癇風險不變。",
    ),
    "Trends, exposure, and overlap": ("趋势、暴露量与重叠", "趨勢、暴露量與重疊"),
    "Units you defined for your doses": ("你为剂量定义的单位", "你為劑量定義的單位"),
    "Used %lld of %lld days (%lld%%).": (
        "%2$lld 天中使用了 %1$lld 天（%3$lld%%）。",
        "%2$lld 天中使用了 %1$lld 天（%3$lld%%）。",
    ),
    "Used %lld of %lld days; longest break %lld days.": (
        "%2$lld 天中使用了 %1$lld 天；最长间断 %3$lld 天。",
        "%2$lld 天中使用了 %1$lld 天；最長間斷 %3$lld 天。",
    ),
    "Values are body content in the dose's units.": (
        "数值为体内含量，单位与剂量相同。",
        "數值為體內含量，單位與劑量相同。",
    ),
    "View substance card": ("查看物质卡片", "查看物質卡片"),
    "Warm": ("温暖", "溫暖"),
    "We found an existing backup in your iCloud. Pick up where you left off, or start fresh.": (
        "在你的 iCloud 中发现已有备份。接着上次继续，或重新开始。",
        "在你的 iCloud 中發現已有備份。接著上次繼續，或重新開始。",
    ),
    "Where each regularly dosed substance settles, based on your log's cadence": (
        "根据你的记录节奏，每种规律服用的物质将稳定在何处",
        "根據你的記錄節奏，每種規律服用的物質將穩定在何處",
    ),
    "Yesterday's %@ weren't logged": ("昨天的 %@ 未记录", "昨天的 %@ 未記錄"),
    "α₂-agonists": ("α₂ 激动剂", "α₂ 促效劑"),
    "α₂-agonists (clonidine)": ("α₂ 激动剂（可乐定）", "α₂ 促效劑（可樂定）"),
    "Vial concentration": ("药瓶浓度", "藥瓶濃度"),
    "Manual schedule": ("手动方案", "手動方案"),
    "%lld injections from your log": ("来自你记录的 %lld 次注射", "來自你記錄的 %lld 次注射"),
    "Every": ("每", "每"),
    "Estimated %@ level": ("预计%@水平", "預計%@水平"),
    "Estimated level over time": (
        "估算水平随时间的变化",
        "估算水平隨時間的變化",
    ),
    "Ranges from about %lld to %lld %@ across the cycle": (
        "整个周期内约在 %lld 到 %lld %@ 之间",
        "整個週期內約在 %lld 到 %lld %@ 之間",
    ),
    "Estimated trough": ("预计谷值", "預計谷值"),
    "Estimated peak": ("预计峰值", "預計峰值"),
    "Time in range": ("在范围内的时间", "在範圍內的時間"),
    "of the cycle, between your lines": (
        "周期内，位于两条参考线之间",
        "週期內，位於兩條參考線之間",
    ),
    "Estradiol": ("雌二醇", "雌二醇"),
    "Testosterone": (
        "睾酮",
        "睪固酮",
    ),
    "Uncalibrated": ("未校准", "未校準"),
    "1 result": ("1 项结果", "1 項結果"),
    "Calibrated · %lld results": ("已校准 · %lld 项结果", "已校準 · %lld 項結果"),
    "Add lab result": ("添加化验结果", "加入化驗結果"),
    "Reference lines": ("参考线", "參考線"),
    "Low line": ("下参考线", "下參考線"),
    "High line": ("上参考线", "上參考線"),
    "More on injectable estradiol dosing (diyhrt.info)": (
        "更多注射用雌二醇剂量信息（diyhrt.info）",
        "更多注射用雌二醇劑量資訊（diyhrt.info）",
    ),
    "Personal calibration": ("个人校准", "個人校準"),
    "Enter the vial's concentration — a volume alone isn't a dose.": (
        "请输入药瓶的浓度——仅有体积并不构成剂量。",
        "請輸入藥瓶的濃度——僅有體積並不構成劑量。",
    ),
    "1M": ("1个月", "1個月"),
    "3M": ("3个月", "3個月"),
    "6M": ("6个月", "6個月"),
    "Edit concentrations…": ("编辑浓度…", "編輯濃度…"),
    "Concentrations": ("浓度", "濃度"),
    "New concentration": ("新建浓度", "新增濃度"),
    "Edit concentration": ("编辑浓度", "編輯濃度"),
    "Concentration emoji": ("浓度表情符号", "濃度表情符號"),
    "Name (e.g. EV 40)": ("名称（例如 EV 40）", "名稱（例如 EV 40）"),
    "Draw date": ("采血日期", "採血日期"),
    "Serum level": (
        "血清水平",
        "血清濃度",
    ),
    "Included in calibration": ("已纳入校准", "已納入校準"),
    "Excluded from calibration": ("已排除于校准", "已排除於校準"),
    # Timeline options menu (2026-09-02)
    "Compress Empty Time": ("压缩空闲时间", "壓縮空閒時間"),
    "Curves": ("曲线", "曲線"),
    # Notes follow-up (2026-09-02)
    "Notes at their T+ offsets, descriptors by domain — 1 session with notes": (
        "按 T+ 偏移列出的笔记，按领域分组的描述词——1 个场次有笔记",
        "按 T+ 偏移列出的筆記，按領域分組的描述詞——1 個場次有筆記",
    ),
    "Notes at their T+ offsets, descriptors by domain — %lld sessions with notes": (
        "按 T+ 偏移列出的笔记，按领域分组的描述词——%lld 个场次有笔记",
        "按 T+ 偏移列出的筆記，按領域分組的描述詞——%lld 個場次有筆記",
    ),
    "Notes live here": ("笔记在这里", "筆記在這裡"),
    "Notes, check-ins and splitting live under this menu.": (
        "笔记、状态确认和拆分都在这个菜单里。",
        "筆記、狀態確認和拆分都在這個選單裡。",
    ),
    "Notes at their T+ offsets, descriptors by domain — none of the selected sessions has notes yet": (
        "按 T+ 偏移列出的笔记，按领域分组的描述词——所选场次还没有笔记",
        "按 T+ 偏移列出的筆記，按領域分組的描述詞——所選場次還沒有筆記",
    ),
    # Library "Yours" card (2026-09-02)
    "Yours": ("你的", "你的"),
    "Star a substance to keep it here": ("给物质加星即可收藏在此", "為物質加星即可收藏於此"),
    "Substances you added or customized": ("你添加或自定义的物质", "你新增或自訂的物質"),
    # b46 feature batches (2026-09-02)
    '"How is it going?" at set points in a session, opening a timestamped note. Turned on per session; off unless you ask.': (
        "在场次中的几个时点提示“现在感觉如何？”，并打开一条带时间戳的笔记。按场次开启；默认关闭。",
        "在場次中的幾個時點提示「現在感覺如何？」，並開啟一則帶時間戳的筆記。按場次開啟；預設關閉。",
    ),
    "%lld notes": ("%lld 条笔记", "%lld 則筆記"),
    "1 note": ("1 条笔记", "1 則筆記"),
    "A rare, peak, transcendental state — a serene and all-encompassing experience; the person, and the rating, are describing something outside the ordinary scale.": (
        "罕见的巅峰、超越性状态——宁静而包容一切的体验；这个人和这个评级描述的都是常规量表之外的东西。",
        "罕見的巔峰、超越性狀態——寧靜而包容一切的體驗；這個人和這個評級描述的都是常規量表之外的東西。",
    ),
    "About the Shulgin scale": ("关于舒尔金量表", "關於舒爾金量表"),
    "Add Summary": ("添加总结", "新增總結"),
    "Add a note to your session — what you notice, at this moment.": (
        "为这场添加一条笔记——此刻你注意到了什么。",
        "為這場新增一則筆記——此刻你注意到了什麼。",
    ),
    "Check in as it unfolds?": (
        "要在过程中确认一下自己的状态吗？",
        "要在過程中確認一下自己的狀態嗎？",
    ),
    "Check-in": (
        "状态确认",
        "狀態確認",
    ),
    "Check-ins": (
        "状态确认提醒",
        "狀態確認提醒",
    ),
    "Collapses the group": ("收起分组", "收起分組"),
    "Definite, but the nature or duration not yet clear; ordinary activity possible.": (
        "确定有效应，但性质或持续时间尚不清楚；可进行日常活动。",
        "確定有效應，但性質或持續時間尚不清楚；可進行日常活動。",
    ),
    "Delete this note?": ("删除这条笔记？", "刪除這則筆記？"),
    "Descriptors": ("描述词", "描述詞"),
    "Edit Summary": ("编辑总结", "編輯總結"),
    "Every hour": ("每小时", "每小時"),
    "Expands the group": ("展开分组", "展開分組"),
    "Full effect; the experience is the thing, ordinary activity set aside.": (
        "完全的效应；体验本身就是一切，日常活动被搁置。",
        "完全的效應；體驗本身就是一切，日常活動被擱置。",
    ),
    "How is it going?": ("现在感觉如何？", "現在感覺如何？"),
    "How was it, overall?": ("整体感觉如何？", "整體感覺如何？"),
    "Markdown — notes with T+ offsets": (
        "Markdown——带 T+ 偏移的笔记",
        "Markdown——帶 T+ 偏移的筆記",
    ),
    "Mood": ("心情", "心情"),
    "Not recorded": ("未记录", "未記錄"),
    "Removes the descriptor": ("移除描述词", "移除描述詞"),
    "Search effects": ("搜索效应", "搜尋效應"),
    'Shulgin & Shulgin, PiHKAL: A Chemical Love Story (1991), "The Shulgin Rating Scale".': (
        "Shulgin & Shulgin，《PiHKAL: A Chemical Love Story》(1991)，“The Shulgin Rating Scale”。",
        "Shulgin & Shulgin，《PiHKAL: A Chemical Love Story》(1991)，「The Shulgin Rating Scale」。",
    ),
    "Shulgin scale": ("舒尔金量表", "舒爾金量表"),
    "Stimulated": ("兴奋", "興奮"),
    "T+30 m, 1 h, 2 h, 4 h, 6 h": (
        "T+30 分、1 时、2 时、4 时、6 时",
        "T+30 分、1 時、2 時、4 時、6 時",
    ),
    "The Apple Health sample nearest this time.": (
        "最接近此时间的 Apple 健康样本。",
        "最接近此時間的 Apple 健康樣本。",
    ),
    "The Shulgin Rating Scale": ("舒尔金评级量表", "舒爾金評級量表"),
    "Threshold — a real effect, its nature not yet clear.": (
        "阈值——真实的效应，性质尚不清楚。",
        "閾值——真實的效應，性質尚不清楚。",
    ),
    "Trip Report": (
        "体验报告",
        "體驗報告",
    ),
    "Unmistakable effect and duration; ordinary activity possible but disinclined.": (
        "效应和持续时间清晰无误；可进行日常活动但不太想做。",
        "效應和持續時間清晰無誤；可進行日常活動但不太想做。",
    ),
    "What do you notice?": ("你注意到了什么？", "你注意到了什麼？"),
    "Use shared effect descriptors to record what you noticed and find it later.": (
        "用统一的效应描述词记录你的感受，方便之后查找。",
        "用統一的效應描述詞記錄你的感受，方便之後尋找。",
    ),
    "%@ due": ("%@ 待服", "%@ 待服"),
    "%@ is": ("%@ 是", "%@ 是"),
    "%@ since %@": ("距%2$@ %1$@", "距%2$@ %1$@"),
    "Add Label": ("添加标签", "新增標籤"),
    "Add Label…": ("添加标签…", "新增標籤…"),
    "Add Shortcut": ("添加快捷方式", "新增捷徑"),
    "Add Shortcut…": ("添加快捷方式…", "新增捷徑…"),
    "Dock Label": ("底栏标签", "底欄標籤"),
    "Dock Shortcuts": ("底栏快捷方式", "底欄捷徑"),
    "Edit Label": ("编辑标签", "編輯標籤"),
    "Kind": ("类型", "類型"),
    "Meds Due": ("待服药物", "待服藥物"),
    "Next: %@ in %@": ("下次：%@，%@ 后", "下次：%@，%@ 後"),
    "Opens Log with that substance and its usual dose filled in. Tap Log to record it.": (
        "打开“记录”并填入该物质及其常用剂量。点按“记录”才会保存。",
        "開啟「記錄」並填入該物質及其常用劑量。點按「記錄」才會儲存。",
    ),
    "Shown while the time is inside this range. A range ending before it starts wraps past midnight.": (
        "在此时间范围内显示；结束早于开始则跨越午夜。",
        "在此時間範圍內顯示；結束早於開始則跨越午夜。",
    ),
    "Shows “2 due”, or the med’s name when exactly one is due. Otherwise, shows the next applicable label.": (
        "显示“2 项到时间”，只有一种用药到时间时则显示药名。否则显示下一个适用的标签。",
        "顯示「2 項到時間」，只有一種用藥到時間時則顯示藥名。否則顯示下一個適用的標籤。",
    ),
    "Since last dose": ("距上次剂量", "距上次劑量"),
    "Stage a Substance": ("预置物质", "預置物質"),
    "Text": ("文本", "文字"),
    "The first label that applies is shown. When none does, the dock shows “—”.": (
        "显示第一个适用的标签；都不适用时显示“——”。",
        "顯示第一個適用的標籤；都不適用時顯示「——」。",
    ),
    "Timed Text": ("定时文本", "定時文字"),
    "Timer": ("计时", "計時"),
    "Until": ("到", "到"),
    "Until next med": ("距下次药物", "距下次藥物"),
    "Up to %lld characters.": ("最多 %lld 个字符。", "最多 %lld 個字元。"),
    "Up to three, shown at the left of the dock.": (
        "最多三个，显示在底栏左侧。",
        "最多三個，顯示在底欄左側。",
    ),
    "“2 due”, or the med’s name when one is due": (
        "“2 项待服”，或仅一项时的药名",
        "「2 項待服」，或僅一項時的藥名",
    ),
    "%@ is due": ("%@ 该服用了", "%@ 該服用了"),
    "%@ · %lld days left": ("%@ · 剩余 %lld 天", "%@ · 剩餘 %lld 天"),
    "Add Title…": ("添加标题…", "新增標題…"),
    "By Category": ("按类别", "按類別"),
    "By Substance": ("按物质", "按物質"),
    "Grouped": ("分组", "分組"),
    "Hides this notice": ("隐藏此提示", "隱藏此提示"),
    "Next: %@ at %@": ("下一次：%@，%@", "下一次：%@，%@"),
    "Opens the restock form": ("打开补货表单", "開啟補貨表單"),
    "Rename…": ("重命名…", "重新命名…"),
    "Share Report": ("分享报告", "分享報告"),
    "Yesterday's %@ wasn't logged": ("昨天的%@未记录", "昨天的%@未記錄"),
    "Yesterday's afternoon dose of %@ wasn't logged": (
        "昨天下午的%@剂量未记录",
        "昨天下午的%@劑量未記錄",
    ),
    "Yesterday's evening dose of %@ wasn't logged": (
        "昨天晚上的%@剂量未记录",
        "昨天晚上的%@劑量未記錄",
    ),
    "Yesterday's morning dose of %@ wasn't logged": (
        "昨天早上的%@剂量未记录",
        "昨天早上的%@劑量未記錄",
    ),
    "Yesterday's night dose of %@ wasn't logged": (
        "昨天夜间的%@剂量未记录",
        "昨天夜間的%@劑量未記錄",
    ),
    "Compact Entries": ("紧凑条目", "緊湊項目"),
    "Show Timeline Axis": ("显示时间轴", "顯示時間軸"),
    "%@ mL": ("%@ 毫升", "%@ 毫升"),
    "%@ pieces": ("%@ 件", "%@ 件"),
    "%lld lines read": ("已读取 %lld 行", "已讀取 %lld 行"),
    "Add to Inventory": ("加入库存", "加入庫存"),
    "Barcode": ("条码", "條碼"),
    "Barcode read · %@": ("已读取条码 · %@", "已讀取條碼 · %@"),
    "Barcode recognized · %@": ("已识别条码 · %@", "已識別條碼 · %@"),
    "Barcodes are matched offline against the US and French registries the app ships with. Anything else resolves by name.": (
        "条码离线匹配 App 内置的美国和法国药品登记数据；其他情况按名称解析。",
        "條碼離線比對 App 內建的美國和法國藥品登記資料；其他情況按名稱解析。",
    ),
    "Brand": ("品牌", "品牌"),
    "Capsule": ("胶囊", "膠囊"),
    "Identify": ("识别", "識別"),
    "Identify a Box": ("识别药盒", "識別藥盒"),
    "In the library": ("在资料库中", "在資料庫中"),
    "Liquid": ("液体", "液體"),
    "Log This": ("记录此项", "記錄此項"),
    "Not in the library": (
        "不在物质库中",
        "不在物質庫中",
    ),
    "No match in Piru's database, and no medication name could be read clearly enough to search.": (
        "Piru 的数据库中没有匹配项，也未能清楚识别出可用于搜索的药品名称。",
        "Piru 的資料庫中沒有符合項目，也未能清楚辨識出可用於搜尋的藥品名稱。",
    ),
    "No match in Piru's database. Look up “%@” elsewhere:": (
        "Piru 的数据库中没有匹配项。到其他来源查找“%@”：",
        "Piru 的資料庫中沒有符合項目。到其他來源查找「%@」：",
    ),
    "Couldn't read any text clearly.": (
        "未能清楚识别任何文字。",
        "未能清楚辨識任何文字。",
    ),
    "Pack size": ("包装规格", "包裝規格"),
    "Pieces": ("件", "件"),
    "Point at any medication box to see what's inside it": (
        "对准任意药盒，查看里面是什么",
        "對準任意藥盒，查看裡面是什麼",
    ),
    "Point at the box — name, strength, barcode": (
        "对准药盒——名称、规格、条码",
        "對準藥盒——名稱、規格、條碼",
    ),
    "Point the camera at a medication box — the brand, the printed name, or the barcode — and Piru opens what it knows about the substance inside: the pharmacology, the doses on record, the interactions.": (
        "把相机对准药盒——品牌、印刷名称或条码——Piru 会打开它对其中物质的了解：药理、已记录的剂量、相互作用。",
        "把相機對準藥盒——品牌、印刷名稱或條碼——Piru 會開啟它對其中物質的了解：藥理、已記錄的劑量、交互作用。",
    ),
    "Read from the box": ("从药盒读取", "從藥盒讀取"),
    "Scan Another": ("再扫一个", "再掃一個"),
    "Scan a Box": ("扫描药盒", "掃描藥盒"),
    "Scan a box": ("扫描药盒", "掃描藥盒"),
    "Scanning isn't available on this device.": ("此设备不支持扫描。", "此裝置不支援掃描。"),
    "Search PubChem": ("搜索 PubChem", "搜尋 PubChem"),
    "Search Wikipedia": ("搜索维基百科", "搜尋維基百科"),
    "Tablet": ("片剂", "錠劑"),
    "What a box says is what is shown. Not medical advice.": (
        "显示的即为药盒所印内容。非医疗建议。",
        "顯示的即為藥盒所印內容。非醫療建議。",
    ),
    "What is this box?": ("这是什么药盒？", "這是什麼藥盒？"),
    "confident": ("确定", "確定"),
    "probable": ("可能", "可能"),
    "unrecognized": ("未识别", "未識別"),
    # b46 feedback batches (2026-09-01)
    "Backups, export & import are under Tools › Data & Backup; preferences are under Settings.": (
        "备份、导出与导入在“工具 › 数据与备份”；偏好设置在“设置”。",
        "備份、匯出與匯入在「工具 › 資料與備份」；偏好設定在「設定」。",
    ),
    "· %lld of %lld": ("· 已服 %1$lld / %2$lld", "· 已服 %1$lld / %2$lld"),
    "%lld of %lld logged today": ("今天已记录 %1$lld / %2$lld", "今天已記錄 %1$lld / %2$lld"),
    "Colors": ("颜色", "顏色"),
    "A color for every substance you log": (
        "为你记录的每种物质配一个颜色",
        "為你記錄的每種物質配一個顏色",
    ),
    "Export, import, and encrypted backups": ("导出、导入与加密备份", "匯出、匯入與加密備份"),
    "Which source wins when they disagree.": (
        "来源冲突时以哪个为准。",
        "來源衝突時以哪個為準。",
    ),
    "Tap a dot to name it": ("点一下圆点显示名称", "點一下圓點顯示名稱"),
    "Name on plot": ("在图上显示名称", "在圖上顯示名稱"),
    "%@, this substance": ("%@，当前物质", "%@，目前物質"),
    "%@, measured in the same study": ("%@，同一研究中测得", "%@，同一研究中測得"),
    # Unified timeline (Journal → Active Now / Timeline grouping)
    "No Entries Yet": (
        "还没有记录",
        "還沒有記錄",
    ),
    "Projected · %@": (
        "预测 · %@",
        "預測 · %@",
    ),
    "Effect curves": (
        "效应曲线",
        "效應曲線",
    ),
    "Body load (PK)": (
        "体内负荷（药代）",
        "體內負荷（藥動）",
    ),
    "Display Options": (
        "显示选项",
        "顯示選項",
    ),
    "Previous Year": (
        "上一年",
        "上一年",
    ),
    "Next Year": (
        "下一年",
        "下一年",
    ),
    # The three category floors rewritten so they stop asserting an efficacy or a
    # generation for every member they describe (7-OH read "Full Agonist" above its own
    # partial-agonist rows).
    "μ-Opioid Receptor Ligand": (
        "μ-阿片受体配体",
        "μ-鴉片受體配體",
    ),
    "Acts at μ-opioid receptors (MOR), G-protein coupled receptors distributed throughout the central and peripheral nervous system. MOR activation inhibits adenylyl cyclase, opens inwardly rectifying potassium channels, and closes voltage-gated calcium channels, reducing neuronal excitability and neurotransmitter release — producing analgesia, euphoria, respiratory depression, and slowed gastrointestinal transit. How far this particular compound activates the receptor, and whether it also engages κ or δ, is not characterized here; the receptor panel below carries whatever has been measured for it.": (
        "作用于 μ-阿片受体（MOR）——一类分布于中枢与外周神经系统的 G 蛋白偶联受体。MOR 激活会抑制腺苷酸环化酶、开放内向整流钾通道并关闭电压门控钙通道，降低神经元兴奋性与神经递质释放，产生镇痛、欣快、呼吸抑制以及胃肠蠕动减慢。此处未说明该化合物对受体的激活程度，也未说明它是否同时作用于 κ 或 δ；下方的受体面板列出的是已实测到的数据。",
        "作用於 μ-鴉片受體（MOR）——一類分布於中樞與周邊神經系統的 G 蛋白偶聯受體。MOR 活化會抑制腺苷酸環化酶、開放內向整流鉀通道並關閉電壓閘控鈣通道，降低神經元興奮性與神經傳導物質釋放，產生鎮痛、欣快、呼吸抑制以及胃腸蠕動減慢。此處未說明該化合物對受體的活化程度，也未說明它是否同時作用於 κ 或 δ；下方的受體面板列出的是已實測到的資料。",
    ),
    "Antipsychotic (Dopamine Receptor Antagonist)": (
        "抗精神病药（多巴胺受体拮抗剂）",
        "抗精神病藥（多巴胺受體拮抗劑）",
    ),
    "Blocks dopamine D2 receptors in the mesolimbic pathway, reducing positive psychotic symptoms. Whether this compound also carries the 5-HT2A antagonism that distinguishes the second-generation agents, and the histamine, muscarinic and adrenergic activity that drives sedation and orthostasis, varies across the class and is not characterized here.": (
        "阻断中脑边缘通路的多巴胺 D2 受体，减轻精神病性阳性症状。该化合物是否同时具有区分第二代药物的 5-HT2A 拮抗作用，以及导致镇静与体位性低血压的组胺、毒蕈碱与肾上腺素能活性，在同类药物中各不相同，此处未作说明。",
        "阻斷中腦邊緣通路的多巴胺 D2 受體，減輕精神病性陽性症狀。該化合物是否同時具有區分第二代藥物的 5-HT2A 拮抗作用，以及導致鎮靜與姿勢性低血壓的組織胺、蕈毒鹼與腎上腺素能活性，在同類藥物中各不相同，此處未作說明。",
    ),
    "Histamine H1 Receptor Antagonist": (
        "组胺 H1 受体拮抗剂",
        "組織胺 H1 受體拮抗劑",
    ),
    "Blocks histamine H1 receptors, reducing the itching, flare, wheal and vasodilation of the histamine response. Whether this compound crosses into the central nervous system — the difference between a sedating first-generation antihistamine with a muscarinic load and a peripherally selective second-generation one — is not characterized here.": (
        "阻断组胺 H1 受体，减轻组胺反应中的瘙痒、红晕、风团与血管扩张。该化合物是否进入中枢神经系统——这正是具有毒蕈碱负荷、会引起嗜睡的第一代抗组胺药与外周选择性的第二代抗组胺药之间的区别——此处未作说明。",
        "阻斷組織胺 H1 受體，減輕組織胺反應中的搔癢、紅暈、風疹塊與血管擴張。該化合物是否進入中樞神經系統——這正是具有蕈毒鹼負荷、會引起嗜睡的第一代抗組織胺藥與周邊選擇性的第二代抗組織胺藥之間的區別——此處未作說明。",
    ),
    # The methamphetamine class-mechanism description — the one MOA template literal that was
    # never translated, found when the class prose moved into the bundled DB.
    # The opioid converter's picker label for transdermal fentanyl: fentanyl shares
    # one substance row across every route, so the route is what disambiguates it.
    "%@ (transdermal)": (
        "%@（透皮贴）",
        "%@（經皮貼片）",
    ),
    # Why the converter will not convert methadone. CDC 2022 does publish a single
    # factor (4.7) for population-level accounting; Piru declines to use it, so the
    # copy states Piru's choice rather than a claim about CDC.
    "Methadone's half-life is long and variable, and its peak effect on breathing arrives later and lasts longer than its peak pain relief — so a converted dose can look adequate while the risk is still building. CDC publishes a single factor for population-level accounting; Piru will not use it to convert a dose. This one belongs to a clinician.": (
        "美沙酮的半衰期长且个体差异大，对呼吸的最强抑制出现得比镇痛高峰更晚、持续更久——因此换算出的剂量看起来足够时，风险可能仍在累积。CDC 确实公布了一个用于人群统计的换算系数，但 Piru 不会用它来换算剂量。这一项应交由临床医生处理。",
        "美沙酮的半衰期長且個體差異大，對呼吸的最強抑制出現得比鎮痛高峰更晚、持續更久——因此換算出的劑量看起來足夠時，風險可能仍在累積。CDC 確實公布了一個用於人群統計的換算係數，但 Piru 不會用它來換算劑量。這一項應交由臨床醫師處理。",
    ),
    # Why transdermal fentanyl cannot share the mg-based table.
    # Why buprenorphine is excluded from MME entirely.
    # The signalling cascade's own label in the pharmacology card, so it does
    # not read as a second mechanism description.
    "Downstream": ("下游", "下游"),
    # Shown in place of "Fully eliminated" when no half-life is known, so an
    # unmodelable dose is not reported as gone.
    "No half-life data": (
        "无半衰期数据",
        "無半衰期資料",
    ),
    # Contraindication flag labels — Piru's own wording for a normalized
    # label contraindication (see Piru/Domain/ContraindicationFlag.swift).
    "Urinary retention": ("尿潴留", "尿滯留"),
    "Children": ("儿童", "兒童"),
    "Patterns": ("规律", "規律"),
    "Days used, exposure, dose trend, and overlap": (
        "用药天数、暴露、剂量趋势与重叠",
        "用藥天數、暴露、劑量趨勢與重疊",
    ),
    # Reports & Export hub (Insights → Reports)
    "Reports": ("报告", "報告"),
    "Latest": ("最近", "最近"),
    "By Date": ("按日期", "按日期"),
    "Select sessions": (
        "选择场次",
        "選擇場次",
    ),
    "Select Sessions": (
        "选择场次",
        "選擇場次",
    ),
    "%lld of %lld sessions": (
        "%lld / %lld 个场次",
        "%lld / %lld 個場次",
    ),
    "Session Images": (
        "场次图片",
        "場次圖片",
    ),
    "Stitched Image": ("拼接图片", "拼接圖片"),
    "All selected sessions in one tall image": (
        "所有选中的场次合成为一张长图",
        "所有選取的場次合成為一張長圖",
    ),
    "Plain-text session data — for notes, AI, or records": (
        "纯文本场次数据——用于笔记、AI 或存档",
        "純文字場次資料——用於筆記、AI 或存檔",
    ),
    "· %lld entries": ("· %lld 条记录", "· %lld 條記錄"),
    "%lld sessions as individual images": (
        "%lld 个场次导出为单独图片",
        "%lld 個場次匯出為單獨圖片",
    ),
    "Sessions in this range as individual images": (
        "此范围内的场次导出为单独图片",
        "此範圍內的場次匯出為單獨圖片",
    ),
    "Nothing to Summarize": ("暂无可汇总内容", "暫無可彙總內容"),
    "Nothing logged in this range.": ("此范围内没有记录。", "此範圍內沒有記錄。"),
    "Days used": ("用药天数", "用藥天數"),
    "of %lld days": ("共 %lld 天", "共 %lld 天"),
    "of days": ("天数占比", "天數占比"),
    "longest break": ("最长间断", "最長間斷"),
    "since last": ("距上次", "距上次"),
    "Cumulative exposure": ("累积暴露", "累積暴露"),
    "Benzodiazepines ≈ %@ mg diazepam-eq/day": (
        "苯二氮䓬类 ≈ %@ mg 地西泮当量/天",
        "苯二氮平類 ≈ %@ mg 地西泮當量/天",
    ),
    "Opioids: peak day ≈ %@ MME": ("阿片类：单日峰值 ≈ %@ MME", "鴉片類：單日峰值 ≈ %@ MME"),
    "Average %@ MME/day over the range": ("此范围内平均 %@ MME/天", "此範圍內平均 %@ MME/天"),
    "%@: %@ %@ total": ("%@：共 %@ %@", "%@：共 %@ %@"),
    "Dose trend": ("剂量趋势", "劑量趨勢"),
    "steady": ("平稳", "平穩"),
    "rising": ("上升", "上升"),
    "falling": ("下降", "下降"),
    "%@: dose %@, %@": ("%@：剂量%@，%@", "%@：劑量%@，%@"),
    "Active together": ("同时活跃", "同時活躍"),
    "%@ and %@: %@ active together": ("%@ 与 %@：同时活跃 %@", "%@ 與 %@：同時活躍 %@"),
    "MME": ("MME", "MME"),
    "mg diazepam-eq": ("mg 地西泮当量", "mg 地西泮當量"),
    "common doses": ("常见剂量", "常見劑量"),
    "In your body over time": ("体内留存变化", "體內留存變化"),
    "Nothing to Model": ("暂无可建模数据", "暫無可建模資料"),
    "None of the chosen substances have a modeled curve in this range": (
        "所选物质在此范围内都没有可建模的曲线",
        "所選物質在此範圍內都沒有可建模的曲線",
    ),
    "None of your logged substances in this range have a modeled elimination curve.": (
        "此范围内记录的物质都没有可建模的消除曲线。",
        "此範圍內記錄的物質都沒有可建模的消除曲線。",
    ),
    "A model estimate, not a measurement. What's in your body and what you feel don't always line up.": (
        "模型估算，非实测。体内留存与体感并不总是一致。",
        "模型估算，非實測。體內留存與體感並不總是一致。",
    ),
    "Nothing in your body at this time": ("此刻体内没有留存", "此刻體內沒有留存"),
    "When and how much you log": ("你在何时、记录了多少", "你在何時、記錄了多少"),
    "What's still active in your body right now": (
        "此刻体内仍在起作用的物质",
        "此刻體內仍在起作用的物質",
    ),
    "How body-load has moved over time": ("体内留存随时间的变化", "體內留存隨時間的變化"),
    "Receptor load over time": ("受体负荷变化", "受體負荷變化"),
    "Receptor Load": ("受体负荷", "受體負荷"),
    "How hard each mechanism has been driven over time": (
        "各机制随时间被驱动的程度",
        "各機制隨時間被驅動的程度",
    ),
    "None of your logged substances in this range drive a modeled mechanism.": (
        "此范围内记录的物质都不驱动任何可建模的机制。",
        "此範圍內記錄的物質都不驅動任何可建模的機制。",
    ),
    "Nothing driven at this time": ("此刻没有被驱动的机制", "此刻沒有被驅動的機制"),
    "Toggles this mechanism's line": ("切换该机制的曲线", "切換該機制的曲線"),
    "Steady state": ("稳态", "穩態"),
    "Where a regular dose settles, from your own cadence": (
        "按你自己的节奏，规律剂量最终稳定在何处",
        "按你自己的節奏，規律劑量最終穩定在何處",
    ),
    "Plateau": ("平台", "平台"),
    "Buildup": ("累积", "累積"),
    "Reaches": ("达到", "達到"),
    "Between doses": ("两次用药之间", "兩次用藥之間"),
    "about daily": ("约每天", "約每天"),
    "about every 2 days": ("约每2天", "約每2天"),
    "<1 day": ("不到1天", "不到1天"),
    "clears, no buildup": ("清除，无累积", "清除，無累積"),
    "every ~%lld h": ("约每 %lld 小时", "約每 %lld 小時"),
    "every ~%@ days": ("约每 %@ 天", "約每 %@ 天"),
    "Accumulation curve for %@": ("%@ 的累积曲线", "%@ 的累積曲線"),
    "Plateaus around %@, %@× one dose, reached in %@": (
        "稳定在约 %@，为单次剂量的 %@ 倍，在 %@ 内达到",
        "穩定在約 %@，為單次劑量的 %@ 倍，在 %@ 內達到",
    ),
    "Clears between doses; each peaks around %@": (
        "两次用药之间清除；每次峰值约 %@",
        "兩次用藥之間清除；每次峰值約 %@",
    ),
    "%@ now at %@ %@": ("%@ 现为 %@ %@", "%@ 現為 %@ %@"),
    "%@ now at %@": ("%@ 现为 %@", "%@ 現為 %@"),
    # ---- Steady State tool (Aug 2026) ----
    "Steady State": ("稳态", "穩態"),
    "Where a repeated dose settles, and when": (
        "重复用药最终稳定在何处，以及需要多久",
        "重複用藥最終穩定在何處，以及需要多久",
    ),
    "Dose each time": ("每次剂量", "每次劑量"),
    "Taken every": ("用药间隔", "用藥間隔"),
    "Every 4 hours": ("每 4 小时", "每 4 小時"),
    "Every 6 hours": ("每 6 小时", "每 6 小時"),
    "Every 8 hours": ("每 8 小时", "每 8 小時"),
    "Every 12 hours": ("每 12 小时", "每 12 小時"),
    "Once daily": ("每天一次", "每天一次"),
    "Twice daily": ("每天两次", "每天兩次"),
    "Steady state by": ("达到稳态", "達到穩態"),
    "fully settled in %@": (
        "%@ 后完全稳定",
        "%@ 後完全穩定",
    ),
    "Accumulation": ("蓄积", "蓄積"),
    "at the peak, vs. one dose": ("峰值时，相对于单次剂量", "峰值時，相對於單次劑量"),
    "Plateau range": ("平台范围", "平台範圍"),
    "%@ · trough to peak": ("%@ · 谷值到峰值", "%@ · 谷值到峰值"),
    "Fluctuation": ("波动", "波動"),
    "smooth": ("平稳", "平穩"),
    "moderate swing": ("中等波动", "中等波動"),
    "spiky": ("起伏大", "起伏大"),
    "days": ("天", "天"),
    "Climbs from one dose to a steady-state range of %@ to %@ %@, reached in about %lld days": (
        "从单次剂量上升到 %@ 到 %@ %@ 的稳态范围，约 %lld 天达到",
        "從單次劑量上升到 %@ 到 %@ %@ 的穩態範圍，約 %lld 天達到",
    ),
    "Taking this daily? See where the level settles": (
        "每天服用？看看会稳定在何处",
        "每天服用？看看會穩定在何處",
    ),
    # ---- Benzo effect ladder + occupancy / withdrawal (Aug 2026) ----
    "%lld days": ("%lld 天", "%lld 天"),
    "Muscle relaxation": ("肌肉松弛", "肌肉鬆弛"),
    "Coordination": ("协调", "協調"),
    "About %lld%% of your recent peak GABA-A load right now, summed across everything active.": (
        "当前 GABA-A 负荷约为近期峰值的 %lld%%，已合并计入所有仍在起效的物质。",
        "目前 GABA-A 負荷約為近期峰值的 %lld%%，已合併計入所有仍在起效的物質。",
    ),
    "GABA-A receptor load over time": (
        "随时间变化的 GABA-A 受体负荷",
        "隨時間變化的 GABA-A 受體負荷",
    ),
    "Estimating how much is still in your system…": (
        "正在估算你体内还剩多少……",
        "正在估算你體內還剩多少……",
    ),
    "Your modeled GABA-A load has essentially cleared — past the point where the drug itself is still leaving your system. The bands below say when symptoms tend to follow.": (
        "你的 GABA-A 负荷模型显示已基本清除——药物本身已过了仍在离开体内的阶段。下方的区间表示症状通常何时随之出现。",
        "你的 GABA-A 負荷模型顯示已基本清除——藥物本身已過了仍在離開體內的階段。下方的區間表示症狀通常何時隨之出現。",
    ),
    "Effect-selective tolerance": ("效应选择性耐受", "效應選擇性耐受"),
    "Some effects fade, others don't": ("有些效应会减弱，有些不会", "有些效應會減弱，有些不會"),
    "For most drugs every effect tolerizes together. Benzodiazepines are the exception: sedation fades almost completely in about two weeks, while the anxiety relief, memory impairment and loss of coordination barely change. That's why the benzodiazepine card shows an effect ladder instead of one bar.": (
        "对大多数药物来说，所有效应会一起产生耐受。苯二氮䓬是个例外：镇静作用大约在两周内几乎完全减弱，而抗焦虑、记忆损害和协调能力下降却几乎不变。这就是为什么苯二氮䓬卡片显示的是效应阶梯，而不是单一条形。",
        "對大多數藥物來說，所有效應會一起產生耐受。苯二氮平是個例外：鎮靜作用大約在兩週內幾乎完全減弱，而抗焦慮、記憶損害和協調能力下降卻幾乎不變。這就是為什麼苯二氮平卡片顯示的是效應階梯，而不是單一條形。",
    ),
    "Why — the receptor comes in subtypes": ("原因——受体分为多种亚型", "原因——受體分為多種亞型"),
    "GABA-A is built from several α-subtypes that adapt at different rates. α1 carries sedation and desensitizes (it uncouples, then the receptors are pulled from the synapse); α5 is required for that sedative tolerance to develop at all; α2 and α3, which carry the anxiety relief, don't adapt. So the dose that no longer makes you sleepy impairs your memory and coordination exactly as much as it did on day one — which is how tolerance quietly drives the dose up.": (
        "GABA-A 由多种 α 亚型构成，它们以不同的速度适应。α1 负责镇静并会脱敏（先解偶联，随后受体被从突触中移除）；α5 是镇静耐受得以形成的必要条件；而负责抗焦虑的 α2 和 α3 并不适应。因此，那个不再让你困倦的剂量，对记忆和协调能力的损害与第一天完全一样——耐受就是这样悄悄把剂量推高的。",
        "GABA-A 由多種 α 亞型構成，它們以不同的速度適應。α1 負責鎮靜並會脫敏（先解偶聯，隨後受體被從突觸中移除）；α5 是鎮靜耐受得以形成的必要條件；而負責抗焦慮的 α2 和 α3 並不適應。因此，那個不再讓你睏倦的劑量，對記憶和協調能力的損害與第一天完全一樣——耐受就是這樣悄悄把劑量推高的。",
    ),
    "Why these effects differ": ("这些效应为何不同", "這些效應為何不同"),
    # ---- Custom units (Settings) ----
    "Custom Units": ("自定义单位", "自訂單位"),
    "No Custom Units": ("暂无自定义单位", "尚無自訂單位"),
    "Add Custom Unit": ("添加自定义单位", "新增自訂單位"),
    "Edit Custom Unit": ("编辑自定义单位", "編輯自訂單位"),
    "unit": ("单位", "單位"),
    "1 %@ =": ("1 %@ =", "1 %@ ="),
    "Unit label (e.g. capsule)": ("单位名称（如 胶囊）", "單位名稱（如 膠囊）"),
    'This substance already has a "%@" unit.': (
        "该物质已有“%@”单位。",
        "此物質已有「%@」單位。",
    ),
    "Logs in this unit convert to the mass automatically.": (
        "以该单位记录时会自动换算为质量。",
        "以此單位記錄時會自動換算為質量。",
    ),
    'Define a unit like "1 capsule = 30 mg" and it appears in the dose picker for that substance — log half a capsule, get 15 mg.': (
        "定义一个单位，例如“1 胶囊 = 30 mg”，它就会出现在该物质的剂量选择器中——记录半个胶囊，即得 15 mg。",
        "定義一個單位，例如「1 膠囊 = 30 mg」，它就會出現在該物質的劑量選擇器中——記錄半個膠囊，即得 15 mg。",
    ),
    # ---- Approximate dose flag ----
    "Approximate amount": ("近似用量", "近似用量"),
    "Unknown amount": ("用量未知", "用量未知"),
    "unknown amount": ("用量未知", "用量未知"),
    "Logs the dose with no number; it stays out of curves, totals, and tolerance.": (
        "不记录数值；这条记录不会计入曲线、总量和耐受性。",
        "不記錄數值；這條記錄不會計入曲線、總量和耐受性。",
    ),
    "Logged with no number — stays out of curves, totals, and tolerance.": (
        "已记录，但未填数值——不计入曲线、总量和耐受性。",
        "已記錄，但未填數值——不計入曲線、總量和耐受性。",
    ),
    "Shows the dose with a ~; the estimate still drives the curves.": (
        "剂量会显示为 ~；这个估计值仍会用于绘制曲线。",
        "劑量會顯示為 ~；這個估計值仍會用於繪製曲線。",
    ),
    "approximately %@ %@": ("大约 %@ %@", "大約 %@ %@"),
    # ---- Label scanner (camera → QuickLog) ----
    "Regular": ("常规", "常規"),
    # QuickLog "Form" pill accessibility label — the isomer × release form selector.
    "Formulation": ("剂型", "劑型"),
    # QuickLog brand picker — release group + niche-brand submenu.
    "Extended-release": ("缓释", "緩釋"),
    "More…": ("更多…", "更多…"),
    "Scan a label": ("扫描标签", "掃描標籤"),
    "Close scanner": ("关闭扫描", "關閉掃描"),
    "Point at a barcode or label, then tap a highlighted area": (
        "对准条形码或标签，然后轻点高亮区域",
        "對準條碼或標籤，然後輕點醒目提示的區域",
    ),
    "Add to Log": ("添加到记录", "新增至記錄"),
    "Scan Again": ("重新扫描", "重新掃描"),
    "No match": ("无匹配", "無匹配"),
    "Point the camera at the printed drug name.": (
        "将相机对准印刷的药品名称。",
        "將相機對準印刷的藥品名稱。",
    ),
    "Camera Access Needed": ("需要相机权限", "需要相機權限"),
    "Scanning Unavailable": ("无法扫描", "無法掃描"),
    "Enable camera access in Settings to scan medication labels.": (
        "在“设置”中允许相机访问以扫描药品标签。",
        "在「設定」中允許相機存取以掃描藥品標籤。",
    ),
    "Label scanning isn't available on this device.": (
        "此设备不支持标签扫描。",
        "此裝置不支援標籤掃描。",
    ),
    # ---------------------------------------------------------------
    # I.ref — GABA withdrawal reference card (WithdrawalReferenceView).
    # Population-level relapse/rebound/withdrawal taxonomy + onset bands.
    # ---------------------------------------------------------------
    'What stopping looks like, at the population level — three things people call "withdrawal" that behave differently, and roughly when each starts for drugs like the ones you\'ve logged. Timing is from research populations, not a prediction for you.': (
        "从群体层面看停药会怎样——人们所说的“戒断”其实包含三种表现不同的情况，以及对于你记录过的这类药物，每种大约何时开始。这些时间来自研究人群，并非对你个人的预测。",
        "從群體層面看停藥會怎樣——人們所說的「戒斷」其實包含三種表現不同的情況，以及對於你記錄過的這類藥物，每種大約何時開始。這些時間來自研究人群，並非對你個人的預測。",
    ),
    "long-acting": ("长效", "長效"),
    "intermediate": ("中效", "中效"),
    "short-acting": ("短效", "短效"),
    # ---------------------------------------------------------------
    # Live Activity timer labels — orphaned in PiruLiveActivityExtension's own
    # catalog, so they shipped English to zh users on the Lock Screen.
    # Four parallel lanes merged 2026-08-03: class signatures (Lane A),
    # Insights > Usage v2 (Lane B), med-time consequence + heavy-tier band
    # + combination metabolites (Lane D), Sources ledger (Lane E).
    # ---------------------------------------------------------------
    # ---- Lane A — class signatures on the substance detail screen ----
    "Efficacy axis": ("效能轴", "效能軸"),
    "Measurement basis": ("测量基准", "測量基準"),
    "Release EC₅₀": ("释放 EC₅₀", "釋放 EC₅₀"),
    "Functional EC₅₀": ("功能 EC₅₀", "功能 EC₅₀"),
    "Reuptake IC₅₀": ("再摄取 IC₅₀", "再攝取 IC₅₀"),
    "Binding Kᵢ": ("结合 Kᵢ", "結合 Kᵢ"),
    "release EC₅₀": ("释放 EC₅₀", "釋放 EC₅₀"),
    "functional EC₅₀": ("功能 EC₅₀", "功能 EC₅₀"),
    "reuptake-inhibition IC₅₀": ("再摄取抑制 IC₅₀", "再攝取抑制 IC₅₀"),
    "binding Kᵢ": ("结合 Kᵢ", "結合 Kᵢ"),
    "inhibition IC₅₀": ("抑制 IC₅₀", "抑制 IC₅₀"),
    "efficacy τ": ("效能 τ", "效能 τ"),
    "intrinsic activity": ("内在活性", "內在活性"),
    "Emax": ("Emax", "Emax"),
    "Full agonist": ("完全激动剂", "完全促效劑"),
    "Partial agonist": ("部分激动剂", "部分促效劑"),
    "no activation": ("无激活", "無活化"),
    "full activation": ("完全激活", "完全活化"),
    "full activation · %@": ("完全激活 · %@", "完全活化 · %@"),
    "mixed species": ("混合物种", "混合物種"),
    "one panel": ("同一组实验", "同一組實驗"),
    "one study": ("同一研究", "同一研究"),
    "across studies": ("跨研究", "跨研究"),
    "different study": ("不同研究", "不同研究"),
    "nothing comparable to rank it against": ("没有可比对象供排序", "沒有可比對象供排序"),
    "perception": ("感知", "感知"),
    "body": ("身体", "身體"),
    "balanced": ("均衡", "均衡"),
    "%@ to %@ balance": ("%1$@ 与 %2$@ 的平衡", "%1$@ 與 %2$@ 的平衡"),
    "%@ vs %@": ("%1$@ 对 %2$@", "%1$@ 對 %2$@"),
    "%@ at %@": ("%1$@ 于 %2$@", "%1$@ 於 %2$@"),
    "Transporter potency share": ("转运体效价占比", "轉運體效價占比"),
    # ---- Lane B — Insights › Usage, eight analytical sections ----
    "This period": ("本期", "本期"),
    "1Y": ("1年", "1年"),
    "Activity heatmap": ("活动热力图", "活動熱力圖"),
    "Day of week": ("星期分布", "星期分佈"),
    "Hour of day": ("时段分布", "時段分佈"),
    "Hour": ("小时", "小時"),
    "Bucket": ("区间", "區間"),
    "Selected": ("已选中", "已選取"),
    "Trend": ("趋势", "趨勢"),
    "Per week": ("每周", "每週"),
    "%@/wk": ("%@/周", "%@/週"),
    "Dose levels": ("剂量档位", "劑量檔位"),
    "Dose levels over time": ("剂量档位随时间变化", "劑量檔位隨時間變化"),
    "Substance trends": ("物质趋势", "物質趨勢"),
    "Regularity": ("规律性", "規律性"),
    "Used together": ("同时使用", "同時使用"),
    "Very regular": ("非常规律", "非常規律"),
    "Somewhat regular": ("较为规律", "較為規律"),
    "Irregular": ("不规律", "不規律"),
    "Sporadic": ("零星", "零星"),
    "Hidden": ("已隐藏", "已隱藏"),
    "Entries per week, 7-day rolling average": (
        "每周条目数，7 天滚动平均",
        "每週條目數，7 天滾動平均",
    ),
    "Entries per week, 4-week rolling average": (
        "每周条目数，4 周滚动平均",
        "每週條目數，4 週滾動平均",
    ),
    "Common doses per week, 7-day rolling average": (
        "每周中等剂量数，7 天滚动平均",
        "每週中等劑量數，7 天滾動平均",
    ),
    "Common doses per week, 4-week rolling average": (
        "每周中等剂量数，4 周滚动平均",
        "每週中等劑量數，4 週滾動平均",
    ),
    "Common doses": (
        "中等剂量",
        "中等劑量",
    ),
    "Common doses per day": (
        "每天中等剂量数",
        "每天中等劑量數",
    ),
    "Common-dose units by weekday, most on %@": (
        "按星期统计的中等剂量单位，%@ 最多",
        "按星期統計的中等劑量單位，%@ 最多",
    ),
    "No common dose defined for these substances": (
        "这些物质未定义中等剂量",
        "這些物質未定義中等劑量",
    ),
    "No common dose defined": (
        "未定义中等剂量",
        "未定義中等劑量",
    ),
    "Common-dose units count each dose as a multiple of its common dose. %lld of %lld substances have one.": (
        "中等剂量单位将每次剂量按其中等剂量的倍数计。已定义：%lld / %lld 种物质。",
        "中等劑量單位將每次劑量按其中等劑量的倍數計。已定義：%lld / %lld 種物質。",
    ),
    "%@ common-dose units across %lld entries": (
        "%@ 个中等剂量单位，共 %lld 条目",
        "%@ 個中等劑量單位，共 %lld 條目",
    ),
    "Most active: %@": ("最活跃：%@", "最活躍：%@"),
    "%lld new this period": ("本期新增 %lld 种", "本期新增 %lld 種"),
    "at common or above": (
        "达到中等或以上",
        "達到中等或以上",
    ),
    "at common or above · %lld heavy": (
        "达到中等或以上 · %lld 次大剂量",
        "達到中等或以上 · %lld 次大劑量",
    ),
    "Based on %lld of %lld entries with dose data": (
        "基于 %2$lld 条条目中有剂量数据的 %1$lld 条",
        "基於 %2$lld 筆條目中有劑量資料的 %1$lld 筆",
    ),
    "No dose ladders matched": ("没有匹配的剂量阶梯", "沒有匹配的劑量階梯"),
    "No dose levels resolved": ("未能解析出剂量档位", "未能解析出劑量檔位"),
    "No entries in the previous period": ("上一期没有条目", "上一期沒有條目"),
    "No entries in this window": ("此时间范围内没有条目", "此時間範圍內沒有條目"),
    "Nothing logged in this window": ("此时间范围内没有记录", "此時間範圍內沒有記錄"),
    "No pairs in this class": ("此类别下没有组合", "此類別下沒有組合"),
    "Nothing in This Range": ("此范围内没有数据", "此範圍內沒有資料"),
    "Pick a longer time range to see your history.": (
        "选择更长的时间范围以查看历史记录。",
        "選擇更長的時間範圍以查看歷史記錄。",
    ),
    "Not enough history yet": ("历史记录还不够", "歷史記錄還不夠"),
    "Show all %lld": ("显示全部 %lld 项", "顯示全部 %lld 項"),
    "Show fewer": ("收起", "收起"),
    "Clear selected day": ("清除所选日期", "清除所選日期"),
    "every %@ days": ("每 %@ 天一次", "每 %@ 天一次"),
    "up %lld percent": ("上升百分之 %lld", "上升百分之 %lld"),
    "down %lld percent": ("下降百分之 %lld", "下降百分之 %lld"),
    "↑ %lld%% vs previous %@": ("↑ %1$lld%% 相比上一个%2$@", "↑ %1$lld%% 相比上一個%2$@"),
    "↓ %lld%% vs previous %@": ("↓ %1$lld%% 相比上一个%2$@", "↓ %1$lld%% 相比上一個%2$@"),
    "%@ entries across seven equal slices of the period.": (
        "按本期七等分统计的 %@ 条条目。",
        "按本期七等分統計的 %@ 筆條目。",
    ),
    "%@ entries per day": ("每日 %@ 条条目", "每日 %@ 筆條目"),
    "%@ entries per day, most active on %@": (
        "每日 %1$@ 条条目，%2$@最活跃",
        "每日 %1$@ 筆條目，%2$@最活躍",
    ),
    "%lld entries": ("%lld 条记录", "%lld 筆記錄"),
    "%lld distinct substances": ("%lld 种不同物质", "%lld 種不同物質"),
    "%lld distinct substances, %lld new this period": (
        "%1$lld 种不同物质，本期新增 %2$lld 种",
        "%1$lld 種不同物質，本期新增 %2$lld 種",
    ),
    "%lld entries, %@ versus the previous period": (
        "%1$lld 条条目，较上一期%2$@",
        "%1$lld 筆條目，較上一期%2$@",
    ),
    "%lld entries, busiest around %@": (
        "%1$lld 条条目，%2$@前后最密集",
        "%1$lld 筆條目，%2$@前後最密集",
    ),
    "%@ common-dose units, busiest around %@": (
        "%1$@ 个中等剂量单位，%2$@前后最密集",
        "%1$@ 個中等劑量單位，%2$@前後最密集",
    ),
    "%@ common-dose units": (
        "%@ 个中等剂量单位",
        "%@ 個中等劑量單位",
    ),
    "%lld entries, busiest on %@ with %lld": (
        "%1$lld 条条目，%2$@最多，共 %3$lld 条",
        "%1$lld 筆條目，%2$@最多，共 %3$lld 筆",
    ),
    "%lld entries: %@": ("%1$lld 条条目：%2$@", "%1$lld 筆條目：%2$@"),
    "%lld percent of %lld placed doses were common or above, %lld heavy": (
        "在 %2$lld 次可定位的剂量中，百分之 %1$lld 达到中等或以上，其中 %3$lld 次为大剂量",
        "在 %2$lld 次可定位的劑量中，百分之 %1$lld 達到中等或以上，其中 %3$lld 次為大劑量",
    ),
    "No entries could be placed on a dose ladder": (
        "没有条目能对应到剂量阶梯",
        "沒有條目能對應到劑量階梯",
    ),
    "%lld days together, %lld percent of the days either was logged": (
        "共同出现 %1$lld 天，占任一方被记录天数的百分之 %2$lld",
        "共同出現 %1$lld 天，佔任一方被記錄天數的百分之 %2$lld",
    ),
    "%@, about every %@ days across %lld entries": (
        "%1$@，%3$lld 条条目中大约每 %2$@ 天一次",
        "%1$@，%3$lld 筆條目中大約每 %2$@ 天一次",
    ),
    "%@ rising to %@ per week": ("%1$@ 上升至每周 %2$@", "%1$@ 上升至每週 %2$@"),
    "%@ falling to %@ per week": ("%1$@ 下降至每周 %2$@", "%1$@ 下降至每週 %2$@"),
    "%@ steady at %@ per week": ("%1$@ 稳定在每周 %2$@", "%1$@ 穩定在每週 %2$@"),
    "%@ rising to %@ per day": ("%1$@ 上升至每天 %2$@", "%1$@ 上升至每天 %2$@"),
    "%@ falling to %@ per day": ("%1$@ 下降至每天 %2$@", "%1$@ 下降至每天 %2$@"),
    "%@ steady at %@ per day": ("%1$@ 稳定在每天 %2$@", "%1$@ 穩定在每天 %2$@"),
    "%@ with %@": ("%1$@ 与 %2$@", "%1$@ 與 %2$@"),
    "%@ %lld percent": ("%1$@ 百分之 %2$lld", "%1$@ 百分之 %2$lld"),
    "%lld %@": ("%1$lld %2$@", "%1$lld %2$@"),
    "%lld. %@": ("%1$lld. %2$@", "%1$lld. %2$@"),
    "%lld/%lld": ("%1$lld/%2$lld", "%1$lld/%2$lld"),
    "Entries by hour of day": ("按时段统计的条目", "按時段統計的條目"),
    "Days with entries are listed one by one. Select a day to filter the hour chart below.": (
        "有条目的日期会逐一列出。选择某一天可筛选下方的时段图表。",
        "有條目的日期會逐一列出。選擇某一天可篩選下方的時段圖表。",
    ),
    "Toggles this substance's line": ("切换该物质的曲线显示", "切換該物質的曲線顯示"),
    # ---- Lane D — med times, heavy-tier band, combination metabolites ----
    "Kicks in ~%@": ("约 %@ 起效", "約 %@ 起效"),
    "Kicks in ~%@ · easing off ~%@": (
        "约 %1$@ 起效 · 约 %2$@ 开始消退",
        "約 %1$@ 起效 · 約 %2$@ 開始消退",
    ),
    "Clear for sleep ~%@": ("约 %@ 消退，不影响睡眠", "約 %@ 消退，不影響睡眠"),
    "Clear for sleep ~%@ — after most bedtimes.": (
        "约 %@ 后才不再影响入睡——晚于多数人的就寝时间。",
        "約 %@ 後才不再影響入睡——晚於多數人的就寢時間。",
    ),
    "heavy": ("大剂量", "大劑量"),
    "This curve reaches the heavy dose range": ("此曲线达到大剂量区间", "此曲線達到大劑量區間"),
    "Formed With": ("联合生成", "聯合生成"),
    "A third compound your body makes from this dose and something else in the session — not from either alone.": (
        "你的身体用这次剂量和本场中的另一种物质生成的第三种化合物——单独任何一种都不会产生。",
        "你的身體用這次劑量和本場中的另一種物質生成的第三種化合物——單獨任何一種都不會產生。",
    ),
    # ---- Lane E — Sources screen ledger ----
    "dose": ("剂量", "劑量"),
    "duration": ("持续时间", "持續時間"),
    "effects": ("效应", "效應"),
    "overview": ("概述", "概述"),
    "pharmacology": ("药理学", "藥理學"),
    "pharmacokinetics": ("药代动力学", "藥物動力學"),
    "tolerance": ("耐受性", "耐受性"),
    "prescribing": ("处方信息", "處方資訊"),
    "interactions": ("相互作用", "相互作用"),
    "chemistry": ("化学", "化學"),
    "names & tags": ("名称与标签", "名稱與標籤"),
    "supplies %@": ("提供 %@", "提供 %@"),
    "licensed %@": ("授权协议 %@", "授權條款 %@"),
    "Each row lists what that source supplied here. Links open the source's own page — always verify against the original.": (
        "每一行列出该来源在此提供的内容。链接会打开来源自身的页面——请始终对照原始资料核实。",
        "每一行列出該來源在此提供的內容。連結會開啟來源自身的頁面——請始終對照原始資料核實。",
    ),
    # Substance-detail round 5 (2026-08-01) — dose/effects split, the dose-source
    # comparison sheet, the folded Prescribing card, and the Log CTA under the
    # dose card.
    "Log this": ("记录这次", "記錄這次"),
    "Fewer": ("收起", "收起"),
    "Dose sources": ("剂量来源", "劑量來源"),
    "In use": ("使用中", "使用中"),
    "About metabolites": ("关于代谢物", "關於代謝物"),
    "Compare all %lld sources": ("对比全部 %lld 个来源", "對比全部 %lld 個來源"),
    "%@ · %lld sources": ("%1$@ · %2$lld 个来源", "%1$@ · %2$lld 個來源"),
    "Every bar is drawn on the same scale. Piru shows the source you rank highest.": (
        "所有条形按同一刻度绘制。Piru 显示你排序最高的来源。",
        "所有長條按同一刻度繪製。Piru 顯示你排序最高的來源。",
    ),
    "%@ · %@ · %lld sources": ("%1$@ · %2$@ · %3$lld 个来源", "%1$@ · %2$@ · %3$lld 個來源"),
    # TestFlight feedback round, build 33 (2026-07-27) — card overflow menu.
    "More actions": ("更多操作", "更多操作"),
    # Substance-detail redesign v2 (proto8/proto10) — header chips, dose card,
    # bar-first pharmacology, tappable metabolites (2026-07-24).
    "+ %lld chemical names": ("+ %lld 个化学名称", "+ %lld 個化學名稱"),
    "Also known as %@.": ("又称 %@。", "又稱 %@。"),
    "Also known as %@, and %lld other names.": (
        "又称 %@，以及另外 %lld 个名称。",
        "又稱 %@，以及另外 %lld 個名稱。",
    ),
    "Effect over time: rises over the come-up, plateaus at peak, then falls.": (
        "效果随时间变化：在上升期逐渐增强，在高峰期保持平稳，随后减弱。",
        "效果隨時間變化：在上升期逐漸增強，在高峰期保持平穩，隨後減弱。",
    ),
    "Duration of action": ("作用持续时间", "作用持續時間"),
    "Acts on": ("作用靶点", "作用標靶"),
    "reuptake": ("再摄取", "再攝取"),
    "via %@": ("经 %@", "經 %@"),
    "Opens %@": ("打开 %@", "打開 %@"),
    # Inventory manager: collapsible class sections + class arrangement (2026-07-21).
    "Arrange Classes": ("排列类别", "排列類別"),
    "Arrange Classes…": ("排列类别…", "排列類別…"),
    "Collapse All": ("全部折叠", "全部折疊"),
    "Expand All": ("全部展开", "全部展開"),
    "Double tap to collapse": ("轻点两下以折叠", "點兩下以折疊"),
    "Double tap to expand": ("轻点两下以展开", "點兩下以展開"),
    "Drag to set the order class sections appear in. Reset to let the current sort decide.": (
        "拖动以设置类别分区的显示顺序。重置后将由当前排序方式决定。",
        "拖動以設定類別分區的顯示順序。重置後將由目前排序方式決定。",
    ),
    # Inventory manager: search, sort, filter, group-by-class (2026-07-21).
    "Search Inventory": ("搜索库存", "搜尋庫存"),
    "Sort By": ("排序方式", "排序方式"),
    "Supply Level": ("存量水平", "存量水準"),
    "Recently Updated": ("最近更新", "最近更新"),
    "Manual": ("手动", "手動"),
    "Group by Class": ("按类别分组", "按類別分組"),
    "Status": ("状态", "狀態"),
    "Class": ("类别", "類別"),
    "In Stock": ("有库存", "有庫存"),
    "Remove filter": ("移除筛选", "移除篩選"),
    "No Matching Items": ("无匹配项目", "無符合項目"),
    "No tracked substance matches the current search and filters.": (
        "没有符合当前搜索和筛选条件的追踪物质。",
        "沒有符合目前搜尋與篩選條件的追蹤物質。",
    ),
    # Source-priority screen rework (2026-07-19).
    "Reset": ("重置", "重置"),
    "When several sources report the same fact — a dose, a duration — Piru shows the one nearest the top. Drag to set which you trust most.": (
        "当多个来源报告同一事实（如剂量、时长）时，Piru 会显示最靠上的那个。拖动以设置你最信任的来源。",
        "當多個來源報告同一事實（如劑量、時長）時，Piru 會顯示最靠上的那個。拖動以設定你最信任的來源。",
    ),
    "%@, priority %lld": (
        "%1$@，优先级 %2$lld",
        "%1$@，優先順序 %2$lld",
    ),
    # Source-attribution explainer + priority surfacing (2026-07-19).
    "Shown from": ("显示来源", "顯示來源"),
    "Why this source": ("为何选此来源", "為何選此來源"),
    "Shown": ("采用", "採用"),
    "Also has this": ("也有此项", "也有此項"),
    "Manage source priority": (
        "管理来源优先级",
        "管理來源優先順序",
    ),
    "Where this comes from": (
        "这些来自哪里",
        "這些來自哪裡",
    ),
    "Source Priority": (
        "来源优先级",
        "來源優先順序",
    ),
    "Piru shows the highest-priority source you've enabled that has this data — and you choose the order.": (
        "Piru 会显示你已启用的、拥有该数据的最高优先级来源——顺序由你决定。",
        "Piru 會顯示你已啟用的、擁有該資料的最高優先順序來源——順序由你決定。",
    ),
    "Higher-priority sources that don't list this field are skipped.": (
        "优先级更高但未提供此项的来源会被跳过。",
        "優先順序更高但未提供此項的來源會被跳過。",
    ),
    "Open %@ page": ("打开 %@ 页面", "開啟 %@ 頁面"),
    "Explains why this source was used and lets you reorder sources": (
        "说明为何采用此来源，并可重新排序来源",
        "說明為何採用此來源，並可重新排序來源",
    ),
    # Share-card redesign — effects-mode toggle + effects section (2026-07-19).
    "Minimal": ("简约", "簡約"),
    "Standard": ("标准", "標準"),
    "Rich": ("详尽", "詳盡"),
    "EFFECT OVER TIME": ("效应时程", "效應時程"),
    "Most common effects · by dose": ("最常见效应 · 按剂量", "最常見效應 · 按劑量"),
    "release": ("释放", "釋放"),
    "uptake": ("再摄取", "再攝取"),
    "Reported effects": ("报告的效应", "報告的效應"),
    "Most reported": ("最多报告", "最多報告"),
    # Notifications management screen — unified per-type toggles (2026-07-17).
    "Pause All Notifications": ("暂停所有通知", "暫停所有通知"),
    "Silences everything without losing your choices below.": (
        "静音全部通知，但保留你在下方的选择。",
        "靜音全部通知，但保留你在下方的選擇。",
    ),
    "Safety & Supplies": ("安全与库存", "安全與庫存"),
    "Session Alerts": (
        "场次提醒",
        "場次提醒",
    ),
    "All on": ("全部开启", "全部開啟"),
    "All off": ("全部关闭", "全部關閉"),
    "Comedown": (
        "下头",
        "下頭",
    ),
    "Hydration": ("补水", "補水"),
    "Sleep": ("睡眠", "睡眠"),
    "Phase": ("阶段", "階段"),
    "Re-ask %lld": ("第 %lld 次再问", "第 %lld 次再問"),
    "Add Re-ask": (
        "添加再次提醒",
        "新增再次提醒",
    ),
    "Remove Last": ("移除最后一个", "移除最後一個"),
    "5 min": ("5 分钟", "5 分鐘"),
    "10 min": ("10 分钟", "10 分鐘"),
    "15 min": ("15 分钟", "15 分鐘"),
    "20 min": ("20 分钟", "20 分鐘"),
    "30 min": ("30 分钟", "30 分鐘"),
    "45 min": ("45 分钟", "45 分鐘"),
    "60 min": ("60 分钟", "60 分鐘"),
    "Reminders fire at each med's times. Quiet meds share one reminder per time of day. Logging a dose clears its follow-ups.": (
        "提醒按每种药物的设定时间触发。静默用药在每个时段共用一条提醒。记录剂量后后续提醒自动取消。",
        "提醒按每種藥物的設定時間觸發。靜默用藥在每個時段共用一則提醒。記錄劑量後後續提醒自動取消。",
    ),
    "Timed from the typical onset and duration of each dose you log, for its substance and route. These are estimates from published data — Piru doesn't sense anything.": (
        "按你记录的每一剂所属物质和给药途径，根据典型的起效时间和持续时间计时。这些是基于已发表数据的估算——Piru 并不检测你身上的任何东西。",
        "按你記錄的每一劑所屬物質和給藥途徑，根據典型的起效時間和持續時間計時。這些是基於已發表資料的估算——Piru 並不偵測你身上的任何東西。",
    ),
    "Totals include scheduled meds, as-needed doses, and everything else.": (
        "总量包括定时用药、按需用药及其他所有剂量。",
        "總量包括定時用藥、按需用藥及其他所有劑量。",
    ),
    "If a dose isn't logged, ask again after these intervals. Applies to every med. A med can override or opt out in its own settings.": (
        "如果一剂还未记录，就按这些间隔再次提醒。适用于所有用药。每种用药都可以在自己的设置中更改或关闭。",
        "如果一劑還未記錄，就按這些間隔再次提醒。適用於所有用藥。每種用藥都可以在自己的設定中更改或關閉。",
    ),
    "Notifications Enabled": ("通知已开启", "通知已開啟"),
    "Notifications Are Off": ("通知已关闭", "通知已關閉"),
    "Allow Notifications": ("允许通知", "允許通知"),
    "Asking…": ("正在请求…", "正在請求…"),
    "Checking Permission…": ("正在检查权限…", "正在檢查權限…"),
    "Next: %@": ("下一次：%@", "下一次：%@"),
    "Hydration Reminders": ("补水提醒", "補水提醒"),
    "Sleep Reminders": ("睡眠提醒", "睡眠提醒"),
    "Phase Alerts": ("阶段提醒", "階段提醒"),
    "Cumulative Dose Warnings": ("累积剂量警告", "累積劑量警告"),
    "Low Stock Alerts": ("低库存提醒", "低庫存提醒"),
    "Timing cues at onset, come-up, and peak so you can anchor what you feel to the timeline.": (
        "在起效、上升期和高峰期时给出时间提示，让你把感受对应到时间线上。",
        "在起效、上升期和高峰期時給出時間提示，讓你把感受對應到時間線上。",
    ),
    "A heads-up when something you track runs low or out — before the empty bottle surprises you.": (
        "当你追踪的物品所剩不多或已用完时提前提醒——别等到瓶子空了才发现。",
        "當你追蹤的物品所剩不多或已用完時提前提醒——別等到瓶子空了才發現。",
    ),
    "Notification Settings": ("通知设置", "通知設定"),
    # Notifications Stage 3+4 — occurrences, next-dose, quiet hours, actions,
    # progressive onboarding (2026-07-18).
    "Next-dose window reminder": (
        "下一剂时段提醒",
        "下一劑時段提醒",
    ),
    "Next-dose window — %@": (
        "下一剂时段——%@",
        "下一劑時段——%@",
    ),
    "Quiet Hours": ("勿扰时段", "勿擾時段"),
    "Start time": ("开始时间", "開始時間"),
    "End time": ("结束时间", "結束時間"),
    "Start": ("开始", "開始"),
    "End": ("结束", "結束"),
    "Skip Today": ("今天跳过", "今天跳過"),
    "Notifications, your pick": ("通知，由你决定", "通知，由你決定"),
    "Choose what Piru may send. Everything stays adjustable in Settings, switch by switch.": (
        "选择 Piru 可以发送的内容。所有开关之后都能在设置中逐一调整。",
        "選擇 Piru 可以傳送的內容。所有開關之後都能在設定中逐一調整。",
    ),
    "Never miss a dose": ("不漏掉任何一剂", "不漏掉任何一劑"),
    "Reminders at each routine's time — and, if you want, a gentle re-ask a little later, like snooze.": (
        "在每个日常设定的时间提醒你——如果需要，稍后还会像闹钟稍后提醒一样轻轻再问一次。",
        "在每個日常設定的時間提醒你——如果需要，稍後還會像鬧鐘稍後提醒一樣輕輕再問一次。",
    ),
    "During a session": (
        "场次进行中",
        "場次進行中",
    ),
    "Hydration and wind-down nudges, wearing-off alerts, and onset/peak timing cues while something is active.": (
        "在有物质起效期间，提供补水与放松提醒、药效消退警示，以及起效/高峰期时间提示。",
        "在有物質起效期間，提供補水與放鬆提醒、藥效消退警示，以及起效/高峰期時間提示。",
    ),
    "A safety net": ("一道安全网", "一道安全網"),
    "A heads-up if one substance's daily total climbs into a heavy range, or tracked stock runs low.": (
        "当某一物质的当日总量攀升至大剂量范围，或追踪的库存不足时提醒你。",
        "當某一物質的當日總量攀升至大劑量範圍，或追蹤的庫存不足時提醒你。",
    ),
    "Enable Selected": ("开启所选", "開啟所選"),
    # Snooze-style routine follow-up reminders (2026-07-17).
    "Time Sensitive": ("时效性通知", "時效性通知"),
    "Time Sensitive notifications can break through Focus modes and the notification summary. Turn off any you'd rather have wait.": (
        "时效性通知可以突破专注模式和通知摘要。不希望立即送达的可以在这里关闭。",
        "時效性通知可以突破專注模式和通知摘要。不希望立即送達的可以在這裡關閉。",
    ),
    "Ask Again": ("再次提醒", "再次提醒"),
    "Calibrated": ("已校准", "已校準"),
    "%lld min later": ("%lld 分钟后", "%lld 分鐘後"),
    "%lld h later": ("%lld 小时后", "%lld 小時後"),
    "%lld h %lld m later": ("%1$lld 小时 %2$lld 分后", "%1$lld 小時 %2$lld 分後"),
    "Releaser": ("释放剂", "釋放劑"),
    "Reference dose": ("参考剂量", "參考劑量"),
    "Species": ("物种", "物種"),
    "µ-opioid drive": ("µ-阿片受体驱动", "µ-鴉片受體驅動"),
    "GABA-A drive": ("GABA-A 驱动", "GABA-A 驅動"),
    "start": ("起始", "起始"),
    # Pill picker — branded fixed-strength meds logged as tablets/capsules (2026-07-17).
    "extended-release": ("缓释", "緩釋"),
    "immediate-release": ("速释", "速釋"),
    "depot": ("长效", "長效"),
    "%@ tablet": ("%@ 片", "%@ 片"),
    "%@ tablets": ("%@ 片", "%@ 片"),
    "%@ capsule": ("%@ 粒", "%@ 粒"),
    "%@ capsules": ("%@ 粒", "%@ 粒"),
    "Custom milligrams": ("自定义毫克", "自訂毫克"),
    "Fewer pills": ("减少药片", "減少藥片"),
    "More pills": ("增加药片", "增加藥片"),
    "Quantity": ("数量", "數量"),
    # Apple Health vitals overlay — heart rate / blood pressure on sessions (2026-07-06).
    "Heart rate": ("心率", "心率"),
    "Blood pressure": ("血压", "血壓"),
    "Connect Apple Health": ("连接“健康”App", "連接「健康」App"),
    # Apple Health onboarding step redesign (2026-07-07).
    "Synced from Apple Health — check the number looks right.": (
        "已从“健康”同步——请确认数值无误。",
        "已從「健康」同步——請確認數值無誤。",
    ),
    "Couldn't read a weight from Health. Set it above instead.": (
        "无法从“健康”读取体重，请在上方手动设置。",
        "無法從「健康」讀取體重，請在上方手動設定。",
    ),
    "Connecting…": ("连接中…", "連線中…"),
    "Alcohol": ("酒精", "酒精"),
    "A couple of drinks, with the heart rate a watch recorded alongside.": (
        "两杯酒，以及手表同时记录的心率。",
        "兩杯酒，以及手錶同時記錄的心率。",
    ),
    "Example chart: an alcohol effect curve with heart rate rising and falling alongside it.": (
        "示例图表：酒精效应曲线，心率随之起伏。",
        "範例圖表：酒精效應曲線，心率隨之起伏。",
    ),
    # Unified Apple Health settings + session vitals discovery banner (2026-07-07).
    "Dismiss": ("关闭", "關閉"),
    "See your heart rate here": ("在这里查看你的心率", "在這裡查看你的心率"),
    "Turn On Apple Health": ("开启“健康”", "開啟「健康」"),
    # Redesigned unified Apple Health settings — weight footnotes by source (2026-07-07).
    "Synced from Apple Health. Your weight sizes every dose estimate — the same dose hits harder the less you weigh.": (
        "已从“健康”同步。体重决定每项剂量估算——越轻，同样的剂量作用越强。",
        "已從「健康」同步。體重決定每項劑量估算——越輕，同樣的劑量作用越強。",
    ),
    "Entered manually. Your weight sizes every dose estimate — the same dose hits harder the less you weigh.": (
        "已手动输入。体重决定每项剂量估算——越轻，同样的剂量作用越强。",
        "已手動輸入。體重決定每項劑量估算——越輕，同樣的劑量作用越強。",
    ),
    "Using the average 60 kg. Set yours above so estimates fit your body — the same dose hits harder the less you weigh.": (
        "正使用平均值 60 kg。在上方设置你的体重，让估算贴合你自己——越轻，同样的剂量作用越强。",
        "正使用平均值 60 kg。在上方設定你的體重，讓估算貼合你自己——越輕，同樣的劑量作用越強。",
    ),
    "Use the average (60 kg)": ("使用平均值（60 kg）", "使用平均值（60 kg）"),
    "Show heart data on sessions": (
        "在场次中显示心脏数据",
        "在場次中顯示心臟資料",
    ),
    "Heart data": (
        "心脏数据",
        "心臟資料",
    ),
    "On": ("开", "開"),
    "Off": ("关", "關"),
    "avg %lld · peak %lld bpm": ("平均 %lld · 峰值 %lld bpm", "平均 %lld · 峰值 %lld bpm"),
    "%lld bpm": ("%lld bpm", "%lld bpm"),
    "Elevated vs your resting %lld bpm": ("高于静息心率 %lld bpm", "高於靜息心率 %lld bpm"),
    "Includes %lld min of workout — the dose rows leave it out": (
        "其中含 %lld 分钟锻炼——单次用药行已排除",
        "其中含 %lld 分鐘運動——單次用藥列已排除",
    ),
    "In line with your resting %lld bpm": ("与静息心率 %lld bpm 相当", "與靜息心率 %lld bpm 相當"),
    "Heart rate %lld rising to %lld beats per minute": (
        "心率 %lld，升至每分钟 %lld 次",
        "心率 %lld，升至每分鐘 %lld 次",
    ),
    "Heart rate %lld falling to %lld beats per minute": (
        "心率 %lld，降至每分钟 %lld 次",
        "心率 %lld，降至每分鐘 %lld 次",
    ),
    "Heart rate %lld beats per minute, no clear change": (
        "心率每分钟 %lld 次，无明显变化",
        "心率每分鐘 %lld 次，無明顯變化",
    ),
    "overlaps %@": ("与 %@ 重叠", "與 %@ 重疊"),
    # Share sheet previews + session image (2026-07-06).
    "Cumulative": ("累计", "累計"),
    "Image": ("图片", "圖片"),
    # Export any session (historical) — 2026-07-06.
    "Session Report": (
        "场次报告",
        "場次報告",
    ),
    "Session Data": (
        "场次数据",
        "場次資料",
    ),
    "View session image": (
        "查看场次图片",
        "查看場次圖片",
    ),
    "Tap to edit": ("轻点编辑", "輕點編輯"),
    # Consolidated "Share Session" sheet + entry points (2026-07-05).
    "Share Session": (
        "分享场次",
        "分享場次",
    ),
    "Share session": (
        "分享场次",
        "分享場次",
    ),
    "Session Image": (
        "场次图片",
        "場次圖片",
    ),
    "PDF": ("PDF", "PDF"),
    "Markdown": ("Markdown", "Markdown"),
    "Share": ("分享", "分享"),
    "Share Current State…": ("分享当前状态…", "分享目前狀態…"),
    "Share Current State": ("分享当前状态", "分享目前狀態"),
    # Session state export — PDF report + Markdown (2026-07-05).
    "Session Snapshot": (
        "场次快照",
        "場次快照",
    ),
    "Generated": ("生成时间", "產生時間"),
    "Session started %@ · %@ in progress": (
        "场次开始于 %1$@ · %2$@ 进行中",
        "場次開始於 %1$@ · %2$@ 進行中",
    ),
    "Right now — subjective state": (
        "此刻——主观感受",
        "此刻——主觀感受",
    ),
    "Elimination": ("消除", "消除"),
    "Taken": ("摄入", "攝入"),
    "Skipped": ("已跳过", "已跳過"),
    "Skipped for today": ("今天已跳过", "今天已跳過"),
    "Intensity": ("强度", "強度"),
    "Next": ("下一阶段", "下一階段"),
    "baseline": ("基线", "基線"),
    "gone": ("已消除", "已消除"),
    "left in body": ("体内剩余", "體內剩餘"),
    "50% eliminated": ("消除 50%", "消除 50%"),
    "90% eliminated": ("消除 90%", "消除 90%"),
    "Effectively clear": ("基本清除", "基本清除"),
    "Sober": ("清醒", "清醒"),
    "zero-order": ("零级动力学", "零級動力學"),
    # Opioid Equivalence + Pharma Table + Insights/Education (2026-07-04) — CLI-added, not yet extracted.
    "Loading pharmacology…": ("正在加载药理学数据…", "正在載入藥理學資料…"),
    "Targets": ("靶点", "靶點"),
    "Potency": ("效价", "效價"),
    "Show": ("显示", "顯示"),
    "All substances": ("所有物质", "所有物質"),
    "PK columns": (
        "药代动力学列",
        "藥物動力學欄",
    ),
    "Filters and columns": (
        "筛选与列",
        "篩選與欄位",
    ),
    "mechanism of action": ("作用机制", "作用機制"),
    "primary receptor targets": ("主要受体靶点", "主要受體靶點"),
    "primary target potency": ("主要靶点效价", "主要靶點效價"),
    "Related": ("相关", "相關"),
    "Model a single dose's decay over time": (
        "模拟单次剂量随时间的衰减",
        "模擬單次劑量隨時間的衰減",
    ),
    "See what's active in your body right now": (
        "查看当前体内仍活跃的物质",
        "查看當前體內仍活躍的物質",
    ),
    "entries": ("条记录", "筆記錄"),
    "%@/day": ("%@/天", "%@/天"),
    "%lld in the last 14 days": ("过去 14 天共 %lld 次", "過去 14 天共 %lld 次"),
    "%@ this month": ("本月 %@", "本月 %@"),
    "This month's adherence calendar": ("本月依从性日历", "本月依從性日曆"),
    "No notable predicted tolerance right now": ("当前无明显的预测耐受", "當前無明顯的預測耐受"),
    "Morphine": ("吗啡", "嗎啡"),
    "Codeine": ("可待因", "可待因"),
    "Tramadol": ("曲马多", "曲馬多"),
    "Tapentadol": ("他喷他多", "他噴他多"),
    "Methadone": ("美沙酮", "美沙酮"),
    "Buprenorphine": ("丁丙诺啡", "丁丙諾啡"),
    "Convert a dose of one opioid to another through oral morphine milligram equivalents (MME), using the CDC 2022 conversion factors.": (
        "通过口服吗啡毫克当量（MME），使用 CDC 2022 换算系数，将一种阿片类药物的剂量换算为另一种。",
        "透過口服嗎啡毫克當量（MME），使用 CDC 2022 換算係數，將一種鴉片類藥物的劑量換算為另一種。",
    ),
    "≈ %@ mg oral morphine equivalent": ("≈ %@ mg 口服吗啡当量", "≈ %@ mg 口服嗎啡當量"),
    "This opioid can't be linearly converted — see the note below.": (
        "该阿片类药物无法进行线性换算——请参见下方说明。",
        "該鴉片類藥物無法進行線性換算——請參見下方說明。",
    ),
    "The target opioid can't be linearly converted — see the note below.": (
        "目标阿片类药物无法进行线性换算——请参见下方说明。",
        "目標鴉片類藥物無法進行線性換算——請參見下方說明。",
    ),
    "Pick two opioids and a dose.": (
        "请选择两种阿片类药物和一个剂量。",
        "請選擇兩種鴉片類藥物和一個劑量。",
    ),
    "When switching opioids, the equianalgesic dose is an over-estimate: tolerance to one opioid doesn't fully transfer to another. Clinicians start the new opioid **25–50% lower** than the calculated dose (more for high doses or frail/elderly people) and re-titrate. Never take the full converted dose.": (
        "更换阿片类药物时，等效镇痛剂量会被高估：对一种阿片类药物的耐受不会完全转移到另一种。临床医生会将新阿片类药物的起始剂量定为比计算值 **低 25–50%**（剂量高或体弱/年长者更低），再重新滴定。切勿直接服用完整的换算剂量。",
        "更換鴉片類藥物時，等效鎮痛劑量會被高估：對一種鴉片類藥物的耐受不會完全轉移到另一種。臨床醫生會將新鴉片類藥物的起始劑量定為比計算值 **低 25–50%**（劑量高或體弱/年長者更低），再重新滴定。切勿直接服用完整的換算劑量。",
    ),
    "Don't use alone and don't mix with other downers. An overdose is a sudden blackout with no warning — you can't naloxone yourself, so someone with you needs it and should call emergency services.": (
        "不要独自使用，也不要与其他抑制剂混用。过量会毫无预兆地突然失去意识——你无法给自己使用纳洛酮，因此身边的人需要备有纳洛酮，并应拨打急救电话。",
        "不要獨自使用，也不要與其他抑制劑混用。過量會毫無預兆地突然失去意識——你無法給自己使用納洛酮，因此身邊的人需要備有納洛酮，並應撥打急救電話。",
    ),
    "%lld%% tolerance": ("耐受 %lld%%", "耐受 %lld%%"),
    "Education": ("学习", "學習"),
    "How dosing, tolerance, and recovery work": (
        "了解给药、耐受与恢复的原理",
        "了解給藥、耐受與恢復的原理",
    ),
    "Expand": ("展开", "展開"),
    "%@ + %@": ("%@ + %@", "%@ + %@"),
    "Pharma Table": ("药理表格", "藥理表格"),
    "Search substances": ("搜索物质", "搜尋物質"),
    "Has half-life": ("有半衰期数据", "有半衰期資料"),
    "Sort by substance name": ("按物质名称排序", "按物質名稱排序"),
    "Sort by %@": ("按 %@ 排序", "按 %@ 排序"),
    "Not sorted": ("未排序", "未排序"),
    "Sorted ascending": ("升序排列", "升序排列"),
    "Sorted descending": ("降序排列", "降序排列"),
    "No substances match these filters.": (
        "没有物质符合这些筛选条件。",
        "沒有物質符合這些篩選條件。",
    ),
    "Tmax": ("Tmax", "Tmax"),
    "Cmax": ("Cmax", "Cmax"),
    "Vd": ("Vd", "Vd"),
    "half-life": ("半衰期", "半衰期"),
    "time to peak": ("达峰时间", "達峰時間"),
    "bioavailability": ("生物利用度", "生物利用度"),
    "maximum concentration": ("最高血药浓度", "最高血藥濃度"),
    "protein binding": ("血浆蛋白结合", "血漿蛋白結合"),
    "volume of distribution": ("分布容积", "分佈容積"),
    "clearance": ("清除率", "清除率"),
    "%@ h": ("%@ 小时", "%@ 小時"),
    "Convert opioid doses to morphine (MME)": (
        "将阿片类药物剂量换算为吗啡（MME）",
        "將鴉片類藥物劑量換算為嗎啡（MME）",
    ),
    "Why effects fade and how receptors recover": (
        "为何效果减弱以及受体如何恢复",
        "為何效果減弱以及受體如何恢復",
    ),
    "Browse pharmacokinetics for every substance": (
        "浏览每种物质的药代动力学",
        "瀏覽每種物質的藥物動力學",
    ),
    # Tolerance improvements (2026-07-02): stimulant CV two-mechanism copy (§6) + Insights card (§7).
    # Alcohol by-drink logging (2026-07-02) — preset list, steppers, a11y labels.
    "Drink": ("饮品", "飲品"),
    "Choose drink": ("选择饮品", "選擇飲品"),
    "Opens your drink presets": ("打开你的饮品预设", "開啟你的飲品預設"),
    "Fixed serving size": ("固定分量", "固定份量"),
    "Name (e.g. IPA)": ("名称（如 IPA）", "名稱（如 IPA）"),
    "Drink emoji": ("饮品表情", "飲品表情"),
    "Lower strength": ("降低浓度", "降低濃度"),
    "Raise strength": ("提高浓度", "提高濃度"),
    "Lower volume": ("减少容量", "減少容量"),
    "Raise volume": ("增加容量", "增加容量"),
    "· %@ std drinks": ("· %@ 标准杯", "· %@ 標準杯"),
    "Drink: %@": ("饮品：%@", "飲品：%@"),
    "Log %@, %@": ("记录 %@，%@", "記錄 %@，%@"),
    # Tolerance tool toolbar cleanup (2026-07-01) — Mail-style options menu + per-substance mode.
    # ("By mechanism" already lives in the tolerance-explainer block below — reused here.)
    "By substance": ("按物质", "按物質"),
    "Display options": ("显示选项", "顯示選項"),
    "Log a few doses and each substance's tolerance shows up here.": (
        "记录几次剂量后，每种物质的耐受性都会显示在这里。",
        "記錄幾次劑量後，每種物質的耐受性都會顯示在這裡。",
    ),
    "Show less": ("收起", "收起"),
    "Calculating each substance's contribution…": (
        "正在计算每种物质的贡献……",
        "正在計算每種物質的貢獻……",
    ),
    "Each card is that substance's own contribution. Mechanisms are shared, so your overall level (the chart above, or By mechanism) can be higher.": (
        "每张卡片是该物质自身的贡献。机制是共享的，所以你的整体水平（上方图表或“按机制”）可能更高。",
        "每張卡片是該物質自身的貢獻。機制是共享的，所以你的整體水平（上方圖表或「按機制」）可能更高。",
    ),
    # Onboarding redesign (2026-07-01): 8-step first-run flow — welcome, privacy, tour, depth, weight, reminders, import, done, tips.
    "Track what you take — and understand how it affects your body.": (
        "记录你摄入的一切——并了解它如何影响你的身体。",
        "記錄你攝入的一切——並了解它如何影響你的身體。",
    ),
    "Piru is built for sensitive data. Yours never leaves your device unless you choose.": (
        "Piru 专为敏感数据而打造。除非你选择，你的数据绝不会离开设备。",
        "Piru 專為敏感資料而打造。除非你選擇，你的資料絕不會離開裝置。",
    ),
    "Backups are opt-in and end-to-end encrypted with your key.": (
        "备份需你主动开启，并用你的密钥进行端到端加密。",
        "備份需你主動開啟，並用你的密鑰進行端到端加密。",
    ),
    "There are no ads and no trackers. Your data is yours alone.": (
        "没有广告，也没有追踪器。你的数据只属于你。",
        "沒有廣告，也沒有追蹤器。你的資料只屬於你。",
    ),
    "How much detail?": ("想看多少细节？", "想看多少細節？"),
    "Piru can keep it simple or go deep into the pharmacology. Change this anytime in Settings.": (
        "Piru 可以保持简洁，也可以深入药理。随时可在设置中更改。",
        "Piru 可以保持簡潔，也可以深入藥理。隨時可在設定中更改。",
    ),
    "Turning On…": ("正在开启…", "正在開啟…"),
    "Your data lives here": ("你的数据都在这里", "你的資料都在這裡"),
    "Not Now": ("暂不", "暫不"),
    "You're all set": ("一切就绪", "一切就緒"),
    "Live Activity, when you want it": ("需要时，随手开启实时活动", "需要時，隨手開啟即時動態"),
    "Start one from any active session to watch it on your Lock Screen.": (
        "从任何进行中的场次开启，即可在锁定屏幕上查看。",
        "從任何進行中的場次開啟，即可在鎖定畫面上查看。",
    ),
    "Track your stock": ("追踪你的库存", "追蹤你的庫存"),
    "Keep tabs on what you have on hand and get a heads-up when it runs low.": (
        "随时掌握你的现有量，库存不足时提醒你。",
        "隨時掌握你的現有量，庫存不足時提醒你。",
    ),
    "Back up anytime": ("随时备份", "隨時備份"),
    "Turn on end-to-end encrypted backups whenever you're ready.": (
        "准备好后，随时开启端到端加密备份。",
        "準備好後，隨時開啟端到端加密備份。",
    ),
    "Start Using Piru": ("开始使用 Piru", "開始使用 Piru"),
    "Log it in seconds": ("几秒即可记录", "幾秒即可記錄"),
    "Each dose appears on a timeline so you can see what's active — and when it fades.": (
        "每一剂都会显示在时间轴上，让你看清哪些物质正在起效，以及何时消退。",
        "每一劑都會顯示在時間軸上，讓你看清哪些物質正在起效，以及何時消退。",
    ),
    "1,500+ substances": ("1,500+ 种物质", "1,500+ 種物質"),
    "Browse by family — dosing, duration, effects, and interactions, sourced and cited.": (
        "按类别浏览——剂量、持续时间、效果与相互作用，皆有来源和引用。",
        "按類別瀏覽——劑量、持續時間、效果與相互作用，皆有來源與引用。",
    ),
    "Tools that have your back": ("为你保驾护航的工具", "為你保駕護航的工具"),
    "Check interactions, model tolerance, track your stock, and dose liquids safely.": (
        "检查相互作用、模拟耐受、追踪库存，并安全地量取液体剂量。",
        "檢查相互作用、模擬耐受、追蹤庫存，並安全地量取液體劑量。",
    ),
    "See your patterns": ("看清你的规律", "看清你的規律"),
    "Usage over time, times of day, and what's in your system right now — at a glance.": (
        "一目了然地查看长期用量、各时段分布，以及此刻体内的活性物质。",
        "一目了然地查看長期用量、各時段分佈，以及此刻體內的活性物質。",
    ),
    "Morning": ("上午", "上午"),
    "Afternoon": ("下午", "下午"),
    "Evening": ("晚上", "晚上"),
    "Night": ("夜间", "夜間"),
    "Half-Life": ("半衰期", "半衰期"),
    "Your body weight": ("你的体重", "你的體重"),
    "I'll Set This Later": ("稍后再设置", "稍後再設定"),
    "Continue": ("继续", "繼續"),
    "Bring your history": ("带上你的历史记录", "帶上你的歷史記錄"),
    "Already keep a journal? Import a Piru backup or a PsyLog-format export — or start with a clean slate.": (
        "已经在记录了？导入 Piru 备份或 PsyLog 格式的导出文件——或者从头开始。",
        "已經在記錄了？匯入 Piru 備份或 PsyLog 格式的匯出檔案——或者從頭開始。",
    ),
    "Import complete. Your data is ready.": (
        "导入完成，你的数据已就绪。",
        "匯入完成，你的資料已就緒。",
    ),
    "Piru backup": ("Piru 备份", "Piru 備份"),
    "Restore a full journal you exported from Piru.": (
        "恢复你从 Piru 导出的完整日记。",
        "還原你從 Piru 匯出的完整日記。",
    ),
    "PsyLog format": ("PsyLog 格式", "PsyLog 格式"),
    "Import from PsyLog or any app that shares its format — both old and new versions.": (
        "从 PsyLog 或任何使用该格式的应用导入——新旧版本均支持。",
        "從 PsyLog 或任何使用該格式的應用程式匯入——新舊版本皆支援。",
    ),
    "Start Fresh": ("从头开始", "從頭開始"),
    "Tap here any time to record what you've taken — it only takes a few seconds.": (
        "随时点这里记录你所摄入的——只需几秒钟。",
        "隨時點這裡記錄你所攝入的——只需幾秒鐘。",
    ),
    # Substance inventory tracking (2026-06-30): manager, detail, restock/edit forms, stock cards, widget.
    "Inventory": ("库存", "庫存"),
    "No Inventory Yet": ("还没有库存", "尚無庫存"),
    "Track a substance to see how much you have left as you log doses.": (
        "追踪某种物质，随着记录剂量查看剩余用量。",
        "追蹤某種物質，隨著記錄劑量查看剩餘用量。",
    ),
    "Track a Substance": ("追踪物质", "追蹤物質"),
    "Track Substance": ("追踪物质", "追蹤物質"),
    "Restock · %@": ("补充 · %@", "補充 · %@"),
    "Track · %@": ("追踪 · %@", "追蹤 · %@"),
    "Add Inventory Item": ("添加库存项目", "新增庫存項目"),
    "Track how much you have on hand": ("追踪你的现有用量", "追蹤你的現有用量"),
    "Starting amount": ("初始数量", "初始數量"),
    "Amount added": ("补充数量", "補充數量"),
    "Use as baseline": ("用作基准量", "用作基準量"),
    "Set as new baseline": ("设为新基准量", "設為新基準量"),
    "Marks the amount after this as a full supply, so the bar can show how full you are. Leave off if this isn't a full restock.": (
        "将此操作后的数量标记为满量，进度条便能显示你的充足程度。如果这不是一次补满，请关闭。",
        "將此操作後的數量標記為滿量，進度條便能顯示你的充足程度。如果這不是一次補滿，請關閉。",
    ),
    "Custom substance — its doses count by exact name match.": (
        "自定义物质——其剂量按名称精确匹配计入。",
        "自訂物質——其劑量按名稱精確匹配計入。",
    ),
    "Restock": ("补充", "補充"),
    "Track": ("追踪", "追蹤"),
    "Not tracked": ("未追踪", "未追蹤"),
    "On hand": ("现有量", "現有量"),
    "Baseline (100%)": (
        "基准量（100%）",
        "基準量（100%）",
    ),
    "Single dose": ("单次剂量", "單次劑量"),
    "Warn when below": ("低于此值时提醒", "低於此值時提醒"),
    "The exact amount you have now. Changing it is logged as a correction.": (
        "你当前的确切数量。修改后会记录为一次校正。",
        "你目前的確切數量。修改後會記錄為一次校正。",
    ),
    "The amount that counts as a full supply for the bar. Set to 0 to hide the bar.": (
        "作为进度条满量基准的数量。设为 0 可隐藏进度条。",
        "作為進度條滿量基準的數量。設為 0 可隱藏進度條。",
    ),
    "Used to show how many doses you have left. Set to 0 to disable.": (
        "用于显示你还剩多少次剂量。设为 0 可停用。",
        "用於顯示你還剩多少次劑量。設為 0 可停用。",
    ),
    "Your remaining amount stands out once it drops below this. Set to 0 to disable.": (
        "当剩余量低于此值时会突出显示。设为 0 可停用。",
        "當剩餘量低於此值時會突出顯示。設為 0 可停用。",
    ),
    "History": ("历史记录", "歷史記錄"),
    "Initial": ("初始量", "初始量"),
    "Adjustment": ("校正", "校正"),
    "Out": ("用尽", "用盡"),
    "Out of stock": ("库存用尽", "庫存用盡"),
    "Run-out estimate": ("用尽预估", "用盡預估"),
    "Estimated from your average daily use over the last 7 days. Shown only when you've dosed on most days, so a one-off doesn't skew it.": (
        "根据你过去 7 天的日均用量估算。仅在大多数日子都用药时显示，以免偶尔一次造成偏差。",
        "根據你過去 7 天的日均用量估算。僅在大多數日子都用藥時顯示，以免偶爾一次造成偏差。",
    ),
    "How this is calculated": ("如何计算", "如何計算"),
    "Daily avg %@": ("日均 %@", "日均 %@"),
    "Single dose %@ %@ · daily avg %@": ("单次剂量 %@ %@ · 日均 %@", "單次劑量 %@ %@ · 日均 %@"),
    "Doses in other units aren't counted.": ("其他单位的剂量不计入。", "其他單位的劑量不計入。"),
    "last dose %@": ("上次剂量 %@", "上次劑量 %@"),
    "~%lld doses left": ("剩约 %lld 次", "剩約 %lld 次"),
    "~%lld doses · %@ left": ("剩约 %lld 次 · %@", "剩約 %lld 次 · %@"),
    "%@, %@ %@ in stock": ("%@，库存 %@ %@", "%@，庫存 %@ %@"),
    "%@, %@ %@ in stock, low": ("%@，库存 %@ %@，偏低", "%@，庫存 %@ %@，偏低"),
    "%@, out of stock": ("%@，库存用尽", "%@，庫存用盡"),
    "Increase": ("增加", "增加"),
    "Decrease": ("减少", "減少"),
    "You're out of %@. Restock when you can.": (
        "你的 %@ 已用尽。方便时再补上。",
        "你的 %@ 已用盡。方便時再補上。",
    ),
    "Nothing tracked": ("未追踪任何物质", "未追蹤任何物質"),
    # Positional specifiers: EN order is (remaining, unit, substance) but zh
    # leads with the substance — the old "共 %@" rendered the drug NAME as a
    # "total" quantity.
    "Out of %@": ("%@已用尽", "%@已用盡"),
    "Running low on %@": ("%@所剩不多", "%@所剩不多"),
    "%@ of %@ %@ remaining": ("剩 %1$@，共 %2$@ %3$@", "剩 %1$@，共 %2$@ %3$@"),
    "Piru and PsychonautWiki files are plain JSON. Imports add to your journal (duplicates skipped). Encrypted restores can merge or replace. Inventory is included in Piru and encrypted backups, but not PsychonautWiki files.": (
        "Piru 和 PsychonautWiki 文件是纯 JSON。导入会添加到你的日记（重复项跳过）。加密备份可合并或替换。库存包含在 Piru 和加密备份中，但不含 PsychonautWiki 文件。",
        "Piru 和 PsychonautWiki 檔案是純 JSON。匯入會新增到你的日記（重複項略過）。加密備份可合併或取代。庫存包含在 Piru 和加密備份中，但不含 PsychonautWiki 檔案。",
    ),
    # Pharmacology card hybrid redesign (2026-06-29): nav-bar detail-level (tier) switcher + merged card.
    "Detail level": ("详细程度", "詳細程度"),
    "Pharmacology": ("药理学", "藥理學"),
    # Step 3 — class-specific receptor-panel heroes (opioid / benzo / dissociative).
    "Minor / off-targets": ("次要／脱靶", "次要／脫靶"),
    "Full μ-opioid agonist": (
        "μ-阿片受体完全激动剂",
        "μ-鴉片受體完全促效劑",
    ),
    "Partial μ-opioid agonist": (
        "μ-阿片受体部分激动剂",
        "μ-鴉片受體部分促效劑",
    ),
    "μ-opioid antagonist": (
        "μ-阿片受体拮抗剂",
        "μ-鴉片受體拮抗劑",
    ),
    "GABA-A positive modulator": ("GABA-A 正向调节剂", "GABA-A 正向調節劑"),
    "Amplifies GABA — it doesn't open the channel on its own.": (
        "增强 GABA 的作用——它本身并不打开通道。",
        "增強 GABA 的作用——它本身並不打開通道。",
    ),
    "NMDA channel blocker": ("NMDA 通道阻滞剂", "NMDA 通道阻滯劑"),
    "Lower IC₅₀ / Kᵢ = more potent block.": (
        "IC₅₀／Kᵢ 越低 = 阻断作用越强。",
        "IC₅₀／Kᵢ 越低 = 阻斷作用越強。",
    ),
    "Sedation": ("镇静", "鎮靜"),
    "Anxiolysis": ("抗焦虑", "抗焦慮"),
    "Muscle": ("肌肉松弛", "肌肉鬆弛"),
    "Memory": ("记忆", "記憶"),
    # Step 4 — grouped receptor-literature table: short transporter-mechanism row labels.
    "Release": ("释放", "釋放"),
    "Reuptake": ("再摄取抑制", "再攝取抑制"),
    # Navbar consolidation: Share + one overflow "More" menu (Files-app pattern).
    "More": ("更多", "更多"),
    "Personalize Substance…": ("个性化此物质…", "個人化此物質…"),
    # Pharmacology card round-3 phase-2 (2026-06-28): elimination rows in the Metabolism card render as a
    # plain excretion line instead of a bogus "→ unchanged parent [active]" metabolite.
    "Renal excretion": ("经肾排泄", "經腎排泄"),
    "Biliary excretion": ("经胆汁排泄", "經膽汁排泄"),
    # 5-HT2B valvulopathy flag — plain, drug-relevant copy (dropped fenfluramine / "mechanistic flag").
    "Activates 5-HT2B, which is linked to heart-valve damage (valvulopathy) with chronic or heavy use.": (
        "激活 5-HT2B；长期或大量使用与心脏瓣膜损害（瓣膜病变）相关。",
        "活化 5-HT2B；長期或大量使用與心臟瓣膜損害（瓣膜病變）相關。",
    ),
    # Pharmacology card harmony pass — round 3 (2026-06-28): receptor strength help-sheet copy now
    # spells out the measurement-aware bands.
    "Measures how tightly the drug grips the target (Ki). A smaller number means a tighter grip — under 100 nM is strong, over 1000 nM is weak.": (
        "衡量药物与靶点结合的紧密程度（Ki）。数值越小，结合越紧密——低于 100 nM 为强，高于 1000 nM 为弱。",
        "衡量藥物與靶點結合的緊密程度（Ki）。數值越小，結合越緊密——低於 100 nM 為強，高於 1000 nM 為弱。",
    ),
    "Measures the dose needed to actually switch the target on or block it, rather than just stick to it. These run about 10× higher than binding, so the dots use a matching scale (under 1 µM strong, over 10 µM weak).": (
        "衡量真正激活或阻断靶点（而非仅仅附着其上）所需的剂量。其数值通常比结合亲和力高约 10 倍，因此圆点采用相应的刻度（低于 1 µM 为强，高于 10 µM 为弱）。",
        "衡量真正活化或阻斷靶點（而非僅僅附著其上）所需的劑量。其數值通常比結合親和力高約 10 倍，因此圓點採用相應的刻度（低於 1 µM 為強，高於 10 µM 為弱）。",
    ),
    # Pharmacology card harmony pass — round 2 (2026-06-28): shorter metabolic-modulation headlines
    # (drop substrate + period; we're on the substance's own card) + per-card help-sheet "about" text.
    "Repeated doses build up faster than the dose suggests": (
        "反复用药会比单次剂量所暗示的更快蓄积",
        "反覆用藥會比單次劑量所暗示的更快蓄積",
    ),
    "%@ may raise levels": ("%@ 可能升高其血药浓度", "%@ 可能升高其血藥濃度"),
    "%@ may lower levels": ("%@ 可能降低其血药浓度", "%@ 可能降低其血藥濃度"),
    "How the drug acts in the body — which receptors and transporters it targets, and what it does at each (switches them on, blocks them, and so on). The dots show how strongly it acts at each target.": (
        "药物在体内如何起作用——它作用于哪些受体和转运体，以及在每个靶点上做什么（激活、阻断等）。圆点表示它在各靶点上的作用强度。",
        "藥物在體內如何起作用——它作用於哪些受體和轉運體，以及在每個靶點上做什麼（活化、阻斷等）。圓點表示它在各靶點上的作用強度。",
    ),
    "How your body breaks the drug down — which liver enzymes do the work, what byproducts (metabolites) form, and whether those are still active. The percentage is each enzyme's rough share of clearance.": (
        "身体如何分解药物——由哪些肝酶完成、生成哪些副产物（代谢物），以及这些代谢物是否仍具活性。百分比是每种酶在清除中的大致占比。",
        "身體如何分解藥物——由哪些肝酶完成、生成哪些副產物（代謝物），以及這些代謝物是否仍具活性。百分比是每種酶在清除中的大致占比。",
    ),
    # Pharmacology card harmony pass (2026-06-28) — receptor binding/functional tags, PK + receptor
    # plain-language help sheet, "Additional Info" rename. Simple-vocabulary register to match the
    # English (these are the "complex things made understandable" glossary entries).
    "binding": ("结合", "結合"),
    "functional": ("功能", "功能"),
    "Binding": ("结合", "結合"),
    "Functional": ("功能", "功能"),
    "What do these mean?": ("这些是什么意思？", "這些是什麼意思？"),
    "Receptor data": (
        "受体数据",
        "受體資料",
    ),
    "Additional Info": ("更多信息", "更多資訊"),
    "Strength dots": ("强度圆点", "強度圓點"),
    "nM (nanomolar)": ("nM（纳摩尔）", "nM（奈莫耳）"),
    "Human vs animal": (
        "人体与动物数据",
        "人體與動物資料",
    ),
    "These are population averages from research — your own values vary with genetics, body size, and how the drug is taken.": (
        "这些是研究得出的群体平均值——你的实际数值会因遗传、体型以及用药方式而不同。",
        "這些是研究得出的群體平均值——你的實際數值會因遺傳、體型以及用藥方式而不同。",
    ),
    "Stronger doesn't mean more dangerous — it's just how tightly the drug grips that one target in the lab.": (
        "更强并不代表更危险——它只是表示在实验室中药物与该靶点结合的紧密程度。",
        "更強並不代表更危險——它只是表示在實驗室中藥物與該靶點結合的緊密程度。",
    ),
    "How much of a dose actually reaches your bloodstream. Swallowing a drug usually delivers less than injecting it.": (
        "一次用药中真正进入血液的比例。口服通常比注射进入血液的量更少。",
        "一次用藥中真正進入血液的比例。口服通常比注射進入血液的量更少。",
    ),
    "How long after taking it the level in your blood is highest — roughly when effects peak.": (
        "用药后多久血液中的浓度达到最高——大致也是效果最强的时刻。",
        "用藥後多久血液中的濃度達到最高——大致也是效果最強的時刻。",
    ),
    "The time for your body to clear half of what's left. It takes about five half-lives to clear almost all of it.": (
        "身体清除掉其中一半所需的时间。大约经过五个半衰期才能几乎完全清除。",
        "身體清除掉其中一半所需的時間。大約經過五個半衰期才能幾乎完全清除。",
    ),
    "The share that rides along stuck to blood proteins. Only the unbound rest is free to act.": (
        "附着在血浆蛋白上随之运行的比例。只有未结合的那部分才能发挥作用。",
        "附著在血漿蛋白上隨之運行的比例。只有未結合的那部分才能發揮作用。",
    ),
    "How widely the drug spreads from blood into the rest of the body. A bigger number means it soaks into tissues rather than staying in the blood.": (
        "药物从血液扩散到全身其他部位的广泛程度。数值越大，表示它越多渗入组织而非停留在血液中。",
        "藥物從血液擴散到全身其他部位的廣泛程度。數值越大，表示它越多滲入組織而非停留在血液中。",
    ),
    "How fast your body removes the drug, mostly via the liver and kidneys.": (
        "身体清除药物的速度，主要通过肝脏和肾脏。",
        "身體清除藥物的速度，主要透過肝臟和腎臟。",
    ),
    "The highest concentration reached in the blood after a dose.": (
        "一次用药后血液中达到的最高浓度。",
        "一次用藥後血液中達到的最高濃度。",
    ),
    "A quick read of how potent the drug is at that target — three dots is strong, one is weak. The same scale is used on the Mechanism card.": (
        "快速判断药物对该靶点的作用强度——三个点表示强，一个点表示弱。与“作用机制”卡片使用同一标准。",
        "快速判斷藥物對該靶點的作用強度——三個點表示強，一個點表示弱。與「作用機制」卡片使用同一標準。",
    ),
    "The concentration unit these values use. Lower numbers always mean the drug works at smaller amounts.": (
        "这些数值所用的浓度单位。数字越小，表示药物在更低的量下就能起作用。",
        "這些數值所用的濃度單位。數字越小，表示藥物在更低的量下就能起作用。",
    ),
    "Many values come from animal or lab-dish studies. Human data is the most reliable — the source tag tells you which it is.": (
        "许多数值来自动物或体外（培养皿）实验。人体数据最为可靠——来源标签会标明属于哪一种。",
        "許多數值來自動物或體外（培養皿）實驗。人體資料最為可靠——來源標籤會標明屬於哪一種。",
    ),
    # Pharmacology axis — RC-expansion UI: monoamine profile / provenance / contraceptive
    # caution / gabapentinoid ceiling (2026-06-24). Terminology grounded in a Chinese
    # clinical-pharmacology register: 5-羟色胺 (not 血清素), 再摄取 (not 重摄取),
    # 激动剂 (not 兴奋剂), 拮抗剂 for receptors; CYP/DAT/SERT/MDMA/α2δ kept in Latin.
    # MonoamineProfileCard — section header + mechanism labels
    "Monoamine Profile": ("单胺特征", "單胺特徵"),
    "Substrate releaser": ("释放剂（转运体底物）", "釋放劑（轉運體底物）"),
    "Reuptake blocker": ("再摄取抑制剂", "再攝取抑制劑"),
    "Mixed (releaser / blocker)": ("混合型（释放剂／抑制剂）", "混合型（釋放劑／抑制劑）"),
    # MonoamineProfileCard — lean labels
    "Balance not characterized (DAT or SERT data missing)": (
        "未能确定平衡（缺少 DAT 或 SERT 数据）",
        "未能確定平衡（缺少 DAT 或 SERT 資料）",
    ),
    "Serotonin-leaning (entactogenic)": (
        "偏向 血清素（共情剂类）",
        "偏向 血清素（共情劑類）",
    ),
    "Balanced — empathogen-like": (
        "较为均衡——类似共情剂",
        "較為均衡——類似共情劑",
    ),
    "Dopamine-leaning — more stimulant in character": (
        "偏向多巴胺——兴奋作用更突出",
        "偏向多巴胺——興奮作用更突出",
    ),
    "Strongly dopaminergic (SERT-sparing)": (
        "强多巴胺能（对 SERT 作用很弱）",
        "強多巴胺能（對 SERT 作用很弱）",
    ),
    "Serotonin": (
        "血清素",
        "血清素",
    ),
    "Dopamine": ("多巴胺", "多巴胺"),
    # MonoamineProfileCard — harm-reduction flags + footnote
    "Often mis-sold as MDMA / “molly,” but it is pharmacologically a reuptake blocker — longer, more stimulant and anxiogenic, and more dangerous on an empathogen-style redose.": (
        "常被冒充为 MDMA／“molly”出售，但其药理上是再摄取抑制剂——作用更持久、更偏兴奋和致焦虑，按共情剂的方式补服时更危险。",
        "常被冒充為 MDMA／「molly」出售，但其藥理上是再攝取抑制劑——作用更持久、更偏興奮和致焦慮，按共情劑的方式補服時更危險。",
    ),
    # ProvenanceBadge — method labels + accessibility
    "Human": ("人体", "人體"),
    "Rat": ("大鼠", "大鼠"),
    "Mouse": ("小鼠", "小鼠"),
    "Animal": ("动物", "動物"),
    "In-vitro": ("体外", "體外"),
    "Aggregated": ("综合来源", "綜合來源"),
    "Curated": ("人工整理", "人工整理"),
    "human assay": (
        "人源测定",
        "人源測定",
    ),
    "rat assay": ("大鼠实验", "大鼠實驗"),
    "mouse assay": ("小鼠实验", "小鼠實驗"),
    "animal assay": ("动物实验", "動物實驗"),
    "in-vitro assay": (
        "体外测定",
        "體外測定",
    ),
    "aggregator source": ("综合来源", "綜合來源"),
    "curated entry": ("人工整理条目", "人工整理條目"),
    "Evidence source: %@, %@": (
        "证据来源：%@，%@",
        "證據來源：%@，%@",
    ),
    # ContraceptionCautionBanner
    "May reduce hormonal birth-control efficacy": (
        "可能降低激素类避孕药的效果",
        "可能降低激素類避孕藥的效果",
    ),
    "Induces %@, which clears the hormones in the combined pill, patch, ring, implant and hormonal IUD — lowering their levels. Anyone relying on hormonal contraception should consider a backup method. Often noted on the label, but easy to miss.": (
        "可诱导 %@，加速复方口服避孕药、避孕贴剂、阴道避孕环、皮下埋植剂及含激素宫内节育器中激素的代谢，从而降低其血药浓度。依赖激素类避孕的人群应考虑采用备用避孕措施。说明书中通常有提示，但容易被忽略。",
        "可誘導 %@，加速複方口服避孕藥、避孕貼劑、陰道避孕環、皮下埋植劑及含激素宮內節育器中激素的代謝，從而降低其血藥濃度。依賴激素類避孕的人群應考慮採用備用避孕措施。說明書中通常有提示，但容易被忽略。",
    ),
    # MetabolicModulation catalog — modafinil / armodafinil as CYP3A4 inducers
    "Modafinil": ("莫达非尼", "莫達非尼"),
    "Armodafinil": ("阿莫达非尼", "阿莫達非尼"),
    # CeilingEffectToolView — gabapentinoid comparison card + readouts
    "Same class, opposite behavior": ("同类药物，行为相反", "同類藥物，行為相反"),
    "Bioavailability versus dose: gabapentin falls as the dose rises, pregabalin stays flat.": (
        "生物利用度随剂量的变化：加巴喷丁随剂量升高而下降，普瑞巴林保持平稳。",
        "生物利用度隨劑量的變化：加巴噴丁隨劑量升高而下降，普瑞巴林保持平穩。",
    ),
    "Saturable absorption — exposure climbs slower than dose": (
        "可饱和吸收——暴露量的上升慢于剂量",
        "可飽和吸收——暴露量的上升慢於劑量",
    ),
    # SaturablePharmacology — gabapentinoid comparison + gabapentin/tramadol profiles
    # Pharmacology axis Stage 3b — Combined depression index (2026-06-21)
    "Severe": ("严重", "嚴重"),
    "High": ("高", "高"),
    "Moderate": ("中等", "中等"),
    "Estimated from effect curves · %@.": (
        "依据效应曲线估算 · %@。",
        "依據效應曲線估算 · %@。",
    ),
    "%lld of %lld substances from receptor occupancy, the rest estimated from effect curves · %@.": (
        "%lld/%lld 种物质来自受体占有率，其余依据效应曲线估算 · %@。",
        "%lld/%lld 種物質來自受體佔有率，其餘依據效應曲線估算 · %@。",
    ),
    # Pharmacology axis Stage 3c — effect attenuation (2026-06-21)
    "serotonin transporter": ("血清素转运体", "血清素轉運體"),
    # Pharmacology axis Stage 4a — cross-tolerance readout (2026-06-21)
    # Pharmacology axis Stage 4d — combination metabolite / cocaethylene (2026-06-22)
    "Combination Products": (
        "复方制剂",
        "複方製劑",
    ),
    "Cocaethylene": ("可卡乙烯", "古柯乙烯"),
    "Cocaine and alcohol together form cocaethylene — an active stimulant your body makes only while both are present. It lasts noticeably longer than cocaine, so the stimulant effect (and its strain) is drawn out.": (
        "可卡因与酒精同时使用时，身体会生成可卡乙烯——一种只在两者同时存在时才形成的活性兴奋剂。它的持续时间明显长于可卡因，因此兴奋作用（及其带来的负担）会被拉长。",
        "古柯鹼與酒精同時使用時，身體會生成古柯乙烯——一種只在兩者同時存在時才形成的活性興奮劑。它的持續時間明顯長於古柯鹼，因此興奮作用（及其帶來的負擔）會被拉長。",
    ),
    # Pharmacology axis Stage 4c — metabolic modulation (2026-06-21)
    "Predicted": (
        "预测",
        "預測",
    ),
    "Time to peak": (
        "达峰时间",
        "達峰時間",
    ),
    "Protein binding": (
        "血浆蛋白结合",
        "血漿蛋白結合",
    ),
    "Distribution": (
        "分布容积",
        "分布容積",
    ),
    "Clearance": (
        "清除率",
        "清除率",
    ),
    "Peak level": (
        "峰浓度",
        "峰濃度",
    ),
    "Grapefruit dose logging": ("西柚剂量记录", "葡萄柚劑量記錄"),
    "Metabolism Interactions": ("代谢相互作用", "代謝交互作用"),
    # Off-Target Effects card. The concern chips describe the *consequence*, not
    # the binding strength — a bare 高/低 beside a receptor name would read as
    # affinity, which is the one thing this column never means.
    # ---------------------------------------------------------------
    # 2026-08-04 negative-clause sweep. "Say what it is, never what it isn't":
    # every ", not X" clause below was cut from the English, so the Chinese loses
    # its matching 而非／並非／不是 clause. Kept only where the negation is mandated
    # elsewhere — "not medical advice", "not clinical potency", and the
    # tolerance-by-receptor title, which name a belief the reader actively holds.
    "Approximate — equivalence tables disagree. Treat this as a ballpark.": (
        "仅为近似——各等效换算表并不一致。请将其视为大致参考。",
        "僅為近似——各等效換算表並不一致。請將其視為大致參考。",
    ),
    "Based on first-pass metabolism of oral THC · educational. Onset and duration vary with dose, product, and tolerance.": (
        "基于口服 THC 的首过代谢 · 仅供教育参考。起效与持续时间因剂量、产品和耐受性而异。",
        "基於口服 THC 的首過代謝 · 僅供教育參考。起效與持續時間因劑量、產品和耐受性而異。",
    ),
    "Based on your self-reported alcohol flush · educational.": (
        "依据你自报的喝酒脸红 · 仅供参考。",
        "依據你自報的喝酒臉紅 · 僅供參考。",
    ),
    "Don't try to 'figure it all out' right now. Integration takes days.": (
        "现在不要试图“想通一切”。整合需要数天。",
        "現在不要試圖「想通一切」。整合需要數天。",
    ),
    "The foggy feeling will clear. Give it hours.": (
        "迷糊感会消散。需要数小时。",
        "迷糊感會消散。需要數小時。",
    ),
    "The low mood is chemical. It lifts.": (
        "情绪低落源于化学变化。它会过去。",
        "情緒低落源於化學變化。它會過去。",
    ),
    "This is a rebound effect. It passes.": (
        "这是反弹效应。它会过去。",
        "這是反彈效應。它會過去。",
    ),
    "Doses are milligrams of THC. Flower needed ≈ desired THC ÷ the strain's %THC (e.g. 3 mg ÷ 18% ≈ 0.02 g). Smoking loses 50–80% to combustion, so real flower amounts run higher.": (
        "剂量是 THC 的毫克数。所需花量 ≈ 目标 THC ÷ 品系的 THC 含量百分比（例如 3 mg ÷ 18% ≈ 0.02 g）。吸食会因燃烧损失 50–80%，因此实际所需花量更高。",
        "劑量是 THC 的毫克數。所需花量 ≈ 目標 THC ÷ 品系的 THC 含量百分比（例如 3 mg ÷ 18% ≈ 0.02 g）。吸食會因燃燒損失 50–80%，因此實際所需花量更高。",
    ),
    "Estimates from primary literature.": (
        "数据为原始文献中的估计值。",
        "資料為原始文獻中的估計值。",
    ),
    "Kick-in and wear-off come from this med's own duration data — the same model the timeline draws. An estimate.": (
        "起效与消退时间来自这款药物自身的持续时间数据——与时间线所用的模型相同。这是估算。",
        "起效與消退時間來自這款藥物自身的持續時間資料——與時間線所用的模型相同。這是估算。",
    ),
    "MME is a population risk metric. CDC states the calculated MME should not be used to determine the dose when switching opioids.": (
        "MME 是群体风险指标。CDC 指出，更换阿片类药物时不应使用计算得出的 MME 来确定剂量。",
        "MME 是群體風險指標。CDC 指出，更換鴉片類藥物時不應使用計算得出的 MME 來確定劑量。",
    ),
    "Runs down with use and returns over weeks. MDMA-type use is slower because it dents serotonin supply as well as the receptors.": (
        "用着用着会减弱，要好几周才回得来。MDMA 这类更慢，因为它除了受体，还会消耗血清素的储备。",
        "用著用著會減弱，要好幾週才回得來。MDMA 這類更慢，因為它除了受體，還會消耗血清素的儲備。",
    ),
    "These values were not measured together — each is its own study. Ranked here for scale.": (
        "这些数值并非在同一实验中测得——每个都来自各自的研究。此处排列只为呈现量级。",
        "這些數值並非在同一實驗中測得——每個都來自各自的研究。此處排列只為呈現量級。",
    ),
    "MDA is an active drug of its own — more amphetamine-like and more hallucinogenic than MDMA, and longer-lived — so the later hours can feel qualitatively different from the peak.": (
        "MDA 本身就是一种活性药物——比 MDMA 更像苯丙胺、致幻性更强，也更持久——因此后段时间的体验在性质上会与高峰期不同。",
        "MDA 本身就是一種活性藥物——比 MDMA 更像安非他命、致幻性更強，也更持久——因此後段時間的體驗在性質上會與高峰期不同。",
    ),
    "Model estimates from population half-lives and your logged doses — individual clearance varies. Intensity is relative to each dose's own peak. Not medical advice.": (
        "基于群体半衰期与你记录的剂量的模型估算——个体清除速度各异。强度相对于每次剂量自身的峰值。不构成医疗建议。",
        "基於群體半衰期與你記錄的劑量的模型估算——個體清除速度各異。強度相對於每次劑量自身的峰值。不構成醫療建議。",
    ),
    "%@ acts through %@ — the pharmacology below is %@'s.": (
        "%@ 通过 %@ 起效——下方的药理数据来自 %@。",
        "%@ 透過 %@ 起效——下方的藥理資料來自 %@。",
    ),
    "Off-Target Effects": ("脱靶作用", "脫靶作用"),
    "Significant": ("影响明确", "影響明確"),
    "Limited": ("影响有限", "影響有限"),
    "Minor": ("影响轻微", "影響輕微"),
    "Real but bounded": ("确有影响但有限", "確有影響但有限"),
    # Benzodiazepine duration ladder. The caption's negation is deliberate: every
    # reader arrives believing half-life is how long the drug is felt.
    "How Long It Stays": ("在体内停留多久", "在體內停留多久"),
    "Elimination half-life — not how long you feel it.": (
        "消除半衰期——不是你能感觉到的时长。",
        "消除半衰期——不是你能感覺到的時長。",
    ),
    "Metabolite of the above": ("上一项的代谢产物", "上一項的代謝產物"),
    # Antidepressant class card.
    "Drug Class": ("药物类别", "藥物類別"),
    "The rest of the family": ("同类其他药物", "同類其他藥物"),
    "%lld hours": (
        "%lld小时",
        "%lld小時",
    ),
    "Both raise serotonin, so serotonin syndrome is possible — agitation, tremor, sweating, a racing heart — and most likely in the first weeks. This pairing is prescribed and monitored on purpose; SSRIs do not raise lithium levels.": (
        "两者都会升高血清素，因此可能出现血清素综合征——躁动、震颤、出汗、心跳加快，最常见于开始用药的头几周。这个组合本就是医生有意开出并加以监测的；SSRI 不会升高锂的血药浓度。",
        "兩者都會升高血清素，因此可能出現血清素症候群——躁動、顫抖、出汗、心跳加快，最常見於開始用藥的頭幾週。這個組合本就是醫師有意開出並加以監測的；SSRI 不會升高鋰的血藥濃度。",
    ),
    "Both raise serotonin, so serotonin syndrome is possible — agitation, tremor, sweating, a racing heart — and most likely in the first weeks. This pairing is prescribed and monitored on purpose; SNRIs do not raise lithium levels.": (
        "两者都会升高血清素，因此可能出现血清素综合征——躁动、震颤、出汗、心跳加快，最常见于开始用药的头几周。这个组合本就是医生有意开出并加以监测的；SNRI 不会升高锂的血药浓度。",
        "兩者都會升高血清素，因此可能出現血清素症候群——躁動、顫抖、出汗、心跳加快，最常見於開始用藥的頭幾週。這個組合本就是醫師有意開出並加以監測的；SNRI 不會升高鋰的血藥濃度。",
    ),
    "A large serotonin load on top of lithium's own. The lithium label names tramadol and fentanyl in this group; serotonin syndrome can start within hours.": (
        "在锂本身的血清素负荷之上再叠加一份很大的负荷。锂的说明书把曲马多和芬太尼列在这一组里；血清素综合征可在数小时内发作。",
        "在鋰本身的血清素負荷之上再疊加一份很大的負荷。鋰的說明書把曲馬多和吩坦尼列在這一組裡；血清素症候群可在數小時內發作。",
    ),
    "MAOIs block the enzyme that clears serotonin, so the load builds instead of levelling off. Serotonin syndrome is the risk; MAOIs do not raise lithium levels.": (
        "MAOI 阻断清除血清素的酶，因此负荷会不断累积而不是趋于平稳。风险是血清素综合征；MAOI 不会升高锂的血药浓度。",
        "MAOI 阻斷清除血清素的酶，因此負荷會不斷累積而不是趨於平穩。風險是血清素症候群；MAOI 不會升高鋰的血藥濃度。",
    ),
    "Of 62 reports of this combination, 47% described a seizure and 39% involved medical attention — against none of 34 reports for lamotrigine. Self-reported, so the rate is not a measured one, but no other pairing shows a signal like it.": (
        "在这一组合的62份报告中，47% 描述了癫痫发作，39% 涉及就医——而拉莫三嗪的34份报告中一例也没有。这些都是自我报告，所以这个比例并非实测值，但没有别的组合出现过这样的信号。",
        "在這一組合的62份報告中，47% 描述了癲癇發作，39% 涉及就醫——而拉莫三嗪的34份報告中一例也沒有。這些都是自我報告，所以這個比例並非實測值，但沒有別的組合出現過這樣的訊號。",
    ),
    "MDMA releases serotonin in bulk and lithium adds to it, so serotonin syndrome is the main risk. Seizures are reported for lithium with classic psychedelics; MDMA has not been looked at the same way.": (
        "MDMA 会大量释放血清素，锂在此之上再加一份，因此主要风险是血清素综合征。锂与经典迷幻剂合用有癫痫发作的报告；MDMA 没有被同样地研究过。",
        "MDMA 會大量釋放血清素，鋰在此之上再加一份，因此主要風險是血清素症候群。鋰與經典迷幻劑合用有癲癇發作的報告；MDMA 沒有被同樣地研究過。",
    ),
    "Not in the Ashton Manual's equivalence table, and not sourced elsewhere — treat the number as a rough guide and dose by this drug's own threshold.": (
        "不在 Ashton 手册的等效剂量表中，也没有其他来源——这个数字只能当作粗略参考，请按这个药自身的阈值来把握剂量。",
        "不在 Ashton 手冊的等效劑量表中，也沒有其他來源——這個數字只能當作粗略參考，請按這個藥自身的閾值來拿捏劑量。",
    ),
    "Which class this belongs in is argued over — the label is the conventional one, not a settled one.": (
        "它该归到哪一类是有争议的——这个标签是约定俗成的说法，而不是定论。",
        "它該歸到哪一類是有爭議的——這個標籤是約定俗成的說法，而不是定論。",
    ),
    "Selective serotonin reuptake inhibitor": (
        "选择性血清素再摄取抑制剂",
        "選擇性血清素再攝取抑制劑",
    ),
    "Serotonin–noradrenaline reuptake inhibitor": (
        "血清素-去甲肾上腺素再摄取抑制剂",
        "血清素-正腎上腺素再攝取抑制劑",
    ),
    "Noradrenaline reuptake inhibitor": (
        "去甲肾上腺素再摄取抑制剂",
        "正腎上腺素再攝取抑制劑",
    ),
    "Noradrenaline–dopamine reuptake inhibitor": (
        "去甲肾上腺素-多巴胺再摄取抑制剂",
        "正腎上腺素-多巴胺再攝取抑制劑",
    ),
    "Serotonin modulator and stimulator": (
        "血清素调节剂与激动剂",
        "血清素調節劑與促效劑",
    ),
    "Tricyclic antidepressant": ("三环类抗抑郁药", "三環類抗憂鬱藥"),
    "Monoamine oxidase inhibitor": ("单胺氧化酶抑制剂", "單胺氧化酶抑制劑"),
    "Serotonin antagonist and reuptake inhibitor": (
        "血清素拮抗与再摄取抑制剂",
        "血清素拮抗與再攝取抑制劑",
    ),
    "Noradrenergic and specific serotonergic antidepressant": (
        "去甲肾上腺素能与特异性血清素能抗抑郁药",
        "正腎上腺素能與特異性血清素能抗憂鬱藥",
    ),
    "Blocks the serotonin transporter and little else, which is why its effects and its side effects are both mostly serotonergic.": (
        "几乎只阻断血清素转运体，因此它的作用与副作用大多都是血清素能的。",
        "幾乎只阻斷血清素轉運體，因此它的作用與副作用大多都是血清素性的。",
    ),
    "Blocks serotonin and noradrenaline reuptake together. The noradrenaline share grows with dose, so a low dose can behave much like an SSRI.": (
        "同时阻断血清素和去甲肾上腺素的再摄取。去甲肾上腺素那一份随剂量增大，因此低剂量时表现可以很像SSRI。",
        "同時阻斷血清素和正腎上腺素的再攝取。正腎上腺素那一份隨劑量增大，因此低劑量時表現可以很像SSRI。",
    ),
    "Blocks the noradrenaline transporter and leaves the other two. In the prefrontal cortex that same transporter is what clears dopamine, so the effect there is not as purely noradrenergic as the name reads.": (
        "只阻断去甲肾上腺素转运体，另外两种不动。在前额叶皮层，清除多巴胺的正是同一个转运体，所以那里的作用并不像名字读起来那样纯粹是去甲肾上腺素性的。",
        "只阻斷正腎上腺素轉運體，另外兩種不動。在前額葉皮質，清除多巴胺的正是同一個轉運體，所以那裡的作用並不像名字讀起來那樣純粹是正腎上腺素性的。",
    ),
    "Blocks noradrenaline and dopamine reuptake, leaving serotonin alone — the activating end of the family.": (
        "阻断去甲肾上腺素和多巴胺的再摄取，不动血清素——这一类里偏兴奋的一端。",
        "阻斷正腎上腺素和多巴胺的再攝取，不動血清素——這一類裡偏興奮的一端。",
    ),
    "Blocks serotonin reuptake and acts on several serotonin receptors directly, agonist at some and antagonist at others. The receptor work is what separates it from an SSRI, not the transporter block they share.": (
        "既阻断血清素再摄取，又直接作用于多个血清素受体，对一些是激动，对另一些是拮抗。把它和SSRI区分开的是受体上的这部分作用，而不是两者共有的转运体阻断。",
        "既阻斷血清素再攝取，又直接作用於多個血清素受體，對一些是促效，對另一些是拮抗。把它和SSRI區分開的是受體上的這部分作用，而不是兩者共有的轉運體阻斷。",
    ),
    "Blocks serotonin and noradrenaline reuptake like an SNRI, and also histamine, muscarinic and α₁ receptors. That extra binding is the sedation, the dry mouth, and the narrow margin in overdose.": (
        "像SNRI一样阻断血清素和去甲肾上腺素的再摄取，同时还结合组胺、毒蕈碱和α₁受体。多出来的这部分结合，就是镇静、口干，以及过量时安全范围狭窄的来源。",
        "像SNRI一樣阻斷血清素和正腎上腺素的再攝取，同時還結合組織胺、蕈毒鹼和α₁受體。多出來的這部分結合，就是鎮靜、口乾，以及過量時安全範圍狹窄的來源。",
    ),
    "Blocks the enzyme that breaks monoamines down, rather than the transporters that recycle them, so all three rise. The tyramine restriction and the long interaction list both follow from that.": (
        "阻断的是分解单胺的酶，而不是回收它们的转运体，所以三种单胺都会升高。酪胺饮食限制和那一长串相互作用，都由此而来。",
        "阻斷的是分解單胺的酶，而不是回收它們的轉運體，所以三種單胺都會升高。酪胺飲食限制和那一長串交互作用，都由此而來。",
    ),
    "Blocks 5-HT₂A while weakly inhibiting serotonin reuptake. The receptor block dominates at low doses, which is why trazodone reached far more people as a sleep drug than as an antidepressant.": (
        "阻断5-HT₂A，同时弱抑制血清素再摄取。低剂量时受体阻断占主导，这就是曲唑酮作为助眠药的使用者远多于作为抗抑郁药的原因。",
        "阻斷5-HT₂A，同時弱抑制血清素再攝取。低劑量時受體阻斷佔主導，這就是曲唑酮作為助眠藥的使用者遠多於作為抗憂鬱藥的原因。",
    ),
    "Raises noradrenaline and serotonin release by blocking the α₂ autoreceptors that normally brake it, instead of blocking reuptake. The H₁ block alongside it is the sedation and the appetite.": (
        "通过阻断本来起刹车作用的α₂自身受体来提高去甲肾上腺素和血清素的释放，而不是阻断再摄取。与之并行的H₁阻断，就是镇静和食欲的来源。",
        "透過阻斷本來起煞車作用的α₂自身受體來提高正腎上腺素和血清素的釋放，而不是阻斷再攝取。與之並行的H₁阻斷，就是鎮靜和食慾的來源。",
    ),
    "Had grapefruit with this dose": ("此剂量同服了西柚", "此劑量同服了葡萄柚"),
    # Stage 4c — modulator catalog display names + notes
    "Grapefruit": ("西柚", "葡萄柚"),
    "Carbamazepine": ("卡马西平", "卡馬西平"),
    "MDMA": ("MDMA", "MDMA"),
    # Antidepressant + empathogen reframed as myth-buster (blunting, not serotonin syndrome) (2026-06-21)
    # Serotonergic special cases — evidence-grounded rules (Foundation-C run, 2026-06-22)
    "Serotonin syndrome risk — these drugs add serotonin on top of an empathogen's surge. Some (tramadol, meperidine) can also trigger seizures.": (
        "血清素综合征风险——这些药物会在共情剂已升高的血清素之上继续增加。部分药物（曲马多、哌替啶）还可能诱发癫痫发作。",
        "血清素症候群風險——這些藥物會在共情劑已升高的血清素之上繼續增加。部分藥物（曲馬多、哌替啶）還可能誘發癲癇發作。",
    ),
    "Serotonin syndrome risk — two serotonin-raising drugs stacked together.": (
        "血清素综合征风险——两种升高血清素的药物叠加使用。",
        "血清素症候群風險——兩種升高血清素的藥物疊加使用。",
    ),
    "Serotonin syndrome risk — a serotonin-raising drug stacked with an SSRI.": (
        "血清素综合征风险——升高血清素的药物与 SSRI 叠加。",
        "血清素症候群風險——升高血清素的藥物與 SSRI 疊加。",
    ),
    "Serotonin syndrome risk — a serotonin-raising drug stacked with an SNRI.": (
        "血清素综合征风险——升高血清素的药物与 SNRI 叠加。",
        "血清素症候群風險——升高血清素的藥物與 SNRI 疊加。",
    ),
    "Serotonin syndrome risk — a serotonin-raising drug stacked with a tricyclic antidepressant.": (
        "血清素综合征风险——升高血清素的药物与三环类抗抑郁药叠加。",
        "血清素症候群風險——升高血清素的藥物與三環類抗憂鬱藥疊加。",
    ),
    # Alpha-2 agonists + beta-blockers (Foundation-C run, 2026-06-22)
    "Heavy sedation with a dangerously slow heart rate and breathing. Naloxone reverses the opioid but NOT the alpha-2 part — give rescue breaths and call for help even after naloxone.": (
        "强烈镇静，伴心率和呼吸危险性减慢。纳洛酮能逆转阿片，但无法逆转 alpha-2 的作用——即使用了纳洛酮，也要进行人工呼吸并呼叫求助。",
        "強烈鎮靜，伴心率和呼吸危險性減慢。納洛酮能逆轉鴉片，但無法逆轉 alpha-2 的作用——即使用了納洛酮，也要進行人工呼吸並呼叫求助。",
    ),
    "Compounded sedation and low blood pressure — stronger drowsiness and dizziness.": (
        "镇静与低血压叠加——困倦和头晕加重。",
        "鎮靜與低血壓疊加——睏倦和頭暈加重。",
    ),
    "Additive sedation and low blood pressure — increased drowsiness and dizziness.": (
        "镇静与低血压叠加——困倦和头晕增加。",
        "鎮靜與低血壓疊加——睏倦和頭暈增加。",
    ),
    "Tricyclics can cancel out clonidine-type blood-pressure lowering, so blood pressure may rise — a medical issue more than an overdose risk.": (
        "三环类抗抑郁药可能抵消可乐定类药物的降压作用，使血压升高——这更多是医疗问题，而非过量风险。",
        "三環類抗憂鬱藥可能抵消可樂定類藥物的降壓作用，使血壓升高——這更多是醫療問題，而非過量風險。",
    ),
    "Both can lower blood pressure and add to dizziness — you may feel faint, especially standing up.": (
        "两者都会降低血压并增加头晕——可能感到眩晕，尤其是起身时。",
        "兩者都會降低血壓並增加頭暈——可能感到眩暈，尤其是起身時。",
    ),
    # Pharmacology axis Stage 2 — Tolerance tool (2026-06-21)
    "Tolerance": ("耐受性", "耐受性"),
    "Psychedelics (5-HT2A)": ("迷幻剂（5-HT2A）", "迷幻劑（5-HT2A）"),
    "Opioids (μ)": ("阿片类（μ）", "鴉片類（μ）"),
    "Stimulants (DAT/NET)": ("兴奋剂（DAT/NET）", "興奮劑（DAT/NET）"),
    "Serotonin releasers (SERT)": ("血清素释放剂（SERT）", "血清素釋放劑（SERT）"),
    "GABA (benzos / alcohol)": ("GABA（苯二氮䓬／酒精）", "GABA（苯二氮平／酒精）"),
    "Dissociatives (NMDA)": ("解离剂（NMDA）", "解離劑（NMDA）"),
    "Cannabinoids (CB1)": ("大麻素（CB1）", "大麻素（CB1）"),
    "Adenosine (caffeine)": ("腺苷（咖啡因）", "腺苷（咖啡因）"),
    "Nicotinic (nAChR)": ("烟碱型（nAChR）", "菸鹼型（nAChR）"),
    "Nothing to show yet": ("暂无可显示内容", "暫無可顯示內容"),
    "~%lld months": ("~%lld 个月", "~%lld 個月"),
    "~%lld weeks": ("~%lld 周", "~%lld 週"),
    "~%lld days": ("~%lld 天", "~%lld 天"),
    "~%lld hours": ("~%lld 小时", "~%lld 小時"),
    # Tolerance tool + explainer rewrite (Stage J, 2026-06-30). Friendly, second-person register
    # (a knowledgeable friend, not a textbook): 你, plain verbs, no academic 使/之/其, no cutesy particles.
    "Your brain adapts to what you keep giving it": (
        "你一直用，大脑就会去适应它",
        "你一直用，大腦就會去適應它",
    ),
    "Use a drug repeatedly and your brain learns to expect it, then pushes back to cancel the effect — so the same dose does less. That push-back is tolerance. Stop, and it relaxes back. It's not the drug “running out”; it's your system re-balancing around it.": (
        "一种药你反复用，大脑就学会了预判它，然后反过来抵消它的作用——所以同样的剂量效果就变小了。这种反向的推力就是耐受。你一停，它又会慢慢松回去。这不是药“用完了”，而是你的身体在围着它重新找平衡。",
        "一種藥你反覆用，大腦就學會了預判它，然後反過來抵消它的作用——所以同樣的劑量效果就變小了。這種反向的推力就是耐受。你一停，它又會慢慢鬆回去。這不是藥「用完了」，而是你的身體在圍著它重新找平衡。",
    ),
    "Why stopping can feel like the opposite": (
        "为什么一停反而像反过来了",
        "為什麼一停反而像反過來了",
    ),
    "When you stop, that push-back is briefly left unopposed — which is why withdrawal or a comedown often feels like the mirror of the drug's effects (a stimulant's flatness, an opioid's aches).": (
        "你一停，这股反向的推力会有一阵子没了对手——所以戒断或者下头往往像药效的镜像（兴奋剂之后的提不起劲、阿片之后的浑身酸痛）。",
        "你一停，這股反向的推力會有一陣子沒了對手——所以戒斷或者下頭往往像藥效的鏡像（興奮劑之後的提不起勁、鴉片之後的渾身痠痛）。",
    ),
    "The idea": ("原理", "原理"),
    "Within a session": (
        "同一场次之内",
        "同一場次之內",
    ),
    "Over days to weeks": ("几天到几周之间", "幾天到幾週之間"),
    "Receptors and enzymes adjust, and your baseline shifts down — this is the tolerance most people mean, and what the bar on each card shows. It returns once you stop, at a pace set by the receptor.": (
        "受体和酶会做出调整，你的基线也往下移——大多数人说的耐受就是这种，每张卡片上那条进度条显示的也是它。停用后基线就会回升，快慢由受体决定。",
        "受體和酶會做出調整，你的基線也往下移——大多數人說的耐受就是這種，每張卡片上那條進度條顯示的也是它。停用後基線就會回升，快慢由受體決定。",
    ),
    "With heavy, prolonged use": ("长期大量使用之后", "長期大量使用之後"),
    "This can entrench a deeper change that takes months to relax. It shows up only well past everyday or therapeutic doses — steady use doesn't reach it.": (
        "这会留下一种更深的变化，要好几个月才松得下来。它只在远超日常或治疗剂量时才出现——持续稳定地用也碰不到它。",
        "這會留下一種更深的變化，要好幾個月才鬆得下來。它只在遠超日常或治療劑量時才出現——持續穩定地用也碰不到它。",
    ),
    "Three timescales": ("三种时间尺度", "三種時間尺度"),
    "Two different drugs that hit the same receptor share tolerance. Recent LSD blunts a mushroom trip because both work at 5-HT2A; one benzodiazepine carries to another; one opioid to the next. That's why tolerance is tracked per receptor here, and why a “new” drug in the same family can still feel weak.": (
        "两种不同的药只要作用在同一个受体上，就会共享耐受。最近用过 LSD 会让蘑菇的体验变弱，因为两者都作用在 5-HT2A 上；一种苯二氮䓬会带到另一种；一种阿片类药物会带到下一种。所以这里的耐受是按受体来算的，也是为什么同一类里一种“新”药用起来还是可能很弱。",
        "兩種不同的藥只要作用在同一個受體上，就會共享耐受。最近用過 LSD 會讓蘑菇的體驗變弱，因為兩者都作用在 5-HT2A 上；一種苯二氮平會帶到另一種；一種鴉片類藥物會帶到下一種。所以這裡的耐受是按受體來算的，也是為什麼同一類裡一種「新」藥用起來還是可能很弱。",
    ),
    "Your body learns when to brace": ("你的身体会学着做好准备", "你的身體會學著做好準備"),
    "When a drug is taken repeatedly in the same place, with the same ritual, the body learns to pre-compensate — it starts pushing back before the dose even arrives. That conditioned response is a real part of tolerance: you feel less, partly because your system saw the cues and braced for it.": (
        "在同一个地方、按同一套习惯反复用药，身体会学着提前代偿——还没等剂量生效就开始做出反向调整。这种条件反应确实是耐受的一部分：你感觉减弱了，有一部分原因正是你的系统看到了那些信号，提前做好了准备。",
        "在同一個地方、按同一套習慣反覆用藥，身體會學著提前代償——還沒等劑量生效就開始做出反向調整。這種條件反應確實是耐受的一部分：你感覺減弱了，有一部分原因正是你的系統看到了那些訊號，提前做好了準備。",
    ),
    "Change the setting, lose the bracing": ("换个地方，准备就不在了", "換個地方，準備就不在了"),
    "In a new place, the conditioned push-back doesn't fire, and the same dose hits as if tolerance were lower. Heroin-tolerant rats given a familiar dose in a novel environment died at markedly higher rates than ones dosed in their usual cage — the pharmacology was the same, the conditioning was not (Siegel et al., Science 1982).": (
        "换一个地方，那种条件性的反向调整就不会启动，同样剂量的作用会像耐受更低时那样强。对海洛因已有耐受的大鼠在一个陌生环境下注射惯常剂量，死亡率明显高于在平时笼子里注射的——药理作用是一样的，条件反应不一样（Siegel 等，Science 1982）。",
        "換一個地方，那種條件性的反向調整就不會啟動，同樣劑量的作用會像耐受更低時那樣強。對海洛因已有耐受的大鼠在一個陌生環境下注射慣常劑量，死亡率明顯高於在平時籠子裡注射的——藥理作用是一樣的，條件反應不一樣（Siegel 等，Science 1982）。",
    ),
    "The cues alone can produce the opposite": (
        "光是信号就能引出反向效果",
        "光是訊號就能引出反向效果",
    ),
    "Once the compensatory response is conditioned, presenting the cues without the drug leaves the push-back running unopposed. The result feels like the drug's mirror: a stimulant's familiar setting without the stimulant can produce fatigue, an opioid's without the opioid can produce aches. This is one route into situational withdrawal.": (
        "一旦代偿反应被条件化了，只给信号不给药，反向调整就会在无抵消的情况下运作。感觉就像药效的反面：兴奋剂的熟悉环境里没有兴奋剂，可能会产生疲惫感；阿片类药物的熟悉环境里没有阿片类药物，可能会出现酸痛。这是情境性戒断的一条路径。",
        "一旦代償反應被條件化了，只給訊號不給藥，反向調整就會在無抵消的情況下運作。感覺就像藥效的反面：興奮劑的熟悉環境裡沒有興奮劑，可能會產生疲憊感；鴉片類藥物的熟悉環境裡沒有鴉片類藥物，可能會出現痠痛。這是情境性戒斷的一條路徑。",
    ),
    "Some tolerance only develops if you experience the effect": (
        "有些耐受只有在你体验到那种效果时才会形成",
        "有些耐受只有在你體驗到那種效果時才會形成",
    ),
    "Tolerance to amphetamine's appetite suppression does not build at all unless food is available while intoxicated — the tolerance is an instrumental response, not a receptor count (Carlton & Wolgin 1971). This means tolerance to one effect of a drug can exist while tolerance to another has never started.": (
        "苯丙胺对食欲的抑制，除非在药效期间有食物可吃，否则根本不会形成耐受——这种耐受是一种工具性反应，不是受体数量问题（Carlton & Wolgin 1971）。这意味着对一种药的某个效果可以有耐受，而对另一个效果的耐受可能从未开始。",
        "安非他命對食慾的抑制，除非在藥效期間有食物可吃，否則根本不會形成耐受——這種耐受是一種工具性反應，不是受體數量問題（Carlton & Wolgin 1971）。這意味著對一種藥的某個效果可以有耐受，而對另一個效果的耐受可能從未開始。",
    ),
    "The learned part of tolerance": ("耐受中学习来的部分", "耐受中學習來的部分"),
    "Model boundary": ("模型边界", "模型邊界"),
    "What this number does not include": ("这个数字没有包含的部分", "這個數字沒有包含的部分"),
    "Every layer above is pharmacodynamic — it is computed from your dose log and the clock. A large part of real tolerance is associative and context-specific: it attaches to the setting, the ritual and the cues around a dose, which is why tolerance measured in a familiar context can be substantially higher than tolerance in an unfamiliar one, and why the same cues without the dose can produce the opposite of the drug's effect. Piru cannot see any of that, because it does not record where you were or what you were doing. Treat the shift as a pharmacological estimate, not a total.": (
        "上面所有层级都是药效动力学层面的——根据你的剂量记录和时间来计算。真实耐受中有很大一部分是联结性的、跟环境绑定的：它和用药时的地点、仪式、周围的线索绑在一起。这就是为什么在熟悉环境下测到的耐受可以远高于陌生环境，也是为什么同样的线索、没有药物时，身体可以产生药效的反面。Piru 看不到这些，因为它不记录你在哪里、在做什么。把这个数字当作药理学估计来看，不是总量。",
        "上面所有層級都是藥效學層面的——根據你的劑量記錄和時間來計算。真實耐受中有很大一部分是聯結性的、跟環境綁定的：它和用藥時的地點、儀式、周圍的線索綁在一起。這就是為什麼在熟悉環境下測到的耐受可以遠高於陌生環境，也是為什麼同樣的線索、沒有藥物時，身體可以產生藥效的反面。Piru 看不到這些，因為它不記錄你在哪裡、在做什麼。把這個數字當作藥理學估計來看，不是總量。",
    ),
    "Real tolerance that drops after a break or a change of setting — which is exactly what makes returning to an old dose dangerous.": (
        "实打实的耐受，停一阵子或换了环境就会掉——这正是为什么回到以前的剂量会很危险。",
        "實打實的耐受，停一陣子或換了環境就會掉——這正是為什麼回到以前的劑量會很危險。",
    ),
    "Builds its own tolerance, and can also slow opioid tolerance when taken together.": (
        "自己会形成耐受，和阿片一起用时，还能减慢阿片耐受的形成。",
        "自己會形成耐受，和鴉片一起用時，還能減慢鴉片耐受的形成。",
    ),
    "Clean, predictable tolerance — the caffeine case.": (
        "干净、好预测的耐受——咖啡因就是这种。",
        "乾淨、好預測的耐受——咖啡因就是這種。",
    ),
    "Mostly fast receptor desensitization that recovers between uses rather than a lasting change.": (
        "主要是受体的快速脱敏，在两次使用之间就会恢复，而不是一种持久的变化。",
        "主要是受體的快速去敏感化，在兩次使用之間就會恢復，而不是一種持久的變化。",
    ),
    "Barely builds tolerance — the real risk is stopping suddenly: blood pressure can rebound hard. Taper, don't quit cold.": (
        "几乎不会形成耐受——真正的风险是突然停用：血压可能猛烈反弹。要逐渐减量，别一下子停掉。",
        "幾乎不會形成耐受——真正的風險是突然停用：血壓可能猛烈反彈。要逐漸減量，別一下子停掉。",
    ),
    "Barely builds tolerance — the real risk is stopping suddenly: heart rate and blood pressure can rebound. Taper, don't quit cold.": (
        "几乎不会形成耐受——真正的风险是突然停用：心率和血压可能反弹。要逐渐减量，别一下子停掉。",
        "幾乎不會形成耐受——真正的風險是突然停用：心率和血壓可能反彈。要逐漸減量，別一下子停掉。",
    ),
    "Generic class-default kinetics at the lowest confidence.": (
        "采用通用的类别默认动力学，可信度最低。",
        "採用通用的類別預設動力學，可信度最低。",
    ),
    "Log a few doses and your predicted tolerance shows up here. Anything you haven't taken recently counts as no tolerance.": (
        "记几次剂量，你的预测耐受就会出现在这里。最近没用过的都算没耐受。",
        "記幾次劑量，你的預測耐受就會出現在這裡。最近沒用過的都算沒耐受。",
    ),
    "Can't predict yet": ("还无法预测", "還無法預測"),
    "no tolerance": ("没耐受", "沒耐受"),
    "Most of it fades in %@ if you stop now.": (
        "如果现在停用，大部分会在 %@ 内消退。",
        "如果現在停用，大部分會在 %@ 內消退。",
    ),
    "Most of it fades in %@ if you stop now — the deep part takes months.": (
        "如果现在停用，大部分会在 %@ 内消退——最深的那部分要几个月。",
        "如果現在停用，大部分會在 %@ 內消退——最深的那部分要幾個月。",
    ),
    "After a break or in a new setting, tolerance drops — a dose that felt fine before can stop your breathing. Restart low.": (
        "停一阵子或换了环境后耐受会掉——以前没事的剂量，这时可能让你停止呼吸。重新开始一定要减量。",
        "停一陣子或換了環境後耐受會掉——以前沒事的劑量，這時可能讓你停止呼吸。重新開始一定要減量。",
    ),
    "Regular use over weeks builds physical dependence — stopping abruptly can be dangerous even if you don't feel tolerant. Taper gradually.": (
        "连续数周的规律使用会形成身体依赖——即使你没有感觉到耐受，突然停用也可能很危险。要逐步减量。",
        "連續數週的規律使用會形成身體依賴——即使你沒有感覺到耐受，突然停用也可能很危險。要逐步減量。",
    ),
    "Don't stop α₂-agonists cold after regular use — blood pressure can rebound. Taper.": (
        "规律使用 α₂ 激动剂后别一下子停掉——血压可能反弹。要逐渐减量。",
        "規律使用 α₂ 促效劑後別一下子停掉——血壓可能反彈。要逐漸減量。",
    ),
    "Don't stop beta-blockers cold after regular use — heart rate and blood pressure can rebound. Taper.": (
        "规律使用 β 受体阻滞剂后别一下子停掉——心率和血压可能反弹。要逐渐减量。",
        "規律使用 β 受體阻滯劑後別一下子停掉——心率和血壓可能反彈。要逐漸減量。",
    ),
    "Heavy chronic use has shifted your baseline; the deepest part recovers over months.": (
        "长期大量使用已经把你的基线压低了；最深的那部分要几个月才能恢复。",
        "長期大量使用已經把你的基線壓低了；最深的那部分要幾個月才能恢復。",
    ),
    "acute": ("急性", "急性"),
    "deep": ("深层", "深層"),
    "synthesis": ("合成", "合成"),
    "Tachyphylaxis": ("快速耐受", "快速耐受"),
    "Deep": ("深层", "深層"),
    "none": ("无", "無"),
    "now": ("现在", "現在"),
    "high": ("高", "高"),
    "low": ("低", "低"),
    "%lldmo": ("%lld 个月", "%lld 個月"),
    "%lldwk": ("%lld 周", "%lld 週"),
    "%lldd": ("%lld 天", "%lld 天"),
    # Pharmacology axis Stage 0 — confidence tiers + body-weight UI (2026-06-21)
    "High confidence": ("高可信度", "高可信度"),
    "Medium confidence": ("中等可信度", "中等可信度"),
    "Low confidence": ("低可信度", "低可信度"),
    "Unverified": ("未核实", "未核實"),
    "Your weight": ("你的体重", "你的體重"),
    "Source": ("来源", "來源"),
    "Apple Health": ("Apple 健康", "Apple 健康"),
    "Open Settings": ("打开设置", "打開設定"),
    "Apple Health isn't available on this device.": (
        "此设备不支持 Apple 健康。",
        "此裝置不支援 Apple 健康。",
    ),
    "kg": ("kg", "kg"),
    # Bottom-accessory "Log a dose" CTA 2026-06
    "Log a dose": ("记录剂量", "記錄劑量"),
    # Cake (PsychonautWiki 🍰 April-Fools entry) — emoji off the title, joke in detail
    # Detail-view Design D 2026-06 — merged dose/duration card, Show All effects,
    # Erowid as its own group, two-column Info/Chemistry grids, merged Sources.
    "Dose & Duration": ("剂量与时长", "劑量與時長"),
    # FreeOD Wiki overview section (locale-first Chinese substance descriptions).
    "Overview": ("概述", "概述"),
    "Machine-translated from FreeOD Wiki": ("由 FreeOD Wiki 机器翻译", "由 FreeOD Wiki 機器翻譯"),
    "Read more": ("展开", "展開"),
    "Read less": ("收起", "收起"),
    "+%lld more": ("还有 %lld 项", "還有 %lld 項"),
    "Show All": ("查看全部", "查看全部"),
    "Default route": ("默认途径", "預設途徑"),
    "PubChem CID": ("PubChem CID", "PubChem CID"),
    # Detail-view restructure 2026-06 — effects merge + chemistry fold + copyable
    "Search experiences on Erowid": ("在 Erowid 上搜索体验报告", "在 Erowid 上搜尋體驗報告"),
    "All effects": ("全部效应", "全部效應"),
    "All effects (%lld)": ("全部效应（%lld）", "全部效應（%lld）"),
    # PsychonautWiki effect categories (dynamic LocalizedStringKey — not auto-extracted)
    "Physical": ("身体", "身體"),
    "Cognitive": ("认知", "認知"),
    "Visual": ("视觉", "視覺"),
    "Auditory": ("听觉", "聽覺"),
    "Tactile": ("触觉", "觸覺"),
    "Multisensory": ("多重感官", "多重感官"),
    "Sensory": ("感官", "感官"),
    "Smell and taste": ("嗅觉与味觉", "嗅覺與味覺"),
    "Transpersonal": ("超个人", "超個人"),
    "Disconnective": ("解离", "解離"),
    # DB cleanup 2026-06 — sources/references merge
    "Databases": ("数据库", "資料庫"),
    # DB cleanup 2026-06 — RC taxonomy rename, Other bucket, limited-data badge
    "Other / Miscellaneous": ("其他 / 杂项", "其他 / 雜項"),
    "Everything that doesn't fit a class above.": (
        "不属于以上任何类别的物质。",
        "不屬於以上任何類別的物質。",
    ),
    "Limited data": ("数据有限", "資料有限"),
    # Library redesign — family cards, taxonomy renames, sub-class blurbs
    "Stimulants": ("兴奋剂", "興奮劑"),
    "Empathogens": ("共情剂", "共情劑"),
    "Hallucinogens": ("致幻剂", "致幻劑"),
    "Cannabinoids": ("大麻素", "大麻素"),
    "Opioids": (
        "阿片类",
        "鴉片類",
    ),
    "Sedatives & Depressants": ("镇静与抑制剂", "鎮靜與抑制劑"),
    "Peptides": ("肽类", "肽類"),
    "Mind & Cognition": ("精神与认知", "精神與認知"),
    "Pharmaceuticals": ("药品", "藥品"),
    "Supplements": (
        "膳食补充剂",
        "膳食補充劑",
    ),
    "Research Chemicals": ("研究化学品", "研究化學品"),
    "Sedative-Hypnotic": ("镇静催眠药", "鎮靜催眠藥"),
    "Everyday substances, by the names most people know.": (
        "日常物质，以大多数人熟知的名称呈现。",
        "日常物質，以大多數人熟知的名稱呈現。",
    ),
    "Energy, focus, and wakefulness.": ("提升精力、专注与清醒。", "提升精力、專注與清醒。"),
    "Warmth, empathy, and emotional openness.": (
        "温暖、共情与情感开放。",
        "溫暖、共情與情感開放。",
    ),
    "Alter perception, thought, and sense of reality.": (
        "改变知觉、思维与现实感。",
        "改變知覺、思維與現實感。",
    ),
    "Relaxation, euphoria, and altered senses.": (
        "放松、欣快与感官改变。",
        "放鬆、欣快與感官改變。",
    ),
    "Pain relief, euphoria, and sedation.": ("镇痛、欣快与镇静。", "鎮痛、欣快與鎮靜。"),
    "Calm and slow the central nervous system.": (
        "平静并减缓中枢神经系统。",
        "平靜並減緩中樞神經系統。",
    ),
    "GLP-1, healing, and research peptides.": (
        "GLP-1、修复与研究类肽。",
        "GLP-1、修復與研究類肽。",
    ),
    "Mood, psychiatric, and cognitive medications.": (
        "情绪、精神与认知类药物。",
        "情緒、精神與認知類藥物。",
    ),
    "Vitamins, minerals, and nutrients.": ("维生素、矿物质与营养素。", "維生素、礦物質與營養素。"),
    "Novel and lesser-characterized compounds.": (
        "新型且研究较少的化合物。",
        "新型且研究較少的化合物。",
    ),
    "Serotonergic — LSD, psilocybin, mescaline.": (
        "血清素能——LSD、裸盖菇素、麦司卡林。",
        "血清素能——LSD、裸蓋菇素、麥司卡林。",
    ),
    "NMDA antagonists — ketamine, DXM, PCP.": (
        "NMDA 拮抗剂——氯胺酮、右美沙芬、苯环利定。",
        "NMDA 拮抗劑——氯胺酮、右美沙芬、苯環利定。",
    ),
    "Anticholinergic — DPH, datura, Benadryl.": (
        "抗胆碱能——苯海拉明、曼陀罗、Benadryl。",
        "抗膽鹼能——苯海拉明、曼陀羅、Benadryl。",
    ),
    "GABA-A modulators — diazepam, alprazolam.": (
        "GABA-A 调节剂——地西泮、阿普唑仑。",
        "GABA-A 調節劑——地西泮、阿普唑侖。",
    ),
    "Barbiturates, sedative-hypnotics, and Z-drugs.": (
        "巴比妥类、镇静催眠药与 Z 类药物。",
        "巴比妥類、鎮靜催眠藥與 Z 類藥物。",
    ),
    "SSRIs, SNRIs, and MAOIs.": ("SSRI、SNRI 与 MAOI。", "SSRI、SNRI 與 MAOI。"),
    "Dopamine antagonists — quetiapine, risperidone.": (
        "多巴胺拮抗剂——喹硫平、利培酮。",
        "多巴胺拮抗劑——喹硫平、利培酮。",
    ),
    "Racetams, choline, and cognitive aids.": (
        "拉西坦类、胆碱与认知辅助剂。",
        "拉西坦類、膽鹼與認知輔助劑。",
    ),
    "AMPA-receptor positive modulators.": ("AMPA 受体正向调节剂。", "AMPA 受體正向調節劑。"),
    "Wakefulness — modafinil, armodafinil.": (
        "促清醒——莫达非尼、阿莫达非尼。",
        "促清醒——莫達非尼、阿莫達非尼。",
    ),
    "Non-opioid pain relief — NSAIDs, paracetamol.": (
        "非阿片类镇痛——NSAID、对乙酰氨基酚。",
        "非鴉片類鎮痛——NSAID、乙醯胺酚。",
    ),
    "Allergy and sleep antihistamines.": (
        "抗过敏与助眠抗组胺药。",
        "抗過敏與助眠抗組織胺藥。",
    ),
    "Blood pressure, heart, and cholesterol.": ("血压、心脏与胆固醇。", "血壓、心臟與膽固醇。"),
    "Antibiotics, antivirals, and antifungals.": (
        "抗生素、抗病毒与抗真菌药。",
        "抗生素、抗病毒與抗真菌藥。",
    ),
    "Acid, nausea, and gut motility.": ("胃酸、恶心与胃肠动力。", "胃酸、噁心與胃腸動力。"),
    "Inhalers, decongestants, and cough.": (
        "吸入剂、减充血剂与止咳药。",
        "吸入劑、減充血劑與止咳藥。",
    ),
    "Hormones, thyroid, and metabolic drugs.": (
        "激素、甲状腺与代谢药物。",
        "激素、甲狀腺與代謝藥物。",
    ),
    "Immune modulators and steroids.": ("免疫调节剂与类固醇。", "免疫調節劑與類固醇。"),
    "Seizure and mood-stabilizing drugs.": (
        "抗癫痫与情绪稳定药物。",
        "抗癲癇與情緒穩定藥物。",
    ),
    "Highest overdose risk": ("过量风险最高", "過量風險最高"),
    # Quick-log redesign — dose tray (staging, shared When/Tags/Location, inline editor)
    "%lld min ago": ("%lld 分钟前", "%lld 分鐘前"),
    "Pick date & time…": ("选择日期和时间…", "選擇日期和時間…"),
    "Remove": ("移除", "移除"),
    "When": ("时间", "時間"),
    "Add note…": ("添加备注…", "新增備註…"),
    "Collapse": ("收起", "收合"),
    "Collapses the editor": ("收起编辑器", "收合編輯器"),
    "Expands the editor": ("展开编辑器", "展開編輯器"),
    "Log %@ %@ of %@": ("记录 %3$@ %1$@ %2$@", "記錄 %3$@ %1$@ %2$@"),
    "Log %@ of %@": ("记录 %2$@ %1$@", "記錄 %2$@ %1$@"),
    # Journal state card (2026-07-22 plan/state/log restructure)
    "Active Now": ("当前活跃", "目前活躍"),
    # My Meds row split + Active Now → session (2026-07-22)
    "Opens this session.": (
        "打开这个场次。",
        "開啟這個場次。",
    ),
    "Opens this med": ("打开此用药", "打開此用藥"),
    "%@ details": ("%@ 详情", "%@ 詳情"),
    # Quick-log VoiceOver audit fixes (2026-07-12)
    "Active dose": ("活性剂量", "活性劑量"),
    "Shows dosing advice": ("显示用药建议", "顯示用藥建議"),
    "Collapses the dosing advice": ("收起用药建议", "收起用藥建議"),
    "Custom dose of %@": ("自定 %@ 剂量", "自訂 %@ 劑量"),
    "Staged %@": ("已暂存 %@", "已暫存 %@"),
    "%lld staged": ("已暂存 %lld", "已暫存 %lld"),
    "Decrease amount": ("减少剂量", "減少劑量"),
    "Increase amount": ("增加剂量", "增加劑量"),
    "Dose unit": ("剂量单位", "劑量單位"),
    "Salt form": ("盐形式", "鹽形式"),
    "Isomer": ("异构体", "異構體"),
    "^[%lld item](inflect: true), all logged today": (
        "%lld 项，今天已全部记录",
        "%lld 項，今天已全部記錄",
    ),
    "^[%lld tag](inflect: true)": ("%lld 个标签", "%lld 個標籤"),
    "Reminder on": ("提醒已开启", "提醒已開啟"),
    # App-wide VoiceOver audit — Journal / Library / Tools / Insights / Settings (2026-07-12)
    "%@ in %@ at %lld percent": ("%@ 处于%@，%lld%%", "%@ 處於%@，%lld%%"),
    "%@ at %lld percent": ("%@ %lld%%", "%@ %lld%%"),
    "Dose level": ("剂量级别", "劑量級別"),
    "%@ range, %@": ("%@ 范围，%@", "%@ 範圍，%@"),
    "Session options": (
        "场次选项",
        "場次選項",
    ),
    "Moving here will ask for a new time": (
        "移到此处将要求输入新时间",
        "移到此處將要求輸入新時間",
    ),
    "Edits the note": ("编辑备注", "編輯備註"),
    "Previous month": ("上个月", "上個月"),
    "Next month": ("下个月", "下個月"),
    "%@, Today": ("%@，今天", "%@，今天"),
    "Opens in Maps": ("在地图中打开", "在地圖中開啟"),
    "Used by %@": ("已用于 %@", "已用於 %@"),
    "Progress": ("进度", "進度"),
    "Step %lld of %lld": ("第 %lld 步，共 %lld 步", "第 %lld 步，共 %lld 步"),
    "Page %lld of %lld": ("第 %lld 页，共 %lld 页", "第 %lld 頁，共 %lld 頁"),
    "Locating…": ("定位中…", "定位中…"),
    "Concentration over time": ("浓度随时间变化", "濃度隨時間變化"),
    "Recovery by mechanism": ("按机制的恢复", "按機制的恢復"),
    "morning": ("上午", "上午"),
    "afternoon": ("下午", "下午"),
    "evening": ("傍晚", "傍晚"),
    "night": ("夜间", "夜間"),
    "%lld doses plotted; the largest reaches about %@× the total exposure of one reference dose.": (
        "已绘制 %lld 个剂量；最大者约达单次参考剂量总暴露量的 %@ 倍。",
        "已繪製 %lld 個劑量；最大者約達單次參考劑量總暴露量的 %@ 倍。",
    ),
    "%@ and %@ over time; both active from %@ to %@.": (
        "%@ 与 %@ 随时间变化；两者均在 %@ 至 %@ 期间具活性。",
        "%@ 與 %@ 隨時間變化；兩者均在 %@ 至 %@ 期間具活性。",
    ),
    "%@ and %@ over time; no overlapping active window.": (
        "%@ 与 %@ 随时间变化；无重叠的活性时段。",
        "%@ 與 %@ 隨時間變化；無重疊的活性時段。",
    ),
    "Starts at %@, fading toward none.": (
        "从 %@ 开始，逐渐消退至无。",
        "從 %@ 開始，逐漸消退至無。",
    ),
    "Now %@; peaked %@ about %@ after the first dose": (
        "当前 %1$@；在首次剂量后约 %3$@ 达到峰值 %2$@",
        "目前 %1$@；在首次劑量後約 %3$@ 達到峰值 %2$@",
    ),
    "Now %@; expected to peak %@ about %@ after the first dose": (
        "当前 %1$@；预计在首次剂量后约 %3$@ 达到峰值 %2$@",
        "目前 %1$@；預計在首次劑量後約 %3$@ 達到峰值 %2$@",
    ),
    "View citation": ("查看引用", "查看引用"),
    "Binding strength": ("结合强度", "結合強度"),
    "%lld of 3": ("%lld / 3", "%lld / 3"),
    "%lld nM": ("%lld nM", "%lld nM"),
    "Enantiomer potency": ("对映体效价", "對映體效價"),
    "Dopamine–serotonin lean": ("多巴胺–血清素倾向", "多巴胺–血清素傾向"),
    "About this section": ("关于此部分", "關於此部分"),
    # Quick-log v2 — morphing dock, Daily routine card
    "Add another…": ("再添加一个…", "再新增一個…"),
    "≈%@ %@ active · %@ ago · %@ left": (
        "体内约 %1$@ %2$@ · %3$@前 · 剩 %4$@",
        "體內約 %1$@ %2$@ · %3$@前 · 剩 %4$@",
    ),
    "≈%@ %@ active · %@ ago": ("体内约 %1$@ %2$@ · %3$@前", "體內約 %1$@ %2$@ · %3$@前"),
    "Create custom substance": ("创建自定义物质", "建立自訂物質"),
    "Find a Place…": ("查找地点…", "尋找地點…"),
    "Location access is off": ("定位权限已关闭", "定位權限已關閉"),
    "Turn on location access in Settings to use your current location.": (
        "请在设置中开启定位权限，以使用你的当前位置。",
        "請在設定中開啟定位權限，以使用你的目前位置。",
    ),
    "Location: %@": ("位置：%@", "位置：%@"),
    "Dose time: %@": ("剂量时间：%@", "劑量時間：%@"),
    "Recents": ("最近", "最近"),
    # Routines (multi-routine rework; Routine = 日常, established term)
    "Remind Me": ("提醒我", "提醒我"),
    "Clear search": ("清除搜索", "清除搜尋"),
    "Common %@–%@ %@": ("常用 %1$@–%2$@ %3$@", "常用 %1$@–%2$@ %3$@"),
    # Settings restructure — progressive disclosure cleanup
    "Notifications": ("通知", "通知"),
    "Data": ("数据", "資料"),
    "No Substance Colors": ("暂无物质配色", "暫無物質配色"),
    "No Substances Yet": ("暂无物质", "暫無物質"),
    "Colors appear here after you log your first entry. Tap one to change it.": (
        "记录第一条条目后，配色会显示在这里。点按即可更改。",
        "記錄第一筆項目後，配色會顯示在這裡。點按即可更改。",
    ),
    "Substances you create or personalize appear here. You can also create them from the Quick Log search.": (
        "你创建或个性化的物质会显示在这里。你也可以在快捷记录搜索中创建它们。",
        "你建立或個人化的物質會顯示在這裡。你也可以在快捷記錄搜尋中建立它們。",
    ),
    # Session model — Journal grouping, detail, overrides, widget
    "Yesterday": ("昨天", "昨天"),
    "Medications": ("用药", "用藥"),
    "Session": (
        "场次",
        "場次",
    ),
    "No active session": (
        "暂无进行中的场次",
        "暫無進行中的場次",
    ),
    "No Sessions": (
        "暂无场次",
        "暫無場次",
    ),
    "Move to Session…": (
        "移至其他场次…",
        "移至其他場次…",
    ),
    "Move %@": ("移动 %@", "移動 %@"),
    "New Session": (
        "新建场次",
        "新增場次",
    ),
    "Move To": ("移至", "移至"),
    "Nowhere to Move": ("无处可移", "無處可移"),
    "This is the only session.": (
        "这是唯一的场次。",
        "這是唯一的場次。",
    ),
    "Move": ("移动", "移動"),
    "Set Time": ("设置时间", "設定時間"),
    "New time on %@": ("%@ 的新时间", "%@ 的新時間"),
    "%@ is logged on a different day. Pick a time within this session's day so the session stays a single day.": (
        "%@ 记录于另一天。请在本场所在的当天选择一个时间，使其保持在同一天内。",
        "%@ 記錄於另一天。請在本場所在的當天選擇一個時間，使其保持在同一天內。",
    ),
    "Location": ("位置", "位置"),
    "Current Location": ("当前位置", "目前位置"),
    "Results": ("搜索结果", "搜尋結果"),
    "Add Location": ("添加位置", "新增位置"),
    "Change Location": ("更改位置", "變更位置"),
    "Remove location": ("移除位置", "移除位置"),
    "Search for a place or address": ("搜索地点或地址", "搜尋地點或地址"),
    "Location access is off. Turn it on in Settings to use your current location.": (
        "位置访问已关闭。请在“设置”中开启以使用当前位置。",
        "位置存取已關閉。請在「設定」中開啟以使用目前位置。",
    ),
    "Piru Backup": ("Piru 备份", "Piru 備份"),
    "A complete backup you can restore into Piru": (
        "可恢复到 Piru 的完整备份",
        "可還原至 Piru 的完整備份",
    ),
    "PsychonautWiki Format": ("PsychonautWiki 格式", "PsychonautWiki 格式"),
    "For importing into the PsychonautWiki app": (
        "用于导入 PsychonautWiki 应用",
        "用於匯入 PsychonautWiki 應用程式",
    ),
    "Data & Backup": ("数据与备份", "資料與備份"),
    "iCloud Backup": ("iCloud 备份", "iCloud 備份"),
    "Encrypted Backup…": ("加密备份…", "加密備份…"),
    "Passphrase-protected — save or send it anywhere": (
        "由口令保护——可保存或发送到任何地方",
        "由通行碼保護——可儲存或傳送到任何地方",
    ),
    "Import from a File…": ("从文件导入…", "從檔案匯入…"),
    "A Piru or PsychonautWiki JSON file": (
        "Piru 或 PsychonautWiki 的 JSON 文件",
        "Piru 或 PsychonautWiki 的 JSON 檔案",
    ),
    "Restore Encrypted Backup…": ("恢复加密备份…", "還原加密備份…"),
    "A passphrase-protected .piruenc file": (
        "由口令保护的 .piruenc 文件",
        "由通行碼保護的 .piruenc 檔案",
    ),
    "From your automatic iCloud backups": (
        "来自你的自动 iCloud 备份",
        "來自你的自動 iCloud 備份",
    ),
    "Import Failed": ("导入失败", "匯入失敗"),
    "Import Complete": ("导入完成", "匯入完成"),
    "Your data was imported.": ("你的数据已导入。", "你的資料已匯入。"),
    "The file is missing a required field: %@.": (
        "文件缺少必需字段：%@。",
        "檔案缺少必要欄位：%@。",
    ),
    "The file has an empty value for a required field: %@.": (
        "文件的必需字段为空值：%@。",
        "檔案的必要欄位為空值：%@。",
    ),
    "The file isn't valid JSON.": ("文件不是有效的 JSON。", "檔案不是有效的 JSON。"),
    "The file has an unexpected value at: %@.": (
        "文件在此处包含意外的值：%@。",
        "檔案在此處包含非預期的值：%@。",
    ),
    "Delete Failed": ("删除失败", "刪除失敗"),
    # Data storage & recovery (DataStorageView, store-recovery + diagnostics UI)
    "%lld records": ("%lld 条记录", "%lld 筆記錄"),
    "Auto-recovered Data": ("自动恢复的数据", "自動還原的資料"),
    "Before a Restore": ("恢复前", "還原前"),
    "Before You Deleted Everything": ("删除全部数据前", "刪除全部資料前"),
    "Checking for recoverable copies…": ("正在检查可恢复的副本…", "正在檢查可還原的副本…"),
    "Couldn't Prepare Logs": ("无法准备日志", "無法準備記錄檔"),
    "Couldn't prepare the diagnostics file.": ("无法准备诊断文件。", "無法準備診斷檔案。"),
    "Custom Colors": ("自定义颜色", "自訂顏色"),
    "Daily Medications": ("每日用药", "每日用藥"),
    "Everything Piru stores locally. Your dose data lives only on this device unless you turn on iCloud backup.": (
        "Piru 在本机存储的全部内容。除非开启 iCloud 备份，你的剂量数据只保存在这台设备上。",
        "Piru 在本機儲存的全部內容。除非開啟 iCloud 備份，你的劑量資料只保存在這部裝置上。",
    ),
    "Export & Import": ("导出与导入", "匯出與匯入"),
    "Export…": ("导出…", "匯出…"),
    "From a file, an encrypted backup, or iCloud": (
        "从文件、加密备份或 iCloud",
        "從檔案、加密備份或 iCloud",
    ),
    "Generated by Piru · kagerou.glass/piru": (
        "由 Piru 生成 · kagerou.glass/piru",
        "由 Piru 產生 · kagerou.glass/piru",
    ),
    "Import & Restore…": ("导入与恢复…", "匯入與還原…"),
    "No recoverable copies on this device.": (
        "此设备上没有可恢复的副本。",
        "此裝置上沒有可還原的副本。",
    ),
    "On This Device": ("在此设备上", "在此裝置上"),
    "Piru couldn't open your journal this time, so it's running with temporary storage. **Nothing has been deleted** — your doses and sessions are safe on this device and a future update will restore them automatically.\n\nSending the logs helps us ship that fix faster. They describe the storage problem only — never your dose data.": (
        "Piru 这次未能打开你的日记，目前正以临时存储运行。**没有任何数据被删除**——你的剂量和场次仍安全保存在这台设备上，未来的更新会自动恢复它们。\n\n发送日志能帮助我们更快推出修复。日志只描述存储问题本身——绝不包含你的剂量数据。",
        "Piru 這次未能開啟你的日記，目前正以暫時儲存空間執行。**沒有任何資料被刪除**——你的劑量和場次仍安全保存在這部裝置上，未來的更新會自動還原它們。\n\n傳送記錄檔能幫助我們更快推出修正。記錄檔只描述儲存問題本身——絕不包含你的劑量資料。",
    ),
    "Piru, PsychonautWiki, or an encrypted backup": (
        "Piru、PsychonautWiki 或加密备份",
        "Piru、PsychonautWiki 或加密備份",
    ),
    "Quick-Log Shortcuts": (
        "快捷记录快捷项",
        "快捷記錄快捷項目",
    ),
    "Recoverable Copies": ("可恢复的副本", "可還原的副本"),
    "Recovered Data": ("恢复的数据", "還原的資料"),
    "Restore This Copy?": ("恢复此副本？", "還原此副本？"),
    "Restored": ("已恢复", "已還原"),
    "Saved Copy": ("已保存的副本", "已儲存的副本"),
    "Send Logs to Developer": ("向开发者发送日志", "傳送記錄檔給開發者"),
    "Sessions": (
        "场次",
        "場次",
    ),
    "Store Size": ("存储大小", "儲存空間大小"),
    "Summary": ("摘要", "摘要"),
    "This replaces your current data with the %@ in this copy. A snapshot of your current data is taken first, so it's reversible. Restart Piru afterwards to load it.": (
        "这将用此副本中的 %@ 替换你当前的数据。替换前会先为当前数据创建快照，因此可以撤销。之后请重新启动 Piru 以加载。",
        "這會用此副本中的 %@ 取代你目前的資料。取代前會先為目前資料建立快照，因此可以復原。之後請重新啟動 Piru 以載入。",
    ),
    "unknown date": ("未知日期", "未知日期"),
    "unreadable": ("无法读取", "無法讀取"),
    "When on, Piru encrypts your journal and saves it to your private iCloud Drive each time you leave the app. The key is stored only in your iCloud Keychain, so it's end-to-end encrypted — **neither Apple nor Piru can read it** — and it restores on your other devices signed in to the same Apple Account.": (
        "开启后，每次你离开 App 时，Piru 都会加密你的日记并保存到你的私人 iCloud 云盘。密钥只存储在你的 iCloud 钥匙串中，因此是端到端加密——**Apple 和 Piru 都无法读取**——并且会在登录同一 Apple 账户的其他设备上自动恢复。",
        "開啟後，每次你離開 App 時，Piru 都會加密你的日記並儲存到你的私人 iCloud 雲碟。金鑰只儲存在你的 iCloud 鑰匙圈中，因此是端對端加密——**Apple 和 Piru 都無法讀取**——並且會在登入同一 Apple 帳號的其他裝置上自動還原。",
    ),
    "Your Data Is Safe": ("你的数据是安全的", "你的資料是安全的"),
    "Your data was restored. Please force-quit and reopen Piru to load it.": (
        "你的数据已恢复。请强制退出并重新打开 Piru 以加载。",
        "你的資料已還原。請強制結束並重新開啟 Piru 以載入。",
    ),
    "Rename Session": (
        "重命名场次",
        "重新命名場次",
    ),
    "Session title": (
        "场次标题",
        "場次標題",
    ),
    "Add Title": ("添加标题", "新增標題"),
    "Rename": ("重命名", "重新命名"),
    "Add Note": ("添加备注", "新增備註"),
    "Edit Note": ("编辑备注", "編輯備註"),
    "Delete Note": ("删除备注", "刪除備註"),
    "Merge with Previous": ("与上一段合并", "與上一段合併"),
    "Note": ("备注", "備註"),
    "Split Session Here": (
        "在此拆分场次",
        "在此拆分場次",
    ),
    "Split at Longest Break (%@)": ("在最长间隔处拆分（%@）", "在最長間隔處拆分（%@）"),
    "No substances logged in this session.": (
        "本场没有记录任何物质。",
        "本場沒有記錄任何物質。",
    ),
    "Current Session": (
        "当前场次",
        "目前場次",
    ),
    # Substance detail — consolidated dose/duration card + share
    "Release Window": (
        "释放时间窗",
        "釋放時間窗",
    ),
    "Share drug info": ("分享药物信息", "分享藥物資訊"),
    "Move to Front": ("移到最前", "移到最前"),
    "Move to Back": ("移到最后", "移到最後"),
    "Select": ("选择", "選擇"),
    "Remove from Quick Log": (
        "从快捷记录中移除",
        "從快捷記錄中移除",
    ),
    "Expand Session Graph": (
        "展开场次图表",
        "展開場次圖表",
    ),
    "Always show the full-height timeline. When off, graphs start compact — expand from the graph menu.": (
        "始终显示全高时间线。关闭后图表以紧凑模式显示——从图表菜单展开。",
        "始終顯示全高時間軸。關閉後圖表以精簡模式顯示——從圖表選單展開。",
    ),
    # Categories (SubstanceCategory)
    "Stimulant": ("兴奋剂", "興奮劑"),
    "Psychedelic": (
        "迷幻剂",
        "迷幻劑",
    ),
    "Dissociative": ("解离剂", "解離劑"),
    "Dysdelic": ("暗幻剂", "暗幻劑"),
    "Opioid": (
        "阿片类",
        "鴉片類",
    ),
    "Benzodiazepine": (
        "苯二氮䓬类",
        "苯二氮平類",
    ),
    "GABAergic": ("GABA 类", "GABA 類"),
    "Empathogen": ("共情剂", "共情劑"),
    "Cannabinoid": ("大麻素", "大麻素"),
    "Nootropic": (
        "益智药",
        "益智藥",
    ),
    "AMPAkine": ("安帕金", "安帕金"),
    "Eugeroic": ("促醒剂", "促醒劑"),
    "Depressant": ("抑制剂", "抑制劑"),
    "Orexin Antagonist": ("食欲素拮抗剂", "食慾素拮抗劑"),
    # DORA (orexin antagonist) mechanism of action + interactions (2026-07-05).
    "Dual Orexin Receptor Antagonist (DORA)": (
        "双重食欲素受体拮抗剂（DORA）",
        "雙重食慾素受體拮抗劑（DORA）",
    ),
    'Competitively blocks the orexin (hypocretin) receptors OX1R and OX2R, the targets of the wake-promoting neuropeptides orexin-A and orexin-B released from the lateral hypothalamus. Rather than broadly sedating the brain like a GABAergic hypnotic, it withdraws a specific "stay awake" drive that stabilizes arousal — permitting the natural transition into sleep with largely preserved sleep architecture and arousability. Because it does not enhance GABA or depress brainstem respiratory centers, it lacks the respiratory-depression synergy and dependence liability characteristic of benzodiazepines, Z-drugs, and other GABAergic sedatives.': (
        "竞争性阻断食欲素（下丘脑分泌素）受体 OX1R 和 OX2R，这两种受体是外侧下丘脑释放的促醒神经肽食欲素-A 和食欲素-B 的作用靶点。它不像 GABA 能催眠药那样广泛抑制大脑，而是撤除一种维持觉醒的特定“保持清醒”驱动力——让人自然过渡到睡眠，同时基本保留睡眠结构和可唤醒性。由于它既不增强 GABA，也不抑制脑干呼吸中枢，因此没有苯二氮䓬类、Z 类药物及其他 GABA 能镇静剂所特有的呼吸抑制协同作用和依赖风险。",
        "競爭性阻斷食慾素（下視丘分泌素）受體 OX1R 和 OX2R，這兩種受體是外側下視丘釋放的促醒神經肽食慾素-A 和食慾素-B 的作用標的。它不像 GABA 能催眠藥那樣廣泛抑制大腦，而是撤除一種維持覺醒的特定「保持清醒」驅動力——讓人自然過渡到睡眠，同時基本保留睡眠結構和可喚醒性。由於它既不增強 GABA，也不抑制腦幹呼吸中樞，因此沒有苯二氮平類、Z 類藥物及其他 GABA 能鎮靜劑所特有的呼吸抑制協同作用和依賴風險。",
    ),
    "Alcohol stacks psychomotor and memory impairment on top of the sleep med (and raises lemborexant's blood levels) — expect worse next-day grogginess and unsteadiness. The labels advise against drinking with these.": (
        "酒精会在这类安眠药之上叠加精神运动和记忆损害（并会升高莱博雷生的血药浓度）——次日昏沉和站立不稳会更明显。药品说明书建议服用期间不要饮酒。",
        "酒精會在這類安眠藥之上疊加精神運動和記憶損害（並會升高萊博雷生的血藥濃度）——隔日昏沉和站立不穩會更明顯。藥品仿單建議服用期間不要飲酒。",
    ),
    "Antidepressant": (
        "抗抑郁药",
        "抗憂鬱藥",
    ),
    "Antipsychotic": ("抗精神病药", "抗精神病藥"),
    "Analgesic": ("镇痛药", "鎮痛藥"),
    "Antihistamine": (
        "抗组胺药",
        "抗組織胺藥",
    ),
    "Cardiovascular": ("心血管药", "心血管藥"),
    "Antimicrobial": ("抗菌药", "抗菌藥"),
    "Gastrointestinal": ("胃肠药", "胃腸藥"),
    "Respiratory": ("呼吸系统药", "呼吸系統藥"),
    "Endocrine": ("内分泌药", "內分泌藥"),
    "Immunological": ("免疫药", "免疫藥"),
    "Supplement": (
        "膳食补充剂",
        "膳食補充劑",
    ),
    "Peptide": ("肽类", "肽類"),
    "Anticonvulsant": (
        "抗惊厥药",
        "抗痙攣藥",
    ),
    "Other": ("其他", "其他"),
    # Routes of administration
    "Oral": ("口服", "口服"),
    "Sublingual": ("舌下", "舌下"),
    "Buccal": ("颊黏膜", "頰黏膜"),
    "Insufflation": ("鼻吸", "鼻吸"),
    "Inhalation": ("吸入", "吸入"),
    "Intravenous": ("静脉注射", "靜脈注射"),
    "Intramuscular": ("肌肉注射", "肌肉注射"),
    "Subcutaneous": ("皮下注射", "皮下注射"),
    "Transdermal": ("透皮", "透皮"),
    "Rectal": ("直肠给药", "直腸給藥"),
    # Dose levels
    "Sub-threshold": ("阈下", "閾下"),
    "Threshold": ("阈值", "閾值"),
    "Light": (
        "轻微",
        "輕微",
    ),
    "Common": (
        "中等",
        "中等",
    ),
    "Strong": (
        "强烈",
        "強烈",
    ),
    "Heavy": ("大剂量", "大劑量"),
    # Binding actions (BindingAction)
    "Agonist": (
        "激动剂",
        "促效劑",
    ),
    "Partial Agonist": (
        "部分激动剂",
        "部分促效劑",
    ),
    "Antagonist": ("拮抗剂", "拮抗劑"),
    "Inverse Agonist": (
        "反向激动剂",
        "反向促效劑",
    ),
    "PAM": (
        "正向变构调节剂（PAM）",
        "正向變構調節劑（PAM）",
    ),
    "NAM": (
        "负向变构调节剂（NAM）",
        "負向變構調節劑（NAM）",
    ),
    "Reuptake Inhibitor": ("再摄取抑制剂", "再攝取抑制劑"),
    "Releasing Agent": ("释放剂", "釋放劑"),
    "Enzyme Inhibitor": ("酶抑制剂", "酶抑制劑"),
    "Channel Blocker": ("通道阻滞剂", "通道阻滯劑"),
    "Modulator": ("调节剂", "調節劑"),
    # Phases
    "Onset": ("起效", "起效"),
    "Come-up": ("上升期", "上升期"),
    "Peak": (
        "高峰期",
        "高峰期",
    ),
    "Offset": (
        "消退期",
        "消退期",
    ),
    "Afterglow": ("余韵", "餘韻"),
    "Effects ended": ("效果已结束", "效果已結束"),
    "Total": ("总计", "總計"),
    "~%@ hours": ("约 %@ 小时", "約 %@ 小時"),
    "~%@ – %@ hours": ("约 %1$@ – %2$@ 小时", "約 %1$@ – %2$@ 小時"),
    "~%lld minutes": ("约 %lld 分钟", "約 %lld 分鐘"),
    "~%lld – %lld minutes": ("约 %1$lld – %2$lld 分钟", "約 %1$lld – %2$lld 分鐘"),
    # Frequencies
    "Daily": ("每日", "每日"),
    "Every other day": ("隔日", "隔日"),
    "Weekly": ("每周", "每週"),
    "Every 2 weeks": ("每两周", "每兩週"),
    "Monthly": ("每月", "每月"),
    "Specific days": ("指定日期", "指定日期"),
    "Every 2 days": ("每两天", "每兩天"),
    "Biweekly": ("两周一次", "兩週一次"),
    "Custom days": (
        "自定日期",
        "自訂日期",
    ),
    # Navigation / Tabs
    "Journal": (
        "日记",
        "日記",
    ),
    "Library": ("物质库", "物質庫"),
    "Tools": ("工具", "工具"),
    "Insights": ("洞察", "洞察"),
    "Settings": ("设置", "設定"),
    "Calculator": ("计算器", "計算器"),
    "Get Help": (
        "获取帮助",
        "取得協助",
    ),
    "Search entries...": ("搜索记录…", "搜尋記錄…"),
    "Search substances...": ("搜索物质…", "搜尋物質…"),
    # Quick-log native dock sheet (2026-07-07)
    "Cancel search": ("取消搜索", "取消搜尋"),
    "Edit Drinks…": ("编辑饮品…", "編輯飲品…"),
    "Drinks": ("饮品", "飲品"),
    "New Drink": ("新增饮品", "新增飲品"),
    "Edit Drink": ("编辑饮品", "編輯飲品"),
    "Edit routines and favorites": ("编辑日常与收藏", "編輯日常與收藏"),
    "Collapsed": ("已折叠", "已折疊"),
    "Expanded": ("已展开", "已展開"),
    "Needs an amount": ("需要填写剂量", "需要填寫劑量"),
    "Search": ("搜索", "搜尋"),
    # Search redesign 2026-06 (landing + class grid + journal→library fallback)
    "Recently Searched": ("最近搜索", "最近搜尋"),
    "Browse by class": ("按类别浏览", "按類別瀏覽"),
    "Search Library instead": ("改为搜索物质库", "改為搜尋物質庫"),
    "Help & Safety": ("帮助与安全", "幫助與安全"),
    "Crisis resources, safety basics, and what's active right now.": (
        "危机求助资源、安全基础知识，以及当前活跃的物质。",
        "危機求助資源、安全基礎知識，以及目前活躍的物質。",
    ),
    "Clear": ("清除", "清除"),
    # Common UI actions
    "Add": ("添加", "新增"),
    "Add Preset": ("添加预设", "新增預設"),
    "Reset to Defaults": ("恢复默认", "恢復預設"),
    "That preset already exists.": ("该预设已存在。", "該預設已存在。"),
    "Choose at least one minute.": ("请至少选择一分钟。", "請至少選擇一分鐘。"),
    "Adds “%@”.": ("添加“%@”。", "新增「%@」。"),
    "%lld h": ("%lld 小时", "%lld 小時"),
    "Minutes": ("分钟", "分鐘"),
    "Cancel": ("取消", "取消"),
    "Save": ("保存", "儲存"),
    "Delete": ("删除", "刪除"),
    "Edit": ("编辑", "編輯"),
    "OK": ("好", "好"),
    "Done": ("完成", "完成"),
    "Skip": ("跳过", "跳過"),
    "Change": ("更改", "變更"),
    "Copy": ("复制", "複製"),
    "Copied": ("已复制", "已複製"),
    "Filter": ("筛选", "篩選"),
    "Jump to Date": ("跳转到日期", "跳轉到日期"),
    "Adjust Time": ("调整时间", "調整時間"),
    # Timeline graph + journal tag filter
    # Settings sections
    "Live Activity": ("实时活动", "即時動態"),
    "Timeline": ("时间轴", "時間軸"),
    "Day Starts At": ("一天起始时间", "一天起始時間"),
    "Sources": ("数据来源", "資料來源"),
    "Import Data": ("导入数据", "匯入資料"),
    "Delete Everything": ("删除所有数据", "刪除所有資料"),
    "Custom Substances": ("自定义物质", "自訂物質"),
    "Substance Colors": ("物质颜色", "物質顏色"),
    "Interaction Alerts": ("相互作用警报", "相互作用警示"),
    # Common labels
    "Substance": ("物质", "物質"),
    "Substance name": ("物质名称", "物質名稱"),
    "Dose": ("剂量", "劑量"),
    "Dosage": ("剂量", "劑量"),
    "Amount": ("剂量", "劑量"),
    "Unit": ("单位", "單位"),
    "Route": ("给药途径", "給藥途徑"),
    "Removes this filter.": ("移除此筛选条件。", "移除此篩選條件。"),
    "Form": ("盐型", "鹽型"),
    "≈ %@ %@ elemental": ("≈ %@ %@ 元素含量", "≈ %@ %@ 元素含量"),
    "%lld%% elemental": ("%lld%% 元素含量", "%lld%% 元素含量"),
    "<1% elemental": ("<1% 元素含量", "<1% 元素含量"),
    "Default Route": ("默认途径", "預設途徑"),
    "Category": ("类别", "類別"),
    "All categories": ("全部类别", "全部類別"),
    "Frequency": ("频次", "頻次"),
    "Notes": ("备注", "備註"),
    "Notes (Optional)": ("备注（可选）", "備註（可選）"),
    "Tags": ("标签", "標籤"),
    "Name": ("名称", "名稱"),
    "Color": ("颜色", "顏色"),
    "Time": ("时间", "時間"),
    "Date": ("日期", "日期"),
    "Date & Time": ("日期与时间", "日期與時間"),
    "Date Range": ("日期范围", "日期範圍"),
    "Time Range": ("时间范围", "時間範圍"),
    "Time of Day": ("时段", "時段"),
    "Time Taken": ("服用时间", "服用時間"),
    "Period": ("时段", "時段"),
    "Hours": ("小时", "小時"),
    "hours": ("小时", "小時"),
    "Days": ("天", "天"),
    "Mode": ("模式", "模式"),
    "Active": ("活跃", "活躍"),
    "Recent": ("最近", "最近"),
    "Count": ("数量", "數量"),
    "Now": ("现在", "現在"),
    "All": ("全部", "全部"),
    "None": ("无", "無"),
    "Custom": ("自定义", "自訂"),
    "Classification": ("分类", "分類"),
    "Safety": ("安全性", "安全性"),
    "What is this?": ("这是什么？", "這是什麼？"),
    "From": ("从", "從"),
    "To": ("到", "到"),
    "min": ("最小", "最小"),
    "max": ("最大", "最大"),
    # Onboarding
    "Welcome to Piru": ("欢迎使用 Piru", "歡迎使用 Piru"),
    "Get Started": ("开始使用", "開始使用"),
    # Loading states
    # Empty states
    "No Results": ("无结果", "無結果"),
    "No Entries": ("无记录", "無記錄"),
    "No Logged Entries": ("无已记录的条目", "無已記錄的條目"),
    "No Previous Substances": ("无历史物质", "無歷史物質"),
    "No data": ("无数据", "無資料"),
    "No known interactions found.": ("未发现已知的相互作用。", "未發現已知的相互作用。"),
    "Try a different search term.": ("尝试其他搜索词。", "嘗試其他搜尋詞。"),
    "Try adjusting your filters.": ("尝试调整筛选条件。", "嘗試調整篩選條件。"),
    "Tap + to log your first entry.": ("点按 + 来记录第一条。", "點按 + 來記錄第一條。"),
    "Search for a substance to log your first entry.": (
        "搜索一个物质开始第一次记录。",
        "搜尋一個物質開始第一次記錄。",
    ),
    "Log some entries to see usage stats.": (
        "记录一些条目以查看使用统计。",
        "記錄一些條目以查看使用統計。",
    ),
    # Quick Log
    "Quick Log": ("快捷记录", "快捷記錄"),
    "Log Anyway": ("仍要记录", "仍要記錄"),
    "Frequently used": ("常用", "常用"),
    "Favorite": ("收藏", "收藏"),
    "Unfavorite": ("取消收藏", "取消收藏"),
    "Favorites": ("收藏", "收藏"),
    "Relevant to you": (
        "与你相关",
        "與你相關",
    ),
    "Toggle off any you don't want to log today": (
        "关闭今天不需要记录的项目",
        "關閉今天不需要記錄的項目",
    ),
    # Entries
    "Delete Entry": ("删除条目", "刪除條目"),
    "Delete this entry?": ("删除此条目？", "刪除此條目？"),
    "Show all %lld entries": ("显示全部 %lld 条记录", "顯示全部 %lld 筆記錄"),
    "Entries per day": ("每日条目", "每日條目"),
    # Profile & Disclosure Tier
    "Casual": ("休闲", "休閒"),
    "Curious": ("好奇", "好奇"),
    # Mechanistic effect lenses + readouts (2026-07-08).
    "Feeling": ("感受", "感受"),
    "Energy": ("精力", "精力"),
    "Euphoric": ("欣快", "欣快"),
    "Good": ("良好", "良好"),
    "Level": ("平稳", "平穩"),
    "Wired": ("亢奋", "亢奮"),
    "Driven": ("起劲", "起勁"),
    "Flat": ("平淡", "平淡"),
    "Sedated": ("镇静", "鎮靜"),
    "Craving": ("渴望", "渴望"),
    "Bliss": ("极乐", "極樂"),
    "Low": ("低", "低"),
    "Expand Graph": ("展开图表", "展開圖表"),
    "Shrink Graph": ("收起图表", "收起圖表"),
    "bpm": ("次/分", "次/分"),
    "mmHg": ("mmHg", "mmHg"),
    "Tags: %@": ("标签：%@", "標籤：%@"),
    # Database & Settings
    "Substance Database": ("物质数据库", "物質資料庫"),
    # Prescriptions / Daily Doses
    "Prescriptions": ("处方", "處方"),
    "Current Medications": ("目前用药", "目前用藥"),
    "Reminders": ("提醒", "提醒"),
    "Schedule": ("计划", "排程"),
    "Starting from": ("开始日期", "開始日期"),
    # Form
    "Unit (e.g. mg, ml, µg)": ("单位（如 mg、ml、µg）", "單位（如 mg、ml、µg）"),
    "Custom duration": ("自定义时长", "自訂時長"),
    "Custom half-life": ("自定义半衰期", "自訂半衰期"),
    "Use Custom Half-Life": ("使用自定义半衰期", "使用自訂半衰期"),
    "Dosing Defaults": ("剂量默认值", "劑量預設值"),
    "Dose Reference": ("剂量参考", "劑量參考"),
    "Custom substance (no dose data)": ("自定义物质（无剂量数据）", "自訂物質（無劑量資料）"),
    "Optional notes about this substance for your reference.": (
        "关于此物质的可选备注，供你参考。",
        "關於此物質的可選備註，供你參考。",
    ),
    "Choose Color": ("选择颜色", "選擇顏色"),
    "Change Color": ("更改颜色", "變更顏色"),
    "New Custom Substance": ("新建自定义物质", "新建自訂物質"),
    "Edit Substance": ("编辑物质", "編輯物質"),
    "Duplicate Name": ("名称重复", "名稱重複"),
    # Help / Alerts
    # Notification copy
    "Stay hydrated": ("保持水分", "保持水分"),
    "Hydration check": ("饮水检查", "飲水檢查"),
    "Time to rest": ("该休息了", "該休息了"),
    "Drink some water. Stimulants mask thirst — your body needs more fluids than you realize.": (
        "喝点水。兴奋剂会掩盖口渴感——你的身体需要的水分比你意识到的更多。",
        "喝點水。興奮劑會掩蓋口渴感——你的身體需要的水分比你意識到的更多。",
    ),
    "Sip some water — a glass every 30-60 minutes. Don't overdo it, just stay steady.": (
        "小口喝水——每 30 至 60 分钟一杯。不要过量，保持稳定即可。",
        "小口喝水——每 30 至 60 分鐘一杯。不要過量，保持穩定即可。",
    ),
    "Have some water if you can. Your body needs fluids even if you don't feel thirsty.": (
        "尽量喝点水。即使你不觉得渴，身体也需要水分。",
        "盡量喝點水。即使你不覺得渴，身體也需要水分。",
    ),
    "Drink some water. Your body needs it, especially right now.": (
        "喝点水。你的身体需要水分，尤其是现在。",
        "喝點水。你的身體需要水分，尤其是現在。",
    ),
    "Have some water and a snack if you haven't recently.": (
        "如果最近还没喝水或吃东西，可以喝点水、吃点东西。",
        "如果最近還沒喝水或吃東西，可以喝點水、吃點東西。",
    ),
    "You've been going for over %lld hours. Try to wind down — dim the lights, put the phone away, and let yourself sleep.": (
        "你已持续超过 %lld 小时。试着放松——调暗灯光、放下手机，让自己入睡。",
        "你已持續超過 %lld 小時。試著放鬆——調暗燈光、放下手機，讓自己入睡。",
    ),
    "It's been a long session. Your body and brain need sleep to recover. Try to wind down.": (
        "这一场已经持续了很长时间。你的身体和大脑需要睡眠来恢复。试着放松一下。",
        "這一場已經持續了很長時間。你的身體和大腦需要睡眠來恢復。試著放鬆一下。",
    ),
    "Effects should start within %lld-%lld minutes.": (
        "效果应在 %lld 至 %lld 分钟内出现。",
        "效果應在 %lld 至 %lld 分鐘內出現。",
    ),
    "Tracking started. Effects on the way.": (
        "追踪已开始。效果即将出现。",
        "追蹤已開始。效果即將出現。",
    ),
    "First effects starting now. Find your spot.": (
        "初步效果开始出现。找一个舒适的位置。",
        "初步效果開始出現。找一個舒適的位置。",
    ),
    "Peak is hitting. Stay safe and aware.": (
        "高峰期来临。保持安全和警觉。",
        "高峰期來臨。保持安全和警覺。",
    ),
    # Comedown messages
    "The low mood is temporary and normal. Eat light foods, stay warm, and rest. Be kind to yourself over the next few days.": (
        "情绪低落是暂时且正常的。吃清淡食物、保暖、休息。接下来几天善待自己。",
        "情緒低落是暫時且正常的。吃清淡食物、保暖、休息。接下來幾天善待自己。",
    ),
    "You're coming back to baseline. Rest, eat something light. Give yourself time to process the experience.": (
        "你正在回到基线状态。休息、吃些清淡的东西。给自己时间来消化这次体验。",
        "你正在回到基線狀態。休息、吃些清淡的東西。給自己時間來消化這次體驗。",
    ),
    "Stay hydrated. Don't redose to chase it — it doesn't work.": (
        "保持水分。不要为了追求感觉而补服——没用的。",
        "保持水分。不要為了追求感覺而補服——沒用的。",
    ),
    "Rebound anxiety is temporary. Avoid caffeine and alcohol. Breathing exercises: 4 in, 7 hold, 8 out.": (
        "反弹性焦虑是暂时的。避免咖啡因和酒精。呼吸练习：吸气 4 秒、屏住 7 秒、呼气 8 秒。",
        "反彈性焦慮是暫時的。避免咖啡因和酒精。呼吸練習：吸氣 4 秒、屏住 7 秒、呼氣 8 秒。",
    ),
    "Take care of yourself — eat, hydrate, and rest. The effects will fade with time.": (
        "照顾好自己——吃饭、补水、休息。效果会随时间消退。",
        "照顧好自己——吃飯、補水、休息。效果會隨時間消退。",
    ),
    # Cumulative tips
    "Remember to hydrate, eat, and try to get some sleep. Your heart has been working hard.": (
        "记得补水、吃饭并尝试入睡。你的心脏一直在努力工作。",
        "記得補水、吃飯並嘗試入睡。你的心臟一直在努力工作。",
    ),
    "Your serotonin system is taking a hit. Rest.": (
        "你的血清素系统正承受压力。休息。",
        "你的血清素系統正承受壓力。休息。",
    ),
    "High cumulative benzo doses impair memory and coordination. Stay somewhere safe.": (
        "苯二氮䓬累积剂量较高会损害记忆和协调能力。留在安全的地方。",
        "苯二氮平累積劑量較高會損害記憶和協調能力。留在安全的地方。",
    ),
    "Stay somewhere safe. Don't drive. Your coordination and judgment are affected.": (
        "留在安全的地方。不要开车。你的协调能力和判断力受到影响。",
        "留在安全的地方。不要開車。你的協調能力和判斷力受到影響。",
    ),
    "Take it easy. Hydrate, eat, and rest.": (
        "放轻松。补水、吃饭、休息。",
        "放輕鬆。補水、吃飯、休息。",
    ),
    # File operations
    "Couldn't access the selected file.": ("无法访问所选文件。", "無法存取所選檔案。"),
    # Interactions
    "Interaction Timeline": ("相互作用时间轴", "相互作用時間軸"),
    "Interaction Warning": ("相互作用警告", "相互作用警告"),
    "1 Interaction Found": ("发现 1 个相互作用", "發現 1 個相互作用"),
    "%lld Interactions Found": ("发现 %lld 个相互作用", "發現 %lld 個相互作用"),
    "^[%lld interaction](inflect: true) detected": (
        "检测到 %lld 个相互作用",
        "偵測到 %lld 個相互作用",
    ),
    "Choose at least 2 substances": ("请至少选择 2 种物质", "請至少選擇 2 種物質"),
    "A one-compartment model with population-average half-lives. Real overlap depends on your metabolism, dose, route, and tolerance.": (
        "单室模型，使用群体平均半衰期。实际重叠取决于你的代谢、剂量、途径和耐受性。",
        "單室模型，使用群體平均半衰期。實際重疊取決於你的代謝、劑量、途徑和耐受性。",
    ),
    # MoA / Pharmacology
    "Mechanism of Action": ("作用机制", "作用機制"),
    # Stage 4 — chemistry card + pharmacokinetics disclosure
    "Pharmacokinetics": ("药代动力学", "藥物動力學"),
    "Metabolism": ("代谢", "代謝"),
    "Computed from the molecular structure (PubChem, NPS-DataHub) rather than measured in a lab.": (
        "由分子结构计算得出（PubChem、NPS-DataHub），非实验室实测值。",
        "由分子結構計算得出（PubChem、NPS-DataHub），非實驗室實測值。",
    ),
    "Recreational doses — not a prescribed amount": (
        "娱乐用剂量——并非处方用量。",
        "娛樂用劑量——並非處方用量。",
    ),
    "LD50 is rodent toxicity (order of magnitude) — not a human safe dose.": (
        "LD50 为啮齿动物毒性（数量级参考），并非人体安全剂量。",
        "LD50 為齧齒動物毒性（數量級參考），並非人體安全劑量。",
    ),
    "IUPAC name": ("IUPAC 名称", "IUPAC 名稱"),
    "Molecular structure": ("分子结构", "分子結構"),
    "%lld atoms": ("%lld 个原子", "%lld 個原子"),
    "H-bond acceptors": ("氢键受体", "氫鍵受體"),
    "H-bond donors": ("氢键供体", "氫鍵供體"),
    "Melting point": ("熔点", "熔點"),
    "Boiling point": ("沸点", "沸點"),
    "LD50 (oral, rodent)": ("LD50（口服，啮齿动物）", "LD50（口服，齧齒動物）"),
    "LD50 (dermal, rodent)": ("LD50（皮肤，啮齿动物）", "LD50（皮膚，齧齒動物）"),
    "active": ("有活性", "有活性"),
    "inactive": ("无活性", "無活性"),
    "Primary Targets: ": (
        "主要作用位点：",
        "主要作用位點：",
    ),
    "Also known as": ("别名", "別名"),
    # Substance detail — redesign (misconceptions + "for the curious" launcher)
    "Common misconceptions": ("常见误解", "常見誤解"),
    "Combinations": ("组合", "組合"),
    "Water & heat": ("水分与温度", "水分與溫度"),
    "Danger": ("危险", "危險"),
    "Guideline: %@": ("指南：%@", "指南：%@"),
    "For the curious": ("给好奇的你", "給好奇的你"),
    "Myth: %@": ("误解：%@", "誤解：%@"),
    "Retracted source: %@": ("已撤稿的来源：%@", "已撤稿的來源：%@"),
    # Calculator / PK
    "Concentration Curve": ("浓度曲线", "濃度曲線"),
    "Concentration Curves": ("浓度曲线", "濃度曲線"),
    "Current Estimated Amount": (
        "当前体内估算量",
        "目前體內估算量",
    ),
    "Peak concentration": ("峰值浓度", "峰值濃度"),
    "Reached after %@": ("%@ 后达到", "%@ 後達到"),
    "Peak %@": (
        "高峰期 %@",
        "高峰期 %@",
    ),
    "Conc": ("浓度", "濃度"),
    "Estimates from pharmacokinetic modeling.": (
        "基于药代动力学建模的估算。",
        "基於藥物動力學建模的估算。",
    ),
    "Half-life data not available for %@.": ("没有 %@ 的半衰期数据。", "沒有 %@ 的半衰期資料。"),
    "Half-life data unavailable for %@": ("无 %@ 的半衰期数据", "無 %@ 的半衰期資料"),
    "%lld with half-life data": ("%lld 个有半衰期数据", "%lld 個有半衰期資料"),
    "No effect timeline for this substance and route.": (
        "此物质和途径暂无效果时间轴。",
        "此物質和途徑暫無效果時間軸。",
    ),
    # "Also Active" — the metabolite surface.
    # "Also Active" — Xcode extracts these with NON-positional %@ keys, so the
    # positional %1$@ variants authored earlier went stale and their zh values
    # never reached a user. Keys must match what the extractor emits; the
    # translated VALUES still use %1$@/%2$@ to reorder, which is allowed.
    "%@ stays active in your body long after %@ itself is gone.": (
        "在 %2$@ 本身已排出后很久，%1$@ 仍在体内保持活性。",
        "在 %2$@ 本身已排出後很久，%1$@ 仍在體內保持活性。",
    ),
    "About %@× %@'s activity at the %@.": (
        "在%3$@上，活性约为 %2$@ 的 %1$@ 倍。",
        "在%3$@上，活性約為 %2$@ 的 %1$@ 倍。",
    ),
    "About %@× %@'s activity, by one measurement.": (
        "据一项测定，活性约为 %2$@ 的 %1$@ 倍。",
        "據一項測定，活性約為 %2$@ 的 %1$@ 倍。",
    ),
    "About %@× as strong as %@, dose for dose.": (
        "按相同剂量计，强度约为 %2$@ 的 %1$@ 倍。",
        "按相同劑量計，強度約為 %2$@ 的 %1$@ 倍。",
    ),
    "About as strong as %@ at the %@.": (
        "在%2$@上，强度与 %1$@ 相当。",
        "在%2$@上，強度與 %1$@ 相當。",
    ),
    "Also measured at %@× %@'s %@ at the %@ — a lab measurement, not clinical potency.": (
        "另在%4$@上测定值为 %2$@ %3$@的 %1$@ 倍——这是实验室测定值，并非临床效价。",
        "另在%4$@上測定值為 %2$@ %3$@的 %1$@ 倍——這是實驗室測定值，並非臨床效價。",
    ),
    "Also measured at %@× %@'s %@ — a lab measurement, not clinical potency.": (
        "另有测定值为 %2$@ %3$@的 %1$@ 倍——这是实验室测定值，并非临床效价。",
        "另有測定值為 %2$@ %3$@的 %1$@ 倍——這是實驗室測定值，並非臨床效價。",
    ),
    "Measured at %@× %@'s %@ at the %@ — a lab measurement, not clinical potency.": (
        "在%4$@上测定值为 %2$@ %3$@的 %1$@ 倍——这是实验室测定值，并非临床效价。",
        "在%4$@上測定值為 %2$@ %3$@的 %1$@ 倍——這是實驗室測定值，並非臨床效價。",
    ),
    "Measured at %@× %@'s %@ — a lab measurement, not clinical potency.": (
        "测定值为 %2$@ %3$@的 %1$@ 倍——这是实验室测定值，并非临床效价。",
        "測定值為 %2$@ %3$@的 %1$@ 倍——這是實驗室測定值，並非臨床效價。",
    ),
    "Molecule for molecule, %@ is about %@× as strong as %@ — but how much of a dose converts isn't recorded here.": (
        "按分子计，%1$@ 的强度约为 %3$@ 的 %2$@ 倍——但一次剂量中有多少会转化，此处尚无记录。",
        "按分子計，%1$@ 的強度約為 %3$@ 的 %2$@ 倍——但一次劑量中有多少會轉化，此處尚無記錄。",
    ),
    "Molecule for molecule, %@ is about %@× as strong as %@ — but only about %@%% of a dose becomes it.": (
        "按分子计，%1$@ 的强度约为 %3$@ 的 %2$@ 倍——但一次剂量中只有约 %4$@%% 会转化为它。",
        "按分子計，%1$@ 的強度約為 %3$@ 的 %2$@ 倍——但一次劑量中只有約 %4$@%% 會轉化為它。",
    ),
    "Molecule for molecule, %@ is about as strong as %@.": (
        "按分子计，%1$@ 的强度与 %2$@ 相当。",
        "按分子計，%1$@ 的強度與 %2$@ 相當。",
    ),
    "Molecule for molecule, about %@× as strong as %@.": (
        "按分子计，强度约为 %2$@ 的 %1$@ 倍。",
        "按分子計，強度約為 %2$@ 的 %1$@ 倍。",
    ),
    "What your body makes from this dose. Not a measured level.": (
        "身体从这次剂量中生成的物质。并非实测数值。",
        "身體從這次劑量中生成的物質。並非實測數值。",
    ),
    "Your body turns %@ into %@, which is active too.": (
        "身体会将 %1$@ 转化为 %2$@，后者同样具有活性。",
        "身體會將 %1$@ 轉化為 %2$@，後者同樣具有活性。",
    ),
    "Also Active": ("同时活跃", "同時活躍"),
    "Made by": ("生成酶", "生成酶"),
    "Share of dose": ("占剂量比例", "佔劑量比例"),
    "About as strong as %@, dose for dose.": (
        "按相同剂量计，强度与 %@ 相当。",
        "按相同劑量計，強度與 %@ 相當。",
    ),
    "Acts differently from %@ — not simply stronger or weaker.": (
        "作用方式与 %@ 不同——并非单纯更强或更弱。",
        "作用方式與 %@ 不同——並非單純更強或更弱。",
    ),
    # ---- Curated divergent-metabolite editorial notes (MetaboliteEditorial.swift) ----
    "Tramadol is itself a weak opioid that also raises serotonin and noradrenaline. Most of the opioid effect people feel comes from this metabolite — and how much you make of it depends on a CYP2D6 gene, so the same dose can be a real opioid for one person and almost none for another.": (
        "曲马多本身是一种弱阿片类药物，同时也会升高血清素和去甲肾上腺素。大多数人感受到的阿片效应来自这个代谢物——而生成量取决于 CYP2D6 基因，因此同样的剂量对一些人来说是真正的阿片效应，对另一些人则几乎没有。",
        "曲馬多本身是一種弱鴉片類藥物，同時也會升高血清素和正腎上腺素。大多數人感受到的鴉片效應來自這個代謝物——而生成量取決於 CYP2D6 基因，因此同樣的劑量對一些人來說是真正的鴉片效應，對另一些人則幾乎沒有。",
    ),
    "mCPP acts on serotonin in a different way than trazodone — it tends to feel activating or anxious rather than sedating, which is part of why trazodone's later hours can feel unlike its calm onset.": (
        "mCPP 以不同于曲唑酮的方式作用于血清素——它倾向于产生激活感或焦虑感，而非镇静，这是曲唑酮后半段感受可能与平静的起效阶段不同的部分原因。",
        "mCPP 以不同於曲唑酮的方式作用於血清素——它傾向於產生亢奮感或焦慮感，而非鎮靜，這是曲唑酮後半段感受可能與平靜的起效階段不同的部分原因。",
    ),
    "Noribogaine is long-lived and acts differently from ibogaine — it leans more on serotonin reuptake and κ-opioid signaling, and it is a large part of the extended after-effect rather than a continuation of the peak.": (
        "去甲伊博加因半衰期长，作用方式与伊博加因不同——更依赖血清素再摄取和 κ-阿片信号传导，构成延长后效应的重要部分，而非高峰期的延续。",
        "去甲伊博加因半衰期長，作用方式與伊博加因不同——更依賴血清素再攝取和 κ-鴉片訊號傳導，構成延長後效應的重要部分，而非高峰期的延續。",
    ),
    "Normeperidine isn't a painkiller — it's a stimulating metabolite that builds up with repeated or high doses and lowers the seizure threshold. It's why meperidine isn't used for long-term pain.": (
        "去甲哌替啶不是止痛药——它是一种兴奋性代谢物，在反复或大剂量使用时蓄积，降低癫痫发作阈值。这是哌替啶不用于长期镇痛的原因。",
        "去甲哌替啶不是止痛藥——它是一種興奮性代謝物，在反覆或大劑量使用時蓄積，降低癲癇發作閾值。這是哌替啶不用於長期鎮痛的原因。",
    ),
    "Dextrorphan blocks NMDA receptors more strongly than DXM itself does — it's the more dissociative species, and the main reason the character shifts at higher doses rather than simply lasting longer.": (
        "右啡烷对 NMDA 受体的阻断作用强于右美沙芬本身——它是更具解离性的活性种，也是高剂量时体验特征转变而非仅仅持续更久的主要原因。",
        "右啡烷對 NMDA 受體的阻斷作用強於右美沙芬本身——它是更具解離性的活性種，也是高劑量時體驗特徵轉變而非僅僅持續更久的主要原因。",
    ),
    "Meprobamate is a long-lived, barbiturate-like sedative in its own right — it acts more like a classic downer than carisoprodol, and much of the sedation and the dependence potential come from it rather than the parent.": (
        "美普罗巴酯本身就是一种长效的类巴比妥镇静剂——它比卡立普多更像经典的镇静药物，大部分镇静作用和依赖潜力来自于它而非母体药物。",
        "美普羅巴酯本身就是一種長效的類巴比妥鎮靜劑——它比卡立普多更像經典的鎮靜藥物，大部分鎮靜作用和依賴潛力來自於它而非母體藥物。",
    ),
    "Nortriptyline is a marketed antidepressant in its own right, and it leans more on noradrenaline than amitriptyline does — so the metabolite's character is more activating than the parent's.": (
        "去甲替林本身就是一种上市的抗抑郁药，比阿米替林更偏向去甲肾上腺素——因此代谢物的特征比母体药物更具激活性。",
        "去甲替林本身就是一種上市的抗憂鬱藥，比阿米替林更偏向正腎上腺素——因此代謝物的特徵比母體藥物更具活化性。",
    ),
    "Desipramine is a marketed antidepressant in its own right, and more noradrenergic than imipramine — so as it forms, the effect shifts toward the more activating end.": (
        "地昔帕明本身就是一种上市的抗抑郁药，比丙咪嗪更偏向去甲肾上腺素能——因此随着它的生成，效应向更具激活性的方向转移。",
        "地昔帕明本身就是一種上市的抗憂鬱藥，比丙咪嗪更偏向正腎上腺素能——因此隨著它的生成，效應向更具活化性的方向轉移。",
    ),
    "The desmethyl metabolite shifts clomipramine's strongly serotonergic action toward noradrenaline, so the two don't act quite alike — the balance moves as the metabolite accumulates.": (
        "去甲基代谢物将氯丙咪嗪强烈的血清素能作用向去甲肾上腺素方向转移，因此两者的作用并不完全相同——随着代谢物蓄积，平衡发生变化。",
        "去甲基代謝物將氯丙咪嗪強烈的血清素能作用向正腎上腺素方向轉移，因此兩者的作用並不完全相同——隨著代謝物蓄積，平衡發生變化。",
    ),
    "Norquetiapine adds effects quetiapine largely lacks — noradrenaline reuptake inhibition and antidepressant-like activity — so it contributes a different character than the parent's sedation.": (
        "去甲喹硫平增加了喹硫平基本不具备的作用——去甲肾上腺素再摄取抑制和抗抑郁样活性——因此它贡献的特征不同于母体药物的镇静作用。",
        "去甲喹硫平增加了喹硫平基本不具備的作用——正腎上腺素再攝取抑制和抗憂鬱樣活性——因此它貢獻的特徵不同於母體藥物的鎮靜作用。",
    ),
    "This metabolite (HNK) barely touches the NMDA receptor ketamine acts on — it's studied for a separate, non-dissociative antidepressant effect, so it isn't simply ketamine continuing.": (
        "这种代谢物（HNK）几乎不作用于氯胺酮所靶向的 NMDA 受体——它被研究的是一种独立的、非解离性的抗抑郁效应，因此并非氯胺酮效果的简单延续。",
        "這種代謝物（HNK）幾乎不作用於氯胺酮所靶向的 NMDA 受體——它被研究的是一種獨立的、非解離性的抗憂鬱效應，因此並非氯胺酮效果的簡單延續。",
    ),
    "Norbuprenorphine acts differently from buprenorphine — it behaves more like a full opioid agonist and contributes to respiratory effects, which buprenorphine's own ceiling doesn't fully predict.": (
        "去甲丁丙诺啡的作用方式不同于丁丙诺啡——它更像完全阿片激动剂，对呼吸抑制有贡献，而丁丙诺啡自身的天花板效应并不能完全预测这一点。",
        "去甲丁丙諾啡的作用方式不同於丁丙諾啡——它更像完全鴉片促效劑，對呼吸抑制有貢獻，而丁丙諾啡自身的天花板效應並不能完全預測這一點。",
    ),
    "Cetirizine — a common non-drowsy antihistamine — is hydroxyzine's main metabolite. It's far less sedating, so hydroxyzine's calming effect gives way to a plainer antihistamine as it converts.": (
        "西替利嗪——一种常见的非嗜睡抗组胺药——是羟嗪的主要代谢物。它的镇静作用弱得多，因此随着转化，羟嗪的镇静效果逐渐让位于单纯的抗组胺作用。",
        "西替利嗪——一種常見的非嗜睡抗組織胺藥——是羥嗪的主要代謝物。它的鎮靜作用弱得多，因此隨著轉化，羥嗪的鎮靜效果逐漸讓位於單純的抗組織胺作用。",
    ),
    "Norephedrine (phenylpropanolamine) is a peripheral sympathomimetic — it raises blood pressure and narrows blood vessels more than amphetamine's central action would predict. It adds cardiovascular load the parent's CNS profile doesn't warn about.": (
        "去甲麻黄碱（苯丙醇胺）是一种外周拟交感神经药——它升高血压和收缩血管的程度超过苯丙胺的中枢作用所能预测的。它增加了母体药物 CNS 特征所未提示的心血管负荷。",
        "去甲麻黃鹼（苯丙醇胺）是一種周邊擬交感神經藥——它升高血壓和收縮血管的程度超過安非他命的中樞作用所能預測的。它增加了母體藥物 CNS 特徵所未提示的心血管負荷。",
    ),
    "7-aminoclonazepam has no meaningful activity at GABA-A — it's an inactive metabolite used as a urinary marker for clonazepam exposure, not a contributor to the drug's effect.": (
        "7-氨基氯硝西泮在 GABA-A 上无显著活性——它是一种无活性代谢物，用作氯硝西泮暴露的尿液标志物，不参与药物效应。",
        "7-胺基氯硝西泮在 GABA-A 上無顯著活性——它是一種無活性代謝物，用作氯硝西泮暴露的尿液標誌物，不參與藥物效應。",
    ),
    "Norfenfluramine is a more potent serotonin releaser than fenfluramine itself — it drives much of the pharmacological effect, including the 5-HT₂B agonism linked to cardiac valve damage in the 1990s weight-loss era.": (
        "去甲芬氟拉明是比芬氟拉明更强效的血清素释放剂——它驱动了大部分药理效应，包括与 1990 年代减肥时期心脏瓣膜损伤相关的 5-HT₂B 激动作用。",
        "去甲芬氟拉明是比芬氟拉明更強效的血清素釋放劑——它驅動了大部分藥理效應，包括與 1990 年代減肥時期心臟瓣膜損傷相關的 5-HT₂B 促效作用。",
    ),
    "This unusual Phase II conjugate retains the nor-mephedrone core — whether it has pharmacological activity is unknown, but its long plasma half-life means it lingers well past mephedrone's short duration.": (
        "这种不寻常的 II 相结合物保留了去甲甲卡西酮的核心结构——是否具有药理活性尚不明确，但其较长的血浆半衰期意味着它在甲卡西酮的短暂作用期过后仍会存留。",
        "這種不尋常的 II 相結合物保留了去甲甲卡西酮的核心結構——是否具有藥理活性尚不明確，但其較長的血漿半衰期意味著它在甲卡西酮的短暫作用期過後仍會存留。",
    ),
    "Cotinine has negligible nicotinic activity — it's the standard biomarker for tobacco exposure, not a continuation of nicotine's effect. Its long half-life (~16 hours) is why it's detectable in blood and urine days after the last cigarette.": (
        "可替宁的烟碱活性可忽略——它是烟草暴露的标准生物标志物，而非尼古丁效应的延续。其约 16 小时的长半衰期是最后一支烟后数天仍可在血液和尿液中检出的原因。",
        "可替寧的菸鹼活性可忽略——它是菸草暴露的標準生物標誌物，而非尼古丁效應的延續。其約 16 小時的長半衰期是最後一支菸後數天仍可在血液和尿液中檢出的原因。",
    ),
    "EDDP has no opioid activity — it's the primary urinary marker for methadone compliance monitoring, not a contributor to the drug's effect or duration.": (
        "EDDP 无阿片活性——它是美沙酮依从性监测的主要尿液标志物，不参与药物效应或持续时间。",
        "EDDP 無鴉片活性——它是美沙酮依從性監測的主要尿液標誌物，不參與藥物效應或持續時間。",
    ),
    "M3G is morphine's major metabolite (~60% of the dose) and has no analgesic activity — at high concentrations it's neuroexcitatory, contributing to myoclonus and paradoxical pain increase rather than pain relief. It accumulates in renal impairment, which is why morphine dosing needs adjustment when kidneys are compromised.": (
        "M3G 是吗啡的主要代谢物（约占剂量的 60%），无镇痛活性——高浓度时具有神经兴奋性，导致肌阵挛和矛盾性疼痛加重而非缓解。它在肾功能损害时蓄积，这是肾功能不全时需要调整吗啡剂量的原因。",
        "M3G 是嗎啡的主要代謝物（約佔劑量的 60%），無鎮痛活性——高濃度時具有神經興奮性，導致肌陣攣和矛盾性疼痛加重而非緩解。它在腎功能損害時蓄積，這是腎功能不全時需要調整嗎啡劑量的原因。",
    ),
    "A binding-affinity measurement, not clinical potency.": (
        "这是受体结合亲和力的测定值，并非临床效价。",
        "這是受體結合親和力的測定值，並非臨床效價。",
    ),
    "A lab measurement, not clinical potency.": (
        "这是实验室测定值，并非临床效价。",
        "這是實驗室測定值，並非臨床效價。",
    ),
    "How strong it is compared to %@ hasn't been established.": (
        "其相对于 %@ 的强度尚无定论。",
        "其相對於 %@ 的強度尚無定論。",
    ),
    "binding affinity": ("结合亲和力", "結合親和力"),
    "activity": ("活性", "活性"),
    "Opens this substance in the library.": ("在物质库中打开该物质。", "在物質庫中開啟該物質。"),
    "%@ days": ("%@ 天", "%@ 天"),
    "µ-opioid receptor": ("µ-阿片受体", "µ-鴉片受體"),
    "\u03ba-opioid receptor": ("\u03ba-阿片受体", "\u03ba-鴉片受體"),
    "\u03b4-opioid receptor": ("\u03b4-阿片受体", "\u03b4-鴉片受體"),
    "norepinephrine transporter": (
        "去甲肾上腺素转运体",
        "正腎上腺素轉運體",
    ),
    "dopamine transporter": ("多巴胺转运体", "多巴胺轉運體"),
    "GABA-A receptor": ("GABA-A 受体", "GABA-A 受體"),
    "NMDA receptor": ("NMDA 受体", "NMDA 受體"),
    "nicotinic receptor": ("烟碱型受体", "菸鹼型受體"),
    "Add per-phase timing so this substance gets a Live-Activity timeline like library substances.": (
        "添加分阶段计时，让此物质拥有与库中物质一样的实时活动时间轴。",
        "新增分階段計時，讓此物質擁有與庫中物質一樣的即時動態時間軸。",
    ),
    "Minutes for each phase. Leave a phase blank to skip it; the timeline will interpolate from what you provide.": (
        "每个阶段的分钟数。留空可跳过；时间轴会根据你提供的数据进行插值。",
        "每個階段的分鐘數。留空可跳過；時間軸會根據你提供的資料進行插值。",
    ),
    "eliminated": ("已消除", "已消除"),
    "t½ = %@": ("半衰期 = %@", "半衰期 = %@"),
    "t½ %@": ("半衰期 %@", "半衰期 %@"),
    "%lld%% eliminated": ("%lld%% 已消除", "%lld%% 已消除"),
    # Volumetric dosing
    "Extremely Potent Substance": ("极强效物质", "極強效物質"),
    "Active in micrograms — a thousandth of a milligram. Always measure volumetrically. You cannot dose this by eye.": (
        "微克量级即有效——一毫克的千分之一。必须容积法测量。无法靠目测给药。",
        "微克量級即有效——一毫克的千分之一。必須容積法測量。無法靠目測給藥。",
    ),
    "Calculate measurements for dissolving substances in liquid solvents.": (
        "计算物质溶于液体溶剂的测量值。",
        "計算物質溶於液體溶劑的測量值。",
    ),
    # Help / Crisis
    "If you need help right now:": (
        "如果你现在需要帮助：",
        "如果你現在需要幫助：",
    ),
    "While you wait or if you just need to calm down:": (
        "在等待时，或如果你只是想冷静下来：",
        "在等待時，或如果你只是想冷靜下來：",
    ),
    "Breathe slowly: 4 seconds in, hold for 4, out for 4.": (
        "慢慢呼吸：吸气 4 秒、屏住 4 秒、呼气 4 秒。",
        "慢慢呼吸：吸氣 4 秒、屏住 4 秒、呼氣 4 秒。",
    ),
    "Breathe slowly. 4 seconds in, hold for 4, out for 4. You are safe.": (
        "慢慢呼吸。吸气 4 秒、屏住 4 秒、呼气 4 秒。你是安全的。",
        "慢慢呼吸。吸氣 4 秒、屏住 4 秒、呼氣 4 秒。你是安全的。",
    ),
    "Put your feet flat on the floor. Feel the ground beneath you.": (
        "将双脚平放在地板上。感受脚下的地面。",
        "將雙腳平放在地板上。感受腳下的地面。",
    ),
    "Name 5 things you can see. 4 you can touch. 3 you can hear.": (
        "说出 5 件你看到的事物、4 件能触摸的、3 件能听到的。",
        "說出 5 件你看到的事物、4 件能觸摸的、3 件能聽到的。",
    ),
    "Take a deep breath.": ("深呼吸。", "深呼吸。"),
    "Take a breath.": ("深呼吸。", "深呼吸。"),
    "You are not alone. People care about you and help is available.": (
        "你并不孤单。有人关心你，也有可用的帮助。",
        "你並不孤單。有人關心你，也有可用的幫助。",
    ),
    "Help is available. You don't have to do this alone.": (
        "帮助就在身边。你不必独自面对。",
        "幫助就在身邊。你不必獨自面對。",
    ),
    "You're going to be okay. This feeling is temporary.": (
        "一切都会好的。这种感觉是暂时的。",
        "一切都會好的。這種感覺是暫時的。",
    ),
    "You're going to be okay. Whatever you're feeling right now is temporary.": (
        "一切都会好的。你现在的任何感受都是暂时的。",
        "一切都會好的。你現在的任何感受都是暫時的。",
    ),
    "Emergency Services": ("紧急服务", "緊急服務"),
    "Emergency Services — %@": (
        "紧急服务——%@",
        "緊急服務——%@",
    ),
    "Copy Summary for Emergency Services": ("为紧急服务复制摘要", "為緊急服務複製摘要"),
    "Copies a plain-text summary of substances and recent doses to share with emergency responders.": (
        "将物质和最近剂量的纯文本摘要复制到剪贴板，以便与急救人员分享。",
        "將物質和最近劑量的純文字摘要複製到剪貼簿，以便與急救人員分享。",
    ),
    # Recovery / Comedown
    "Recovery Guide": ("恢复指南", "恢復指南"),
    "Recovery — Right Now": (
        "恢复——此刻",
        "恢復——此刻",
    ),
    "Recovery tips": ("恢复提示", "恢復提示"),
    "Recovery Tips": ("恢复提示", "恢復提示"),
    "Total in Your Body": ("体内总量", "體內總量"),
    # Dose detail redesign — session language (2026-07-12).
    "In Your Body": (
        "体内",
        "體內",
    ),
    "Part of Session": (
        "所属场次",
        "所屬場次",
    ),
    "About %@ (%@)": ("关于%1$@（%2$@）", "關於%1$@（%2$@）"),
    "with %@": ("同服 %@", "同服 %@"),
    "+ %lld more": ("还有 %lld 条", "還有 %lld 條"),
    "Effects ended ~%@": ("效果已于 ~%@ 结束", "效果已於 ~%@ 結束"),
    "Effects ended ~%@ · cleared ~%@": (
        "效果已于 ~%1$@ 结束 · 约 %2$@ 清除",
        "效果已於 ~%1$@ 結束 · 約 %2$@ 清除",
    ),
    "Universal recovery basics": ("通用恢复基础", "通用恢復基礎"),
    "Hydrate — water or electrolyte drinks, sip steadily": (
        "补水——水或电解质饮料，小口慢饮",
        "補水——水或電解質飲料，小口慢飲",
    ),
    "Eat something nutritious — protein, carbs, and fruit": (
        "吃些营养食物——蛋白质、碳水化合物和水果",
        "吃些營養食物——蛋白質、碳水化合物和水果",
    ),
    "Sleep when your body lets you — don't fight it": (
        "身体允许时就睡——不要硬撑",
        "身體允許時就睡——不要硬撐",
    ),
    "Fresh air and gentle light help reset your system": (
        "新鲜空气和柔和光线有助于重置身体",
        "新鮮空氣和柔和光線有助於重置身體",
    ),
    "Light movement or stretching — nothing intense": (
        "轻度活动或拉伸——不要剧烈运动",
        "輕度活動或拉伸——不要劇烈運動",
    ),
    "Put the phone down — screens can amplify restlessness": (
        "放下手机——屏幕会加剧躁动感",
        "放下手機——螢幕會加劇躁動感",
    ),
    "Reach out to someone you trust if you feel overwhelmed": (
        "如果感到无法承受，向信任的人倾诉",
        "如果感到無法承受，向信任的人傾訴",
    ),
    # InteractionSeverity / Source labels
    "Dangerous": ("危险", "危險"),
    "Unsafe": ("不安全", "不安全"),
    "Caution": (
        "谨慎",
        "謹慎",
    ),
    "TripSit": ("TripSit", "TripSit"),
    # Adherence status
    "All taken": ("全部已服用", "全部已服用"),
    "Partially taken": ("部分已服用", "部分已服用"),
    "All missed": ("全部漏服", "全部漏服"),
    "Nothing due": ("无到期项", "無到期項"),
    # HelpView reassurance + tips
    "Put on familiar music": ("听熟悉的音乐", "聽熟悉的音樂"),
    "Familiar songs can ground you and bring comfort. Pick something you know well.": (
        "熟悉的歌曲能让你安定下来，也能带来慰藉。选一首你熟悉的。",
        "熟悉的歌曲能讓你安定下來，也能帶來慰藉。選一首你熟悉的。",
    ),
    "Music you know well is one of the most powerful grounding tools — especially during a psychedelic experience.": (
        "你熟悉的音乐是最强大的稳定工具之一——尤其是在迷幻体验期间。",
        "你熟悉的音樂是最強大的穩定工具之一——尤其是在迷幻體驗期間。",
    ),
    "Call a friend or family member": ("打电话给朋友或家人", "打電話給朋友或家人"),
    "Someone who knows you can help more than you’d expect. You don’t have to explain everything — just hearing a familiar voice helps.": (
        "了解你的人比你想象的更能提供帮助。你不必解释一切——只是听到熟悉的声音就有帮助。",
        "了解你的人比你想像的更能提供幫助。你不必解釋一切——只是聽到熟悉的聲音就有幫助。",
    ),
    "Emergency (Ambulance)": (
        "紧急服务（救护车）",
        "緊急服務（救護車）",
    ),
    "Emergency": ("紧急", "緊急"),
    "Suicide & Crisis Lifeline": ("自杀与危机援助热线", "自殺與危機援助熱線"),
    "Suicide Prevention": ("自杀预防", "自殺預防"),
    "Suicide Prevention Hotline": ("自杀预防热线", "自殺預防熱線"),
    "Suicide Crisis Helpline": ("自杀危机援助热线", "自殺危機援助熱線"),
    "Crisis Line": ("危机援助专线", "危機援助專線"),
    "Crisis Hotline": ("危机援助热线", "危機援助熱線"),
    "Crisis Text Line": ("危机短信专线", "危機簡訊專線"),
    "Lifeline": ("生命线", "生命線"),
    "Lifeline Ukraine": ("乌克兰生命线", "烏克蘭生命線"),
    "Poison Control": ("中毒控制中心", "中毒控制中心"),
    "Poison Centre": ("中毒中心", "中毒中心"),
    "Poisons Centre": ("中毒中心", "中毒中心"),
    "Poisons Information": ("中毒信息", "中毒資訊"),
    "Psychological Help": ("心理援助", "心理援助"),
    "SAMHSA Helpline": ("SAMHSA 援助热线", "SAMHSA 援助熱線"),
    # Interaction descriptions
    "Combined respiratory depression — the leading cause of overdose death.": (
        "联合呼吸抑制——过量致死的首要原因。",
        "聯合呼吸抑制——過量致死的首要原因。",
    ),
    "Severe respiratory depression — both substances suppress breathing.": (
        "严重呼吸抑制——两种物质都会抑制呼吸。",
        "嚴重呼吸抑制——兩種物質都會抑制呼吸。",
    ),
    "Respiratory depression and CNS shutdown — potentially fatal combination.": (
        "呼吸抑制及中枢神经停摆——可能致命的组合。",
        "呼吸抑制及中樞神經停擺——可能致命的組合。",
    ),
    "Serotonin syndrome — potentially fatal. Allow 2+ week washout.": (
        "血清素综合征——可能致命。需 2 周以上的清除期。",
        "血清素症候群——可能致命。需 2 週以上的清除期。",
    ),
    "Risk of serotonin syndrome and hypertensive crisis.": (
        "有血清素综合征和高血压危象的风险。",
        "有血清素症候群和高血壓危象的風險。",
    ),
    "Hypertensive crisis — potentially fatal spike in blood pressure.": (
        "高血压危象——血压可能致命性飙升。",
        "高血壓危象——血壓可能致命性飆升。",
    ),
    "Risk of serotonin syndrome, especially with meperidine/pethidine, tramadol, and tapentadol.": (
        "有血清素综合征的风险，尤其是与哌替啶、曲马多和他喷他多。",
        "有血清素症候群的風險，尤其是與哌替啶、曲馬多和他噴他多。",
    ),
    "Respiratory depression and loss of consciousness — very narrow safety margin.": (
        "呼吸抑制和意识丧失——安全边际极窄。",
        "呼吸抑制和意識喪失——安全邊際極窄。",
    ),
    "Severe respiratory depression — both are GABAergic depressants.": (
        "严重呼吸抑制——两者都是 GABA 能中枢抑制药。",
        "嚴重呼吸抑制——兩者都是 GABA 能中樞抑制藥。",
    ),
    "Life-threatening respiratory depression — this combination is a leading cause of overdose death.": (
        "危及生命的呼吸抑制——此组合是过量致死的主要原因。",
        "危及生命的呼吸抑制——此組合是過量致死的主要原因。",
    ),
    "Enhanced respiratory depression — gabapentinoids increase opioid overdose risk.": (
        "加重的呼吸抑制——加巴喷丁类增加阿片类过量风险。",
        "加重的呼吸抑制——加巴噴丁類增加鴉片類過量風險。",
    ),
    "Stacking opioids is unpredictable — respiratory depression risk compounds.": (
        "叠加阿片类不可预测——呼吸抑制风险叠加。",
        "疊加鴉片類不可預測——呼吸抑制風險疊加。",
    ),
    "Additive CNS and respiratory depression — antihistamines potentiate opioid sedation.": (
        "中枢和呼吸抑制相加——抗组胺药增强阿片类的镇静作用。",
        "中樞和呼吸抑制相加——抗組織胺藥增強鴉片類的鎮靜作用。",
    ),
    "Stimulants mask overdose signs — when they wear off, respiratory depression can emerge.": (
        "兴奋剂会掩盖过量的征兆——一旦消退，呼吸抑制可能浮现。",
        "興奮劑會掩蓋過量的徵兆——一旦消退，呼吸抑制可能浮現。",
    ),
    "Excessive sedation and respiratory depression risk.": (
        "过度镇静和呼吸抑制的风险。",
        "過度鎮靜和呼吸抑制的風險。",
    ),
    "Compounded CNS depression — excessive sedation and impaired breathing.": (
        "叠加的中枢抑制——过度镇静和呼吸受损。",
        "疊加的中樞抑制——過度鎮靜和呼吸受損。",
    ),
    "Respiratory depression risk — dissociatives can mask overdose signs.": (
        "有呼吸抑制的风险——解离剂会掩盖过量的征兆。",
        "有呼吸抑制的風險——解離劑會掩蓋過量的徵兆。",
    ),
    "Additive CNS and respiratory depression.": ("中枢和呼吸抑制相加。", "中樞和呼吸抑制相加。"),
    "Serotonin syndrome risk — especially with DXM and other serotonergic dissociatives.": (
        "有血清素综合征的风险——尤其是与 DXM 等血清素能解离剂。",
        "有血清素症候群的風險——尤其是與 DXM 等血清素能解離劑。",
    ),
    "Cardiovascular strain — combined stimulants increase heart rate and blood pressure.": (
        "心血管负荷——兴奋剂合用会提高心率和血压。",
        "心血管負荷——興奮劑合用會提高心率和血壓。",
    ),
    "Increased anxiety and vasoconstriction — stimulants can intensify difficult trips.": (
        "焦虑加剧和血管收缩——兴奋剂会加重艰难的体验。",
        "焦慮加劇和血管收縮——興奮劑會加重艱難的體驗。",
    ),
    "Unpredictable intensification — cannabis can trigger anxiety or thought loops.": (
        "不可预测的强化——大麻可能引发焦虑或思维循环。",
        "不可預測的強化——大麻可能引發焦慮或思緒反覆打轉。",
    ),
    "Risk of respiratory depression, aspiration, and loss of consciousness.": (
        "有呼吸抑制、误吸和意识丧失的风险。",
        "有呼吸抑制、誤吸和意識喪失的風險。",
    ),
    "Severe respiratory depression and loss of consciousness.": (
        "严重呼吸抑制和意识丧失。",
        "嚴重呼吸抑制和意識喪失。",
    ),
    "Stacking benzodiazepines dramatically increases sedation and respiratory depression risk.": (
        "叠加苯二氮䓬类会显著增加镇静和呼吸抑制的风险。",
        "疊加苯二氮平類會顯著增加鎮靜和呼吸抑制的風險。",
    ),
    "SSRIs typically reduce psychedelic effects but may increase risk with some compounds.": (
        "SSRI 通常会减弱迷幻效应，但与某些化合物可能增加风险。",
        "SSRI 通常會減弱迷幻效應，但與某些化合物可能增加風險。",
    ),
    "Serotonin accumulation risk — combining serotonergic agents increases toxicity chance.": (
        "血清素累积的风险——联合血清素能药物会增加毒性几率。",
        "血清素累積的風險——聯合血清素能藥物會增加毒性機率。",
    ),
    "Overlapping serotonin reuptake inhibition — increased serotonin syndrome risk.": (
        "血清素再摄取抑制重叠——血清素综合征的风险增加。",
        "血清素再攝取抑制重疊——血清素症候群的風險增加。",
    ),
    "SSRIs inhibit TCA metabolism — risk of TCA toxicity and serotonin syndrome.": (
        "SSRI 抑制 TCA 代谢——有 TCA 中毒和血清素综合征的风险。",
        "SSRI 抑制 TCA 代謝——有 TCA 中毒和血清素症候群的風險。",
    ),
    "Increased heart rate and blood pressure — cardiovascular strain.": (
        "心率和血压增加——心血管压力。",
        "心率和血壓增加——心血管壓力。",
    ),
    "Stimulants mask alcohol impairment — risk of overconsumption.": (
        "兴奋剂会掩盖酒精损害——有过量饮用的风险。",
        "興奮劑會掩蓋酒精損害——有過量飲用的風險。",
    ),
    "Compounded drowsiness and impaired coordination.": (
        "叠加的嗜睡和协调受损。",
        "疊加的嗜睡和協調受損。",
    ),
    "Measured Interactions": (
        "实测相互作用",
        "實測交互作用",
    ),
    "Kᵢ %@ µM": (
        "Kᵢ %@ µM",
        "Kᵢ %@ µM",
    ),
    "Additive CNS depression — increased sedation and impairment.": (
        "中枢抑制相加——镇静和损害加剧。",
        "中樞抑制相加——鎮靜和損害加劇。",
    ),
    "Combined respiratory depression with no ceiling — barbiturates deepen an opioid's suppression of breathing until it stops.": (
        "呼吸抑制相加且没有封顶——巴比妥类会不断加深阿片类对呼吸的抑制，直到呼吸停止。",
        "呼吸抑制相加且沒有封頂——巴比妥類會不斷加深鴉片類對呼吸的抑制，直到呼吸停止。",
    ),
    "Life-threatening respiratory depression. A barbiturate opens the GABA-A channel directly rather than modulating it, so this stacks past the point where benzodiazepines alone level off.": (
        "危及生命的呼吸抑制。巴比妥类直接打开 GABA-A 通道，而不只是调节它，因此这一组合会越过苯二氮䓬类单用时趋于平缓的那个点继续叠加。",
        "危及生命的呼吸抑制。巴比妥類直接打開 GABA-A 通道，而不只是調節它，因此這一組合會越過苯二氮平類單用時趨於平緩的那個點繼續疊加。",
    ),
    "Life-threatening respiratory depression and loss of consciousness — the classic fatal combination.": (
        "危及生命的呼吸抑制与意识丧失——典型的致命组合。",
        "危及生命的呼吸抑制與意識喪失——典型的致命組合。",
    ),
    "Severe respiratory depression — two direct-acting depressants with no shared ceiling.": (
        "严重呼吸抑制——两种直接起效的中枢抑制药，两者之间没有共同的上限。",
        "嚴重呼吸抑制——兩種直接起效的中樞抑制藥，兩者之間沒有共同的上限。",
    ),
    "Doses add with no plateau, and the gap between a sedating dose and a fatal one is narrow to begin with.": (
        "剂量相加且不会趋于平缓，而镇静剂量与致死剂量之间的差距本就很窄。",
        "劑量相加且不會趨於平緩，而鎮靜劑量與致死劑量之間的差距本就很窄。",
    ),
    "Additive sedation and respiratory depression.": (
        "镇静与呼吸抑制相加。",
        "鎮靜與呼吸抑制相加。",
    ),
    "Heavy additive sedation — deep drowsiness and impaired breathing.": (
        "镇静作用强烈相加——深度嗜睡与呼吸受损。",
        "鎮靜作用強烈相加——深度嗜睡與呼吸受損。",
    ),
    "Additive CNS and respiratory depression, with a raised risk of vomiting while unresponsive.": (
        "中枢与呼吸抑制相加，并且在失去反应时呕吐的风险升高。",
        "中樞與呼吸抑制相加，並且在失去反應時嘔吐的風險升高。",
    ),
    "Additive sedation, low blood pressure, and slow heart rate.": (
        "镇静、低血压与心率减慢相加。",
        "鎮靜、低血壓與心率減慢相加。",
    ),
    "Additive sedation and next-day impairment.": (
        "镇静相加，次日仍有功能损害。",
        "鎮靜相加，次日仍有功能損害。",
    ),
    "Additive sedation, dizziness, and slowed reaction time.": (
        "镇静、头晕与反应变慢相加。",
        "鎮靜、頭暈與反應變慢相加。",
    ),
    "Enhanced CNS depression — risk of respiratory depression and death.": (
        "加重的中枢抑制——有呼吸抑制和死亡的风险。",
        "加重的中樞抑制——有呼吸抑制和死亡的風險。",
    ),
    "Stacking gabapentinoids compounds sedation and respiratory depression risk.": (
        "叠加加巴喷丁类会加重镇静和呼吸抑制的风险。",
        "疊加加巴噴丁類會加重鎮靜和呼吸抑制的風險。",
    ),
    "Compounded dissociation — disorientation and loss of motor control.": (
        "叠加的解离——定向障碍和运动控制丧失。",
        "疊加的解離——定向障礙和運動控制喪失。",
    ),
    "Serotonin depletion and neurotoxicity risk — allow adequate recovery between uses.": (
        "血清素耗竭和神经毒性的风险——使用间隔应足够长以便恢复。",
        "血清素耗竭和神經毒性的風險——使用間隔應足夠長以便恢復。",
    ),
    "Some combinations increase serotonin or seizure risk — monitor for symptoms.": (
        "某些组合会增加血清素或癫痫的风险——注意监测症状。",
        "某些組合會增加血清素或癲癇的風險——注意監測症狀。",
    ),
    "Cardiovascular strain and serotonin risk — watch your heart rate and blood pressure.": (
        "心血管负荷与血清素风险——注意你的心率和血压。",
        "心血管負荷與血清素風險——注意你的心率和血壓。",
    ),
    "Combined QTc prolongation risk — monitor cardiac rhythm.": (
        "联合 QTc 延长的风险——监测心律。",
        "聯合 QTc 延長的風險——監測心律。",
    ),
    "Additive CNS depression — increased sedation and impaired coordination.": (
        "中枢抑制相加——镇静加剧、协调受损。",
        "中樞抑制相加——鎮靜加劇、協調受損。",
    ),
    "Additive sedation — may increase drowsiness and impaired coordination.": (
        "镇静相加——可能加剧嗜睡和协调受损。",
        "鎮靜相加——可能加劇嗜睡和協調受損。",
    ),
    "Additive CNS depression — may increase sedation and respiratory depression risk.": (
        "中枢抑制相加——可能加剧镇静和呼吸抑制的风险。",
        "中樞抑制相加——可能加劇鎮靜和呼吸抑制的風險。",
    ),
    "Additive impairment — increased dizziness, drowsiness, and slowed reaction time.": (
        "损害相加——头晕、嗜睡和反应延迟加剧。",
        "損害相加——頭暈、嗜睡和反應延遲加劇。",
    ),
    # Non-English-name emergency services — keep as proper nouns
    "113 Zelfmoordpreventie": ("113 Zelfmoordpreventie", "113 Zelfmoordpreventie"),
    "Acil Yardim": ("Acil Yardim", "Acil Yardim"),
    "Alarmnummer": ("Alarmnummer", "Alarmnummer"),
    "Ambulancia": ("Ambulancia", "Ambulancia"),
    "Befrienders": ("Befrienders", "Befrienders"),
    "Befrienders Kenya": ("Befrienders Kenya", "Befrienders Kenya"),
    "CVV (Centro de Valorização da Vida)": (
        "CVV (Centro de Valorização da Vida)",
        "CVV (Centro de Valorização da Vida)",
    ),
    "Centre Antipoison": ("Centre Antipoison", "Centre Antipoison"),
    "Centre Antipoisons": ("Centre Antipoisons", "Centre Antipoisons"),
    "Centro Antiveleni": ("Centro Antiveleni", "Centro Antiveleni"),
    "Centro de Asistencia al Suicida": (
        "Centro de Asistencia al Suicida",
        "Centro de Asistencia al Suicida",
    ),
    "Die Dargebotene Hand": ("Die Dargebotene Hand", "Die Dargebotene Hand"),
    "EKAB": ("EKAB", "EKAB"),
    "ERAN Crisis Line": ("ERAN Crisis Line", "ERAN Crisis Line"),
    "Emergencias": ("Emergencias", "Emergencias"),
    "Emergencias (ECU 911)": ("Emergencias (ECU 911)", "Emergencias (ECU 911)"),
    "Emergenze": ("Emergenze", "Emergenze"),
    "FRANK Drug Helpline": ("FRANK Drug Helpline", "FRANK Drug Helpline"),
    "Giftinformasjonen": ("Giftinformasjonen", "Giftinformasjonen"),
    "Giftnotruf": ("Giftnotruf", "Giftnotruf"),
    "Hatanumero": ("Hatanumero", "Hatanumero"),
    "Intihar Onleme Hatti": ("Intihar Onleme Hatti", "Intihar Onleme Hatti"),
    "Klimaka Crisis Line": ("Klimaka Crisis Line", "Klimaka Crisis Line"),
    "Kriisipuhelin": ("Kriisipuhelin", "Kriisipuhelin"),
    "Linea 113 Salud": ("Linea 113 Salud", "Linea 113 Salud"),
    "Linea de Crisis": ("Linea de Crisis", "Linea de Crisis"),
    "Linea de Emergencias": ("Linea de Emergencias", "Linea de Emergencias"),
    "Linea de Prevencion del Suicidio": (
        "Linea de Prevencion del Suicidio",
        "Linea de Prevencion del Suicidio",
    ),
    "Linea de la Vida": ("Linea de la Vida", "Linea de la Vida"),
    "Linka bezpeci": ("Linka bezpeci", "Linka bezpeci"),
    "Livslinien": ("Livslinien", "Livslinien"),
    "Mental Helse": ("Mental Helse", "Mental Helse"),
    "Mind Sjalvmordslinjen": ("Mind Sjalvmordslinjen", "Mind Sjalvmordslinjen"),
    "Nodnummer": ("Nodnummer", "Nodnummer"),
    "Notruf": ("Notruf", "Notruf"),
    "Numer alarmowy": ("Numer alarmowy", "Numer alarmowy"),
    "Pieta House": ("Pieta House", "Pieta House"),
    "SADAG Crisis Line": ("SADAG Crisis Line", "SADAG Crisis Line"),
    "SAMU": ("SAMU", "SAMU"),
    "SOS Amitie": ("SOS Amitie", "SOS Amitie"),
    "SOS Voz Amiga": ("SOS Voz Amiga", "SOS Voz Amiga"),
    "Salud Responde": ("Salud Responde", "Salud Responde"),
    "Samaritans": ("Samaritans", "Samaritans"),
    "Samaritans of Singapore": ("Samaritans of Singapore", "Samaritans of Singapore"),
    "Samaritans of Thailand": ("Samaritans of Thailand", "Samaritans of Thailand"),
    "Sanitatsnotruf": ("Sanitatsnotruf", "Sanitatsnotruf"),
    "Servicios de Emergencia": ("Servicios de Emergencia", "Servicios de Emergencia"),
    "Telefon Zaufania": ("Telefon Zaufania", "Telefon Zaufania"),
    "Telefono Amico": ("Telefono Amico", "Telefono Amico"),
    "Telefono de la Esperanza": ("Telefono de la Esperanza", "Telefono de la Esperanza"),
    "Telefonseelsorge": ("Telefonseelsorge", "Telefonseelsorge"),
    "Tisnovka": ("Tisnovka", "Tisnovka"),
    "Tox Info Suisse": ("Tox Info Suisse", "Tox Info Suisse"),
    "Urgences": ("Urgences", "Urgences"),
    "Vandrevala Foundation": ("Vandrevala Foundation", "Vandrevala Foundation"),
    "Yorisoi Hotline": ("Yorisoi Hotline", "Yorisoi Hotline"),
    # Insights stat cards
    "Entries": ("记录", "記錄"),
    "Substances": ("物质", "物質"),
    "All Substances": ("所有物质", "所有物質"),
    "Substances (%lld)": (
        "物质（%lld）",
        "物質（%lld）",
    ),
    "Select All": ("全选", "全選"),
    "Deselect All": ("取消全选", "取消全選"),
    "Per day": ("每日", "每日"),
    "Most logged": ("记录最多", "記錄最多"),
    # Time of day chart
    "Morning\n6–12": ("早上\n6–12", "早上\n6–12"),
    "Afternoon\n12–18": ("下午\n12–18", "下午\n12–18"),
    "Evening\n18–0": ("傍晚\n18–0", "傍晚\n18–0"),
    "Night\n0–6": ("夜间\n0–6", "夜間\n0–6"),
    # Volumetric dosing
    "Desired Concentration": ("所需浓度", "所需濃度"),
    "Substance Amount": ("物质剂量", "物質劑量"),
    "Solvent Volume": ("溶剂体积", "溶劑體積"),
    "Solution Concentration": ("溶液浓度", "溶液濃度"),
    "Always label solutions with substance name and concentration.": (
        "始终用物质名称和浓度标记溶液。",
        "始終用物質名稱和濃度標記溶液。",
    ),
    "Verify calculations independently before use.": (
        "使用前请独立核对计算。",
        "使用前請獨立核對計算。",
    ),
    "Use a milligram scale and graduated cylinder for accuracy.": (
        "使用毫克秤和量筒以确保精确。",
        "使用毫克秤和量筒以確保精確。",
    ),
    "Store solutions in clearly marked, child-proof containers.": (
        "将溶液存放在标识清楚、儿童无法打开的容器中。",
        "將溶液存放在標識清楚、兒童無法打開的容器中。",
    ),
    # Comedown guide section headers
    "What's happening": ("正在发生什么", "正在發生什麼"),
    "Right now": ("此刻", "此刻"),
    "Over the next hours": ("接下来几小时", "接下來幾小時"),
    "What to avoid": ("应避免的事", "應避免的事"),
    # Comedown guide bullet points — Stimulant
    "Your brain burned through dopamine and norepinephrine faster than usual.": (
        "你的大脑比平时更快地消耗了多巴胺和去甲肾上腺素。",
        "你的大腦比平時更快地消耗了多巴胺和正腎上腺素。",
    ),
    "The crash is your nervous system demanding rest and replenishment.": (
        "这次崩溃是你的神经系统在要求休息和补充。",
        "這次崩潰是你的神經系統在要求休息和補充。",
    ),
    "Fatigue, irritability, and low mood are all normal parts of this process.": (
        "疲倦、易怒和情绪低落都是此过程中的正常表现。",
        "疲倦、易怒和情緒低落都是此過程中的正常表現。",
    ),
    "Eat something — even if you're not hungry. Protein and complex carbs help most.": (
        "吃点东西——即使你不饿。蛋白质和复合碳水化合物最有帮助。",
        "吃點東西——即使你不餓。蛋白質和複合碳水化合物最有幫助。",
    ),
    "Drink water or an electrolyte drink. You've been dehydrating without noticing.": (
        "喝水或电解质饮料。你一直在脱水却没有察觉。",
        "喝水或電解質飲料。你一直在脫水卻沒有察覺。",
    ),
    "Magnesium can help with jaw tension and muscle tightness.": (
        "镁有助于缓解下颌紧绷和肌肉僵硬。",
        "鎂有助於緩解下顎緊繃和肌肉僵硬。",
    ),
    "Vitamin C may support your body's recovery.": (
        "维生素 C 可能有助于身体恢复。",
        "維生素 C 可能有助於身體恢復。",
    ),
    "Don't fight the fatigue — lie down even if sleep doesn't come immediately.": (
        "不要对抗疲劳——即使一时无法入睡也躺下休息。",
        "不要對抗疲勞——即使一時無法入睡也躺下休息。",
    ),
    "Dark room, comfortable temperature, no screens.": (
        "昏暗的房间、舒适的温度、远离屏幕。",
        "昏暗的房間、舒適的溫度、遠離螢幕。",
    ),
    "A warm shower or light stretching helps your muscles release.": (
        "温水淋浴或轻度拉伸有助于肌肉放松。",
        "溫水淋浴或輕度拉伸有助於肌肉放鬆。",
    ),
    "Don't redose to escape the crash — it only delays and worsens recovery.": (
        "不要为了逃避崩溃而补服——这只会延迟并加重恢复。",
        "不要為了逃避崩潰而補服——這只會延遲並加重恢復。",
    ),
    "Skip the caffeine — your cardiovascular system has worked hard enough.": (
        "不要喝咖啡因——你的心血管系统已经够累了。",
        "不要喝咖啡因——你的心血管系統已經夠累了。",
    ),
    "Don't make important decisions or send emotionally charged messages right now.": (
        "现在不要做重要决定或发送情绪化的信息。",
        "現在不要做重要決定或發送情緒化的訊息。",
    ),
    "Avoid alcohol — it worsens dehydration and disrupts the sleep you need.": (
        "避免酒精——它会加重脱水并打乱你所需的睡眠。",
        "避免酒精——它會加重脫水並打亂你所需的睡眠。",
    ),
    # Comedown guide — Empathogen
    "Your serotonin reserves are depleted — that's why everything feels flat or low.": (
        "你的血清素储备已耗尽——这就是为什么一切感觉平淡或低落。",
        "你的血清素儲備已耗盡——這就是為什麼一切感覺平淡或低落。",
    ),
    "This is temporary. Your brain will replenish over the next few days.": (
        "这是暂时的。接下来几天你的大脑会补充。",
        "這是暫時的。接下來幾天你的大腦會補充。",
    ),
    "Emotional sensitivity and fatigue are part of it.": (
        "情绪敏感和疲劳都是过程的一部分。",
        "情緒敏感和疲勞都是過程的一部分。",
    ),
    "Stay warm — your body's temperature regulation is still off.": (
        "保暖——你的体温调节仍未恢复。",
        "保暖——你的體溫調節仍未恢復。",
    ),
    "Sip water steadily, but don't overdo it. A glass every 30-60 minutes is fine.": (
        "稳定地小口喝水，但不要过量。每 30 至 60 分钟一杯即可。",
        "穩定地小口喝水，但不要過量。每 30 至 60 分鐘一杯即可。",
    ),
    "Eat light foods: fruit, toast, soup. Your stomach may be sensitive.": (
        "吃清淡食物：水果、吐司、汤。你的胃可能比较敏感。",
        "吃清淡食物：水果、吐司、湯。你的胃可能比較敏感。",
    ),
    "If your jaw is sore, gentle massage and magnesium help.": (
        "如果下颌酸痛，轻柔按摩和镁有帮助。",
        "如果下顎痠痛，輕柔按摩和鎂有幫助。",
    ),
    "Rest in a comfortable, calm space. Soft music or silence both work.": (
        "在舒适、平静的空间里休息。柔和的音乐或安静都可以。",
        "在舒適、平靜的空間裡休息。柔和的音樂或安靜都可以。",
    ),
    "Be patient with yourself for the next 1-3 days. Low mood is the serotonin dip.": (
        "接下来 1 至 3 天对自己耐心点。情绪低落是血清素下降。",
        "接下來 1 至 3 天對自己耐心點。情緒低落是血清素下降。",
    ),
    "A walk outside helps when you're ready.": (
        "准备好的时候，出去走走会有帮助。",
        "準備好的時候，出去走走會有幫助。",
    ),
    "Talk to someone you trust — connection helps more than isolation.": (
        "和你信任的人聊聊——联结比孤立更有帮助。",
        "和你信任的人聊聊——聯結比孤立更有幫助。",
    ),
    "Don't redose — the magic is in spacing. Frequent use causes lasting harm.": (
        "不要补服——关键在于间隔。频繁使用会造成持久伤害。",
        "不要補服——關鍵在於間隔。頻繁使用會造成持久傷害。",
    ),
    "Avoid 5-HTP supplements for at least 24 hours after your last dose.": (
        "最后一次服用后至少 24 小时内避免 5-HTP 补充剂。",
        "最後一次服用後至少 24 小時內避免 5-HTP 補充劑。",
    ),
    "Skip intense social situations — you may feel emotionally raw.": (
        "避免激烈的社交场合——你可能情绪敏感。",
        "避免激烈的社交場合——你可能情緒敏感。",
    ),
    "Don't judge your baseline mood by how you feel right now.": (
        "不要以现在的感受来判断你的基线情绪。",
        "不要以現在的感受來判斷你的基線情緒。",
    ),
    # Comedown guide — Psychedelic
    "Your serotonin receptors are returning to their normal sensitivity.": (
        "你的血清素受体正恢复到正常敏感度。",
        "你的血清素受體正恢復到正常敏感度。",
    ),
    "You may feel emotionally open, contemplative, or just tired.": (
        "你可能感到情感开放、深思，或只是疲倦。",
        "你可能感到情感開放、深思，或只是疲倦。",
    ),
    "Some residual visual or thought patterns can linger — this is normal and fades.": (
        "一些视觉或思维残余可能会持续——这是正常的，会消退。",
        "一些視覺或思維殘餘可能會持續——這是正常的，會消退。",
    ),
    "You're safe. If the experience was intense, remind yourself: it's temporary.": (
        "你是安全的。如果体验很强烈，提醒自己：这是暂时的。",
        "你是安全的。如果體驗很強烈，提醒自己：這是暫時的。",
    ),
    "Eat something grounding — warm food, fruit, or anything that sounds appealing.": (
        "吃些让人安定的东西——温热的食物、水果或任何想吃的。",
        "吃些讓人安定的東西——溫熱的食物、水果或任何想吃的。",
    ),
    "Drink water. Wrap up in something comfortable.": (
        "喝水。裹上舒适的衣物。",
        "喝水。裹上舒適的衣物。",
    ),
    "Write down anything meaningful before the details fade.": (
        "在细节消失前记下任何有意义的内容。",
        "在細節消失前記下任何有意義的內容。",
    ),
    "Rest. Sleep often comes easily once the peak is past.": (
        "休息。一旦高峰期过去，睡眠通常会比较容易。",
        "休息。一旦高峰期過去，睡眠通常會比較容易。",
    ),
    "Nature, art, or quiet music can help you process gently.": (
        "大自然、艺术或宁静的音乐能温柔地帮助你消化。",
        "大自然、藝術或寧靜的音樂能溫柔地幫助你消化。",
    ),
    "Be easy with yourself — big experiences need time to settle.": (
        "善待自己——大的体验需要时间沉淀。",
        "善待自己——大的體驗需要時間沉澱。",
    ),
    "Don't make big life decisions based on acute revelations — wait a week.": (
        "不要根据当下的顿悟做出重大人生决定——等一周再说。",
        "不要根據當下的頓悟做出重大人生決定——等一週再說。",
    ),
    "Avoid screens and doom-scrolling. Your mind is still very impressionable.": (
        "避免使用屏幕和无止境滑动。你的心智仍非常易受影响。",
        "避免使用螢幕和無止境滑動。你的心智仍非常易受影響。",
    ),
    "Don't smoke cannabis unless you know how it interacts with your afterglow.": (
        "不要吸食大麻，除非你了解它与余韵的相互作用。",
        "不要吸食大麻，除非你了解它與餘韻的相互作用。",
    ),
    "Skip intense or crowded environments until you feel grounded.": (
        "在感到稳定前，避开激烈或拥挤的环境。",
        "在感到穩定前，避開激烈或擁擠的環境。",
    ),
    # Comedown guide — Dissociative
    "Your NMDA receptors are returning to baseline, which can feel foggy or unreal.": (
        "你的 NMDA 受体正恢复到基线，可能感觉迷糊或不真实。",
        "你的 NMDA 受體正恢復到基線，可能感覺迷糊或不真實。",
    ),
    "Motor coordination and spatial awareness may still be impaired.": (
        "运动协调和空间感知能力可能仍受影响。",
        "運動協調和空間感知能力可能仍受影響。",
    ),
    "Some dissociative afterglow is common — the world may feel slightly 'off' for a while.": (
        "一些解离性余韵很常见——世界可能在一段时间内感觉略有“不对”。",
        "一些解離性餘韻很常見——世界可能在一段時間內感覺略有「不對」。",
    ),
    "Stay seated or lying down. Your balance may not be what you think it is.": (
        "保持坐姿或躺下。你的平衡感可能不如你以为的好。",
        "保持坐姿或躺下。你的平衡感可能不如你以為的好。",
    ),
    "Drink water. Eat something simple when your stomach allows.": (
        "喝水。胃能接受时吃些简单的食物。",
        "喝水。胃能接受時吃些簡單的食物。",
    ),
    "Stay somewhere safe with someone you trust if possible.": (
        "如果可能，留在安全的地方，有你信任的人在身边。",
        "如果可能，留在安全的地方，有你信任的人在身邊。",
    ),
    "Avoid stairs, sharp objects, and anything requiring fine motor skills.": (
        "避免楼梯、尖锐物体和任何需要精细动作的事。",
        "避免樓梯、尖銳物體和任何需要精細動作的事。",
    ),
    "Sleep when you can — your brain recovers fastest during rest.": (
        "能睡就睡——大脑在休息时恢复最快。",
        "能睡就睡——大腦在休息時恢復最快。",
    ),
    "Gentle sensory input (music, soft textures) can help you reconnect.": (
        "温和的感官输入（音乐、柔软质感）有助于重新连结。",
        "溫和的感官輸入（音樂、柔軟質感）有助於重新連結。",
    ),
    "Don't worry if things feel 'weird' — your perception is still recalibrating.": (
        "如果觉得“奇怪”不必担心——你的感知仍在重新校准。",
        "如果覺得「奇怪」不必擔心——你的感知仍在重新校準。",
    ),
    "Absolutely do not drive or operate machinery.": (
        "绝对不要驾驶或操作机器。",
        "絕對不要駕駛或操作機器。",
    ),
    "Don't mix with depressants (alcohol, benzos, opioids) — respiratory depression risk.": (
        "不要与抑制剂（酒精、苯二氮䓬、阿片类）混用——有呼吸抑制风险。",
        "不要與抑制劑（酒精、苯二氮平、鴉片類）混用——有呼吸抑制風險。",
    ),
    "Avoid hot baths/showers alone — you may not feel temperature accurately.": (
        "避免独自洗热水澡——你可能无法准确感知温度。",
        "避免獨自洗熱水澡——你可能無法準確感知溫度。",
    ),
    "Don't redose while still dissociated — you can't gauge your level clearly.": (
        "仍在解离时不要补服——你无法清楚判断自己的状态。",
        "仍在解離時不要補服——你無法清楚判斷自己的狀態。",
    ),
    # Comedown guide — Opioid
    "Your endorphin system was temporarily overridden. As the drug fades, sensitivity returns.": (
        "你的内啡肽系统暂时被覆盖。药物消退后，敏感度会回归。",
        "你的內啡肽系統暫時被覆蓋。藥物消退後，敏感度會回歸。",
    ),
    "You may feel increased pain sensitivity, restlessness, or mild nausea.": (
        "你可能感到痛觉增强、焦躁或轻度恶心。",
        "你可能感到痛覺增強、焦躁或輕度噁心。",
    ),
    "These effects are proportional to how much and how often you've been using.": (
        "这些影响与你使用的剂量和频率成正比。",
        "這些影響與你使用的劑量和頻率成正比。",
    ),
    "Stay hydrated — opioids are dehydrating and constipating.": (
        "保持水分——阿片类会导致脱水和便秘。",
        "保持水分——鴉片類會導致脫水和便秘。",
    ),
    "Eat something light. Your appetite may be suppressed but food helps.": (
        "吃些清淡的东西。食欲可能受抑制，但食物有帮助。",
        "吃些清淡的東西。食慾可能受抑制，但食物有幫助。",
    ),
    "If you feel nauseous, lie on your side and sip ginger tea or plain water.": (
        "感到恶心时，侧卧并小口喝姜茶或清水。",
        "感到噁心時，側臥並小口喝薑茶或清水。",
    ),
    "Fresh air can help with the foggy, closed-in feeling.": (
        "新鲜空气有助于缓解迷糊和压抑感。",
        "新鮮空氣有助於緩解迷糊和壓抑感。",
    ),
    "Light movement helps — even a short walk speeds recovery.": (
        "轻度活动有帮助——即使短暂散步也能加速恢复。",
        "輕度活動有幫助——即使短暫散步也能加速恢復。",
    ),
    "A warm bath can ease the achy, restless feeling.": (
        "温水浴可以缓解酸痛和不安感。",
        "溫水浴可以緩解痠痛和不安感。",
    ),
    "Sleep if you can. Your body does its best recovery work unconscious.": (
        "能睡就睡。身体在无意识时做最好的恢复工作。",
        "能睡就睡。身體在無意識時做最好的恢復工作。",
    ),
    "Don't redose to chase the feeling — tolerance builds fast and that path is dangerous.": (
        "不要为了追求感觉而补服——耐受性会快速建立，这条路很危险。",
        "不要為了追求感覺而補服——耐受性會快速建立，這條路很危險。",
    ),
    "Never mix with alcohol, benzos, or other depressants.": (
        "绝不要与酒精、苯二氮䓬或其他中枢抑制药混用。",
        "絕不要與酒精、苯二氮平或其他中樞抑制藥混用。",
    ),
    "Don't isolate yourself. Let someone know where you are.": (
        "不要独自一人。让某人知道你在哪里。",
        "不要獨自一人。讓某人知道你在哪裡。",
    ),
    "Avoid driving — reaction time and judgment may still be affected.": (
        "避免驾驶——反应时间和判断力可能仍受影响。",
        "避免駕駛——反應時間和判斷力可能仍受影響。",
    ),
    # Comedown guide — Benzodiazepine
    "Your GABA receptors are readjusting — anxiety or restlessness may temporarily increase.": (
        "你的 GABA 受体正在重新调整——焦虑或不安可能暂时加剧。",
        "你的 GABA 受體正在重新調整——焦慮或不安可能暫時加劇。",
    ),
    "If you've been using regularly, talk to a doctor about tapering — never stop abruptly.": (
        "如果你一直规律使用，和医生商量如何逐渐减量——切勿突然停药。",
        "如果你一直規律使用，和醫生商量如何逐漸減量——切勿突然停藥。",
    ),
    "Stay somewhere calm and safe. The rebound anxiety is temporary.": (
        "留在平静、安全的地方。反弹性焦虑是暂时的。",
        "留在平靜、安全的地方。反彈性焦慮是暫時的。",
    ),
    "Drink water and eat something — stable blood sugar helps mood.": (
        "喝水并吃点东西——稳定的血糖有助于情绪。",
        "喝水並吃點東西——穩定的血糖有助於情緒。",
    ),
    "Breathing exercises: 4 seconds in, 7 seconds hold, 8 seconds out.": (
        "呼吸练习：吸气 4 秒、屏住 7 秒、呼气 8 秒。",
        "呼吸練習：吸氣 4 秒、屏住 7 秒、呼氣 8 秒。",
    ),
    "Avoid caffeine — it amplifies the rebound anxiety.": (
        "避免咖啡因——它会放大反弹性焦虑。",
        "避免咖啡因——它會放大反彈性焦慮。",
    ),
    "Sleep may be disrupted tonight — melatonin or chamomile tea can help.": (
        "今晚睡眠可能受打扰——褪黑素或甘菊茶有帮助。",
        "今晚睡眠可能受打擾——褪黑素或甘菊茶有幫助。",
    ),
    "Light activity like walking helps burn off anxious energy.": (
        "散步等轻度活动有助于消耗焦虑的能量。",
        "散步等輕度活動有助於消耗焦慮的能量。",
    ),
    "The discomfort peaks and then fades. Give it time.": (
        "不适会达到顶峰然后消退。给它时间。",
        "不適會達到頂峰然後消退。給它時間。",
    ),
    "If this is frequent for you, consider talking to a professional about alternatives.": (
        "如果这对你来说很常见，可以考虑和专业人士聊聊替代方案。",
        "如果這對你來說很常見，可以考慮和專業人士聊聊替代方案。",
    ),
    "Don't redose reactively — it reinforces the cycle.": (
        "不要条件反射地补服——这会强化循环。",
        "不要條件反射地補服——這會強化循環。",
    ),
    "Avoid alcohol completely — it acts on the same receptors.": (
        "完全避免酒精——它作用于相同的受体。",
        "完全避免酒精——它作用於相同的受體。",
    ),
    "Don't make this worse by doom-scrolling health anxiety forums.": (
        "不要通过滑动健康焦虑论坛让情况恶化。",
        "不要透過滑動健康焦慮論壇讓情況惡化。",
    ),
    "Never abruptly stop after regular use — benzo withdrawal can be medically serious.": (
        "规律使用后切勿突然停药——苯二氮䓬戒断可能在医学上非常严重。",
        "規律使用後切勿突然停藥——苯二氮平戒斷可能在醫學上非常嚴重。",
    ),
    # Comedown guide — Depressant
    "Your central nervous system was being suppressed and is now rebounding.": (
        "你的中枢神经系统之前被抑制，现在正反弹。",
        "你的中樞神經系統之前被抑制，現在正反彈。",
    ),
    "You may feel shaky, anxious, or nauseous as your body recalibrates.": (
        "身体重新校准时，你可能感到颤抖、焦虑或恶心。",
        "身體重新校準時，你可能感到顫抖、焦慮或噁心。",
    ),
    "Headaches and fatigue are common — this is your body processing the substance.": (
        "头痛和疲劳很常见——这是你的身体在处理物质。",
        "頭痛和疲勞很常見——這是你的身體在處理物質。",
    ),
    "Drink water — depressants are dehydrating, especially alcohol.": (
        "喝水——中枢抑制药会导致脱水，特别是酒精。",
        "喝水——中樞抑制藥會導致脫水，特別是酒精。",
    ),
    "Eat something with salt, protein, and carbs. Your body needs fuel to recover.": (
        "吃些含盐、蛋白质和碳水的食物。你的身体需要燃料恢复。",
        "吃些含鹽、蛋白質和碳水的食物。你的身體需要燃料恢復。",
    ),
    "If nauseous, small sips of water and lying on your side help.": (
        "感到恶心时，小口喝水并侧卧有帮助。",
        "感到噁心時，小口喝水並側臥有幫助。",
    ),
    "An electrolyte drink is better than plain water if available.": (
        "如果有，电解质饮料比清水更好。",
        "如果有，電解質飲料比清水更好。",
    ),
    "Sleep it off if you can — your body needs rest to metabolize and recover.": (
        "能睡就睡过去——你的身体需要休息来代谢和恢复。",
        "能睡就睡過去——你的身體需要休息來代謝和恢復。",
    ),
    "A cool, dark room helps with headaches and overstimulation.": (
        "凉爽、昏暗的房间有助于缓解头痛和过度刺激。",
        "涼爽、昏暗的房間有助於緩解頭痛和過度刺激。",
    ),
    "Light food every few hours, even if you don't feel hungry.": (
        "每隔几小时吃些清淡的食物，即使不饿。",
        "每隔幾小時吃些清淡的食物，即使不餓。",
    ),
    "Fresh air and gentle movement when you're ready.": (
        "准备好时呼吸新鲜空气并轻度活动。",
        "準備好時呼吸新鮮空氣並輕度活動。",
    ),
    "Don't 'hair of the dog' — more depressant just delays recovery.": (
        "不要“以毒攻毒”——更多中枢抑制药只会延迟恢复。",
        "不要「以毒攻毒」——更多中樞抑制藥只會延遲恢復。",
    ),
    "Avoid painkillers that stress the liver (acetaminophen) after heavy alcohol use.": (
        "大量饮酒后避免使用对肝脏有压力的止痛药（对乙酰氨基酚）。",
        "大量飲酒後避免使用對肝臟有壓力的止痛藥（乙醯胺酚）。",
    ),
    "Don't drive or make important decisions until fully sober.": (
        "完全清醒前不要驾驶或做重要决定。",
        "完全清醒前不要駕駛或做重要決定。",
    ),
    "Avoid greasy, heavy food — it sounds good but often makes nausea worse.": (
        "避免油腻、难消化的食物——虽然看着诱人，但常会让恶心更严重。",
        "避免油膩、難消化的食物——雖然看著誘人，但常會讓噁心更嚴重。",
    ),
    # Comedown guide — Cannabinoid
    "Your endocannabinoid system is returning to baseline.": (
        "你的内源性大麻素系统正回到基线。",
        "你的內源性大麻素系統正回到基線。",
    ),
    "You may feel foggy, lethargic, or mildly irritable.": (
        "你可能感到迷糊、嗜睡或轻微易怒。",
        "你可能感到迷糊、嗜睡或輕微易怒。",
    ),
    "Appetite changes and sleep disruption are common after heavy sessions.": (
        "大量使用后，食欲变化和睡眠紊乱很常见。",
        "大量使用後，食慾變化和睡眠紊亂很常見。",
    ),
    "Drink water — cotton mouth means you've been dehydrating.": (
        "喝水——口干意味着你在脱水。",
        "喝水——口乾意味著你在脫水。",
    ),
    "Eat something balanced. The munchies may have had you eating junk.": (
        "吃些均衡的食物。嘴馋可能让你吃了垃圾食品。",
        "吃些均衡的食物。嘴饞可能讓你吃了垃圾食品。",
    ),
    "If you feel anxious, focus on slow breathing. It passes.": (
        "如果感到焦虑，专注于慢呼吸。它会过去。",
        "如果感到焦慮，專注於慢呼吸。它會過去。",
    ),
    "A change of scenery — even moving to a different room — can shift your headspace.": (
        "换个环境——即使只是换到另一个房间——可以改变心境。",
        "換個環境——即使只是換到另一個房間——可以改變心境。",
    ),
    "Physical activity helps clear the fog faster than anything.": (
        "身体活动是清除迷糊感最快的方法。",
        "身體活動是清除迷糊感最快的方法。",
    ),
    "Caffeine in moderation can help with grogginess.": (
        "适量咖啡因有助于缓解昏沉。",
        "適量咖啡因有助於緩解昏沉。",
    ),
    "Sleep quality may be off tonight — melatonin can help.": (
        "今晚睡眠质量可能欠佳——褪黑素有帮助。",
        "今晚睡眠品質可能欠佳——褪黑素有幫助。",
    ),
    "If you feel spacey, grounding exercises: name 5 things you can see, 4 you can touch.": (
        "如果感觉飘忽，做稳定练习：说出 5 件你能看见的、4 件能触摸的。",
        "如果感覺飄忽，做穩定練習：說出 5 件你能看見的、4 件能觸摸的。",
    ),
    "Don't drive until the fog fully clears — it takes longer than you think.": (
        "迷糊感完全消失前不要驾驶——比你想的要久。",
        "迷糊感完全消失前不要駕駛——比你想的要久。",
    ),
    "Avoid more cannabis to 'take the edge off' the comedown.": (
        "不要用更多大麻来“缓解”下头。",
        "不要用更多大麻來「緩解」下頭。",
    ),
    "Don't panic about short-term memory gaps — they resolve with sobriety.": (
        "不要因短期记忆空白而恐慌——它们会随清醒恢复。",
        "不要因短期記憶空白而恐慌——它們會隨清醒恢復。",
    ),
    "Skip intense social obligations if you're not feeling up to it.": (
        "如果状态不佳，跳过繁重的社交义务。",
        "如果狀態不佳，跳過繁重的社交義務。",
    ),
    # Comedown guide — Default (other)
    "Your body is processing and eliminating the substance.": (
        "你的身体正在处理并排出该物质。",
        "你的身體正在處理並排出該物質。",
    ),
    "How you feel depends on what you took, how much, and your body's chemistry.": (
        "感觉如何取决于你服用了什么、多少，以及你的身体化学。",
        "感覺如何取決於你服用了什麼、多少，以及你的身體化學。",
    ),
    "Drink water and eat something nutritious.": ("喝水并吃些营养食物。", "喝水並吃些營養食物。"),
    "Rest in a comfortable, safe environment.": (
        "在舒适、安全的环境中休息。",
        "在舒適、安全的環境中休息。",
    ),
    "If you feel unwell, don't hesitate to call for help.": (
        "如果感到不适，不要犹豫，寻求帮助。",
        "如果感到不適，不要猶豫，尋求協助。",
    ),
    "Sleep is your best recovery tool.": (
        "睡眠是你最好的恢复工具。",
        "睡眠是你最好的恢復工具。",
    ),
    "Light food and fluids every few hours.": (
        "每隔几小时摄入清淡食物和水分。",
        "每隔幾小時攝入清淡食物和水分。",
    ),
    "Give yourself time.": (
        "给自己时间。",
        "給自己時間。",
    ),
    "Don't redose — tolerance builds fast within a session.": (
        "不要补服——耐受在同一场次中上升很快。",
        "不要補服——耐受在同一場次中上升很快。",
    ),
    "Mixing adds risk.": ("混用增加风险。", "混用增加風險。"),
    "Don't drive or make important decisions until you feel baseline.": (
        "感觉回到基线前不要驾驶或做重要决定。",
        "感覺回到基線前不要駕駛或做重要決定。",
    ),
    "View Full Recovery Guide": ("查看完整恢复指南", "查看完整恢復指南"),
    "Get care reminders as effects fade — hydration, rest, and recovery tips.": (
        "效果消退时获得护理提醒——补水、休息和恢复提示。",
        "效果消退時獲得護理提醒——補水、休息和恢復提示。",
    ),
    "Showing guidance for substances in your system. Tap above for the full guide.": (
        "正在显示你体内物质的指导。点击上方查看完整指南。",
        "正在顯示你體內物質的指導。點擊上方查看完整指南。",
    ),
    "Tips as substances wear off — tap a category below.": (
        "物质消退时的建议——点击下方类别查看。",
        "物質消退時的建議——點擊下方類別查看。",
    ),
    # Reports
    "Generate PDF Report": ("生成 PDF 报告", "產生 PDF 報告"),
    "Name (for the report header)": (
        "姓名（用于报告标题）",
        "姓名（用於報告標題）",
    ),
    "These notes will appear at the end of the PDF report.": (
        "这些备注将出现在 PDF 报告末尾。",
        "這些備註將出現在 PDF 報告末尾。",
    ),
    "Report Includes": ("报告包含", "報告包含"),
    # About / Sources
    # Onboarding-style sub-text in Settings
    "Show a Live Activity on your Lock Screen when tracking starts. You can also start one from any session.": (
        "开始追踪时在锁定屏幕上显示实时活动。也可以从任何场次中启动。",
        "開始追蹤時在鎖定畫面上顯示即時動態。也可以從任何場次中啟動。",
    ),
    # Form fields / Pickers
    "Select at least one day.": ("请至少选择一天。", "請至少選擇一天。"),
    # Cumulative
    "Heads up — %@%@ %@ today": (
        "提醒——今日 %@%@ %@",
        "提醒——今日 %@%@ %@",
    ),
    "That's a high cumulative dose. %@": ("这是较高的累积剂量。%@", "這是較高的累積劑量。%@"),
    # Tags
    "Add tag...": ("添加标签…", "新增標籤…"),
    "#%@": ("#%@", "#%@"),
    # Insights stats
    "Activity": ("活动", "活動"),
    "Usage Entries": ("使用记录", "使用記錄"),
    "Most common: %@ %@": (
        "最常见：%@ %@",
        "最常見：%@ %@",
    ),
    "Milestones": ("里程碑", "里程碑"),
    # Frequency-related
    # Distance / time formatted
    "%@ in · %@ left": (
        "已过 %1$@ · 剩 %2$@",
        "已過 %1$@ · 剩 %2$@",
    ),
    "%@ %@ left": ("剩 %@ %@", "剩 %@ %@"),
    "%@ %@ remaining after %@": (
        "%3$@ 后剩 %1$@ %2$@",
        "%3$@ 後剩 %1$@ %2$@",
    ),
    "%@ %@ total · est. ~%lld%% remaining": (
        "总计 %@ %@ · 预计剩约 %lld%%",
        "總計 %@ %@ · 預計剩約 %lld%%",
    ),
    # Adherence
    "Taken %@": ("已服用 %@", "已服用 %@"),
    "Missed %@ of %@": ("漏服 %@ 的 %@", "漏服 %@ 的 %@"),
    "%lld/%lld taken": ("%lld/%lld 已服用", "%lld/%lld 已服用"),
    # Day detail
    # Format strings
    "Log ^[%lld Item](inflect: true)": ("记录 %lld 个项目", "記錄 %lld 個項目"),
    "Couldn't save the report": ("无法保存报告", "無法儲存報告"),
    "Log %@": ("记录 %@", "記錄 %@"),
    'Use "%@"': ('使用 "%@"', '使用 "%@"'),
    'A custom substance named "%@" already exists.': (
        '已存在名为 "%@" 的自定义物质。',
        '已存在名為 "%@" 的自訂物質。',
    ),
    'No substances match "%@"': ('没有匹配 "%@" 的物质', '沒有符合 "%@" 的物質'),
    # Substance entries summary
    "%lld entries across %lld substances": (
        "%lld 条记录，涉及 %lld 种物质",
        "%lld 條記錄，涉及 %lld 種物質",
    ),
    "%lld results": ("%lld 个结果", "%lld 個結果"),
    "%lld%%": ("%lld%%", "%lld%%"),
    "(%@)": ("(%@)", "(%@)"),
    "%lldh": ("%lld 小时", "%lld 小時"),
    "%lld": ("%lld", "%lld"),
    # Single chars / passthrough
    "·": ("·", "·"),
    "•": ("•", "•"),
    "–": ("–", "–"),
    "S": ("S", "S"),
    "#": ("#", "#"),
    "0": ("0", "0"),
    "--": ("--", "--"),
    # Misc UI labels not yet covered
    "Your History": (
        "你的历史",
        "你的歷史",
    ),
    "%@ %@": ("%@ %@", "%@ %@"),
    "%@ - %@ %@": ("%@ - %@ %@", "%@ - %@ %@"),
    "%@ – %@": ("%@ – %@", "%@ – %@"),
    "%@ – %@ %@": ("%@ – %@ %@", "%@ – %@ %@"),
    "%@ %@ — %@": ("%@ %@ — %@", "%@ %@ — %@"),
    "%@ %@ %@ on %@": ("%@ %@ %@ 于 %@", "%@ %@ %@ 於 %@"),
    "%@ — %@": ("%@ — %@", "%@ — %@"),
    "%@: %@ + %@": ("%@:%@ + %@", "%@:%@ + %@"),
    "%@, %@": ("%@,%@", "%@,%@"),
    "%@+ %@": ("%@+ %@", "%@+ %@"),
    "%@ (%lld)": ("%@ (%lld)", "%@ (%lld)"),
    "%@ +%lld more": ("%1$@ +%2$lld 更多", "%1$@ +%2$lld 更多"),
    "Duration": ("持续时间", "持續時間"),
    "30D": ("30天", "30天"),
    "7D": ("7天", "7天"),
    "90D": ("90天", "90天"),
    "Adherence": ("依从性", "依從性"),
    "All Time": ("所有时间", "所有時間"),
    "Concentration": ("浓度", "濃度"),
    "Dose Volume": ("剂量体积", "劑量體積"),
    "Interactions": ("相互作用", "相互作用"),
    "Last 30 Days": ("最近 30 天", "最近 30 天"),
    "Last 7 Days": ("最近 7 天", "最近 7 天"),
    "Last 90 Days": ("最近 90 天", "最近 90 天"),
    "Recovery": ("恢复", "恢復"),
    "Solvent Needed": ("所需溶剂", "所需溶劑"),
    "Usage": ("使用", "使用"),
    "This calculator uses a one-compartment oral pharmacokinetic model with absorption and elimination phases. Absorption rates are estimated from known duration profiles (onset + comeup timing) when available, or use a default 4× elimination rate ratio. Population-average elimination half-lives are sourced from FDA-approved prescribing information, published pharmacokinetic studies (PubMed), and DrugBank. Half-lives for some research chemicals and novel substances are estimated from structurally similar compounds and may be less reliable.\n\nReal pharmacokinetics vary significantly based on individual metabolism, genetics, liver and kidney function, body composition, age, drug interactions, tolerance, and route of administration. Multi-compartment distribution, protein binding, active metabolites, and enterohepatic recirculation are not accounted for. Polydrug use may alter elimination rates unpredictably.\n\nThese figures are approximate population averages — not a substitute for clinical monitoring or professional medical advice. Always consult a qualified healthcare professional.": (
        "此计算器使用一房室口服药代动力学模型，包含吸收和消除两个阶段。如有已知的持续时间数据（起效 + 上升期），则吸收速率会由此估算；否则使用默认的 4× 消除速率比。群体平均消除半衰期来源于 FDA 批准的处方信息、已发表的药代动力学研究（PubMed）以及 DrugBank。部分研究化学品和新型物质的半衰期是根据结构类似的化合物估算的，可能不够可靠。\n\n实际药代动力学因个人代谢、遗传、肝肾功能、体成分、年龄、药物相互作用、耐受性和给药途径而显著不同。多房室分布、蛋白结合、活性代谢物和肠肝循环未被纳入考虑。多药联用可能不可预测地改变消除速率。\n\n这些数字是群体的近似平均值——不能替代临床监测或专业医疗建议。请始终咨询合格的医疗专业人员。",
        "此計算器使用一房室口服藥動學模型，包含吸收和消除兩個階段。如有已知的持續時間資料（起效 + 上升期），則吸收速率會由此估算；否則使用預設的 4× 消除速率比。族群平均消除半衰期來源於 FDA 批准的處方資訊、已發表的藥動學研究（PubMed）以及 DrugBank。部分研究化學品和新型物質的半衰期是根據結構類似的化合物估算的，可能不夠可靠。\n\n實際藥動學因個人代謝、遺傳、肝腎功能、體成分、年齡、藥物相互作用、耐受性和給藥途徑而顯著不同。多房室分布、蛋白質結合、活性代謝物和腸肝循環未被納入考慮。多藥聯用可能不可預測地改變消除速率。\n\n這些數字是族群的近似平均值——不能替代臨床監測或專業醫療建議。請始終諮詢合格的醫療專業人員。",
    ),
    # 2026-06 review fixes — crisis help links (previously plain String, never localized)
    "Emergency: 911": ("紧急情况：911", "緊急情況：911"),
    "Poison Control: 1-800-222-1222": (
        "中毒控制中心：1-800-222-1222",
        "中毒控制中心：1-800-222-1222",
    ),
    "Crisis Lifeline: 988": ("危机生命线：988", "危機生命線：988"),
    "Crisis Text: HOME to 741741": (
        "危机短信：发送 HOME 至 741741",
        "危機簡訊：傳送 HOME 至 741741",
    ),
    "Call 911 (US) or your local emergency number": (
        "拨打 911（美国）或当地紧急电话",
        "撥打 911（美國）或當地緊急電話",
    ),
    "1-800-222-1222 (US)": ("1-800-222-1222（美国）", "1-800-222-1222（美國）"),
    "988 Suicide & Crisis Lifeline": ("988 自杀与危机生命线", "988 自殺與危機生命線"),
    "Call or text 988": ("拨打或发送短信至 988", "撥打或傳送簡訊至 988"),
    "Text HOME to 741741": ("发送 HOME 至 741741", "傳送 HOME 至 741741"),
    "1-800-662-4357 — Free, confidential, 24/7": (
        "1-800-662-4357——免费、保密、全天候",
        "1-800-662-4357——免費、保密、全天候",
    ),
    # 2026-06 review fixes — inflected plurals (replace hand-rolled "s"/"ies" suffixes)
    "^[%lld substance](inflect: true)": ("%lld 种物质", "%lld 種物質"),
    # 2026-08 — the deep-pharmacology sections (Genetics, Target Evidence,
    # concentration thresholds) and the drug-class write-ups moved to
    # Tools > Education.
    "^[%lld group](inflect: true)": ("%lld 个分类", "%lld 個分類"),
    "Genetics": ("基因", "基因"),
    "Target Evidence": ("靶点证据", "靶點證據"),
    "Pathway bias": ("通路偏向", "通路偏向"),
    "Receptor complex": ("受体复合物", "受體複合物"),
    "In vivo": ("体内", "體內"),
    "Drug Classes": ("药物类别", "藥物類別"),
    "What the members of a family share": ("同类药物的共同之处", "同類藥物的共同之處"),
    "No Classes": ("暂无类别", "暫無類別"),
    "Shared mechanism": ("共同机制", "共同機制"),
    "Shared kinetics": ("共同药代动力学", "共同藥物動力學"),
    "Shared safety profile": ("共同安全性特征", "共同安全性特徵"),
    "Structure and activity": ("构效关系", "構效關係"),
    "References": ("参考文献", "參考文獻"),
    "^[%lld other substance](inflect: true)": ("另有 %lld 种物质", "另有 %lld 種物質"),
    "^[%lld more combination](inflect: true)": ("另有 %lld 种组合", "另有 %lld 種組合"),
    "^[%lld entry](inflect: true)": ("%lld 条记录", "%lld 筆記錄"),
    "^[%lld item](inflect: true)": ("%lld 项", "%lld 項"),
    # 2026-06 Library browse redesign — family blurbs, favorites card, not-found
    "κ-opioid agonists — salvia, salvinorin A.": (
        "κ-阿片受体激动剂——墨西哥鼠尾草、沙维诺林A。",
        "κ-鴉片受體促效劑——墨西哥鼠尾草、沙維諾林A。",
    ),
    "GABAergics & gabapentinoids — GHB, pregabalin, phenibut.": (
        "GABA能药物与加巴喷丁类——GHB、普瑞巴林、苯尼布特。",
        "GABA能藥物與加巴噴丁類——GHB、普瑞巴林、苯尼布特。",
    ),
    "Substance Not Found": ("未找到物质", "未找到物質"),
    "“%@” isn’t in the library anymore. It may have been renamed or merged.": (
        "“%@”已不在资料库中，可能已被重命名或合并。",
        "「%@」已不在資料庫中，可能已被重新命名或合併。",
    ),
    # 2026-06 review fixes — accessibility labels & chart descriptions
    "Previous Month": ("上个月", "上個月"),
    "Next Month": ("下个月", "下個月"),
    "Select Month": ("选择月份", "選擇月份"),
    "Opens month picker": ("打开月份选择器", "開啟月份選擇器"),
    "Add Custom Substance": ("添加自定义物质", "新增自訂物質"),
    "Concentration curve": ("浓度曲线", "濃度曲線"),
    "Elimination curve for %@": ("%@ 的消除曲线", "%@ 的消除曲線"),
    "%@ %@ remaining, %lld%% eliminated, half-life %@": (
        "剩余 %1$@ %2$@，已消除 %3$lld%%，半衰期 %4$@",
        "剩餘 %1$@ %2$@，已消除 %3$lld%%，半衰期 %4$@",
    ),
    "Peak after %@, %@ of %@ %@ remaining now": (
        "%1$@ 后达到峰值，%3$@ %4$@ 中目前剩余 %2$@",
        "%1$@ 後達到峰值，%3$@ %4$@ 中目前剩餘 %2$@",
    ),
    # 2026-06 review fixes — color picker validation errors
    # 2026-06 — stacked-lane (small multiples) timeline preference
    "Stack Busy Sessions": (
        "拆分繁忙场次图表",
        "拆分繁忙場次圖表",
    ),
    "Stack From": ("拆分阈值", "拆分閾值"),
    # Pharmacology axis Stage 6 — Ceiling Effect tool (2026-06-22)
    "Ceiling Effect": ("封顶效应", "封頂效應"),
    "When dose and exposure aren't proportional": (
        "当剂量与暴露不成正比时",
        "當劑量與暴露不成正比時",
    ),
    "When dose and effect aren't proportional": (
        "当剂量与效应不成正比时",
        "當劑量與效應不成正比時",
    ),
    "Saturable elimination — exposure climbs faster than dose": (
        "可饱和消除——暴露量比剂量增长得更快",
        "可飽和消除——暴露量比劑量增長得更快",
    ),
    "Saturable activation — effect hits a ceiling": (
        "可饱和激活——效应触及上限",
        "可飽和活化——效應觸及上限",
    ),
    "1 drink": ("1 杯", "1 杯"),
    "%lld drinks": ("%lld 杯", "%lld 杯"),
    "%lld mg": ("%lld 毫克", "%lld 毫克"),
    "Alcohol (ethanol)": ("酒精（乙醇）", "酒精（乙醇）"),
    "GHB / GBL": ("GHB / GBL", "GHB / GBL"),
    "Codeine → morphine": ("可待因 → 吗啡", "可待因 → 嗎啡"),
    # Pharmacology axis Stage 6 — Benzo equivalence converter (2026-06-23)
    "If you have been drinking heavily and daily for weeks, stopping abruptly can be medically dangerous — seizures and delirium tremens peak 2–4 days after the last drink. Seek medical advice before going cold turkey.": (
        "如果你连续数周每天大量饮酒，突然戒断可能非常危险——癫痫发作和震颤性谵妄通常在最后一杯后 2–4 天达到高峰。戒酒前请先咨询医生。",
        "如果你連續數週每天大量飲酒，突然戒斷可能非常危險——癲癇發作和震顫性譫妄通常在最後一杯後 2–4 天達到高峰。戒酒前請先諮詢醫師。",
    ),
    "mg": ("mg", "mg"),
    "Equivalent Dose": ("等效剂量", "等效劑量"),
    "≈ %@ mg": ("≈ %@ mg", "≈ %@ mg"),
    "%@ mg %@ ≈ %@ mg %@": ("%@ mg %@ ≈ %@ mg %@", "%@ mg %@ ≈ %@ mg %@"),
    "(≈ %@ mg diazepam)": ("（≈ %@ mg 地西泮）", "（≈ %@ mg 地西泮）"),
    "This converts and compares — it is not a taper schedule. Plan any dose reduction with a clinician.": (
        "本工具用于换算与比较，并非减量方案。任何减量都应与临床医生一起制定。",
        "本工具用於換算與比較，並非減量方案。任何減量都應與臨床醫師一起制定。",
    ),
    "Never stop a benzodiazepine abruptly. Withdrawal can be dangerous (seizures); a slow taper is the safe path.": (
        "切勿骤然停用苯二氮䓬。戒断可能有危险（癫痫发作）；缓慢递减才是安全之道。",
        "切勿驟然停用苯二氮平。戒斷可能有危險（癲癇發作）；緩慢遞減才是安全之道。",
    ),
    "~%lld min": ("~%lld 分钟", "~%lld 分鐘"),
    "~%@ h": ("~%@ 小时", "~%@ 小時"),
    "~%lld h": ("~%lld 小时", "~%lld 小時"),
    # Pharmacology axis Stage 5 — Cannabis vertical / 11-OH-THC (2026-06-23)
    "11-OH-THC": ("11-OH-THC", "11-OH-THC"),
    "11-OH-THC (edibles)": ("11-OH-THC（食用大麻）", "11-OH-THC（食用大麻）"),
    "Swallowed THC passes through your liver first, which turns much of it into 11-hydroxy-THC — an active by-product that reaches the brain more easily and binds the CB1 receptor far more strongly than THC itself. That's why an edible tends to feel stronger, milligram for milligram, than the same amount smoked.": (
        "口服的 THC 会先经过肝脏，其中大部分被转化为 11-羟基-THC——一种活性代谢物，它更容易进入大脑，并且与 CB1 受体的结合远比 THC 本身更强。这就是为什么按毫克计算，食用大麻通常比吸食同等剂量感觉更强。",
        "口服的 THC 會先經過肝臟，其中大部分被轉化為 11-羥基-THC——一種活性代謝物，它更容易進入大腦，並且與 CB1 受體的結合遠比 THC 本身更強。這就是為什麼按毫克計算，食用大麻通常比吸食同等劑量感覺更強。",
    ),
    "Edibles also come on slowly — usually 30 minutes to 2 hours — and last much longer, often 6–10 hours. That slow start is the redose trap: wait at least 2 hours before taking more, or you can stack a far stronger, longer dose than you meant to.": (
        "食用大麻起效也很慢——通常为 30 分钟到 2 小时——而且持续时间长得多，常达 6–10 小时。这种缓慢起效正是补服的陷阱：再次服用前至少等待 2 小时，否则你可能叠加出远比预期更强、更长的剂量。",
        "食用大麻起效也很慢——通常為 30 分鐘到 2 小時——而且持續時間長得多，常達 6–10 小時。這種緩慢起效正是補服的陷阱：再次服用前至少等待 2 小時，否則你可能疊加出遠比預期更強、更長的劑量。",
    ),
    # Alcohol by-volume input (2026-06-22)
    "By Volume": ("按体积", "按體積"),
    "By Mass": ("按质量", "按質量"),
    "Session complete": (
        "场次已结束",
        "場次已結束",
    ),
    "Volume": ("容量", "容量"),
    "Strength": ("浓度", "濃度"),
    "% ABV": ("% 酒精度", "% 酒精度"),
    "Optional": ("可选", "可選"),
    "Beer": ("啤酒", "啤酒"),
    "Wine": ("葡萄酒", "葡萄酒"),
    "Shot": ("烈酒", "烈酒"),
    "Pint": ("品脱", "品脫"),
    "ethanol · ≈ %@ standard drinks": ("乙醇 · ≈ %@ 标准杯", "乙醇 · ≈ %@ 標準杯"),
    "%lld g": ("%lld g", "%lld g"),
    "Input": ("输入", "輸入"),
    "Volume unit": ("容量单位", "容量單位"),
    # Alcohol ALDH2 / acetaldehyde (2026-06-22, Stage 5)
    "I get the alcohol flush": ("我喝酒会脸红", "我喝酒會臉紅"),
    "Acetaldehyde": ("乙醛", "乙醛"),
    "Acetaldehyde (ALDH2)": ("乙醛（ALDH2）", "乙醛（ALDH2）"),
    "Elevated": ("偏高", "偏高"),
    "Very high": ("极高", "極高"),
    "Your ALDH2 variant clears acetaldehyde — the first, toxic by-product of alcohol — slowly, so it builds up and lingers. That build-up *is* the flush, racing heart, and nausea, and it's a Group 1 carcinogen (IARC): for flush-reactive drinkers each drink carries more long-term throat and esophageal cancer risk. Less alcohol means less acetaldehyde — there's no amount that clears as cleanly as it does for others.": (
        "你的 ALDH2 变异清除乙醛——酒精的第一个毒性副产物——的速度很慢，因此它会堆积并滞留。这种堆积正是脸红、心跳加快和恶心的原因，而乙醛是一级致癌物（IARC）：对喝酒会脸红的人来说，每一杯都带来更高的长期咽喉与食道癌风险。少喝就意味着更少的乙醛——没有任何分量能像对别人那样被干净地清除掉。",
        "你的 ALDH2 變異清除乙醛——酒精的第一個毒性副產物——的速度很慢，因此它會堆積並滯留。這種堆積正是臉紅、心跳加快和噁心的原因，而乙醛是一級致癌物（IARC）：對喝酒會臉紅的人來說，每一杯都帶來更高的長期咽喉與食道癌風險。少喝就意味著更少的乙醛——沒有任何分量能像對別人那樣被乾淨地清除掉。",
    ),
    "Avoid mixing alcohol with metronidazole or certain other antibiotics — they block this same step and can make even a small drink severe.": (
        "避免将酒精与甲硝唑或某些其他抗生素同用——它们会阻断同一步骤，可能使哪怕一小杯也变得严重。",
        "避免將酒精與甲硝唑或某些其他抗生素同用——它們會阻斷同一步驟，可能使哪怕一小杯也變得嚴重。",
    ),
    # Opioid safety axis — reset-after-break overdose (2026-06-22, Stage 5)
    # Tolerance-mechanism explainer (2026-06-22, Stage 5)
    "How tolerance works": ("耐受是如何形成的", "耐受是如何形成的"),
    "Cross-tolerance": ("交叉耐受", "交叉耐受"),
    "Tolerance is shared by receptor, not by name": (
        "耐受按受体共享，而非按名称",
        "耐受按受體共享，而非按名稱",
    ),
    "By mechanism": ("按机制", "按機制"),
    "Recovers in days": ("数天内恢复", "數天內恢復"),
    "Recovers over ~a week": ("约一周内恢复", "約一週內恢復"),
    "Recovers over weeks": ("数周内恢复", "數週內恢復"),
    "Recovers over a month+": ("一个多月内恢复", "一個多月內恢復"),
    "Recovers over months": ("数月内恢复", "數月內恢復"),
    "Tolerance plus physical dependence; stopping abruptly after heavy regular use can be dangerous — taper.": (
        "既有耐受也有躯体依赖；长期大量使用后骤停可能危险——应逐步减量。",
        "既有耐受也有軀體依賴；長期大量使用後驟停可能危險——應逐步減量。",
    ),
    "Fast and real, but recovers fairly quickly once you stop.": (
        "又快又真实，但停用后恢复得相当快。",
        "又快又真實，但停用後恢復得相當快。",
    ),
    # Session detail "In Your Body" section + row redesign (2026-07-09).
    "soon": ("很快", "很快"),
    "All recovery tips": ("全部恢复提示", "全部恢復提示"),
    "Shows the elimination curve": ("显示消除曲线", "顯示消除曲線"),
    # Effect Estimates screen redesign — large title, one model card, taller graphs,
    # two bottom detail groups, and the "How this works" explainer (2026-07-10).
    "Effect Estimates": ("效应估算", "效應估算"),
    "Experimental": ("实验性", "實驗性"),
    # US-spelling renames of existing keys (2026-07-10); zh copied verbatim from the
    # British-spelled originals, which become stale orphans.
    "No half-life data — elimination not modeled": (
        "无半衰期数据——未建模消除",
        "無半衰期資料——未建模消除",
    ),
    "A summary of how the drug affects the brain's three main signaling chemicals — serotonin, dopamine, and noradrenaline — and whether it releases them or blocks their reuptake. The slider shows which one it leans toward.": (
        "概述药物如何影响大脑三种主要的信号化学物质——血清素、多巴胺和去甲肾上腺素——以及它是促进释放还是阻断再摄取。滑块显示它更偏向哪一种。",
        "概述藥物如何影響大腦三種主要的訊號化學物質——血清素、多巴胺和正腎上腺素——以及它是促進釋放還是阻斷再攝取。滑桿顯示它更偏向哪一種。",
    ),
    "A busy session": (
        "繁忙的场次",
        "繁忙的場次",
    ),
    "Modeled from pharmacology": ("基于药理学建模", "基於藥理學建模"),
    "How this works": ("运作原理", "運作原理"),
    "What these curves cover": ("这些曲线涵盖什么", "這些曲線涵蓋什麼"),
    "The model is calibrated on five stimulants: amphetamine, methylphenidate, mephedrone, 3-MMC, and 2-MMC. Other substances shape the curves through how they interact with these. Opioids are read through their dopamine activity, mostly to show those interactions.": (
        "该模型基于五种兴奋剂校准：苯丙胺、哌甲酯、4-甲基甲卡西酮、3-MMC 和 2-MMC。其他物质通过与它们的相互作用来影响曲线。阿片类物质则依据其多巴胺活性来解读，主要用于呈现这些相互作用。",
        "此模型基於五種興奮劑校準：安非他命、哌甲酯、4-甲基甲卡西酮、3-MMC 和 2-MMC。其他物質透過與它們的交互作用來影響曲線。鴉片類物質則依據其多巴胺活性來解讀，主要用於呈現這些交互作用。",
    ),
    "This session logs %@, which sit outside the model, so these curves stay empty.": (
        "本场包含 %@，它们不在模型范围内，因此这些曲线为空。",
        "本場包含 %@，它們不在模型範圍內，因此這些曲線為空。",
    ),
    "These curves are built from %@. %@ sit outside the model.": (
        "这些曲线基于 %@ 构建。%@ 不在模型范围内。",
        "這些曲線基於 %@ 構建。%@ 不在模型範圍內。",
    ),
    "Reading the estimate": ("如何理解估算", "如何理解估算"),
    "Compare the shape of a curve more than its exact height.": (
        "多比较曲线的形状，而非其确切高度。",
        "多比較曲線的形狀，而非其確切高度。",
    ),
    # Unmodeled release-form explainer on session detail — why a Concerta draws a
    # dot, not a curve (D.4.4, 2026-07-16). Named form reorders in zh, so the two
    # drop-ins are positional (%1$@ = product, %2$@ = base substance).
    "Piru doesn't model a timeline for %@ %@. The session shows when each dose was taken, not how long it lasts.": (
        "Piru 无法为 %2$@ 的 %1$@ 绘制时间线。这个场次只显示每次用药的时间，而非其持续时长。",
        "Piru 無法為 %2$@ 的 %1$@ 繪製時間線。這個場次只顯示每次用藥的時間，而非其持續時長。",
    ),
    "Piru doesn't model a timeline for these forms — the session shows when each dose was taken, not how long it lasts.": (
        "Piru 无法为这些剂型绘制时间线——这个场次只显示每次用药的时间，而非其持续时长。",
        "Piru 無法為這些劑型繪製時間線——這個場次只顯示每次用藥的時間，而非其持續時長。",
    ),
    # Meds & reminders redesign — hub, form, detail, card (2026-07-21).
    "My Meds": ("我的用药", "我的用藥"),
    "Set up your daily medications and supplements": (
        "设置你的每日用药和补充剂",
        "設定你的每日用藥和補充劑",
    ),
    "Med": ("用药", "用藥"),
    "Meds": ("用药", "用藥"),
    "%lld meds": ("%lld 项用药", "%lld 項用藥"),
    "No Meds Yet": ("尚无用药", "尚無用藥"),
    "Add a Med": ("添加用药", "新增用藥"),
    "Add Your Meds": ("添加你的用药", "新增你的用藥"),
    "Edit Med": ("编辑用药", "編輯用藥"),
    "Delete Med": ("删除用药", "刪除用藥"),
    "Delete this med?": ("删除这项用药？", "刪除這項用藥？"),
    "Manage Meds…": ("管理用药…", "管理用藥…"),
    "Log Meds": ("记录用药", "記錄用藥"),
    "Meds due": ("待服用药", "待服用藥"),
    "Med Reminders": ("用药提醒", "用藥提醒"),
    "Opens your meds": ("打开你的用药", "開啟你的用藥"),
    "Times": ("时间", "時間"),
    "Add a Time": ("添加时间", "新增時間"),
    "Add Another Time": ("再添加一个时间", "再新增一個時間"),
    "Anytime": ("随时", "隨時"),
    "anytime": ("随时", "隨時"),
    "no set time": ("未设定时间", "未設定時間"),
    "As needed": ("按需", "按需"),
    "as needed": ("按需", "按需"),
    "no schedule": ("无计划", "無計劃"),
    "up to %lld× daily": ("每日最多 %lld 次", "每日最多 %lld 次"),
    "Up to %lld× daily": ("每日最多 %lld 次", "每日最多 %lld 次"),
    "%lld× daily": ("每日 %lld 次", "每日 %lld 次"),
    "also %@": ("另有 %@", "另有 %@"),
    "before 12:00": ("12:00 之前", "12:00 之前"),
    "12:00 – 17:00": ("12:00 – 17:00", "12:00 – 17:00"),
    "17:00 – 21:00": ("17:00 – 21:00", "17:00 – 21:00"),
    "after 21:00": ("21:00 之后", "21:00 之後"),
    "Quiet": ("静默", "靜默"),
    "quiet": ("静默", "靜默"),
    "Quiet med": ("静默用药", "靜默用藥"),
    "Default": ("默认", "預設"),
    "10 min later": ("10 分钟后", "10 分鐘後"),
    "10 and 30 min later": ("10 分钟和 30 分钟后", "10 分鐘和 30 分鐘後"),
    "Reminders on": ("提醒已开启", "提醒已開啟"),
    "Reminders off": ("提醒已关闭", "提醒已關閉"),
    "Keep track of what you take and when — one tap to set up gentle reminders. Prescriptions, supplements, vitamins: anything on a schedule.": (
        "记录你服用了什么、何时服用——轻点一下即可设置温和的提醒。处方药、补剂、维生素：任何按计划服用的东西。",
        "記錄你服用了什麼、何時服用——點一下即可設定溫和的提醒。處方藥、補劑、維生素：任何按計劃服用的東西。",
    ),
    "Quiet meds' reminders arrive silently — no buzz, no lock-screen wake. If you use iOS Scheduled Summary, they batch there.": (
        "静默用药的提醒会无声送达——不震动，也不点亮锁定屏幕。如果你使用 iOS 的定时摘要，它们会汇总到那里。",
        "靜默用藥的提醒會無聲送達——不震動，也不亮起鎖定畫面。如果你使用 iOS 的定時摘要，它們會彙整到那裡。",
    ),
    "Ask Again sends another reminder if a dose isn't logged — “Default” uses the intervals in Notification Settings.": (
        "如果一剂还未记录，“再次提醒”会再发一次提醒。“默认”使用通知设置中的间隔。",
        "如果一劑還未記錄，「再次提醒」會再發一次提醒。「預設」使用通知設定中的間隔。",
    ),
    "Asks again a little later if a med still isn't logged — like snooze for an alarm. Adjustable per med.": (
        "如果某项用药仍未被记录，稍后会再问一次——就像闹钟的稍后提醒。可为每项用药单独调整。",
        "如果某項用藥仍未被記錄，稍後會再問一次——就像鬧鐘的稍後提醒。可為每項用藥單獨調整。",
    ),
    "A reminder at each time. If you don't log it, Piru asks again %@ later.": (
        "在每个设定时间提醒你。如果还未记录，Piru 会在 %@ 后再次提醒。",
        "在每個設定時間提醒你。如果還未記錄，Piru 會在 %@ 後再次提醒。",
    ),
    "No set time — this med still counts toward adherence once per due day.": (
        "未设定时间——这项用药在每个应服日仍计入一次依从性。",
        "未設定時間——這項用藥在每個應服日仍計入一次依從性。",
    ),
    "Time to log %@ — %@.": (
        "该记录 %@ 了——%@。",
        "該記錄 %@ 了——%@。",
    ),
    "Still need to log %@?": ("还需要记录 %@ 吗？", "還需要記錄 %@ 嗎？"),
    "Still need your %@ supplements?": ("还需要服用 %@ 的补剂吗？", "還需要服用 %@ 的補劑嗎？"),
    "%@ supplements (%lld)": ("%@ 补剂（%lld）", "%@ 補劑（%lld）"),
    "Stages this group’s meds": ("将该组用药加入暂存", "將該組用藥加入暫存"),
    "Take All": ("全部服用", "全部服用"),
    "Not taken yet": ("尚未服用", "尚未服用"),
    "Collapses the list": ("折叠列表", "摺疊列表"),
    "Expands the list": ("展开列表", "展開列表"),
    # Quick Log: due-now strip, merged substances section (2026-07-21).
    "Due now": ("现在该服用", "現在該服用"),
    "Due": ("待服用", "待服用"),
    "due": ("待服用", "待服用"),
    "%lld due": ("%lld 项待服用", "%lld 項待服用"),
    "%lld meds due": ("%lld 项用药待服用", "%lld 項用藥待服用"),
    "Staged": ("已暂存", "已暫存"),
    "Your Substances": ("你的物质", "你的物質"),
    # Adherence screen (2026-07-21).
    "Add your meds to see adherence": ("添加你的用药以查看依从性", "新增你的用藥以查看依從性"),
    "Adherence tracks how consistently you take your scheduled meds. Add one and this screen starts working.": (
        "依从性追踪你按计划服药的稳定程度。添加一项用药，这个页面就会开始工作。",
        "依從性追蹤你按計劃服藥的穩定程度。新增一項用藥，這個頁面就會開始運作。",
    ),
    "%lld of %lld taken": ("已服用 %lld / %lld", "已服用 %lld / %lld"),
    # Continuous timeline ribbon (2026-07-21).
    # "Timeline" itself is already translated above (时间轴).
    "Explore the timeline": ("浏览时间线", "瀏覽時間線"),
    # Substance-detail redesign, feedback round 3 (2026-07-24).
    "All phases": ("全部阶段", "全部階段"),
    # PK card: how many distinct studies stand behind one route (2026-07-25).
    "%lld studies": ("%lld 项研究", "%lld 項研究"),
    # Intervention ledger — GABA discontinuation evidence (§J, 2026-08-06).
    "Imipramine": ("丙米嗪", "丙米嗪"),
    "%lld–%lld days": ("%lld–%lld 天", "%lld–%lld 天"),
    "%lld–%lld hours": ("%lld–%lld 小时", "%lld–%lld 小時"),
    "n = %lld": ("n = %lld", "n = %lld"),
    "%lld RCTs": ("%lld项随机对照试验", "%lld項隨機對照試驗"),
    "%lld trials": ("%lld项试验", "%lld項試驗"),
    "Pregabalin": ("普瑞巴林", "普瑞巴林"),
    "Valproate": ("丙戊酸盐", "丙戊酸鹽"),
    "Flumazenil": ("氟马西尼", "氟馬西尼"),
    "Melatonin": ("褪黑素", "褪黑素"),
    "Gabapentin": ("加巴喷丁", "加巴噴丁"),
    "Lithium": ("锂盐", "鋰鹽"),
    "Progesterone": ("黄体酮", "黃體酮"),
    "Ondansetron": ("昂丹司琼", "昂丹司瓊"),
    "Buspirone": ("丁螺环酮", "丁螺環酮"),
    "Propranolol": ("普萘洛尔", "普萘洛爾"),
    "doi:10.3390/ijms27031430": ("doi:10.3390/ijms27031430", "doi:10.3390/ijms27031430"),
    # Gabapentinoid α2δ class (§K.6, 2026-08-06).
    "Gabapentinoids (α2δ)": (
        "加巴喷丁类（α2δ）",
        "加巴噴丁類（α2δ）",
    ),
    "Gabapentinoids": ("加巴喷丁类", "加巴噴丁類"),
    "Sedative tolerance builds; dependence can develop within weeks of daily use. Phenibut withdrawal is among the most severe.": (
        "镇静耐受性会逐渐建立；每日使用数周即可产生依赖。菲尼布特的戒断反应属于最严重的类型之一。",
        "鎮靜耐受性會逐漸建立；每日使用數週即可產生依賴。菲尼布特的戒斷反應屬於最嚴重的類型之一。",
    ),
    # GABA cognitive impairment safety note (§B, 2026-08-06).
    "The dose that no longer makes you sleepy impairs your memory and coordination exactly as much as it did on day one.": (
        "不再让你困倦的剂量对你的记忆和协调能力的损害与第一天完全相同。",
        "不再讓你困倦的劑量對你的記憶和協調能力的損害與第一天完全相同。",
    ),
    # Phenibut protracted-withdrawal warning (§L.2, 2026-08-06).
    "If you are using phenibut or F-phenibut daily, dependence develops within weeks. Protracted withdrawal can last months — taper gradually with medical guidance.": (
        "如果你每天使用苯乙胺丁酸或氟苯乙胺丁酸，数周内就会产生依赖。迁延性戒断可持续数月——在医疗指导下逐步减量。",
        "如果你每天使用苯乙胺丁酸或氟苯乙胺丁酸，數週內就會產生依賴。遷延性戒斷可持續數月——在醫療指導下逐步減量。",
    ),
    # Detail level (UserProfile).
    "Detail Level": (
        "详细程度",
        "詳細程度",
    ),
    "How much pharmacology is shown by default on substance pages and in the Tolerance tool.": (
        "物质页面和耐受工具默认显示多少药理学内容。",
        "物質頁面和耐受工具預設顯示多少藥理學內容。",
    ),
    "Plain names, pharmacology folded away until you open it.": (
        "使用通俗名称，药理内容默认折叠，需要时再展开。",
        "使用通俗名稱，藥理內容預設折疊，需要時再展開。",
    ),
    "Mechanism and pharmacokinetics open on the page, receptor names in the Tolerance tool.": (
        "机制和药代动力学默认展开，耐受工具使用受体名称。",
        "機制和藥物動力學預設展開，耐受工具使用受體名稱。",
    ),
    # Check-in times (CheckInOfferBanner, CheckInScheduleEditor).
    "Use the suggested times": ("使用建议的时间", "使用建議的時間"),
    "Reset to the suggested times": ("恢复为建议的时间", "恢復為建議的時間"),
    "Adjust these times": ("调整这些时间", "調整這些時間"),
    # Skins store (SkinWardrobe, OnboardingSkinsStep).
    "Black, paper and signal cyan, from the effects index": (
        "黑底、纸白与信号青，来自效应索引",
        "黑底、紙白與訊號青，來自效應索引",
    ),
    "In partnership with substance.wiki ↗": (
        "与 substance.wiki 合作 ↗",
        "與 substance.wiki 合作 ↗",
    ),
    "Skins": ("皮肤", "皮膚"),
    "Make it yours": (
        "让它成为你的样子",
        "讓它成為你的樣子",
    ),
    "Skins pay for Piru's development. The journal, the library, and every tool are free.": (
        "皮肤的收入用于支持 Piru 的开发。日记、物质库和所有工具均免费。",
        "皮膚的收入用於支持 Piru 的開發。日記、物質庫和所有工具均免費。",
    ),
    "Free": (
        "免费",
        "免費",
    ),
    "Paid": (
        "付费",
        "付費",
    ),
    "Wearing This Skin": (
        "正在使用此皮肤",
        "正在使用此皮膚",
    ),
    "Use This Skin": (
        "使用此皮肤",
        "使用此皮膚",
    ),
    "Unlock %@ · %@": (
        "解锁 %@ · %@",
        "解鎖 %@ · %@",
    ),
    "Everything, Forever": (
        "全部皮肤，永久拥有",
        "全部皮膚，永久擁有",
    ),
    "Every skin there is and every skin still to come.": (
        "现有的每一款皮肤，以及今后推出的每一款。",
        "現有的每一款皮膚，以及今後推出的每一款。",
    ),
    "Restore Purchases": (
        "恢复购买",
        "回復購買項目",
    ),
    "Waiting for Approval": (
        "等待批准",
        "等待批准",
    ),
    "Nothing to Restore": (
        "没有可恢复的购买",
        "沒有可恢復的購買",
    ),
    "Purchase Not Completed": (
        "购买未完成",
        "購買未完成",
    ),
    "The skin unlocks as soon as the purchase is approved.": (
        "购买获批后，皮肤会立即解锁。",
        "購買獲批後，皮膚會立即解鎖。",
    ),
    "This Apple Account has no Piru purchases.": (
        "此 Apple 账户没有 Piru 的购买记录。",
        "此 Apple 帳號沒有 Piru 的購買記錄。",
    ),
    "Nothing was charged. You can try again.": (
        "没有扣款。你可以再试一次。",
        "沒有扣款。你可以再試一次。",
    ),
    # What CYP2D6 does to a substance (CYP2D6NoteSection).
    "Activated by CYP2D6": ("由 CYP2D6 活化", "由 CYP2D6 活化"),
    "Cleared by CYP2D6": ("由 CYP2D6 清除", "由 CYP2D6 清除"),
    "CYP2D6 converts %@ into an active metabolite.": (
        "CYP2D6 将 %@ 转化为一种活性代谢物。",
        "CYP2D6 將 %@ 轉化為一種活性代謝物。",
    ),
    "CYP2D6 is the main enzyme clearing %@ from the body.": (
        "CYP2D6 是将 %@ 从体内清除的主要酶。",
        "CYP2D6 是將 %@ 從體內清除的主要酶。",
    ),
    # b45 feedback — metabolizer variation chart (C1)
    "Fast metabolizer": ("快代谢型", "快代謝型"),
    "Slow metabolizer": ("慢代谢型", "慢代謝型"),
    "Genetic variation in %@ formation": (
        "%@ 生成的基因变异",
        "%@ 生成的基因變異",
    ),
    "Same dose, different conversion — the effect varies by genotype.": (
        "同样的剂量，不同的转化——效应因基因型而异。",
        "同樣的劑量，不同的轉化——效應因基因型而異。",
    ),
    # b45 feedback — insight group previews (D6)
    "substance modeled": ("种物质已建模", "種物質已建模"),
    "substances modeled": ("种物质已建模", "種物質已建模"),
    # b45 feedback — receptor load zoom (E2)
    "Wide": ("宽", "寬"),
    "Medium": ("中", "中"),
    "Close": ("近", "近"),
    "Zoom": ("缩放", "縮放"),
    # import file errors (2026-09-18)
    "The file is empty. Nothing was saved into it, so export again and wait for the save to finish before importing.": (
        "文件是空的。没有任何内容保存进去，请重新导出，等保存完成后再导入。",
        "檔案是空的。沒有任何內容儲存進去，請重新匯出，等儲存完成後再匯入。",
    ),
    "This file isn't a Piru export or a PsychonautWiki journal.": (
        "此文件不是 Piru 导出文件，也不是 PsychonautWiki 日记。",
        "此檔案不是 Piru 匯出檔案，也不是 PsychonautWiki 日記。",
    ),
    "This is an encrypted Piru backup. Use Restore Encrypted Backup and enter its passphrase.": (
        "这是加密的 Piru 备份。请使用“恢复加密备份”并输入其密码短语。",
        "這是加密的 Piru 備份。請使用「還原加密備份」並輸入其密碼短語。",
    ),
    "This file uses export format %lld, which this version of Piru can't read yet. Update Piru, then import it.": (
        "此文件使用导出格式 %lld，当前版本的 Piru 还无法读取。请更新 Piru 后再导入。",
        "此檔案使用匯出格式 %lld，目前版本的 Piru 還無法讀取。請更新 Piru 後再匯入。",
    ),
    "%@ The file was written by %@.": ("%@ 此文件由 %@ 导出。", "%@ 此檔案由 %@ 匯出。"),
    # b53 feedback batches (2026-09-17)
    "Open Injection Levels": (
        "打开注射水平",
        "開啟注射水平",
    ),
    "Entry": (
        "输入方式",
        "輸入方式",
    ),
    "Count × strength": (
        "片数 × 规格",
        "片數 × 規格",
    ),
    "Added at this strength, in the item's unit.": (
        "按此规格换算后，以该项目的单位计入。",
        "按此規格換算後，以該項目的單位計入。",
    ),
    "Counted in %@. A dose logged in mg is taken off at this strength.": (
        "以 %@ 计数。以 mg 记录的剂量会按此规格扣除。",
        "以 %@ 計數。以 mg 記錄的劑量會按此規格扣除。",
    ),
    "Due at %@": (
        "%@ 应服",
        "%@ 應服",
    ),
    "Your Body": (
        "你的身体",
        "你的身體",
    ),
    "Splits a busy session's overlapping curves into one lane per substance.": (
        "将繁忙场次中重叠的曲线按物质拆分为各自的泳道。",
        "將繁忙場次中重疊的曲線按物質拆分為各自的泳道。",
    ),
    "How many substances a session needs before it splits into lanes.": (
        "一个场次需要多少种物质才会拆分为泳道。",
        "一個場次需要多少種物質才會拆分為泳道。",
    ),
    "Adds a per-dose grapefruit toggle for substances whose breakdown grapefruit slows (CYP3A4), so the entry records it.": (
        "为西柚会减缓其分解（CYP3A4）的物质添加逐剂西柚开关，让记录保留这一信息。",
        "為葡萄柚會減緩其分解（CYP3A4）的物質加入逐劑葡萄柚開關，讓記錄保留這一資訊。",
    ),
    "Shows acetaldehyde buildup on alcohol entries. The ALDH2 variant slows its clearance, causing flushing.": (
        "在酒精记录上显示乙醛蓄积。ALDH2 变异会减慢乙醛清除，导致脸红。",
        "在酒精記錄上顯示乙醛蓄積。ALDH2 變異會減慢乙醛清除，導致臉紅。",
    ),
    # Strings the catalog already carries, restored so the table and the
    # catalog hold the same set.
    "%@": ("%@", "%@"),
    "%@ %@ of %@ left.": ("%3$@还剩 %1$@ %2$@。", "%3$@還剩 %1$@ %2$@。"),
    "%@ %@ · %@": ("%1$@ %2$@ · %3$@", "%1$@ %2$@ · %3$@"),
    "%@ and %@ over time; the model shows no overlapping window.": (
        "%@ 与 %@ 随时间变化；模型显示两者没有重叠的时段。",
        "%@ 與 %@ 隨時間變化；模型顯示兩者沒有重疊的時段。",
    ),
    "%@ g/mol": ("%@ g/mol", "%@ g/mol"),
    "%@ left": ("还剩 %@", "還剩 %@"),
    "%@ mg %@, by the CDC 2022 factor": (
        "%@ mg %@，按 CDC 2022 换算系数",
        "%@ mg %@，按 CDC 2022 換算係數",
    ),
    "%@ modeled active until ~%@": ("%@ 模型估计活跃至约 %@", "%@ 模型估計活躍至約 %@"),
    "%@ → %@": ("%@ → %@", "%@ → %@"),
    "%@, source: %@": ("%@，来源：%@", "%@，來源：%@"),
    "%@h": ("%@ 小时", "%@ 小時"),
    "%@h ago": ("%@ 小时前", "%@ 小時前"),
    "%@–%@ days": ("%@–%@ 天", "%@–%@ 天"),
    "%@–%@ months": ("%@–%@ 个月", "%@–%@ 個月"),
    "%@–%@ weeks": ("%@–%@ 周", "%@–%@ 週"),
    "%lld days logged": ("已记录 %lld 天", "已記錄 %lld 天"),
    "%lld distinct substances, %lld first recorded this period": (
        "%lld 种不同物质，其中 %lld 种为本期首次记录",
        "%lld 種不同物質，其中 %lld 種為本期首次記錄",
    ),
    "%lld doses": ("%lld 剂", "%lld 劑"),
    "%lld first recorded this period": ("本期首次记录 %lld 种", "本期首次記錄 %lld 種"),
    "%lld min": ("%lld 分钟", "%lld 分鐘"),
    "%lld of %lld": ("%lld / %lld", "%lld / %lld"),
    "%lld of %lld days about right or more": (
        "%lld / %lld 天和平时差不多或更强",
        "%lld / %lld 天和平時差不多或更強",
    ),
    "%lldd ago": ("%lld 天前", "%lld 天前"),
    "%lldh %lldm": ("%1$lld 小时 %2$lld 分钟", "%1$lld 小時 %2$lld 分鐘"),
    "%lldh %lldm ago": ("%1$lld 小时 %2$lld 分钟前", "%1$lld 小時 %2$lld 分鐘前"),
    "%lldh ago": ("%lld 小时前", "%lld 小時前"),
    "%lldm": ("%lld 分钟", "%lld 分鐘"),
    "%lldm ago": ("%lld 分钟前", "%lld 分鐘前"),
    "%lldmin": ("%lld 分钟", "%lld 分鐘"),
    "+%lld earlier": ("还有 %lld 次更早", "還有 %lld 次更早"),
    "0m": ("0 分钟", "0 分鐘"),
    "A passphrase is required.": ("需要口令。", "需要通行碼。"),
    "A reminder to drink some water.": ("提醒你喝点水。", "提醒你喝點水。"),
    "A reminder to drink some water. Stimulants can mask thirst.": (
        "提醒你喝点水。兴奋剂可能掩盖口渴。",
        "提醒你喝點水。興奮劑可能掩蓋口渴。",
    ),
    "A reminder to have some water if you can.": (
        "提醒你方便的话喝点水。",
        "提醒你方便的話喝點水。",
    ),
    "A reminder to sip, and to favor electrolytes. With this class more water is not safer.": (
        "提醒你小口喝，并优先选含电解质的饮品。对这一类来说，水喝得更多并不更安全。",
        "提醒你小口喝，並優先選含電解質的飲品。對這一類來說，水喝得更多並不更安全。",
    ),
    "A warm bath can ease the achy, restless feeling — with someone in earshot.": (
        "泡个热水澡能缓解酸痛和坐立不安——让人待在听得见你的地方。",
        "泡個熱水澡能緩解痠痛和坐立不安——讓人待在聽得見你的地方。",
    ),
    "A warm shower or light stretching helps tight muscles.": (
        "冲个热水澡或做点轻柔拉伸，有助于放松紧绷的肌肉。",
        "衝個熱水澡或做點輕柔拉伸，有助於放鬆緊繃的肌肉。",
    ),
    "AI-Assisted Content": ("AI 辅助内容", "AI 輔助內容"),
    "About Piru": ("关于 Piru", "關於 Piru"),
    "Acetaminophen (paracetamol) after heavy alcohol use adds stress to the liver.": (
        "大量饮酒后服用对乙酰氨基酚（扑热息痛）会加重肝脏负担。",
        "大量飲酒後服用乙醯胺酚（撲熱息痛）會加重肝臟負擔。",
    ),
    "Add the guideline reference range (%lld–%lld %@)": (
        "添加指南参考范围（%lld–%lld %@）",
        "新增指南參考範圍（%lld–%lld %@）",
    ),
    "Add to Favorites": ("添加到收藏", "加入收藏"),
    "After a stimulant wears off, fatigue, irritability and low mood are commonly reported.": (
        "兴奋剂消退之后，常有人感到疲劳、易怒和情绪低落。",
        "興奮劑消退之後，常有人感到疲勞、易怒和情緒低落。",
    ),
    "After regular use, a seizure or severe confusion on stopping is an emergency.": (
        "长期规律使用后，停药时出现抽搐或严重意识混乱属于急症。",
        "長期規律使用後，停藥時出現抽搐或嚴重意識混亂屬於急症。",
    ),
    "Alcohol acts on the same receptors, and the combination can stop breathing.": (
        "酒精作用于同一类受体，两者合用可能使呼吸停止。",
        "酒精作用於同一類受體，兩者合用可能使呼吸停止。",
    ),
    "Alcohol disrupts the sleep you need.": (
        "酒精会扰乱你需要的睡眠。",
        "酒精會擾亂你需要的睡眠。",
    ),
    "Alcohol, benzodiazepines and opioids on top of a dissociative raise the risk of stopped breathing.": (
        "在解离剂之上叠加酒精、苯二氮䓬类或阿片类，会提高呼吸停止的风险。",
        "在解離劑之上疊加酒精、苯二氮平類或鴉片類，會提高呼吸停止的風險。",
    ),
    "Alcohol, benzodiazepines and other depressants on top of an opioid raise the risk of stopped breathing.": (
        "在阿片类之上叠加酒精、苯二氮䓬类或其他中枢抑制药，会提高呼吸停止的风险。",
        "在鴉片類之上疊加酒精、苯二氮平類或其他中樞抑制藥，會提高呼吸停止的風險。",
    ),
    "All Database Sources": ("全部数据库来源", "全部資料庫來源"),
    "An estimate from population data, not a measurement. It doesn't say when another dose is safe.": (
        "这是基于人群数据的估计，不是测量值。它不说明何时再服一剂是安全的。",
        "這是基於人群資料的估計，不是測量值。它不說明何時再服一劑是安全的。",
    ),
    "An export or backup is made when you ask and saved where you choose.": (
        "只有在你要求时才会生成导出或备份，并保存到你选择的位置。",
        "只有在你要求時才會生成匯出或備份，並儲存到你選擇的位置。",
    ),
    "An injected ester releases slowly from the oil depot, splits into the free hormone, and clears. This curve sums your logged esters into an illustrative serum estimate. It is not a laboratory result.": (
        "注射的酯从油性储库中缓慢释放，分解为游离激素，然后被清除。这条曲线把你记录的各种酯汇总为一个示意性的血清估计值。它不是化验结果。",
        "注射的酯從油性儲庫中緩慢釋放，分解為游離激素，然後被清除。這條曲線把你記錄的各種酯彙總為一個示意性的血清估計值。它不是化驗結果。",
    ),
    "Any": ("任意", "任意"),
    "You may need food and rest after several hours without them.": (
        "如果已经几个小时没吃东西或休息，你可能需要补充食物和休息。",
        "如果已經幾個小時沒吃東西或休息，你可能需要補充食物和休息。",
    ),
    "Apple Watch": ("Apple Watch", "Apple Watch"),
    "As a benzodiazepine wears off, rebound anxiety and restlessness are commonly reported.": (
        "苯二氮䓬类消退时，常有人出现反跳性焦虑和坐立不安。",
        "苯二氮平類消退時，常有人出現反跳性焦慮和坐立不安。",
    ),
    "As a depressant wears off, feeling shaky, anxious or nauseous is commonly reported.": (
        "中枢抑制药消退时，常有人感到发抖、焦虑或恶心。",
        "中樞抑制藥消退時，常有人感到發抖、焦慮或噁心。",
    ),
    "As an opioid fades, increased pain sensitivity, restlessness and mild nausea are commonly reported.": (
        "阿片类药效消退时，常有人出现痛觉敏感增加、坐立不安和轻度恶心。",
        "鴉片類藥效消退時，常有人出現痛覺敏感增加、坐立不安和輕度噁心。",
    ),
    "Automatic Live Activity": ("自动实时活动", "自動即時動態"),
    "Availability": ("获取方式", "取得方式"),
    "Avoid hot baths or showers alone — you may not feel temperature accurately.": (
        "避免独自泡热水澡或冲热水澡——你可能无法准确感知温度。",
        "避免獨自泡熱水澡或沖熱水澡——你可能無法準確感知溫度。",
    ),
    "Avoid screens and doom-scrolling while you're this impressionable.": (
        "在你还这么容易受影响的时候，避开屏幕和无休止的负面刷屏。",
        "在你還這麼容易受影響的時候，避開螢幕和無休止的負面刷屏。",
    ),
    "Backing up…": ("正在备份…", "正在備份…"),
    "Backup": ("备份", "備份"),
    "Bacteriostatic water": ("抑菌注射用水", "抑菌注射用水"),
    "Be patient with yourself over the next few days.": (
        "接下来几天对自己耐心一点。",
        "接下來幾天對自己耐心一點。",
    ),
    "Breathe slowly. 4 seconds in, hold for 4, out for 4.": (
        "慢慢呼吸。吸气 4 秒，屏住 4 秒，呼气 4 秒。",
        "慢慢呼吸。吸氣 4 秒，屏住 4 秒，呼氣 4 秒。",
    ),
    "CAS": ("CAS 号", "CAS 號"),
    "Caffeine adds to the load on the heart.": (
        "咖啡因会增加心脏的负担。",
        "咖啡因會增加心臟的負擔。",
    ),
    "Caffeine amplifies rebound anxiety.": ("咖啡因会放大反跳性焦虑。", "咖啡因會放大反跳性焦慮。"),
    "Cannabis is widely reported to bring the effects back, sometimes unpleasantly.": (
        "许多报告提到大麻会把效果带回来，有时并不愉快。",
        "許多報告提到大麻會把效果帶回來，有時並不愉快。",
    ),
    "Check how substances interact": ("查看物质间的相互作用", "查看物質間的相互作用"),
    "Check the arithmetic independently.": ("请另行核对这些算术。", "請另行核對這些算術。"),
    "Chemistry": ("化学信息", "化學資訊"),
    "Chest pain, a pounding heart that won't settle, or a severe headache needs medical help.": (
        "胸痛、心跳剧烈且无法平复，或严重头痛，需要就医。",
        "胸痛、心跳劇烈且無法平復，或嚴重頭痛，需要就醫。",
    ),
    "Clear Filters": ("清除筛选", "清除篩選"),
    "Collapses the model estimate": ("收起模型估计", "收起模型估計"),
    "Comedown and aftercare tips": (
        "下头与事后照护建议",
        "下頭與事後照護建議",
    ),
    "Commonly reported early on. Small sips rather than gulps.": (
        "早期常见。小口喝，别大口灌。",
        "早期常見。小口喝，別大口灌。",
    ),
    "Commonly reported here. Some people find moving a little easier than sitting still.": (
        "这里很常见。有些人觉得稍微动一动比坐着不动更好受。",
        "這裡很常見。有些人覺得稍微動一動比坐著不動更好受。",
    ),
    "Commonly reported on the way down. Worth noting when it started.": (
        "下行阶段常见。值得记下它是什么时候开始的。",
        "下行階段常見。值得記下它是什麼時候開始的。",
    ),
    "Commonly reported while a stimulating dose is active. The curve is an estimate and can't say when you will sleep.": (
        "在有兴奋作用的剂量仍然活跃期间很常见。曲线只是估计，无法说明你什么时候能睡着。",
        "在有興奮作用的劑量仍然活躍期間很常見。曲線只是估計，無法說明你什麼時候能睡著。",
    ),
    "Commonly reported with this class. A familiar person or place helps more than arguing with the thought.": (
        "这一类常见的报告。熟悉的人或地方，比和这个念头争辩更有用。",
        "這一類常見的報告。熟悉的人或地方，比和這個念頭爭辯更有用。",
    ),
    "Commonly reported with this class. Something small now still counts.": (
        "这一类常见的报告。现在吃一点小东西也算数。",
        "這一類常見的報告。現在吃一點小東西也算數。",
    ),
    "Commonly reported with this class. The timeline can't say how long yours will last — company and a quieter room are worth having.": (
        "这一类常见的报告。时间线无法说明你的会持续多久——有人陪伴、换个安静点的房间都值得。",
        "這一類常見的報告。時間線無法說明你的會持續多久——有人陪伴、換個安靜點的房間都值得。",
    ),
    "Compounded sedation — stronger, deeper drowsiness. GHB suppresses breathing on its own, and added sedation makes that harder to notice.": (
        "镇静叠加——更强、更深的困倦。GHB 本身就会抑制呼吸，而额外的镇静会让这一点更难被察觉。",
        "鎮靜疊加——更強、更深的睏倦。GHB 本身就會抑制呼吸，而額外的鎮靜會讓這一點更難被察覺。",
    ),
    "Concentration and solvent volume for a solution": (
        "溶液的浓度与溶剂体积",
        "溶液的濃度與溶劑體積",
    ),
    "Confirm Passphrase": ("确认口令", "確認通行碼"),
    "Copies only when you ask": ("只在你要求时才生成副本", "只在你要求時才生成副本"),
    "Couldn't access the secure keychain.": ("无法访问安全钥匙串。", "無法存取安全鑰匙圈。"),
    "Couldn't decrypt this backup. The passphrase may be wrong, or the file may be damaged.": (
        "无法解密此备份。口令可能有误，或文件已损坏。",
        "無法解密此備份。通行碼可能有誤，或檔案已損毀。",
    ),
    "Couldn't derive a key from the passphrase.": (
        "无法从口令派生密钥。",
        "無法從通行碼衍生金鑰。",
    ),
    "Course": ("疗程", "療程"),
    "Coverage is incomplete — absence of a listed interaction does not mean absence of risk.": (
        "覆盖并不完整——没有列出相互作用，不代表没有风险。",
        "覆蓋並不完整——沒有列出相互作用，不代表沒有風險。",
    ),
    "DOI": ("DOI", "DOI"),
    "Data Sources & Licenses": ("数据来源与许可", "資料來源與許可"),
    "Database Sources": ("数据库来源", "資料庫來源"),
    "Deliriant": ("谵妄剂", "譫妄劑"),
    "Diazepam equivalent": ("地西泮等效剂量", "地西泮等效劑量"),
    "Display as (e.g. joint)": ("显示为（例如 joint）", "顯示為（例如 joint）"),
    "Display name": ("显示名称", "顯示名稱"),
    "Distress or perceptual changes that persist for days are worth taking to a professional.": (
        "持续数天的痛苦或知觉变化，值得去找专业人士看看。",
        "持續數天的痛苦或知覺變化，值得去找專業人士看看。",
    ),
    "Do not drive or operate machinery. Feeling normal does not establish that you can drive safely.": (
        "不要开车或操作机械。感觉正常并不能证明你可以安全驾驶。",
        "不要開車或操作機械。感覺正常並不能證明你可以安全駕駛。",
    ),
    "Do not drive. Feeling less sedated does not establish that memory or coordination are unimpaired.": (
        "不要开车。感觉没那么困，并不能证明记忆或协调性没有受损。",
        "不要開車。感覺沒那麼睏，並不能證明記憶或協調性沒有受損。",
    ),
    "Do not drive. Feeling normal does not establish that you can drive safely.": (
        "不要开车。感觉正常并不能证明你可以安全驾驶。",
        "不要開車。感覺正常並不能證明你可以安全駕駛。",
    ),
    "Do not drive. Impairment outlasts the feeling of being high.": (
        "不要开车。功能受损持续的时间比“嗨”的感觉更长。",
        "不要開車。功能受損持續的時間比「嗨」的感覺更長。",
    ),
    "Dose Ranges": ("剂量范围", "劑量範圍"),
    "Dose data": ("剂量数据", "劑量資料"),
    "Draw": ("抽取量", "抽取量"),
    "Drink water and eat something.": ("喝点水，吃点东西。", "喝點水，吃點東西。"),
    "Drink water or an electrolyte drink, in sips.": (
        "小口喝水或电解质饮料。",
        "小口喝水或電解質飲料。",
    ),
    "Drink water, in sips. Eat something light.": (
        "小口喝水。吃点清淡的东西。",
        "小口喝水。吃點清淡的東西。",
    ),
    "Drink water. A dry mouth is an effect of cannabis itself and doesn't by itself mean dehydration.": (
        "喝点水。口干是大麻本身的作用，单凭它并不代表脱水。",
        "喝點水。口乾是大麻本身的作用，單憑它並不代表脫水。",
    ),
    "Duration data": ("持续时间数据", "持續時間資料"),
    "EC50 %@ nM": ("EC50 %@ nM", "EC50 %@ nM"),
    'Each comparison groups your rated days by one factor at a time and counts how often you rated the dose "about right" or more. These describe your entries; they don\'t show that a substance, dose, or timing caused a difference.': (
        "每组对照只按一个因素划分你评过分的日子，统计其中有多少次剂量被评为“和平时差不多”或更强。这些只是在描述你的记录；它们并不说明是某种物质、剂量或时间造成了差异。",
        "每組對照只按一個因素劃分你評過分的日子，統計其中有多少次劑量被評為「和平時差不多」或更強。這些只是在描述你的記錄；它們並不說明是某種物質、劑量或時間造成了差異。",
    ),
    "Each substance page lists which of these supplied each field.": (
        "每个物质页面都会列出各个字段由其中哪个来源提供。",
        "每個物質頁面都會列出各個欄位由其中哪個來源提供。",
    ),
    "Eat light foods: fruit, toast, soup.": (
        "吃点清淡的：水果、吐司、汤。",
        "吃點清淡的：水果、吐司、湯。",
    ),
    "Eat something balanced.": ("吃点营养均衡的东西。", "吃點營養均衡的東西。"),
    "Eat something with salt, protein, and carbs.": (
        "吃点含盐、蛋白质和碳水的东西。",
        "吃點含鹽、蛋白質和碳水的東西。",
    ),
    "Eat something, even without hunger. Protein and complex carbs are the usual suggestion.": (
        "即使不饿也吃点东西。通常建议蛋白质和复合碳水。",
        "即使不餓也吃點東西。通常建議蛋白質和複合碳水。",
    ),
    "Edibles also come on slowly — usually 30 minutes to 2 hours — and last much longer, often 6–10 hours. That slow start is the redose trap: more taken before the first dose has arrived stacks into a far stronger, longer experience than intended.": (
        "食用型起效也慢——通常要 30 分钟到 2 小时——而且持续得久得多，常常 6–10 小时。这种慢起效正是补服的陷阱：在第一剂还没上来之前再吃，叠起来的体验会比预想的强得多、久得多。",
        "食用型起效也慢——通常要 30 分鐘到 2 小時——而且持續得久得多，常常 6–10 小時。這種慢起效正是補服的陷阱：在第一劑還沒上來之前再吃，疊起來的體驗會比預想的強得多、久得多。",
    ),
    "Edit Personalization…": ("编辑个性化…", "編輯個人化…"),
    "Effects": (
        "效应",
        "效應",
    ),
    "Encrypt": ("加密", "加密"),
    "Enter Passphrase": ("输入口令", "輸入通行碼"),
    "Enter a vial amount, diluent volume, and target dose.": (
        "请输入瓶内总量、溶剂体积和目标剂量。",
        "請輸入瓶內總量、溶劑體積與目標劑量。",
    ),
    "Estimate active levels over time": ("估算活性水平随时间的变化", "估算活性水平隨時間的變化"),
    "Estimated decline": ("估计的消退", "估計的消退"),
    "Estimated end of effects": ("估计的效果结束", "估計的效果結束"),
    "Estimated onset": ("估计的起效", "估計的起效"),
    "Estimated onset from reference data. How are you feeling?": (
        "根据参考数据估计的起效时间。你现在感觉怎么样？",
        "根據參考資料估計的起效時間。你現在感覺怎麼樣？",
    ),
    "Estimated onset ~%@": ("估计起效约 %@", "估計起效約 %@"),
    "Estimated onset ~%@ · easing off ~%@": (
        "估计起效约 %@ · 约 %@ 开始减弱",
        "估計起效約 %@ · 約 %@ 開始減弱",
    ),
    "Estimated peak window from reference data. How are you feeling?": (
        "根据参考数据估计的峰值时段。你现在感觉怎么样？",
        "根據參考資料估計的峰值時段。你現在感覺怎麼樣？",
    ),
    "Estimates only. Verify against your product and a clinician.": (
        "仅为估算。请对照你的产品，并向临床医生核实。",
        "僅為估算。請對照你的產品，並向臨床醫師核實。",
    ),
    "European Union Drugs Agency": ("欧盟毒品管理局", "歐盟毒品管理局"),
    "Every source recorded in the substance database that ships with Piru.": (
        "Piru 随附的物质数据库中记录的每一个来源。",
        "Piru 隨附的物質資料庫中記錄的每一個來源。",
    ),
    "Export Failed": ("导出失败", "匯出失敗"),
    "Exports and backups": ("导出与备份", "匯出與備份"),
    "Feeling bad is a listed effect of this class. It still deserves attention — Piru can't tell whether a symptom is harmless.": (
        "感觉糟糕是这一类列出的效应。它仍然值得重视——Piru 无法判断一个症状是否无害。",
        "感覺糟糕是這一類列出的效應。它仍然值得重視——Piru 無法判斷一個症狀是否無害。",
    ),
    "Feeling emotionally open, contemplative, or just tired afterwards is commonly reported.": (
        "事后常有人感到情感开放、若有所思，或只是疲惫。",
        "事後常有人感到情感開放、若有所思，或只是疲憊。",
    ),
    "Feeling foggy or unreal for a while afterwards is commonly reported.": (
        "事后常有人会有一段时间感觉昏沉或不真实。",
        "事後常有人會有一段時間感覺昏沉或不真實。",
    ),
    "Feeling foggy, lethargic or mildly irritable afterwards is commonly reported.": (
        "事后常有人感觉昏沉、倦怠或轻微易怒。",
        "事後常有人感覺昏沉、倦怠或輕微易怒。",
    ),
    "Feeling hot and cold is commonly reported. A high temperature that rest and cooling don't bring down is an emergency.": (
        "常有人忽冷忽热。休息和降温都压不下去的高热属于急症。",
        "常有人忽冷忽熱。休息和降溫都壓不下去的高熱屬於急症。",
    ),
    "Feeling less sedated does not establish that memory or coordination are unimpaired — tolerance to sedation builds faster than tolerance to impairment.": (
        "感觉没那么困，并不能证明记忆或协调性没有受损——对镇静的耐受比对功能受损的耐受形成得更快。",
        "感覺沒那麼睏，並不能證明記憶或協調性沒有受損——對鎮靜的耐受比對功能受損的耐受形成得更快。",
    ),
    "Filters": ("筛选", "篩選"),
    "Find any substance by name or alias.": (
        "按名称或别名查找任意物质。",
        "依名稱或別名尋找任何物質。",
    ),
    "Formula": ("分子式", "分子式"),
    "Freeze": ("冷冻", "冷凍"),
    "Fresh air and gentle light": ("新鲜空气和柔和的光线", "新鮮空氣和柔和的光線"),
    "From a file or an encrypted backup": ("来自文件或加密备份", "來自檔案或加密備份"),
    "From your last 48 hours": ("来自你最近 48 小时", "來自你最近 48 小時"),
    "Gentle massage eases a sore jaw.": ("轻轻按摩能缓解下颌酸痛。", "輕輕按摩能緩解下頜痠痛。"),
    "Group by": ("分组方式", "分組方式"),
    "Half-Life Calculator": ("半衰期计算器", "半衰期計算器"),
    "Half-life": ("半衰期", "半衰期"),
    "Handling & storage": ("处理与储存", "處理與儲存"),
    "Have feedback, questions, or want to discuss the app? Join our Discord — we'd love to hear from you.": (
        "有反馈、疑问，或想讨论这款应用？加入我们的 Discord——期待听到你的声音。",
        "有回饋、疑問，或想討論這款應用程式？加入我們的 Discord——期待聽到你的聲音。",
    ),
    "Headaches and fatigue are common.": ("头痛和疲劳很常见。", "頭痛和疲勞很常見。"),
    "Help": ("帮助", "說明"),
    "How Encryption Works": ("加密原理", "加密原理"),
    "How long that lasts varies between people, and the kinetics in humans aren't well measured.": (
        "持续多久因人而异，人体中的动力学也没有被很好地测量过。",
        "持續多久因人而異，人體中的動力學也沒有被很好地測量過。",
    ),
    "How strong that is tracks how much and how often you've been using.": (
        "其强度取决于你用了多少、多频繁。",
        "其強度取決於你用了多少、多頻繁。",
    ),
    "How you feel depends on what you took, how much, and your own body.": (
        "你的感受取决于你用了什么、用了多少，以及你自己的身体。",
        "你的感受取決於你用了什麼、用了多少，以及你自己的身體。",
    ),
    "If someone is hard to wake or breathing slowly, call emergency services.": (
        "如果有人难以叫醒或呼吸缓慢，请呼叫急救。",
        "如果有人難以叫醒或呼吸緩慢，請呼叫急救。",
    ),
    "If someone is hard to wake, breathing slowly, or has blue lips, call emergency services. Give naloxone if you have it, following its instructions.": (
        "如果有人难以叫醒、呼吸缓慢或嘴唇发紫，请呼叫急救。如果手边有纳洛酮，请按其说明使用。",
        "如果有人難以叫醒、呼吸緩慢或嘴唇發紫，請呼叫急救。如果手邊有納洛酮，請按其說明使用。",
    ),
    "If someone is hard to wake, breathing slowly, or vomiting while drowsy, put them on their side and call emergency services.": (
        "如果有人难以叫醒、呼吸缓慢，或在昏沉中呕吐，请让其侧卧并呼叫急救。",
        "如果有人難以叫醒、呼吸緩慢，或在昏沉中嘔吐，請讓其側臥並呼叫急救。",
    ),
    "If someone is hard to wake, breathing slowly, overheating or having a seizure, call emergency services.": (
        "如果有人难以唤醒、呼吸缓慢、体温过高或癫痫发作，请呼叫急救。",
        "如果有人難以喚醒、呼吸緩慢、體溫過高或癲癇發作，請呼叫急救。",
    ),
    "If the experience was intense: the acute effects of this class are time-limited, and company helps.": (
        "如果体验很强烈：这一类的急性效应是有时限的，有人陪伴会有帮助。",
        "如果體驗很強烈：這一類的急性效應是有時限的，有人陪伴會有幫助。",
    ),
    "If you feel anxious, slow your breathing. Anxiety is a listed effect of this class.": (
        "如果感到焦虑，放慢呼吸。焦虑是这一类列出的效应。",
        "如果感到焦慮，放慢呼吸。焦慮是這一類列出的效應。",
    ),
    "If you feel nauseous, lie on your side.": ("如果感到恶心，请侧卧。", "如果感到噁心，請側臥。"),
    "If you lose this passphrase, the backup can't be recovered. There is no reset.": (
        "如果你丢失此口令，备份将无法恢复。无法重置。",
        "如果你遺失此通行碼，備份將無法還原。無法重設。",
    ),
    "You may think differently about important decisions and emotionally charged messages tomorrow.": (
        "到明天，你对重要决定和带有情绪的消息可能会有不同看法。",
        "到明天，你對重要決定和帶有情緒的訊息可能會有不同看法。",
    ),
    "In your system": ("体内残留", "體內殘留"),
    "InChIKey": ("InChIKey", "InChIKey"),
    "It estimates a level. It never suggests a dose or a target. Your lab results fit the model to your measurements, which doesn't establish accuracy between them.": (
        "它估计一个水平，从不建议剂量或目标。你的化验结果让模型贴合你的测量值，但这并不能证明各次测量之间的准确性。",
        "它估計一個水平，從不建議劑量或目標。你的化驗結果讓模型貼合你的測量值，但這並不能證明各次測量之間的準確性。",
    ),
    "It estimates a level. It never suggests a dose or a target. Your lab results fit the model to your measurements, which doesn't establish accuracy between them. The reference lines are your own.": (
        "它估计一个水平，从不建议剂量或目标。你的化验结果让模型贴合你的测量值，但这并不能证明各次测量之间的准确性。参考线是你自己的。",
        "它估計一個水平，從不建議劑量或目標。你的化驗結果讓模型貼合你的測量值，但這並不能證明各次測量之間的準確性。參考線是你自己的。",
    ),
    "Jaw clenching is commonly reported. Something to chew spares your teeth.": (
        "常有人会咬紧下颌。嚼点东西可以保护牙齿。",
        "常有人會咬緊下頜。嚼點東西可以保護牙齒。",
    ),
    "Join Discord": ("加入 Discord", "加入 Discord"),
    "Join the community": ("加入社区", "加入社群"),
    "Just now": ("刚刚", "剛剛"),
    "Ki %@ nM": ("Ki %@ nM", "Ki %@ nM"),
    "Ki ≤ %lld nM": ("Ki ≤ %lld nM", "Ki ≤ %lld nM"),
    "Last Backup": ("上次备份", "上次備份"),
    "Last backup failed: %@": ("上次备份失败：%@", "上次備份失敗：%@"),
    "Levels vary a lot between people, so an uncalibrated curve is a starting point, not a reading. One blood test fits the height. Two on different days fit the shape too. Retest after any change in dose, ester, interval, or site.": (
        "不同人之间水平差异很大，所以未校准的曲线是一个起点，不是一次读数。一次血检拟合高度，不同日子的两次还能拟合形状。剂量、酯、间隔或注射部位有任何变化后都要重新检测。",
        "不同人之間水平差異很大，所以未校準的曲線是一個起點，不是一次讀數。一次血檢擬合高度，不同日子的兩次還能擬合形狀。劑量、酯、間隔或注射部位有任何變化後都要重新檢測。",
    ),
    "License": ("许可", "許可"),
    "Lie down even if sleep doesn't come immediately.": (
        "即使一时睡不着，也躺下来。",
        "即使一時睡不著，也躺下來。",
    ),
    "Light movement helps — even a short walk.": (
        "轻度活动有帮助——哪怕只是短短走一走。",
        "輕度活動有幫助——哪怕只是短短走一走。",
    ),
    "Limited human data": (
        "人体数据有限",
        "人體資料有限",
    ),
    "Lingering visual or thought patterns are reported too, and usually fade over hours.": (
        "也有报告提到残留的视觉或思维模式，通常会在数小时内消退。",
        "也有報告提到殘留的視覺或思維模式，通常會在數小時內消退。",
    ),
    "Listed for this class. Piru can't tell what is causing a change in vision or when it ends — sudden loss of vision or eye pain needs urgent care.": (
        "这一类列出的效应。Piru 无法判断视觉变化的原因或它何时结束——突然失明或眼痛需要紧急就医。",
        "這一類列出的效應。Piru 無法判斷視覺變化的原因或它何時結束——突然失明或眼痛需要緊急就醫。",
    ),
    "Log": ("记录", "記錄"),
    "Log a few doses and the modeled tolerance shows up here. The model sees only what is logged, so an empty screen says nothing about your actual tolerance.": (
        "记录几次剂量，模型估计的耐受就会显示在这里。模型只看得到已记录的内容，所以空白的页面并不说明你实际的耐受情况。",
        "記錄幾次劑量，模型估計的耐受就會顯示在這裡。模型只看得到已記錄的內容，所以空白的頁面並不說明你實際的耐受情況。",
    ),
    "Log medications and substances, record how you feel, and explore referenced information. Piru is a record and a reference, not medical advice.": (
        "记录药物和物质，记下你的感受，并查阅有出处的信息。Piru 是一份记录和参考资料，不是医疗建议。",
        "記錄藥物和物質，記下你的感受，並查閱有出處的資訊。Piru 是一份記錄和參考資料，不是醫療建議。",
    ),
    "Look up interactions, explore a tolerance model, track your stock, and work out a solution's concentration.": (
        "查询相互作用、探索耐受模型、追踪库存，并计算溶液的浓度。",
        "查詢相互作用、探索耐受模型、追蹤庫存，並計算溶液的濃度。",
    ),
    "Low mood after a stimulant is commonly reported. If it turns into thoughts of harming yourself, use the numbers in Get Help.": (
        "兴奋剂之后常有人情绪低落。如果它变成了伤害自己的念头，请使用“获取帮助”里的号码。",
        "興奮劑之後常有人情緒低落。如果它變成了傷害自己的念頭，請使用「取得協助」裡的號碼。",
    ),
    "Low mood, fatigue and emotional sensitivity in the days after are commonly reported.": (
        "之后几天常有人情绪低落、疲劳、情绪敏感。",
        "之後幾天常有人情緒低落、疲勞、情緒敏感。",
    ),
    "Lower Ki means tighter binding. Affinity below ~100 nM is usually considered high.": (
        "Ki 越低表示结合越紧密。亲和力低于约 100 nM 通常被视为较高。",
        "Ki 越低表示結合越緊密。親和力低於約 100 nM 通常被視為較高。",
    ),
    "Lyophilized powder (vial)": ("冻干粉（药瓶）", "凍乾粉（藥瓶）"),
    "Make an encrypted backup whenever you're ready, from Tools.": (
        "准备好时，随时可以在“工具”中制作加密备份。",
        "準備好時，隨時可以在「工具」中製作加密備份。",
    ),
    "Mechanism": ("作用机制", "作用機制"),
    "Memory and coordination can stay impaired after the sedation lifts.": (
        "镇静感消退后，记忆和协调性仍可能受损。",
        "鎮靜感消退後，記憶和協調性仍可能受損。",
    ),
    "Merge With Current Data": ("与当前数据合并", "與目前資料合併"),
    "Merge keeps your current entries and adds the backup's. Replace deletes your current data first (a recovery snapshot is taken automatically) and restores only the backup.": (
        "合并会保留你当前的记录并加入备份中的记录。替换会先删除你当前的数据（系统会自动创建可恢复的快照），然后仅恢复备份内容。",
        "合併會保留你目前的記錄並加入備份中的記錄。取代會先刪除你目前的資料（系統會自動建立可還原的快照），然後僅還原備份內容。",
    ),
    "Model near zero": ("模型接近零", "模型接近零"),
    "Model reaches zero": ("模型归零", "模型歸零"),
    "Modeled as active": (
        "模型估计仍在起效",
        "模型估計仍在起效",
    ),
    "Modeled effects end ~%@": ("模型估计效果结束于约 %@", "模型估計效果結束於約 %@"),
    "Modeled effects end ~%@ — after most bedtimes.": (
        "模型估计效果结束于约 %@——晚于大多数人的就寝时间。",
        "模型估計效果結束於約 %@——晚於大多數人的就寢時間。",
    ),
    "Modeled level over time": ("模型估计水平随时间变化", "模型估計水平隨時間變化"),
    "Modeled Levels": ("模型估计水平", "模型估計水平"),
    "scheduled": ("已安排", "已排定"),
    "Modeled levels over time": ("模型估计水平随时间变化", "模型估計水平隨時間變化"),
    "Molar mass": ("摩尔质量", "莫耳質量"),
    "Taking more cannabis to ease the comedown delays it.": (
        "为了缓解下头而补服大麻，会延后下头的时间。",
        "為了緩解下頭而補服大麻，會延後下頭的時間。",
    ),
    "Taking more of a depressant to ease the morning symptoms delays recovery.": (
        "为了缓解早晨的不适而补服中枢抑制药，会延迟恢复。",
        "為了緩解早晨的不適而補服中樞抑制藥，會延遲恢復。",
    ),
    "Most entries: %@": ("条目最多：%@", "條目最多：%@"),
    "Never": ("从不", "從不"),
    "No ads, no analytics, no trackers.": (
        "没有广告，没有分析，没有追踪器。",
        "沒有廣告，沒有分析，沒有追蹤器。",
    ),
    "No bindings match these filters.": (
        "没有符合这些筛选条件的结合数据。",
        "沒有符合這些篩選條件的結合資料。",
    ),
    "No daily limit entered": ("未填写每日上限", "未填寫每日上限"),
    "No iCloud backup was found for this account yet.": (
        "尚未找到此账户的 iCloud 备份。",
        "尚未找到此帳戶的 iCloud 備份。",
    ),
    "No interactions found in Piru's database.": (
        "在 Piru 的数据库中未找到相互作用。",
        "在 Piru 的資料庫中未找到相互作用。",
    ),
    "No overlap shown by this model. The interaction may still apply.": (
        "此模型未显示重叠。相互作用仍可能存在。",
        "此模型未顯示重疊。相互作用仍可能存在。",
    ),
    "Not logged: %@ %@": ("未记录：%@ %@", "未記錄：%@ %@"),
    "Nothing active right now": ("当前无活性物质", "目前無活性物質"),
    "Nothing notable in the model": ("模型中没有值得注意的内容", "模型中沒有值得注意的內容"),
    "OTC / Prescription": ("非处方 / 处方", "非處方 / 處方"),
    "On a U-100 syringe": ("U-100 注射器刻度", "U-100 注射器刻度"),
    "Open Source": ("开源", "開源"),
    "Opioid MME": (
        "阿片类 MME",
        "鴉片類 MME",
    ),
    "Opioids release histamine, and itching is commonly reported. Piru can't tell that from an allergy — swelling of the mouth or throat, or trouble breathing, is an emergency.": (
        "阿片类会释放组胺，常有人感到瘙痒。Piru 无法把它与过敏区分开——口腔或喉咙肿胀，或呼吸困难，属于急症。",
        "鴉片類會釋放組織胺，常有人感到瘙癢。Piru 無法把它與過敏區分開——口腔或喉嚨腫脹，或呼吸困難，屬於急症。",
    ),
    "Optional dose tiers, in your chosen unit. Leave blank to keep the library values.": (
        "可选剂量分级，使用你选择的单位。留空则保留库中数值。",
        "可選劑量分級，使用你選擇的單位。留空則保留資料庫數值。",
    ),
    "Optional. Feeds the active-substance and clearance estimates.": (
        "可选。用于活性物质与清除估算。",
        "可選。用於活性物質與清除估算。",
    ),
    "Oral capsule": ("口服胶囊", "口服膠囊"),
    "Over-the-counter": ("非处方", "非處方"),
    "Passphrase": ("口令", "通行碼"),
    "Passphrase backups": ("口令备份", "通行碼備份"),
    "Passphrases don't match yet.": ("两次输入的口令尚不一致。", "兩次輸入的通行碼尚不一致。"),
    "Passphrases match.": ("口令一致。", "通行碼一致。"),
    "Peptide — protocol reference": (
        "肽——方案参考",
        "胜肽——方案參考",
    ),
    "Personalize": ("个性化", "個人化"),
    "Pharma Search": ("药理搜索", "藥理搜尋"),
    "Phenethylamines I Have Known and Loved — Shulgin & Shulgin (1991)": (
        "Phenethylamines I Have Known and Loved — Shulgin & Shulgin (1991)",
        "Phenethylamines I Have Known and Loved — Shulgin & Shulgin (1991)",
    ),
    "Physical activity helps with the fog.": (
        "身体活动有助于驱散昏沉。",
        "身體活動有助於驅散昏沉。",
    ),
    "Piru can't assess heart symptoms. With chest pain, shortness of breath or fainting, call emergency services.": (
        "Piru 无法评估心脏症状。如伴有胸痛、呼吸急促或晕厥，请呼叫急救。",
        "Piru 無法評估心臟症狀。如伴有胸痛、呼吸急促或暈厥，請呼叫急救。",
    ),
    "Piru can't assess how you are. The people at the numbers below can.": (
        "Piru 无法评估你的状况。下面这些号码另一端的人可以。",
        "Piru 無法評估你的狀況。下面這些號碼另一端的人可以。",
    ),
    "Piru does not monitor emergencies. If someone is in danger, call your local emergency number.": (
        "Piru 不会监测紧急情况。如果有人处于危险之中，请拨打当地的急救电话。",
        "Piru 不會監測緊急情況。如果有人處於危險之中，請撥打當地的急救電話。",
    ),
    "Piru doesn't establish a safe interval for adding medicines or supplements. MAOIs are the documented danger with this class.": (
        "Piru 无法给出加用药物或补充剂的安全间隔。对这一类来说，有文献记录的危险是 MAOI。",
        "Piru 無法給出加用藥物或補充劑的安全間隔。對這一類來說，有文獻記錄的危險是 MAOI。",
    ),
    "Piru doesn't measure any of this. It describes what sources report for the class.": (
        "Piru 并不测量其中任何一项。它描述的是各来源对这一类的报告。",
        "Piru 並不測量其中任何一項。它描述的是各來源對這一類的報告。",
    ),
    "Piru doesn't measure any of this. It describes what sources report.": (
        "Piru 并不测量其中任何一项。它描述的是各来源的报告。",
        "Piru 並不測量其中任何一項。它描述的是各來源的報告。",
    ),
    "Piru's source code is available under the GNU GPL v3.": (
        "Piru 的源代码以 GNU GPL v3 许可提供。",
        "Piru 的原始碼以 GNU GPL v3 許可提供。",
    ),
    "Popularity": ("热门程度", "熱門程度"),
    "Prescription medication": ("处方药", "處方藥"),
    "Prescription only": ("仅限处方", "僅限處方"),
    "Privacy": ("隐私", "隱私"),
    "Privacy Policy": ("隐私政策", "隱私政策"),
    "Protect from light": ("避光保存", "避光保存"),
    "Protocol — %@": (
        "方案——%@",
        "方案——%@",
    ),
    "Ready-to-inject solution": ("即用型注射溶液", "即用型注射溶液"),
    "Receptor Literature": ("受体文献", "受體文獻"),
    "Receptor target": ("受体靶点", "受體標靶"),
    "Reconstitute with": ("复溶溶剂", "復溶溶劑"),
    "Reconstitution calculator": ("复溶计算器", "復溶計算器"),
    "Record what you can now. Piru can't tell what caused a gap or whether the memory returns.": (
        "趁现在把能记的记下来。Piru 无法判断断片的原因，也无法判断记忆是否会回来。",
        "趁現在把能記的記下來。Piru 無法判斷斷片的原因，也無法判斷記憶是否會回來。",
    ),
    "Reference": ("参考文献", "參考文獻"),
    "Reference onset for this route: %lld-%lld minutes.": (
        "该途径的参考起效时间：%lld-%lld 分钟。",
        "該途徑的參考起效時間：%lld-%lld 分鐘。",
    ),
    "Refrigerate (2–8 °C)": ("冷藏（2–8 °C）", "冷藏（2–8 °C）"),
    "Release window": (
        "释放时间窗",
        "釋放時間窗",
    ),
    "Remove %@": ("移除 %@", "移除 %@"),
    "Remove from Favorites": ("取消收藏", "取消收藏"),
    "Replace Everything": ("替换全部", "取代全部"),
    "Report a correction": ("报告更正", "報告更正"),
    "Research / performance compound": (
        "研究/提升表现类化合物",
        "研究／提升表現類化合物",
    ),
    "Reset Personalization": ("重置个性化", "重設個人化"),
    "Rest when you can.": ("能休息的时候就休息。", "能休息的時候就休息。"),
    "Rest when your body asks for it": ("身体想休息时就休息", "身體想休息時就休息"),
    "Rest with someone nearby if you can.": (
        "可以的话，在有人在旁的情况下休息。",
        "可以的話，在有人在旁的情況下休息。",
    ),
    "Rest with someone nearby. A person who can't be woken needs help, not sleep.": (
        "在有人在旁的情况下休息。叫不醒的人需要的是救助，不是睡眠。",
        "在有人在旁的情況下休息。叫不醒的人需要的是救助，不是睡眠。",
    ),
    "Restore": ("恢复", "還原"),
    "Restore Backup": ("恢复备份", "還原備份"),
    "Restore Complete": ("恢复完成", "還原完成"),
    "Restore Failed": ("恢复失败", "還原失敗"),
    "Restore Latest iCloud Backup": ("恢复最新的 iCloud 备份", "還原最新的 iCloud 備份"),
    "Results (%lld)": (
        "结果（%lld）",
        "結果（%lld）",
    ),
    "Room temperature": ("室温", "室溫"),
    "Route not yet migrated:": ("路径尚未迁移：", "途徑尚未遷移："),
    "SNRIs usually blunt MDMA — it may feel weaker, and the documented harm is taking more to compensate (overheating, heart strain). Case reports don't show serotonin syndrome from this pair alone; MAOIs are the documented danger.": (
        "SNRI 通常会削弱 MDMA——它可能感觉更弱，而有文献记录的危害是为了补偿而多服（过热、心脏负担）。病例报告并未显示仅这一组合就会引起血清素综合征；有文献记录的危险是 MAOI。",
        "SNRI 通常會削弱 MDMA——它可能感覺更弱，而有文獻記錄的危害是為了補償而多服（過熱、心臟負擔）。病例報告並未顯示僅這一組合就會引起血清素症候群；有文獻記錄的危險是 MAOI。",
    ),
    "SSRIs usually blunt MDMA — it may feel much weaker, and the documented harm is taking more to compensate (overheating, heart strain). Case reports don't show serotonin syndrome from this pair alone; MAOIs are the documented danger.": (
        "SSRI 通常会削弱 MDMA——它可能感觉弱得多，而有文献记录的危害是为了补偿而多服（过热、心脏负担）。病例报告并未显示仅这一组合就会引起血清素综合征；有文献记录的危险是 MAOI。",
        "SSRI 通常會削弱 MDMA——它可能感覺弱得多，而有文獻記錄的危害是為了補償而多服（過熱、心臟負擔）。病例報告並未顯示僅這一組合就會引起血清素症候群；有文獻記錄的危險是 MAOI。",
    ),
    "Schedule %@ (controlled)": ("%@ 类管制药物", "%@ 類管制藥物"),
    "Search Substances": ("搜索物质", "搜尋物質"),
    "See the model's estimate of what is still active": (
        "查看模型对仍在活跃的内容的估计",
        "檢視模型對仍在活躍的內容的估計",
    ),
    "Seeing things that aren't there is listed for this class. If you can't tell what is real, get someone with you. Piru can't predict when it ends.": (
        "看到并不存在的东西是这一类列出的效应。如果你分不清什么是真的，找个人陪着你。Piru 无法预测它何时结束。",
        "看到並不存在的東西是這一類列出的效應。如果你分不清什麼是真的，找個人陪著你。Piru 無法預測它何時結束。",
    ),
    "Sequence": ("氨基酸序列", "胺基酸序列"),
    "Set a Passphrase": ("设置口令", "設定通行碼"),
    "Short-term memory gaps are commonly reported. Piru can't tell what caused one.": (
        "常有人出现短期记忆断片。Piru 无法判断它的原因。",
        "常有人出現短期記憶斷片。Piru 無法判斷它的原因。",
    ),
    "Showing the guide for the classes you logged in the last 48 hours. Tap above for the full guide.": (
        "正在显示你最近 48 小时内所记录类别的指南。点按上方查看完整指南。",
        "正在顯示你最近 48 小時內所記錄類別的指南。點按上方檢視完整指南。",
    ),
    'Shown everywhere in place of "%@". Leave blank to keep the original name. Your dose history is unaffected.': (
        "在所有位置代替“%@”显示。留空则保留原名称。你的剂量记录不受影响。",
        "在所有位置代替「%@」顯示。留空則保留原名稱。你的劑量記錄不受影響。",
    ),
    "Shows the model estimate for your last dose": (
        "显示模型对你上一剂的估计",
        "顯示模型對你上一劑的估計",
    ),
    "Sign in to iCloud and turn on iCloud Drive to enable automatic encrypted backups.": (
        "登录 iCloud 并开启 iCloud 云盘以启用自动加密备份。",
        "登入 iCloud 並開啟 iCloud 雲碟以啟用自動加密備份。",
    ),
    "Sip rather than gulp, and favor electrolytes. Over-drinking water is its own danger with this class — more is not safer.": (
        "小口喝，别大口灌，并优先选含电解质的饮品。对这一类来说，饮水过量本身就是一种危险——喝得更多并不更安全。",
        "小口喝，別大口灌，並優先選含電解質的飲品。對這一類來說，飲水過量本身就是一種危險——喝得更多並不更安全。",
    ),
    "Sleep may be disrupted tonight.": ("今晚的睡眠可能会受到干扰。", "今晚的睡眠可能會受到干擾。"),
    "Sleep quality may be off tonight.": (
        "今晚的睡眠质量可能不佳。",
        "今晚的睡眠品質可能不佳。",
    ),
    "Slow-release implant": ("缓释植入剂", "緩釋植入劑"),
    "Small sips once it settles. Vomiting while very drowsy is an emergency — stay on your side and get help.": (
        "等它平息后小口喝水。在非常昏沉时呕吐属于急症——保持侧卧并寻求帮助。",
        "等它平息後小口喝水。在非常昏沉時嘔吐屬於急症——保持側臥並尋求幫助。",
    ),
    "Solution Math": ("溶液计算", "溶液計算"),
    "Solutions": ("溶液", "溶液"),
    "Some reference text was drafted with AI assistance and reviewed before publication. AI output is not treated as evidence. Quantitative and safety-critical claims are checked against identified sources, which are listed on each substance page.": (
        "部分参考文字由 AI 辅助起草，并在发布前经过审阅。AI 的输出不被当作证据。定量的和与安全相关的说法都会对照已标明的来源进行核对，这些来源列在每个物质页面上。",
        "部分參考文字由 AI 輔助起草，並在發布前經過審閱。AI 的輸出不被當作證據。定量的和與安全相關的說法都會對照已標明的來源進行核對，這些來源列在每個物質頁面上。",
    ),
    "Something to chew eases a tight jaw.": (
        "嚼点东西能缓解紧绷的下颌。",
        "嚼點東西能緩解緊繃的下頜。",
    ),
    "Sort": ("排序", "排序"),
    "Stable ~%@ days once reconstituted": ("复溶后约可稳定 %@ 天", "復溶後約可穩定 %@ 天"),
    "Start Live Activity": ("开启实时活动", "開啟即時動態"),
    "Stay somewhere calm and safe.": ("待在平静、安全的地方。", "待在平靜、安全的地方。"),
    "Stay with someone, or let someone know to check on you. Heavy snoring or gurgling in sleep is a warning sign, not rest.": (
        "和别人待在一起，或者让人知道要来看看你。睡眠中鼾声很重或有咕噜声是警示信号，不是在休息。",
        "和別人待在一起，或者讓人知道要來看看你。睡眠中鼾聲很重或有咕嚕聲是警示訊號，不是在休息。",
    ),
    "Stop Live Activity": ("停止实时活动", "停止即時動態"),
    "Strong encryption": ("强加密", "強加密"),
    "Substance contains…": ("物质包含…", "物質包含…"),
    "Supplied as": ("供应形式", "供應形式"),
    "TCAs usually blunt MDMA rather than boosting it, which leads people to take more; the bigger concern is added strain on heart rate and blood pressure.": (
        "TCA 通常会削弱而不是增强 MDMA，这会让人服用更多；更大的问题是对心率和血压的额外负担。",
        "TCA 通常會削弱而不是增強 MDMA，這會讓人服用更多；更大的問題是對心率和血壓的額外負擔。",
    ),
    "Taking more in reaction to the rebound reinforces the cycle.": (
        "因为反跳就再服，会强化这个循环。",
        "因為反跳就再服，會強化這個循環。",
    ),
    "Taking more to put off the crash delays it.": (
        "为了推迟下头而补服，会延后下头的时间。",
        "為了推遲下頭而補服，會延後下頭的時間。",
    ),
    "Taking more to put off the low mood delays it.": (
        "为了推迟情绪低落而补服，会延后它出现的时间。",
        "為了推遲情緒低落而補服，會延後它出現的時間。",
    ),
    "Taking more within the same session adds to what is still active.": (
        "在同一场次中再服，会叠加到仍在起效的部分上。",
        "在同一場次中再服，會疊加到仍在起效的部分上。",
    ),
    "Target dose": ("目标剂量", "目標劑量"),
    "Text detected from the label. Check the name, strength and formulation before saving — a scan can't verify what is inside the box. Not medical advice.": (
        "从标签上识别出的文字。保存前请核对名称、规格和剂型——扫描无法验证盒子里面装的是什么。非医疗建议。",
        "從標籤上識別出的文字。儲存前請核對名稱、規格和劑型——掃描無法驗證盒子裡面裝的是什麼。非醫療建議。",
    ),
    "That total is in the heavy range of the sources. Overheating, confusion or rigid muscles need emergency help.": (
        "这个总量已处于各来源所列的大剂量范围。过热、意识混乱或肌肉僵直需要紧急救助。",
        "這個總量已處於各來源所列的大劑量範圍。過熱、意識混亂或肌肉僵直需要緊急救助。",
    ),
    "The Endocrine Society / WPATH SOC8 monitoring range for adults on masculinizing testosterone, drawn as reference lines. The range from your clinician or laboratory report takes precedence.": (
        "内分泌学会 / WPATH SOC8 针对接受男性化睾酮治疗的成人的监测范围，绘制为参考线。以你的临床医生或化验报告给出的范围为准。",
        "內分泌學會 / WPATH SOC8 針對接受男性化睪固酮治療的成人的監測範圍，繪製為參考線。以你的臨床醫生或化驗報告給出的範圍為準。",
    ),
    "The fog is reported to clear over hours. If it doesn't, seek medical help.": (
        "有人报告这种迷糊感会在数小时内消退。如果没有消退，请就医。",
        "有人報告這種迷糊感會在數小時內消退。如果沒有消退，請就醫。",
    ),
    "The groups within it": ("其中的分类", "其中的分類"),
    "The model puts ≈%@ %@ of your %@ %@ dose (%@) as still active — ~%lld%%": (
        "模型估计你 %3$@ %4$@ 的剂量（%5$@）中约有 ≈%1$@ %2$@ 仍在活跃——约 %6$lld%%",
        "模型估計你 %3$@ %4$@ 的劑量（%5$@）中約有 ≈%1$@ %2$@ 仍在活躍——約 %6$lld%%",
    ),
    "The old “never mix” warning rests on little — large reviews did not find the harm it predicts. Both still strain the heart.": (
        "过去那条“绝不可混用”的警告依据很少——大型综述并未发现它所预言的危害。两者仍然都会给心脏增加负担。",
        "過去那條「絕不可混用」的警告依據很少——大型綜述並未發現它所預言的危害。兩者仍然都會給心臟增加負擔。",
    ),
    "The protocol below reflects community or investigational use, not validated human dosing or medical advice. Many of these compounds are WADA-prohibited and lack human safety data.": (
        "下方方案反映社区或试验性用途，并非经过验证的人体剂量或医疗建议。其中许多化合物被 WADA 禁用，且缺乏人体安全数据。",
        "下方方案反映社群或試驗性用途，並非經過驗證的人體劑量或醫療建議。其中許多化合物被 WADA 禁用，且缺乏人體安全資料。",
    ),
    "Things feeling 'weird' for a while is commonly reported.": (
        "常有人会有一段时间觉得“怪怪的”。",
        "常有人會有一段時間覺得「怪怪的」。",
    ),
    "This backup uses a newer format (v%lld) than this version of Piru understands. Please update the app.": (
        "此备份使用的格式（v%lld）比当前 Piru 版本更新。请更新应用。",
        "此備份使用的格式（v%lld）比目前 Piru 版本更新。請更新 App。",
    ),
    "This class can stop memories forming while it is active. What you write down now is the record.": (
        "这一类在起效期间可能阻止记忆形成。你现在写下的就是记录。",
        "這一類在起效期間可能阻止記憶形成。你現在寫下的就是記錄。",
    ),
    "This class raises body temperature. Feeling very hot, confused or rigid is an emergency — cool down and call for help.": (
        "这一类会升高体温。感觉非常热、意识混乱或肌肉僵直属于急症——降温并呼叫救助。",
        "這一類會升高體溫。感覺非常熱、意識混亂或肌肉僵直屬於急症——降溫並呼叫救助。",
    ),
    "This compound has no validated human dose data. Information below is for reference only — see the linked sources for primary literature. Do not extrapolate doses from related compounds.": (
        "该化合物没有经过验证的人体剂量数据。以下信息仅供参考——原始文献请参阅所链接的来源。请勿根据相关化合物推算剂量。",
        "該化合物沒有經過驗證的人體劑量資料。以下資訊僅供參考——原始文獻請參閱所連結的來源。請勿根據相關化合物推算劑量。",
    ),
    "This device's backup key isn't available yet. If you just signed in, give iCloud Keychain a moment to sync.": (
        "此设备的备份密钥尚不可用。如果你刚刚登录，请稍候让 iCloud 钥匙串完成同步。",
        "此裝置的備份金鑰尚無法使用。若你剛登入，請稍候讓 iCloud 鑰匙圈完成同步。",
    ),
    "This file is too large to be a Piru backup.": (
        "此文件太大，不是有效的 Piru 备份。",
        "此檔案太大，不是有效的 Piru 備份。",
    ),
    "This file isn't a valid Piru backup.": (
        "此文件不是有效的 Piru 备份。",
        "此檔案不是有效的 Piru 備份。",
    ),
    "Titration": ("剂量滴定", "劑量滴定"),
    "Today": ("今天", "今天"),
    "Tolerance drops quickly after a break. A dose you handled before is the documented cause of many overdoses.": (
        "停用一段时间后耐受会迅速下降。以前承受得住的剂量，是许多过量事件有文献记录的原因。",
        "停用一段時間後耐受會迅速下降。以前承受得住的劑量，是許多過量事件有文獻記錄的原因。",
    ),
    "Too short — use at least %lld characters.": (
        "太短了——请至少使用 %lld 个字符。",
        "太短了——請至少使用 %lld 個字元。",
    ),
    "Tools for the details": ("处理细节的工具", "處理細節的工具"),
    "Topical formulation": ("外用制剂", "外用製劑"),
    "Tracking started.": ("已开始追踪。", "已開始追蹤。"),
    "Tryptamines I Have Known and Loved — Shulgin & Shulgin (1997)": (
        "Tryptamines I Have Known and Loved — Shulgin & Shulgin (1997)",
        "Tryptamines I Have Known and Loved — Shulgin & Shulgin (1997)",
    ),
    "Two sleep-promoting drugs stacked — additive next-day sedation, fall risk and impaired coordination. The labels warn about combining with other CNS depressants.": (
        "两种助眠药叠加——次日镇静、跌倒风险和协调性受损都会叠加。说明书对与其他中枢抑制剂合用提出了警示。",
        "兩種助眠藥疊加——次日鎮靜、跌倒風險和協調性受損都會疊加。說明書對與其他中樞抑制劑合用提出了警示。",
    ),
    "Typical protocol": ("典型方案", "典型方案"),
    "Unknown": ("未知", "未知"),
    "Use at least %lld characters. A phrase of several words is stronger and easier to remember than a short password.": (
        "请至少使用 %lld 个字符。由多个单词组成的短语比短密码更安全，也更容易记住。",
        "請至少使用 %lld 個字元。由多個單字組成的片語比短密碼更安全，也更容易記住。",
    ),
    "Values are modeled body content in the dose's units.": (
        "数值是模型估计的体内含量，以该剂量的单位表示。",
        "數值是模型估計的體內含量，以該劑量的單位表示。",
    ),
    "Vial amount": ("瓶内总量", "瓶內總量"),
    "WHO Expert Committee on Drug Dependence": (
        "世界卫生组织药物依赖性专家委员会",
        "世界衛生組織藥物依賴性專家委員會",
    ),
    "What sources report about the hours after each class wears off. It describes the class, never your condition.": (
        "各来源对每一类消退后数小时的报告。它描述的是这一类，从不描述你的状况。",
        "各來源對每一類消退後數小時的報告。它描述的是這一類，從不描述你的狀況。",
    ),
    "What the model estimates is still active": (
        "模型估计仍在活跃的内容",
        "模型估計仍在活躍的內容",
    ),
    "Work out a solution's concentration, or the solvent a target concentration needs.": (
        "计算溶液的浓度，或达到目标浓度所需的溶剂量。",
        "計算溶液的濃度，或達到目標濃度所需的溶劑量。",
    ),
    "You don't have to do this alone": ("你不必独自面对", "你不必獨自面對"),
    "You don't have to do this alone. Help is one tap away.": (
        "你不必独自面对。帮助只需轻点一下。",
        "你不必獨自面對。協助只需輕點一下。",
    ),
    "Your Notes": ("你的备注", "你的備註"),
    "Your backup was restored.": ("你的备份已恢复。", "你的備份已還原。"),
    "Your journal": (
        "你的日记",
        "你的日記",
    ),
    "Your own read of how affected you are is unreliable while dissociated.": (
        "处于解离状态时，你对自己受影响程度的判断并不可靠。",
        "處於解離狀態時，你對自己受影響程度的判斷並不可靠。",
    ),
    "Your recorded amounts, timing, and self-reported effects — at a glance.": (
        "你记录的用量、时间和自我报告的效果——一目了然。",
        "你記錄的用量、時間和自我報告的效果——一目瞭然。",
    ),
    "amount": ("数量", "數量"),
    "dailymed.nlm.nih.gov — NLM/FDA Drug Label Database": (
        "dailymed.nlm.nih.gov——NLM/FDA 药品说明书数据库",
        "dailymed.nlm.nih.gov——NLM/FDA 藥品說明書資料庫",
    ),
    "drug.community": ("drug.community", "drug.community"),
    "est. %@ %@ active · %@ ago": (
        "估计体内有 %@ %@ · %@ 前",
        "估計體內有 %@ %@ · %@ 前",
    ),
    "estimated %@ %@ active, last dose %@ ago": (
        "估计体内有 %@ %@，上一剂在 %@ 前",
        "估計體內有 %@ %@，上一劑在 %@ 前",
    ),
    "freeodwiki.org": ("freeodwiki.org", "freeodwiki.org"),
    "github.com/Di-lemma/SubFxOnEx — subjective-effects ontology": (
        "github.com/Di-lemma/SubFxOnEx——主观效应本体",
        "github.com/Di-lemma/SubFxOnEx——主觀效應本體",
    ),
    "iCloud Drive isn't available. Check that you're signed in to iCloud and that iCloud Drive is on.": (
        "iCloud 云盘不可用。请确认你已登录 iCloud 并已开启 iCloud 云盘。",
        "iCloud 雲碟無法使用。請確認你已登入 iCloud 並已開啟 iCloud 雲碟。",
    ),
    "just now": ("刚刚", "剛剛"),
    "minutes": ("分钟", "分鐘"),
    "modeled in body": ("模型估计体内含量", "模型估計體內含量"),
    "open.fda.gov — National Drug Code directory": (
        "open.fda.gov——国家药品代码（NDC）目录",
        "open.fda.gov——國家藥品代碼（NDC）目錄",
    ),
    "psychonautwiki.org": ("psychonautwiki.org", "psychonautwiki.org"),
    "pubchem.ncbi.nlm.nih.gov — National Library of Medicine": (
        "pubchem.ncbi.nlm.nih.gov——美国国家医学图书馆",
        "pubchem.ncbi.nlm.nih.gov——美國國家醫學圖書館",
    ),
    "pubmed.ncbi.nlm.nih.gov": ("pubmed.ncbi.nlm.nih.gov", "pubmed.ncbi.nlm.nih.gov"),
    "tripsit.me": ("tripsit.me", "tripsit.me"),
    "wikidata.org": ("wikidata.org", "wikidata.org"),
    "· DOI": ("· DOI", "· DOI"),
    "· PMID %lld": ("· PMID %lld", "· PMID %lld"),
    "≈ %@ MME": ("≈ %@ MME", "≈ %@ MME"),
    # The App Store readiness pass: renamed screens, the modeled-tolerance
    # wording, the license and privacy copy, and the sources rewritten as
    # community databases.
    "%@ mg %@": ("%@ mg %@", "%@ mg %@"),
    "%@ · modeled (%@).": ("%@ · 模型推算（%@）。", "%@ · 模型推算（%@）。"),
    "%lld mechanisms plotted from their modeled level now.": (
        "%lld 条机制，按各自当前的模型推算水平绘制。",
        "%lld 條機制，按各自目前的模型推算水平繪製。",
    ),
    "%lld percent, modeled": ("百分之 %lld，模型推算", "百分之 %lld，模型推算"),
    "A benzodiazepine amount in diazepam, per Ashton": (
        "按 Ashton 换算成地西泮的苯二氮䓬用量",
        "依 Ashton 換算成地西泮的苯二氮平類用量",
    ),
    "A fast within-session fade, plus a modest, slower shift with heavy use. The effect on the heart fades far less than the felt effect.": (
        "场次内的快速衰减，加上重度使用时幅度不大、更慢的变化。对心脏的作用衰减远小于主观感受到的作用。",
        "場次內的快速衰減，加上重度使用時幅度不大、更慢的變化。對心臟的作用衰減遠小於主觀感受到的作用。",
    ),
    "A heads-up when your 12-hour total of one substance reaches the heavy range listed in its sources.": (
        "当某一物质 12 小时内的累计量达到其来源列出的大剂量区间时提醒你。",
        "當某一物質 12 小時內的累計量達到其來源列出的大劑量區間時提醒你。",
    ),
    "A modeled relative load from your logged doses. It models receptor drive, not how you feel.": (
        "根据你记录的剂量推算出的相对负荷。它推算的是受体驱动，不是你的感受。",
        "根據你記錄的劑量推算出的相對負荷。它推算的是受體驅動，不是你的感受。",
    ),
    "A record and a model, not medical advice. Exposure uses published equivalents where they exist, and the substance's typical dose otherwise.": (
        "这是一份记录和一个模型，不是医疗建议。暴露量在有已发表等效换算时采用该换算，否则采用该物质的典型剂量。",
        "這是一份紀錄和一個模型，不是醫療建議。暴露量在有已發表等效換算時採用該換算，否則採用該物質的典型劑量。",
    ),
    "A reminder at each time you set for a med. Tapping it opens Quick Log with that time's meds staged.": (
        "在你为药物设定的每个时间提醒你。点按提醒会打开快捷记录，并预先载入该时间的药物。",
        "在你為藥物設定的每個時間提醒你。點按提醒會開啟快捷記錄，並預先載入該時間的藥物。",
    ),
    "A second dose soon after the first has a weaker effect because the fast-releasing pool has been reduced (tachyphylaxis). It refills overnight, so this differs from the slower tolerance below.": (
        "第一剂后不久补服，效果会更弱，因为快速释放的储备已减少（快速耐受）。这部分储备会在一夜间补充，因此与下方变化较慢的耐受不同。",
        "第一劑後不久補服，效果會更弱，因為快速釋放的儲備已減少（快速耐受）。這部分儲備會在一夜間補充，因此與下方變化較慢的耐受不同。",
    ),
    "A wind-down reminder late into long stimulant sessions.": (
        "在长时间兴奋剂场次的后段提醒你收尾。",
        "在長時間興奮劑場次的後段提醒你收尾。",
    ),
    "Add a note...": ("添加备注…", "新增備註…"),
    "Added drowsiness and next-day grogginess, with more fall and coordination risk. The labels warn about combining with other CNS depressants, opioids included.": (
        "会更困倦、次日更昏沉，跌倒和协调性风险也更高。说明书警告不要与包括阿片类在内的其他中枢神经抑制剂合用。",
        "會更睏倦、次日更昏沉，跌倒和協調性風險也更高。說明書警告不要與包括鴉片類在內的其他中樞神經抑制劑併用。",
    ),
    "Additive sedation and next-day grogginess — more drowsiness, dizziness, and fall risk.": (
        "镇静与次日昏沉相叠加——更困、更晕，跌倒风险更高。",
        "鎮靜與次日昏沉相疊加——更睏、更暈，跌倒風險更高。",
    ),
    "Adds up sedation and lowers blood pressure further — stronger drowsiness and dizziness.": (
        "镇静叠加，血压进一步降低——困倦和头晕更强。",
        "鎮靜疊加，血壓進一步降低——睏倦和頭暈更強。",
    ),
    "After a break or in a new setting, tolerance drops — a dose that felt fine before can stop your breathing.": (
        "停用一段时间后，或换了环境，耐受会下降——以前没事的剂量可能让你停止呼吸。",
        "停用一段時間後，或換了環境，耐受會下降——以前沒事的劑量可能讓你停止呼吸。",
    ),
    "After regular use, stopping abruptly can be dangerous.": (
        "规律使用后，突然停用可能有危险。",
        "規律使用後，突然停用可能有危險。",
    ),
    "All substance data ships with the app. Reorder sources to choose which one wins when they disagree on a fact.": (
        "所有物质数据都随应用一起附带。调整来源顺序，即可决定它们对同一事实有分歧时以哪一个为准。",
        "所有物質資料都隨 App 一起附帶。調整來源順序，即可決定它們對同一事實有分歧時以哪一個為準。",
    ),
    "Barely builds tolerance; stopping suddenly can make blood pressure rebound hard.": (
        "几乎不产生耐受；突然停用可能让血压强烈反弹。",
        "幾乎不產生耐受；突然停用可能讓血壓強烈反彈。",
    ),
    "Barely builds tolerance; stopping suddenly can make heart rate and blood pressure rebound.": (
        "几乎不产生耐受；突然停用可能让心率和血压反弹。",
        "幾乎不產生耐受；突然停用可能讓心率和血壓反彈。",
    ),
    "Biomedical literature index.": ("生物医学文献索引。", "生物醫學文獻索引。"),
    "Both cause drowsiness — additive next-day sedation and grogginess.": (
        "两者都会引起困倦——次日的镇静和昏沉会叠加。",
        "兩者都會引起睏倦——次日的鎮靜和昏沉會疊加。",
    ),
    "CDC excludes buprenorphine from MME.": (
        "CDC 未将丁丙诺啡纳入 MME。",
        "CDC 未將丁基原啡因納入 MME。",
    ),
    "Change what Piru can see anytime in the Health app's settings.": (
        "你随时可以在“健康”App 的设置中更改 Piru 能看到的内容。",
        "你隨時可以在「健康」App 的設定中更改 Piru 能看到的內容。",
    ),
    "Chinese-language community wiki.": ("中文社区维基。", "中文社群維基。"),
    "Commonly reported with this class. A severe tremor, or one that comes with confusion or a high temperature, is a reason to get help now.": (
        "该类药物常有这种报告。严重的震颤，或伴随意识混乱、高热的震颤，应当立刻求助。",
        "該類藥物常有這種回報。嚴重的顫抖，或伴隨意識混亂、高燒的顫抖，應當立刻求助。",
    ),
    "Community database.": ("社区数据库。", "社群資料庫。"),
    "Community database. TripSit's combination data is a quick overview; research each combination further.": (
        "社区数据库。TripSit 的组合数据只是快速概览；请对每一种组合再作查证。",
        "社群資料庫。TripSit 的組合資料只是快速概覽；請對每一種組合再作查證。",
    ),
    "Community encyclopedia.": ("社区百科。", "社群百科。"),
    "Connect Apple Health to show your heart rate on the graph beside your entries.": (
        "连接 Apple Health，即可在条目旁的图表上显示你的心率。",
        "連接 Apple Health，即可在項目旁的圖表上顯示你的心率。",
    ),
    "Content outside those licenses — quotations from published books, manufacturers' label text, and figures from reference tables — belongs to its owners, and is shown for reference under their terms. Piru makes no claim to the correctness of any source.": (
        "这些许可之外的内容——引自出版书籍的段落、生产商的说明书文本、参考表格中的数值——归其所有者所有，并按其条款在此供参考。Piru 不对任何来源的正确性作任何主张。",
        "這些授權之外的內容——引自出版書籍的段落、製造商的說明書文字、參考表格中的數值——歸其所有者所有，並按其條款在此供參考。Piru 不對任何來源的正確性作任何主張。",
    ),
    "Created when you ask and saved where you choose. Exports are unencrypted unless you choose an encrypted backup.": (
        "由你发起创建，保存到你选择的位置。除非你选择加密备份，否则导出的文件不加密。",
        "由你發起建立，儲存到你選擇的位置。除非你選擇加密備份，否則匯出的檔案不加密。",
    ),
    "Data from dose.wiki, Wikidata and openFDA.": (
        "数据来自 dose.wiki、Wikidata 和 openFDA。",
        "資料來自 dose.wiki、Wikidata 和 openFDA。",
    ),
    "Data from published literature, product labels, and community databases, provided as is and without warranty. Not medical advice.": (
        "数据来自已发表文献、产品说明书和社区数据库，按原样提供，不附带任何保证。不是医疗建议。",
        "資料來自已發表文獻、產品說明書和社群資料庫，按原樣提供，不附帶任何保證。不是醫療建議。",
    ),
    "Details are in Settings under About Piru.": (
        "详情见“设置”中的“关于 Piru”。",
        "詳情見「設定」中的「關於 Piru」。",
    ),
    "Diazepam Equivalence": ("地西泮等效量", "地西泮等效量"),
    "Dosing shown reflects published or community protocols, not medical advice. Peptides are injected from reconstituted powder — handle and store as noted below.": (
        "此处所示剂量反映的是已发表或社区的方案，不是医疗建议。肽类由复溶的粉末注射——请按下文说明处理和储存。",
        "此處所示劑量反映的是已發表或社群的方案，不是醫療建議。胜肽由復溶的粉末注射——請按下文說明處理和儲存。",
    ),
    "Each substance page names the source of each field. Text from PsychonautWiki and FreeOD Wiki is used under CC BY-SA 4.0, edited and merged with other sources, and remains available under that license.": (
        "每个物质页面都会标明每个字段的来源。来自 PsychonautWiki 和 FreeOD Wiki 的文本依 CC BY-SA 4.0 使用，经编辑并与其他来源合并，并继续依该许可提供。",
        "每個物質頁面都會標明每個欄位的來源。來自 PsychonautWiki 和 FreeOD Wiki 的文字依 CC BY-SA 4.0 使用，經編輯並與其他來源合併，並繼續依該授權提供。",
    ),
    "Encrypted exports turn your passphrase into a key with 600,000 rounds of PBKDF2. Piru keeps no copy of the passphrase and cannot recover it. Plain exports are unencrypted.": (
        "加密导出会用 600,000 轮 PBKDF2 把你的口令转换成密钥。Piru 不保存口令的副本，也无法找回。普通导出不加密。",
        "加密匯出會用 600,000 輪 PBKDF2 把你的通行碼轉換成金鑰。Piru 不保存通行碼的副本，也無法找回。一般匯出不加密。",
    ),
    "European Union agency publications.": ("欧盟机构出版物。", "歐盟機構出版品。"),
    "Everything Piru stores in the app on this device. Device and iCloud backups made by your settings include it.": (
        "Piru 在本设备的应用内存储的全部内容。按你的设置所做的设备备份和 iCloud 备份也会包含它。",
        "Piru 在本裝置的 App 內儲存的全部內容。按你的設定所做的裝置備份和 iCloud 備份也會包含它。",
    ),
    "Expert committee reviews.": ("专家委员会评审。", "專家委員會審查。"),
    "Export sessions and journal summaries": (
        "导出场次和日记摘要",
        "匯出場次和日記摘要",
    ),
    "GRDB.swift. Copyright © Gwendal Roué.": (
        "GRDB.swift。版权所有 © Gwendal Roué。",
        "GRDB.swift。版權所有 © Gwendal Roué。",
    ),
    "Help is available through the numbers in Get Help.": (
        "可以通过“获取帮助”中的电话号码求助。",
        "可以透過「取得協助」中的電話號碼求助。",
    ),
    "How Modeled Tolerance Works": ("模型推算耐受的原理", "模型推算耐受的原理"),
    "How much is estimated to be in your body, using only data from this session.": (
        "仅用本场次的数据估算出的体内存量。",
        "僅用本場次的資料估算出的體內存量。",
    ),
    "If you have been drinking heavily and daily for weeks, stopping abruptly can be dangerous — seizures and delirium tremens peak 2–4 days after the last drink.": (
        "如果你已经连续数周每日大量饮酒，突然停酒可能有危险——癫痫发作和震颤谵妄在最后一次饮酒后 2–4 天达到高峰。",
        "如果你已經連續數週每日大量飲酒，突然停酒可能有危險——癲癇發作和震顫譫妄在最後一次飲酒後 2–4 天達到高峰。",
    ),
    "Journal Summary": (
        "日记摘要",
        "日記摘要",
    ),
    "Licenses": ("许可", "授權"),
    "Likely to matter": ("可能有影响", "可能有影響"),
    "Logged, but the model has no data for these, so they are left out: %@.": (
        "已记录，但模型没有这些的数据，因此未计入：%@。",
        "已記錄，但模型沒有這些的資料，因此未計入：%@。",
    ),
    "Meds, by class.": ("药物，按类别。", "藥物，依類別。"),
    "Methadone's half-life is long and variable, and its effect on breathing peaks later than its pain relief. CDC publishes a single population factor for it; Piru shows no figure.": (
        "美沙酮的半衰期长且变异大，它对呼吸的作用峰值晚于镇痛的峰值。CDC 只为它发布了一个群体换算系数；Piru 不显示数值。",
        "美沙冬的半衰期長且變異大，它對呼吸的作用峰值晚於止痛的峰值。CDC 只為它發布了一個族群換算係數；Piru 不顯示數值。",
    ),
    "Modeled": ("模型推算", "模型推算"),
    "Modeled Tolerance": ("模型推算耐受", "模型推算耐受"),
    "Modeled Tolerance & Receptors": ("模型推算耐受与受体", "模型推算耐受與受體"),
    "Modeled as Active": (
        "模型估计仍在起效",
        "模型估計仍在起效",
    ),
    "Modeled combined load across your logged GABAergics, relative to your recent peak.": (
        "你记录的 GABA 能物质的模型推算合并负荷，相对于你近期的峰值。",
        "你記錄的 GABA 能物質的模型推算合併負荷，相對於你近期的峰值。",
    ),
    "Modeled combined load across your logged GABAergics, relative to your recent peak. Alcohol is included; it loads the receptor at a different site.": (
        "你记录的 GABA 能物质的模型推算合并负荷，相对于你近期的峰值。酒精也计入其中；它作用于受体的另一个位点。",
        "你記錄的 GABA 能物質的模型推算合併負荷，相對於你近期的峰值。酒精也計入其中；它作用於受體的另一個位點。",
    ),
    "Modeled combined load relative to your recent peak, about %lld percent now.": (
        "相对于你近期峰值的模型推算合并负荷，现在约为百分之 %lld。",
        "相對於你近期峰值的模型推算合併負荷，目前約為百分之 %lld。",
    ),
    "Modeled from receptor occupancy · %@.": (
        "由受体占有率模型推算 · %@。",
        "由受體佔有率模型推算 · %@。",
    ),
    "Modeled receptor load": ("模型推算受体负荷", "模型推算受體負荷"),
    "Modeled tolerance": ("模型推算耐受", "模型推算耐受"),
    "Modeled tolerance by mechanism": ("按机制分的模型推算耐受", "按機制分的模型推算耐受"),
    "Modeled tolerance over time": ("模型推算耐受随时间的变化", "模型推算耐受隨時間的變化"),
    "Name (Optional)": ("名称（可选）", "名稱（選填）"),
    "No account": ("无需账户", "無需帳號"),
    "No ads or trackers": ("无广告、无追踪器", "無廣告、無追蹤程式"),
    "No dosing is shown here. What follows is for recognition and reference only.": (
        "此处不显示剂量。以下内容仅供辨识和参考。",
        "此處不顯示劑量。以下內容僅供辨識和參考。",
    ),
    "No sign-up, and no Piru server that receives your journal.": (
        "无需注册，也没有任何接收你日记的 Piru 服务器。",
        "無需註冊，也沒有任何接收你日記的 Piru 伺服器。",
    ),
    "Not modeled": ("未纳入模型", "未納入模型"),
    "Nothing in Piru encourages or facilitates the use, acquisition or possession of any substance, and you alone are responsible for complying with the laws that apply to you. Piru is for adults 18 and over. Use of Piru is subject to the Terms of Use.": (
        "Piru 中没有任何内容鼓励或便利任何物质的使用、获取或持有，遵守适用于你的法律完全由你自己负责。Piru 供 18 岁及以上的成年人使用。使用 Piru 须遵守《使用条款》。",
        "Piru 中沒有任何內容鼓勵或便利任何物質的使用、取得或持有，遵守適用於你的法律完全由你自己負責。Piru 供 18 歲及以上的成年人使用。使用 Piru 須遵守《使用條款》。",
    ),
    "Nothing modeled.": ("没有模型推算的内容。", "沒有模型推算的內容。"),
    "Open chemistry database.": ("开放化学数据库。", "開放化學資料庫。"),
    "Open knowledge base.": ("开放知识库。", "開放知識庫。"),
    "Other sources are listed above under their own terms, and each substance page names the source of each field.": (
        "其他来源已在上方按各自条款列出，每个物质页面也会标明每个字段的来源。",
        "其他來源已在上方按各自條款列出，每個物質頁面也會標明每個欄位的來源。",
    ),
    "Piru can't tell temporary confusion from a serious symptom. Confusion that deepens, or comes with a high temperature, is a reason to get help now.": (
        "Piru 无法判断意识混乱是一时的不适还是严重症状。不断加重的意识混乱，或伴随高热时，应当立刻求助。",
        "Piru 無法判斷意識混亂是一時的不適還是嚴重症狀。不斷加重的意識混亂，或伴隨高燒時，應當立刻求助。",
    ),
    "Piru is a personal record and a general reference, provided as is and without warranty of any kind. It is not medical advice and not a medical device, and it is not for diagnosis, treatment, dosing decisions or emergencies.": (
        "Piru 是一份个人记录和一份通用参考，按原样提供，不附带任何形式的保证。它不是医疗建议，也不是医疗器械，不用于诊断、治疗、剂量决策或紧急情况。",
        "Piru 是一份個人紀錄和一份通用參考，按原樣提供，不附帶任何形式的保證。它不是醫療建議，也不是醫療器材，不用於診斷、治療、劑量決策或緊急情況。",
    ),
    "Piru's source code.": ("Piru 的源代码。", "Piru 的原始碼。"),
    "Reference content is compiled from third-party, community and curated sources and may be incomplete, outdated or wrong. Every curve, level and estimate is an illustrative model, not a measurement.": (
        "参考内容汇编自第三方、社区和人工整理的来源，可能不完整、已过时或有误。每一条曲线、每一个水平和每一项估算都是示意性的模型，不是测量值。",
        "參考內容彙編自第三方、社群和人工整理的來源，可能不完整、已過時或有誤。每一條曲線、每一個水平和每一項估算都是示意性的模型，不是測量值。",
    ),
    "Reference only": ("仅供参考", "僅供參考"),
    "Reference text by Alexander and Ann Shulgin.": (
        "参考文本由 Alexander 和 Ann Shulgin 撰写。",
        "參考文字由 Alexander 和 Ann Shulgin 撰寫。",
    ),
    "Regular use over weeks builds physical dependence — stopping abruptly can be dangerous even if you don't feel tolerant.": (
        "连续数周规律使用会形成躯体依赖——即使你感觉不到耐受，突然停用也可能有危险。",
        "連續數週規律使用會形成生理依賴——即使你感覺不到耐受，突然停用也可能有危險。",
    ),
    "Repeated vomiting that only hot showers relieve is a recognized syndrome.": (
        "反复呕吐、且只有热水澡能缓解，是一种已被认识的综合征。",
        "反覆嘔吐、且只有熱水澡能緩解，是一種已被認識的症候群。",
    ),
    "Replacing your data on restore takes a recoverable snapshot first.": (
        "恢复时替换你的数据之前，会先做一份可恢复的快照。",
        "還原時取代你的資料之前，會先做一份可還原的快照。",
    ),
    "Restores keep a snapshot": ("恢复会保留快照", "還原會保留快照"),
    "Risk of fatal serotonin syndrome — MAOIs block the enzyme that clears the serotonin an empathogen releases.": (
        "有致命的血清素综合征风险——MAOI 会阻断清除共情剂所释放血清素的酶。",
        "有致命的血清素症候群風險——MAOI 會阻斷清除共情劑所釋放血清素的酵素。",
    ),
    "Serotonin syndrome — potentially fatal. MAOIs block the enzyme that clears serotonin.": (
        "血清素综合征——可能致命。MAOI 会阻断清除血清素的酶。",
        "血清素症候群——可能致命。MAOI 會阻斷清除血清素的酵素。",
    ),
    "Serotonin syndrome — potentially fatal. The labels require a washout of weeks between them.": (
        "血清素综合征——可能致命。说明书要求两者之间有数周的洗脱期。",
        "血清素症候群——可能致命。說明書要求兩者之間有數週的沖洗期。",
    ),
    "Show your body weight and heart rate from Health alongside your journal entries, on the session timeline.": (
        "在场次时间线上，把“健康”中的体重和心率与你的日记记录并排显示。",
        "在場次時間軸上，把「健康」中的體重和心率與你的日記記錄並排顯示。",
    ),
    "Shows your body weight, heart rate, blood pressure and workouts from Health alongside your journal. Change what Piru can see in the Health app's settings.": (
        "把“健康”中的体重、心率、血压和锻炼与你的日记并排显示。可在“健康”App 的设置中更改 Piru 能看到的内容。",
        "把「健康」中的體重、心率、血壓和體能訓練與你的日記並排顯示。可在「健康」App 的設定中更改 Piru 能看到的內容。",
    ),
    "Shows your heart rate and blood pressure on each session's timeline. If something didn't connect — blood pressure especially, which iOS doesn't always prompt for — open **Settings ▸ Privacy & Security ▸ Health ▸ Piru** and turn it on there.": (
        "在每个场次的时间线上显示你的心率和血压。如果有项目没连上——尤其是血压，iOS 并不总会为它弹出询问——请打开 **设置 ▸ 隐私与安全性 ▸ 健康 ▸ Piru**，在那里开启。",
        "在每個場次的時間軸上顯示你的心率和血壓。如果有項目沒連上——尤其是血壓，iOS 並不總會為它跳出詢問——請開啟 **設定 ▸ 隱私權與安全性 ▸ 健康 ▸ Piru**，在那裡開啟。",
    ),
    "Sit or lie down so a fall can't happen. Fainting, or dizziness with chest pain, is a reason to get help now.": (
        "坐下或躺下，让摔倒无从发生。昏厥，或头晕伴胸痛，应当立刻求助。",
        "坐下或躺下，讓摔倒無從發生。昏厥，或頭暈伴胸痛，應當立刻求助。",
    ),
    "Stopping a beta-blocker abruptly after regular use can make heart rate and blood pressure rebound.": (
        "规律使用后突然停用 β 受体阻滞剂，可能让心率和血压反弹。",
        "規律使用後突然停用 β 阻斷劑，可能讓心率和血壓反彈。",
    ),
    "Stopping an α₂-agonist abruptly after regular use can make blood pressure rebound.": (
        "规律使用后突然停用 α₂ 激动剂，可能让血压反弹。",
        "規律使用後突然停用 α₂ 促效劑，可能讓血壓反彈。",
    ),
    "Stopping the clonidine-type drug suddenly while on a beta-blocker can spike blood pressure to dangerous levels.": (
        "在使用 β 受体阻滞剂期间突然停用可乐定类药物，可能让血压飙升到危险水平。",
        "在使用 β 阻斷劑期間突然停用可樂定類藥物，可能讓血壓飆升到危險水準。",
    ),
    "Stored in the app on this device, and in any device or iCloud backup your settings make of it. Anyone who can unlock the device can read it.": (
        "存储在本设备的应用内，以及你的设置为它所做的任何设备备份或 iCloud 备份中。任何能解锁这台设备的人都能读到它。",
        "儲存在本裝置的 App 內，以及你的設定為它所做的任何裝置備份或 iCloud 備份中。任何能解鎖這台裝置的人都能讀到它。",
    ),
    "Strong and fast: a repeat exposure soon after has much less effect. Resets within a few days.": (
        "又强又快：不久之后再次接触，效果会弱得多。几天内恢复。",
        "又強又快：不久之後再次接觸，效果會弱得多。幾天內恢復。",
    ),
    "Subjective-effects vocabulary.": ("主观效应词表。", "主觀效應詞表。"),
    "Terms of Use": ("使用条款", "使用條款"),
    "Text from PsychonautWiki and FreeOD Wiki, as edited and merged in Piru.": (
        "来自 PsychonautWiki 和 FreeOD Wiki 的文本，经 Piru 编辑并合并。",
        "來自 PsychonautWiki 和 FreeOD Wiki 的文字，經 Piru 編輯並合併。",
    ),
    "The SubFxOnEx effects vocabulary. Copyright © Di-lemma.": (
        "SubFxOnEx 效应词表。版权所有 © Di-lemma。",
        "SubFxOnEx 效應詞表。版權所有 © Di-lemma。",
    ),
    "The modeled level from now, fading over the days shown.": (
        "从现在起的模型推算水平，在所示的天数内逐渐衰减。",
        "從現在起的模型推算水平，在所示的天數內逐漸衰減。",
    ),
    "This class can block the signal to the bladder. Not being able to pass urine at all is a reason to get help now rather than wait for the timeline.": (
        "该类药物可能阻断通往膀胱的信号。完全排不出尿，应当立刻求助，而不是等时间线走完。",
        "該類藥物可能阻斷通往膀胱的訊號。完全排不出尿，應當立刻求助，而不是等時間軸走完。",
    ),
    "This deletes your journal, profile, schedules, inventory, custom presets and local recovery copies. Your Watch clears its copy when it reconnects. Exported files, Apple Health records and device backups are not affected.": (
        "这会删除日志、个人资料、计划、库存、自定义预设和本地恢复副本。Watch 会在重新连接后清除其副本。已导出的文件、Apple 健康记录和设备备份不受影响。",
        "這會刪除日誌、個人資料、排程、庫存、自訂預設和本機復原副本。Watch 會在重新連線後清除其副本。已匯出的檔案、Apple 健康記錄和裝置備份不受影響。",
    ),
    "Tolerance plus physical dependence; stopping abruptly after heavy regular use can be dangerous.": (
        "既有耐受，也有躯体依赖；长期大量规律使用后突然停用可能有危险。",
        "既有耐受，也有生理依賴；長期大量規律使用後突然停用可能有危險。",
    ),
    "Total taken this range, in each substance's common-dose unit": (
        "本区间的总摄入量，以各物质的常用剂量单位计",
        "本區間的總攝入量，以各物質的常用劑量單位計",
    ),
    "Transdermal fentanyl is dosed in micrograms per hour, a rate rather than a mass, so it has no figure in this mg-based table.": (
        "透皮芬太尼按每小时微克计量，是速率而不是质量，因此在这张以 mg 为基准的表格中没有数值。",
        "經皮吩坦尼按每小時微克計量，是速率而不是質量，因此在這張以 mg 為基準的表格中沒有數值。",
    ),
    "U.S. government open data.": ("美国政府开放数据。", "美國政府開放資料。"),
    "U.S. product label database. Label text is written by each manufacturer.": (
        "美国产品说明书数据库。说明书文本由各生产商撰写。",
        "美國產品說明書資料庫。說明書文字由各製造商撰寫。",
    ),
    "Unlikely to dominate": ("不太可能占主导", "不太可能佔主導"),
    "Used only when you connect it, for display beside your journal.": (
        "仅在你连接之后使用，用于在你的日记旁显示。",
        "僅在你連接之後使用，用於在你的日記旁顯示。",
    ),
    "Water reminders timed from your entry.": (
        "以你的条目时间为起点的饮水提醒。",
        "以你的項目時間為起點的喝水提醒。",
    ),
    "Where your journal lives": (
        "你的日记存放在哪里",
        "你的日記存放在哪裡",
    ),
    "With daily phenibut or F-phenibut, dependence develops within weeks and withdrawal can be protracted.": (
        "每日使用苯尼布特或 F-苯尼布特，数周内就会形成依赖，戒断可能迁延很久。",
        "每日使用苯尼布特或 F-苯尼布特，數週內就會形成依賴，戒斷可能遷延很久。",
    ),
    "Your entries, your meds and dose trends, as one document": (
        "你的条目、你的药物和剂量趋势，汇为一份文档",
        "你的項目、你的藥物和劑量趨勢，彙為一份文件",
    ),
    "Your journal is stored in the app on this device.": (
        "你的日记存储在本设备的应用内。",
        "你的日記儲存在本裝置的 App 內。",
    ),
    "substance.wiki": ("substance.wiki", "substance.wiki"),
    "swift-collections and swift-async-algorithms. Copyright © Apple Inc. and the Swift project authors.": (
        "swift-collections 和 swift-async-algorithms。版权所有 © Apple Inc. 和 Swift 项目作者。",
        "swift-collections 和 swift-async-algorithms。版權所有 © Apple Inc. 和 Swift 專案作者。",
    ),
    "Record an entry": ("添加记录", "新增記錄"),
    "Add an entry": ("添加记录", "新增記錄"),
    "Remove entry": ("移除记录", "移除記錄"),
    "Discard Entries": ("放弃记录", "捨棄記錄"),
    "Move Entries": ("移动记录", "移動記錄"),
    "Move Entries…": ("移动记录…", "移動記錄…"),
    "Recent Entries (24h)": ("最近记录（24 小时）", "最近記錄（24 小時）"),
    "Record your first entry": ("添加第一条记录", "新增第一筆記錄"),
    "No active entries": ("暂无活跃记录", "目前沒有活躍記錄"),
    "No entries yet": ("暂无记录", "目前沒有記錄"),
    "No recent entries": ("暂无近期记录", "目前沒有近期記錄"),
    "No entries recorded yet": ("尚未添加记录", "尚未新增記錄"),
    "Last Entry": ("最近记录", "最近記錄"),
    "1 entry": ("1 条记录", "1 筆記錄"),
    "Show %lld latest entries": ("显示最近 %lld 条记录", "顯示最近 %lld 筆記錄"),
    "Show %lld more entries": ("再显示 %lld 条记录", "再顯示 %lld 筆記錄"),
    "Record %lld Entries": ("添加 %lld 条记录", "新增 %lld 筆記錄"),
    "Adds a note to this entry": ("为这条记录添加笔记", "為這筆記錄新增筆記"),
    "Adds this entry": ("添加这条记录", "新增這筆記錄"),
    "Records this entry": ("保存这条记录", "儲存這筆記錄"),
    "Removes this entry": ("移除这条记录", "移除這筆記錄"),
    "Shows the remaining entries": ("显示其余记录", "顯示其餘記錄"),
    "Pick an entry to move to another session.": (
        "选择要移到其他场次的记录。",
        "選擇要移到其他場次的記錄。",
    ),
    "Move this entry to a separate session.": (
        "将这条记录移到单独的场次。",
        "將這筆記錄移到獨立的場次。",
    ),
    "Combine Repeated Entries": ("合并重复记录", "合併重複記錄"),
    "Combine repeated entries for the same substance into one curve. When off, each entry has its own curve.": (
        "将同一物质的重复记录合并为一条曲线。关闭时，每条记录各有一条曲线。",
        "將同一物質的重複記錄合併為一條曲線。關閉時，每筆記錄各有一條曲線。",
    ),
    "Entries before this hour count toward the previous day. Set to 12 AM for standard calendar days.": (
        "此时间之前的记录计入前一天。设为 12 AM 即按标准日历日。",
        "此時間之前的記錄計入前一天。設為 12 AM 即按標準日曆日。",
    ),
    "Entries recorded per day over the past two weeks": (
        "过去两周每天添加的记录",
        "過去兩週每天新增的記錄",
    ),
    "See the entries in your current session.": ("查看当前场次的记录。", "查看目前場次的記錄。"),
    "See your most recent entry and when it was recorded.": (
        "查看最近一条记录及其时间。",
        "查看最近一筆記錄及其時間。",
    ),
    "Record an entry to start your first session.": (
        "添加记录，开始第一场。",
        "新增記錄，開始第一場。",
    ),
    "Your timeline will appear here after your first entry.": (
        "添加第一条记录后，时间线会显示在这里。",
        "新增第一筆記錄後，時間線會顯示在這裡。",
    ),
    "Add entries to see your patterns.": ("添加记录以查看规律。", "新增記錄以查看規律。"),
    "Add entries to see modeled levels over time.": (
        "添加记录以查看模型估计的水平变化。",
        "新增記錄以查看模型估計的水平變化。",
    ),
    "Add entries to see modeled receptor load.": (
        "添加记录以查看模型估计的受体负荷。",
        "新增記錄以查看模型估計的受體負荷。",
    ),
    "Each entry appears on the timeline, showing overlaps and when the model estimates the effects will fade.": (
        "每条记录都会显示在时间线上，呈现重叠情况和模型估计的效应消退时间。",
        "每筆記錄都會顯示在時間線上，呈現重疊情況和模型估計的效應消退時間。",
    ),
    "Tap the + button to record your first entry. Tips explain the other features as you use them.": (
        "点按 + 按钮添加第一条记录。使用其他功能时会有提示说明。",
        "點按 + 按鈕新增第一筆記錄。使用其他功能時會有提示說明。",
    ),
    "Based only on the entries in your journal.": (
        "仅根据日记中的记录估计。",
        "僅根據日記中的記錄估計。",
    ),
    "Your entries sync between your iPhone and a paired Apple Watch.": (
        "你的记录会在 iPhone 和已配对的 Apple Watch 之间同步。",
        "你的記錄會在 iPhone 和已配對的 Apple Watch 之間同步。",
    ),
    "No restocks or entries yet.": ("尚无补货或使用记录。", "尚無補貨或使用記錄。"),
    "The quick time options in the “Now” menu when recording an entry.": (
        "添加记录时“现在”菜单中的快捷时间选项。",
        "新增記錄時「現在」選單中的快捷時間選項。",
    ),
    "Reported Dose Ranges": ("来源报告的剂量范围", "來源報告的劑量範圍"),
    "Entry Times": ("记录时间", "記錄時間"),
    "Session notifications use estimated timing from your entries.": (
        "场次通知使用根据记录估计的时间。",
        "場次通知使用根據記錄估計的時間。",
    ),
    "Cumulative amount warnings use your logged entries and reference ranges. Coverage is incomplete.": (
        "累计用量警告基于你的记录和参考范围，覆盖并不完整。",
        "累計用量警告基於你的記錄和參考範圍，涵蓋並不完整。",
    ),
    "Keep substances in a fixed order. When off, recording an entry moves its substance to the front.": (
        "保持物质顺序固定。关闭后，添加记录会将对应物质移到最前。",
        "保持物質順序固定。關閉後，新增記錄會將對應物質移到最前。",
    ),
    "Reminders and adherence tracking stop. Existing entries stay in your journal.": (
        "提醒和依从性追踪将停止。已有记录仍保留在日记中。",
        "提醒和依從性追蹤將停止。已有記錄仍保留在日記中。",
    ),
    "Checked off by an entry for the same substance and route.": (
        "添加同一物质、同一途径的记录即可勾选。",
        "新增同一物質、同一途徑的記錄即可勾選。",
    ),
    "These appear in the “When” menu when recording an entry, alongside Now and the full date picker. Swipe to remove, drag to reorder.": (
        "这些选项显示在添加记录时的“何时”菜单中，与“现在”和完整日期选择器并列。滑动移除，拖动排序。",
        "這些選項顯示在新增記錄時的「何時」選單中，與「現在」和完整日期選擇器並列。滑動移除，拖動排序。",
    ),
    "Deletes journal records, profile, schedules, inventory, custom presets and local recovery copies. Watch deletion takes effect when it reconnects.": (
        "删除日志记录、个人资料、计划、库存、自定义预设和本地恢复副本。Watch 上的删除会在重新连接后生效。",
        "刪除日誌記錄、個人資料、排程、庫存、自訂預設和本機復原副本。Watch 上的刪除會在重新連線後生效。",
    ),
    "Estimation": ("估算", "估算"),
    "Published benzodiazepine equivalence table": (
        "已发表的苯二氮䓬等效量表",
        "已發表的苯二氮平等效量表",
    ),
    "Published oral MME reference factors": (
        "已发表的口服 MME 参考系数",
        "已發表的口服 MME 參考係數",
    ),
    "Published equivalences are approximate and vary between sources. A prescriber must assess any medication change.": (
        "已发表的等效量均为近似值，不同来源之间可能存在差异。任何用药调整都须由处方医生评估。",
        "已發表的等效量均為近似值，不同來源之間可能存在差異。任何用藥調整都須由處方醫師評估。",
    ),
    "Reference table": ("参考表", "參考表"),
    "Ashton Manual, Table 1": ("《Ashton 手册》，表 1", "《Ashton 手冊》，表 1"),
    "Published oral morphine milligram equivalent (MME) factors compare amounts across opioids. They must not be used to choose a replacement dose when switching medications.": (
        "已发表的口服吗啡毫克当量（MME）系数用于比较不同阿片类药物的用量。换药时不得用这些系数确定替代剂量。",
        "已發表的口服嗎啡毫克當量（MME）係數用於比較不同鴉片類藥物的用量。換藥時不得用這些係數確定替代劑量。",
    ),
    "CDC 2022 reference factors. Individual response varies.": (
        "CDC 2022 年参考系数。个体反应存在差异。",
        "CDC 2022 年參考係數。個體反應存在差異。",
    ),
    "%@ MME per mg": ("每 mg 为 %@ MME", "每 mg 為 %@ MME"),
    "Feeling and energy estimated from this session": (
        "根据本场记录估计的感受与精力",
        "根據本場記錄估計的感受與精力",
    ),
    "Feeling and energy curves based on the entries this model supports.": (
        "根据模型支持的记录估计感受与精力曲线。",
        "根據模型支援的記錄估計感受與精力曲線。",
    ),
    "Estimates become less reliable as more entries and substances are combined.": (
        "合并的记录和物质越多，估计结果越不可靠。",
        "合併的記錄和物質越多，估計結果越不可靠。",
    ),
    "Model estimates, not measurements of your response.": (
        "模型估计，并非对你实际反应的测量。",
        "模型估計，並非對你實際反應的測量。",
    ),
    "The model combines estimated stimulant, serotonin and opioid effects with an adaptation term. It uses changes in modeled dopamine activity to approximate the shape of the curve.": (
        "模型将估计的兴奋、血清素和阿片类效应与适应项结合，使用模拟的多巴胺活性变化近似绘制曲线。",
        "模型將估計的興奮、血清素和鴉片類效應與適應項結合，使用模擬的多巴胺活性變化近似繪製曲線。",
    ),
    "The model combines estimated activating and sedating effects over time.": (
        "模型结合随时间变化的激活与镇静效应估计。",
        "模型結合隨時間變化的活化與鎮靜效應估計。",
    ),
    "These curves illustrate model assumptions. They do not measure your feelings, energy, impairment or physical safety. Individual responses and combinations may differ substantially.": (
        "这些曲线用于展示模型假设，并不测量你的感受、精力、功能受损程度或身体安全状况。个体反应和组合效应可能有很大差异。",
        "這些曲線用於展示模型假設，並不測量你的感受、精力、功能受損程度或身體安全狀況。個體反應和組合效應可能有很大差異。",
    ),
    "Use your check-ins to record how you actually felt. Follow prescribed directions and consult a qualified healthcare professional before making medical decisions.": (
        "通过状态确认记下你的实际感受。请遵循处方说明，并在作出医疗决定前咨询合格的医疗专业人员。",
        "透過狀態確認記下你的實際感受。請遵循處方說明，並在作出醫療決定前諮詢合格的醫療專業人員。",
    ),
    "Below model threshold": ("低于模型阈值", "低於模型閾值"),
    "Below model threshold · active metabolite may persist": (
        "低于模型阈值 · 活性代谢物可能仍存在",
        "低於模型閾值 · 活性代謝物可能仍存在",
    ),
    "%lld%% eliminated in model · threshold ~%@": (
        "模型估计已消除 %lld%% · 约 %@ 低于阈值",
        "模型估計已消除 %lld%% · 約 %@ 低於閾值",
    ),
    "Favorite a substance or record an entry on your iPhone to find it here.": (
        "在 iPhone 上收藏物质或添加记录，即可在这里找到。",
        "在 iPhone 上收藏物質或新增記錄，即可在這裡找到。",
    ),
    "^[%lld entry](inflect: true) syncing": ("正在同步 %lld 条记录", "正在同步 %lld 筆記錄"),
    # Accessibility: timeline summary, fold state, Voice Control names
    "Hides the elimination curve": ("收起消除曲线", "收起消除曲線"),
    "Nothing active now": ("目前没有生效中的物质", "目前沒有作用中的物質"),
    "peak %@ to %@": ("高峰期 %1$@ 至 %2$@", "高峰期 %1$@ 至 %2$@"),
    "effects end around %@": ("效果约在 %@ 结束", "效果約在 %@ 結束"),
    "and %lld more": ("另有 %lld 条", "另有 %lld 筆"),
    "Next dose": ("下一次", "下一次"),
    "Record": ("记录", "記錄"),
    "Dose time": ("剂量时间", "劑量時間"),
    "Options": ("选项", "選項"),
    "Info": ("说明", "說明"),
    "Check %@": ("勾选 %@", "勾選 %@"),
    "Interval presets": ("常用间隔", "常用間隔"),
    "Ki ceiling": ("Ki 上限", "Ki 上限"),
    "New tag": ("新标签", "新標籤"),
}

# Widget translations
WT = {
    # Today's Meds interactive widget (2026-07-21).
    "Today's Meds": ("今日用药", "今日用藥"),
    "No meds today": ("今日无用药", "今日無用藥"),
    "All taken": (
        "全部已服用",
        "全部已服用",
    ),
    "That's everything today.": ("今天的都完成了。", "今天的都完成了。"),
    "Due · %@": ("待服用 · %@", "待服用 · %@"),
    "Take %@": ("服用 %@", "服用 %@"),
    "Take all supplements": ("服用全部补剂", "服用全部補劑"),
    "Take Med": ("服用用药", "服用用藥"),
    "Take Supplements": ("服用补剂", "服用補劑"),
    "Med identity": ("用药标识", "用藥識別"),
    "Logs one dose of a scheduled med.": ("记录一次计划内用药。", "記錄一次計劃內用藥。"),
    "Logs your remaining supplements for today.": (
        "记录你今天剩余的补剂。",
        "記錄你今天剩餘的補劑。",
    ),
    "See today's med schedule and take one right from the Home Screen.": (
        "查看今天的用药安排，并直接从主屏幕完成服用。",
        "查看今天的用藥安排，並直接從主畫面完成服用。",
    ),
    "Next Dose": ("下一剂", "下一劑"),
    "Countdown to your next scheduled med.": (
        "距离下一次计划用药的倒计时。",
        "距離下一次計畫用藥的倒計時。",
    ),
    "See how much you have left of what you track.": (
        "查看你追踪的物品还剩多少。",
        "查看你追蹤的物品還剩多少。",
    ),
    "Today": (
        "今天",
        "今天",
    ),
    "Today's Doses": ("今日剂量", "今日劑量"),
    "Last Dose": ("最近剂量", "最近劑量"),
    "No doses today": ("今日无剂量", "今日無劑量"),
    "No doses yet": ("尚无剂量", "尚無劑量"),
    "No recent doses": ("无最近剂量", "無最近劑量"),
    "See what you've taken today at a glance.": (
        "一眼查看今天服用了什么。",
        "一眼查看今天服用了什麼。",
    ),
    "See your most recent dose and how long ago it was.": (
        "查看最近的剂量及多久前服用。",
        "查看最近的劑量及多久前服用。",
    ),
    "%lld dose%@": ("%1$lld 个剂量", "%1$lld 個劑量"),
    "+%lld more": (
        "还有 %lld 项",
        "還有 %lld 項",
    ),
    "%lldm": ("%lld 分钟", "%lld 分鐘"),
    "%lldh %lldm": ("%1$lld 小时 %2$lld 分钟", "%1$lld 小時 %2$lld 分鐘"),
    "%@ %@": ("%@ %@", "%@ %@"),
    "%lld": ("%lld", "%lld"),
}

# Watch app strings. The watch has its own catalog; shared words ("Log",
# "Amount", "Favorite", …) are drawn from `T` so the two never disagree.
WATCH_T = {
    **{
        key: T[key]
        for key in (
            "Amount",
            "Volume",
            "Log",
            "Quick Log",
            "Drink",
            "Favorite",
            "Favorite a substance or record an entry on your iPhone to find it here.",
            "^[%lld entry](inflect: true) syncing",
            # Drink presets and dosing labels from the shared ByVolumeDosing.
            "Beer",
            "Wine",
            "Shot",
            "Pint",
            "By Mass",
            "By Volume",
            "Concentration",
            "Strength",
        )
    },
    "No Favorites Yet": ("还没有收藏", "還沒有收藏"),
    "No Drink Presets": ("没有饮品预设", "沒有飲品預設"),
    "Logged": ("已记录", "已記錄"),
    "Syncing to iPhone": ("正在同步到 iPhone", "正在同步到 iPhone"),
    "Decrease ABV": ("降低酒精度", "降低酒精度"),
    "Increase ABV": ("提高酒精度", "提高酒精度"),
    "%@%% ABV": ("%@%% 酒精度", "%@%% 酒精度"),
    "≈ %@ g · ≈ %@ drinks": ("≈ %1$@ g · ≈ %2$@ 标准杯", "≈ %1$@ g · ≈ %2$@ 標準杯"),
}


def serialize_catalog(data: dict) -> str:
    """Serialize a String Catalog byte-for-byte the way Xcode does, so a no-op
    run produces an empty `git diff`.

    Three details matter and none are json.dumps defaults:
    - `separators=(",", " : ")` — Xcode puts spaces around the key colon.
    - empty entries (extracted-but-untranslated, English-only keys) are written
      `"key" : {\\n\\n    }`, not the collapsed `{}` json emits.
    - NO trailing newline — Xcode ends the file on the closing brace.
    Get any of these wrong and the whole 20k-line file reformats.
    """
    text = json.dumps(
        data,
        indent=2,
        ensure_ascii=False,
        sort_keys=False,
        separators=(",", " : "),
    )
    return text.replace('" : {}', '" : {\n\n    }')


def apply_translations(
    catalog_path: Path,
    translations: dict,
    insert_keys: set | None = None,
    extra_languages: dict[str, dict[str, str]] | None = None,
):
    """Fill zh-Hans/zh-Hant for every catalog key present in `translations`,
    then every language in `extra_languages` ({"es": {English: Spanish}}) for
    every catalog key that language covers.

    By default this only UPDATES keys Xcode has already extracted — never adds
    new ones — so a catalog stays scoped to the strings its target actually
    references (the widget must not inherit all 1000+ app strings).

    `insert_keys` is an explicit allow-list of brand-new keys to insert when
    absent — for strings added from the CLI that Xcode hasn't extracted yet.
    Keep it to the handful you actually added; Xcode folds them into its
    collation order on the next open.
    """
    insert_keys = insert_keys or set()
    data = json.loads(catalog_path.read_text(encoding="utf-8"))
    strings = data.setdefault("strings", {})

    translated_count = 0
    added = []
    for key, (zh_hans, zh_hant) in translations.items():
        entry = strings.get(key)
        if entry is None:
            if key not in insert_keys:
                continue
            entry = {}
            strings[key] = entry
            added.append(key)
        locs = entry.setdefault("localizations", {})
        locs["zh-Hans"] = {"stringUnit": {"state": "translated", "value": zh_hans}}
        locs["zh-Hant"] = {"stringUnit": {"state": "translated", "value": zh_hant}}
        translated_count += 1

    # Languages authored as a flat English -> text dict. Update-only, like the
    # Chinese pass: a key the catalog lacks is skipped unless it is in
    # `insert_keys` (and then the Chinese loop above has already inserted it).
    for lang, table in (extra_languages or {}).items():
        for key, entry in strings.items():
            value = table.get(key)
            if value is None:
                continue
            locs = entry.setdefault("localizations", {})
            locs[lang] = {"stringUnit": {"state": "translated", "value": value}}

    # English-only keys still lacking a translation in T (informational).
    missing = [
        key
        for key, entry in strings.items()
        if key.strip() and "localizations" not in entry and key not in translations
    ]

    catalog_path.write_text(serialize_catalog(data), encoding="utf-8")
    return translated_count, added, missing


CANONICAL_LANGUAGES = ("zh-Hans", "zh-Hant", "es", "es-ES")


def canonicalize_catalogs(project_path: Path, languages=CANONICAL_LANGUAGES) -> bool:
    """Let Xcode re-collate every catalog key into its canonical order.

    Why this exists: `apply_translations` appends brand-new `insert_keys` to the
    end of the catalog (Python dict insertion order). Xcode's String Catalog
    editor stores keys in an ICU-collated order that we can't reproduce in
    Python and that `xcstringstool sync` mangles (it stales/drops live strings
    when invoked outside the build graph — see CLAUDE.md). So instead of sorting
    ourselves, we hand the catalog back to Xcode: an `xcodebuild
    -exportLocalizations` → `-importLocalizations` round-trip rewrites every
    project `.xcstrings` in Xcode's canonical order, byte-for-byte identical to
    what opening the catalog in the IDE produces. The round-trip is idempotent
    (a second pass is a no-op) and non-destructive (no keys dropped, stale marks
    and untranslated entries preserved), so committing its output stops the IDE
    from re-ordering the file on the next build.

    Returns True on success, False if xcodebuild isn't available or fails (in
    which case the script's own serialization is left in place untouched).
    """
    if not project_path.exists():
        print(f"  (skipped canonicalize: {project_path} not found)")
        return False

    with tempfile.TemporaryDirectory(prefix="piru-loc-") as tmp:
        tmp_path = Path(tmp)
        export = [
            "xcodebuild",
            "-exportLocalizations",
            "-project",
            str(project_path),
            "-localizationPath",
            str(tmp_path),
        ]
        for lang in languages:
            export += ["-exportLanguage", lang]

        result = subprocess.run(export, capture_output=True, text=True)
        if result.returncode != 0:
            print("  (canonicalize failed at export — leaving Python output in place)")
            print(result.stderr.strip()[-500:])
            return False

        for lang in languages:
            xcloc = tmp_path / f"{lang}.xcloc"
            if not xcloc.exists():
                print(f"  (canonicalize: no {xcloc.name} produced — skipping)")
                continue
            imp = subprocess.run(
                [
                    "xcodebuild",
                    "-importLocalizations",
                    "-project",
                    str(project_path),
                    "-localizationPath",
                    str(xcloc),
                ],
                capture_output=True,
                text=True,
            )
            if imp.returncode != 0:
                print(f"  (canonicalize failed at import of {lang})")
                print(imp.stderr.strip()[-500:])
                return False

    return True


sys.path.insert(0, str(Path(__file__).resolve().parent / "localization"))
try:
    from moa_translations import MOA_DESCRIPTIONS, MOA_SUMMARIES

    T.update(MOA_SUMMARIES)
    T.update(MOA_DESCRIPTIONS)
except ImportError:
    pass

try:
    from es_translations import ES, ES_ES
except ImportError:
    ES: dict[str, str] = {}
    ES_ES: dict[str, str] = {}

# `es` is neutral Spanish for every region. `es-ES` is authored as only the few
# strings Spain must see differently (the iOS Settings app is "Ajustes" there),
# but written out in full: iOS does NOT fall back per key from es-ES to es — a
# key missing from the es-ES table shows in English on a Spain iPhone.
EXTRA_LANGUAGES = {"es": ES, "es-ES": {**ES, **ES_ES}}

if __name__ == "__main__":
    project_root = Path(__file__).resolve().parent

    # Brand-new strings added from the CLI that Xcode hasn't extracted into the
    # catalog yet. List them here so they get inserted; clear once Xcode has
    # picked them up on a real build (after which they're update-only).
    NEW_KEYS: set[str] = {
        "English Substance Names",
        "Show substances by their English names instead of the names used in your language. Search finds both.",
        "None of the chosen substances have a modeled curve in this range",
        "Hides the elimination curve",
        "Nothing active now",
        "peak %@ to %@",
        "effects end around %@",
        "and %lld more",
        "Next dose",
        "Record",
        "Dose time",
        "Options",
        "Info",
        "Check %@",
        "Interval presets",
        "Ki ceiling",
        "New tag",
        "^[%lld interaction](inflect: true) detected",
        "Log ^[%lld Item](inflect: true)",
        "Couldn't save the report",
        # SubstanceCategory.classSummary (extractor-invisible LocalizedStringResource)
        "Agonists at the 5-HT2A receptor. That single action reshapes perception, thought and the sense of self; the family splits by chemistry — phenethylamines, tryptamines, and the ergolines LSD belongs to.",
        "Block the NMDA glutamate receptor, uncoupling perception from the body that reports it. The effect scales sharply with dose, from analgesia through anesthesia.",
        "Act at the κ-opioid receptor rather than 5-HT2A, which is why the experience is nothing like a classical psychedelic — dysphoric, disorienting, and usually brief.",
        "Block muscarinic acetylcholine receptors. Unlike psychedelics they produce true hallucinations — things that are not there and are not recognized as unreal — alongside amnesia and a narrow margin to toxicity.",
        "Agonists at the µ-opioid receptor: analgesia, warmth and sedation, and depressed breathing by the same mechanism. Tolerance to the first outpaces tolerance to the last, which is what makes the margin narrow.",
        "Positive allosteric modulators at GABA-A — they amplify the brain's own inhibitory signal rather than acting on their own. That ceiling is why they are relatively safe alone and dangerous with anything else that sedates.",
        "Bind the α2δ subunit of voltage-gated calcium channels, reducing excitatory transmitter release. Not GABAergic despite the name.",
        "Release serotonin, along with dopamine and noradrenaline — warmth, closeness and emotional openness rather than the perceptual change of a psychedelic. Most are amphetamines with a methylenedioxy ring.",
        "Act at the CB1 receptor. The phytocannabinoids are partial agonists with a natural ceiling; the synthetic ones are full agonists without it, which is the whole of the difference in risk.",
        "A functional grouping rather than a mechanistic one: compounds taken for cognition, with radically different pharmacology and, mostly, thin human evidence.",
        "Positive allosteric modulators of the AMPA glutamate receptor. The high-impact ones carry convulsant liability; the low-impact ones are safer and weaker.",
        "Promote wakefulness without the dopaminergic surge of a classical stimulant. Mechanism is still argued over; the effect is alertness without much euphoria.",
        "Slow central nervous system activity, mostly through GABA. Their doses add up with each other in a way that is easy to underestimate.",
        "Block the orexin receptors that hold wakefulness in place, rather than enhancing GABA. They add next-day sedation with other depressants but not brainstem respiratory depression.",
        "Raise serotonin, noradrenaline or dopamine signalling over weeks rather than hours. The class matters here mostly for what it blocks or stacks with.",
        "Block dopamine D2 receptors, and usually several serotonin receptors alongside. Sedating, and a common blunting agent for other substances.",
        "Block histamine H1 receptors. The first-generation ones cross into the brain and are strongly anticholinergic, which is why they sedate — and, in quantity, deliriate.",
        "Vitamins, minerals, amino acids and plant preparations. Pharmacologically a mixed bag, and the place where interactions are most often assumed to be absent.",
        "Short chains of amino acids acting at hormone or growth-factor receptors. Almost all are injected, and almost none have long-term human data.",
        "Damp excessive neuronal firing, by sodium-channel block, GABA enhancement or SV2A binding depending on the drug.",
        # Skins
        "Piru",
        "Soft pink, hot pink, liquid glass",
        "ely.pink",
        "Night and pink, stickers and pixels",
        "Tsuki",
        "Deep purple night, a sleeping moon",
        "Starfield",
        "Steel blue and gold under a thousand stars",
        "Jellyfish",
        "Deep water, bioluminescence, jellyfish",
        "Graphite",
        "Neutral grays, nothing moving",
        "Linen",
        "Warm paper and charcoal, quiet",
        "Slate",
        "Cool blue-gray, quiet",
        "Paper Garden",
        "Washi, raked sand, sakura",
        "Aurora",
        "Fireflies over a dark meadow",
        "Hanabi",
        "A night sky, five suits, fireworks",
        "Selenia",
        "Engraved gold, a plum night, a turning wheel",
        "Yuki",
        "Periwinkle, snow and frost",
        "Hebi Arcade",
        "Neon City on a CRT",
        "Kumo",
        "A sky that follows the day",
        "dose.wiki",
        "Plum and fuchsia, from the open encyclopedia",
        "In partnership with dose.wiki ↗",
        "A skin changes the app's colors, cards, and type. Your substance colors, the timeline, and every chart stay exactly as they are.",
        "Follow System",
        "Light Mode",
        "Dark Mode",
        "Every skin has a light and a dark side. Follow System switches with iOS.",
        "Decorations",
        "Stars, hearts, and stickers behind everything. Off automatically with Reduce Motion.",
        # Quick-log Edit sheet (2026-09-04)
        "New Drink…",
        "Add Favorite…",
        "Add Favorite",
        "Add Preset…",
        "Star a substance to keep it in your quick-log favorites.",
        # Brand picker IR/XR grouping (2026-09-04)
        "Unbranded",
        "Immediate-release",
        # Branded formulations section on substance detail (2026-09-12)
        "Branded formulations",
        "Substance default",
        "Doses stay the substance's own — only the duration curve changes.",
        # Injection Levels tool (2026-09-04)
        "Injection Levels",
        "Project hormone levels from injectable esters",
        "Injectable ester data isn't available in this build.",
        "Hormone",
        "Ester",
        "No specific ester",
        "From your log",
        "Manual schedule",
        # Injection Levels mL conversion + schedule origin (2026-09-07)
        "Vial concentration",
        "%lld injections logged in mL are converted at this strength",
        "%lld injections are logged in mL — enter the vial strength to include them",
        "Projected from today",
        "Projected from today, continuing from your log",
        # Injection Levels copy trim + start toggle (2026-09-07)
        "%lld mL injections converted at this strength",
        "%lld injections are in mL. Enter the vial strength to include them.",
        "Start from your log",
        "Starts at today's level from your log. Next dose one interval after your last.",
        "Starting level",
        "The level in your body today, if any. First dose today.",
        "An injected ester releases slowly from the oil depot, splits into the free hormone, and clears. The curve models that from your doses.",
        "No injectable ester data in this build.",
        "Lab calibration",
        "Add a blood test to fit the curve to you. The band narrows.",
        "Use my lab results",
        "Height and shape fit to your results. Terminal release %@.",
        "Height fit to your result. A second test on another day fits the shape too.",
        "Fit shape as well as height",
        "Adjust if you run higher or lower than average. A blood test replaces this with a fit.",
        "%@× faster than average",
        "%@× slower than average",
        "Your own lines. Piru sets no target.",
        "Sources",
        "Older studies used radioimmunoassay; modern LC-MS/MS reads lower. Calibrating to your own results absorbs the difference.",
        "Subcutaneous and intramuscular reach similar levels (196 vs 190 pg/mL head-to-head), so one curve serves both (Herndon 2023; Misakian 2025).",
        "Parameters from estrannaise.js (MIT), checked against the literature",
        "Enter it in your lab's unit. Stored in %@.",
        "%lld injections from your log",
        "Every",
        "Estimated %@ level",
        "Estimated level over time",
        "Ranges from about %lld to %lld %@ across the cycle",
        "Estimated trough",
        "Estimated peak",
        "Time in range",
        "of the cycle, between your lines",
        "An injected ester releases slowly from an oil depot, is cleaved to the free hormone, then cleared. This curve models that from your doses.",
        "It estimates a level from doses you enter — it never recommends a dose or a level to aim for. Add lab results to calibrate it to you.",
        "Estradiol",
        "Testosterone",
        "Calibrate to your lab results",
        "Uncalibrated",
        "1 result",
        "Calibrated · %lld results",
        "Add a blood test to pin this curve to your own levels. The band narrows once you do.",
        "Add lab result",
        "Reference lines",
        "Low line",
        "High line",
        "Lines you choose to see — not a target the app sets.",
        "Where these numbers come from",
        "Older lab data used radioimmunoassay; modern LC-MS/MS reads lower. Calibrating to your own results absorbs whichever assay your lab uses.",
        "Parameters from estrannaise.js (MIT), cross-checked against primary literature",
        # Injection Levels calibration + esters (2026-09-06)
        "Subcutaneous injection reaches levels close to intramuscular for these esters — 196 vs 190 pg/mL in one head-to-head — so the same curve serves both routes (Herndon 2023; Misakian 2025).",
        "More on injectable estradiol dosing (diyhrt.info)",
        "Population curves scatter widely between people, so uncalibrated numbers are a starting point, not a reading. A blood test pins the height to you; two on different days pin the shape as well. Retesting after any change — dose, ester, interval, injection site — keeps the fit honest, because one measurement can't tell a high peak from a slow decline.",
        "Personal calibration",
        "Set from my lab results",
        "Amplitude and shape both fit to your results — your terminal release ran %@.",
        "faster than the population (%@×)",
        "slower than the population (%@×)",
        "Amplitude fit to your result. Add a second test on a different day and the curve's shape fits too.",
        "Fit the curve's shape, not just its height",
        "Nudge this if you run higher or lower than average. A blood test replaces it with a fit to your own levels — far better than a guess.",
        "Enter the vial's concentration — a volume alone isn't a dose.",
        "1M",
        "3M",
        "6M",
        "Edit concentrations…",
        "Concentrations",
        "New concentration",
        "Edit concentration",
        "Concentration emoji",
        "Name (e.g. EV 40)",
        "Draw date",
        "Serum level",
        "Included in calibration",
        "Excluded from calibration",
        "Your result is stored in %@; enter it in whichever unit your lab reported.",
        # Library "Yours" card
        "Yours",
        "Favorites, colors, and the substances you added.",
        "Star a substance to keep it here",
        "Substances you added or customized",
        # b46 feedback batches
        "Backups, export & import are under Tools › Data & Backup; preferences are under Settings.",
        "That's everything today — %lld days and counting",
        "Scale by Dose Strength",
        "· %lld of %lld",
        "%lld of %lld logged today",
        "Edit Dose Times…",
        "Colors",
        "A color for every substance you log",
        "^[%lld substances](inflect: true) with a color",
        "Export, import, and encrypted backups",
        "Which source wins when they disagree.",
        'Cocaethylene adds extra strain on the heart and liver beyond cocaine alone, so this combination is harder on your body. (The widely-repeated "18–25× sudden death" figure is not supported by the evidence — but the added cardiac and liver strain is real.)',
        "Your ALDH2 variant clears acetaldehyde — the first, toxic by-product of alcohol — slowly, so it builds up and lingers. That build-up *is* the flush, racing heart, and nausea, and it's a Group 1 carcinogen (IARC): for flush-reactive drinkers each drink carries more long-term throat and esophageal cancer risk. Less alcohol means less acetaldehyde — there's no amount that clears as cleanly as it does for others.",
        "Tap a dot to name it",
        "Name on plot",
        "%@, this substance",
        "%@, measured in the same study",
        # Unified timeline
        "Compress empty time",
        "Effect curves",
        "How strongly effects are felt over time",
        "Body load (PK)",
        "How much is estimated to remain in your body",
        "Display Options",
        # Reports & Export hub
        "Reports",
        "Export sessions, generate clinical reports",
        "Latest",
        "By Date",
        "Select sessions",
        "Select Sessions",
        "Clinical Report",
        "Key findings, medication summary, dose trends — for your doctor",
        "Session Images",
        "Stitched Image",
        "All selected sessions in one tall image",
        "Plain-text session data — for notes, AI, or records",
        "No entries in this range",
        "· %lld entries",
        "%lld sessions as individual images",
        "Sessions in this range as individual images",
        "No sessions yet",
        # (previous keys below)
        "μ-Opioid Receptor Ligand",
        "Acts at μ-opioid receptors (MOR), G-protein coupled receptors distributed throughout the central and peripheral nervous system. MOR activation inhibits adenylyl cyclase, opens inwardly rectifying potassium channels, and closes voltage-gated calcium channels, reducing neuronal excitability and neurotransmitter release — producing analgesia, euphoria, respiratory depression, and slowed gastrointestinal transit. How far this particular compound activates the receptor, and whether it also engages κ or δ, is not characterized here; the receptor panel below carries whatever has been measured for it.",
        "Antipsychotic (Dopamine Receptor Antagonist)",
        "Blocks dopamine D2 receptors in the mesolimbic pathway, reducing positive psychotic symptoms. Whether this compound also carries the 5-HT2A antagonism that distinguishes the second-generation agents, and the histamine, muscarinic and adrenergic activity that drives sedation and orthostasis, varies across the class and is not characterized here.",
        "Histamine H1 Receptor Antagonist",
        "Blocks histamine H1 receptors, reducing the itching, flare, wheal and vasodilation of the histamine response. Whether this compound crosses into the central nervous system — the difference between a sedating first-generation antihistamine with a muscarinic load and a peripherally selective second-generation one — is not characterized here.",
        "Enters dopamine (DAT), norepinephrine (NET), and serotonin (SERT) nerve terminals and reverses their transporters, releasing all three monoamines. Also agonizes TAAR1 and acts at VMAT2 to redistribute vesicular monoamines into the cytosol.",
        "When it peaks",
        "Worst around %@",
        "%lld hours",
        "From a trial that stopped 57 people abruptly after a year or more of daily use and assessed them every day. Longer-acting drugs peak later because the drug is still leaving your system; active metabolites (diazepam, chlordiazepoxide, clonazepam) push it later still. When symptoms *start* is not shown because no source survives checking — the figures in circulation land at or after the measured peak, which cannot be right.",
        "Peak timing: Rickels K, et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47(10):899-907.",
        "Symptom groups and drug classes: Navarrete F, et al. Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches. Int J Mol Sci. 2026;27(3):1430.",
        "Both raise serotonin, so serotonin syndrome is possible — agitation, tremor, sweating, a racing heart — and most likely in the first weeks. This pairing is prescribed and monitored on purpose; SSRIs do not raise lithium levels.",
        "Both raise serotonin, so serotonin syndrome is possible — agitation, tremor, sweating, a racing heart — and most likely in the first weeks. This pairing is prescribed and monitored on purpose; SNRIs do not raise lithium levels.",
        "A large serotonin load on top of lithium's own. The lithium label names tramadol and fentanyl in this group; serotonin syndrome can start within hours.",
        "MAOIs block the enzyme that clears serotonin, so the load builds instead of levelling off. Serotonin syndrome is the risk; MAOIs do not raise lithium levels.",
        "Of 62 reports of this combination, 47% described a seizure and 39% involved medical attention — against none of 34 reports for lamotrigine. Self-reported, so the rate is not a measured one, but no other pairing shows a signal like it.",
        "MDMA releases serotonin in bulk and lithium adds to it, so serotonin syndrome is the main risk. Seizures are reported for lithium with classic psychedelics; MDMA has not been looked at the same way.",
        "Source: the Ashton Manual's equivalence table, which calls these doses approximate and notes that not every clinician agrees with them.",
        "One of these is from the Ashton Manual's equivalence table; the other is not in it and is not sourced elsewhere. Equivalences are approximate either way.",
        "Which class this belongs in is argued over — the label is the conventional one, not a settled one.",
        "Noradrenaline reuptake inhibitor",
        "Serotonin modulator and stimulator",
        "Blocks the noradrenaline transporter and leaves the other two. In the prefrontal cortex that same transporter is what clears dopamine, so the effect there is not as purely noradrenergic as the name reads.",
        "Blocks serotonin reuptake and acts on several serotonin receptors directly, agonist at some and antagonist at others. The receptor work is what separates it from an SSRI, not the transporter block they share.",
        "%lld–%lld days",
        "%lld–%lld hours",
        "RCT, n = %lld",
        "n = %lld",
        "n = %lld, underpowered",
        "%lld RCTs",
        "%lld trials",
        "1 RCT (n = %lld) + open study (n = 282)",
        "%@ (transdermal)",
        "Transdermal fentanyl is dosed in micrograms per hour — a rate, not a mass, so it shares no unit space with the mg-based table (CDC gives 2.4 MME per mcg/hr). Absorption also changes with heat and other factors.",
        "Buprenorphine is a partial agonist with a ceiling on its effect on breathing, so risk doesn't scale the way a full agonist's does. CDC excludes it from MME entirely and says it should not be counted toward a daily total.",
        "<1% elemental",
        "Curated",
        "curated entry",
        "Crisis resources, safety basics, and what's active right now.",
        "Details & sources",
        "Select Month",
        "Opens month picker",
        "Set up your daily medications and supplements",
        "Data from peer-reviewed literature, FDA labels, and community databases. Not medical advice — talk to a doctor before making decisions about substance use.",
        "Includes %lld min of workout — the dose rows leave it out",
        "Connect once to pull your body weight, heart rate, and blood pressure from Health — all read-only, on your device. Workouts come too, only so a run isn't read as a dose's effect.",
        "Heart rate %lld falling to %lld beats per minute",
        "Heart rate %lld beats per minute, no clear change",
        "overlaps %@",
        "Downstream",
        "No half-life data",
        "Known allergy to it",
        "With an MAOI, or within 14 days of one",
        "With other CNS depressants",
        "With a strong CYP3A4 inhibitor",
        "With a QT-prolonging drug",
        "With a live vaccine",
        "With a nitrate or a guanylate cyclase stimulator",
        "With an anticoagulant",
        "Existing respiratory depression",
        "During an acute asthma attack",
        "Bowel obstruction",
        "Active bleeding",
        "Liver disease",
        "Kidney disease",
        "Anuria",
        "Recent heart attack or heart surgery",
        "Uncontrolled high blood pressure",
        "Heart rhythm disorder",
        "Heart failure",
        "Seizure disorder",
        "Narrow-angle glaucoma",
        "Urinary retention",
        "Adrenal insufficiency",
        "Systemic fungal infection",
        "Porphyria",
        "Pheochromocytoma",
        "Untreated thyroid disease",
        "Breastfeeding",
        "Children",
        "Eating disorder",
        "Myasthenia gravis",
        "Sleep apnea",
        "Smoking over the age of 35",
        "During low blood sugar",
        "Low potassium",
        "High potassium",
        "Personal or family history of thyroid cancer",
        "Marked anxiety or agitation",
        "Around surgery",
        "^[%lld group](inflect: true)",
        "Drug Classes",
        "What the members of a family share",
        "No Classes",
        "^[%lld other substance](inflect: true)",
        "^[%lld more combination](inflect: true)",
        "Patterns",
        "Log doses to see your patterns",
        "Days used, cumulative exposure, dose trend, and overlap — for you or your doctor",
        "Days used, exposure, dose trend, and overlap",
        "Nothing to Summarize",
        "Nothing logged in this range.",
        "A record and a model, not medical advice. Exposure uses clinical equivalents where they're established, and the substance's typical dose otherwise.",
        "Days used",
        "How often, across this range",
        "of %lld days",
        "of days",
        "longest break",
        "since last",
        "Cumulative exposure",
        "Total taken this range, in each substance's clinical or common-dose unit",
        "Benzodiazepines ≈ %@ mg diazepam-eq/day",
        "Opioids: peak day ≈ %@ MME",
        "below the CDC 50 MME/day reference",
        "at or above the CDC 50 MME/day reference",
        "at or above the CDC 90 MME/day reference",
        "Average %@ MME/day over the range",
        "%@: %@ %@ total",
        "Dose trend",
        "Whether your typical dose has moved over this range",
        "steady",
        "rising",
        "falling",
        "%@: dose %@, %@",
        "Active together",
        "Hours two substances were both in your body at once",
        "%@ and %@: %@ active together",
        "MME",
        "mg diazepam-eq",
        "common doses",
        "In your body over time",
        "Estimated amount still circulating, each line a share of its own peak",
        "How much of each substance has been circulating, day by day",
        "Nothing to Model",
        "None of your logged substances in this range have a modeled elimination curve.",
        "A model estimate, not a measurement. What's in your body and what you feel don't always line up.",
        "Nothing in your body at this time",
        "Your streak and this month's rate",
        "When and how much you log",
        "How body-load has moved over time",
        "Receptor load over time",
        "Receptor Load",
        "How hard each mechanism has been driven, relative to your recent baseline",
        "How hard each mechanism has been driven over time",
        "None of your logged substances in this range drive a modeled mechanism.",
        "A predicted relative load from your logged doses, not a measurement. It's a model of receptor drive, not of how you feel.",
        "Nothing driven at this time",
        "Toggles this mechanism's line",
        "Steady state",
        "Where a regular dose settles, from your own cadence",
        "No Steady Cadence Yet",
        "Steady state needs a regular schedule. Log a substance on a consistent cadence and its plateau appears here.",
        "A projection from your median dose and spacing, assuming you keep that cadence and linear kinetics. Body content in the dose's units, not a plasma level.",
        "Plateau",
        "Buildup",
        "Reaches",
        "Between doses",
        "about daily",
        "about every 2 days",
        "<1 day",
        "clears, no buildup",
        "every ~%lld h",
        "every ~%@ days",
        "Accumulation curve for %@",
        "Plateaus around %@, %@× one dose, reached in %@",
        "Clears between doses; each peaks around %@",
        "%@ now at %@ %@",
        "%@ now at %@",
        # Usage toolbar filter + substance sheet (CLI-added; not yet extracted).
        "All Substances",
        "Substances (%lld)",
        "Select All",
        "Deselect All",
        # Custom units (CLI-added; Xcode hasn't extracted them yet).
        "Custom Units",
        "No Custom Units",
        "Add Custom Unit",
        "Edit Custom Unit",
        "unit",
        "1 %@ =",
        "Unit label (e.g. capsule)",
        'This substance already has a "%@" unit.',
        "Logs in this unit convert to the mass automatically.",
        'Define a unit like "1 capsule = 30 mg" and it appears in the dose picker for that substance — log half a capsule, get 15 mg.',
        # Approximate-dose flag (CLI-added; Xcode hasn't extracted them yet).
        "Approximate amount",
        "Shows the dose with a ~; the estimate still drives the curves.",
        "approximately %@ %@",
        # Unknown-dose flag (CLI-added; Xcode hasn't extracted them yet).
        "Unknown amount",
        "unknown amount",
        "Logs the dose with no number; it stays out of curves, totals, and tolerance.",
        "Logged with no number — stays out of curves, totals, and tolerance.",
        # Label scanner strings (CLI-added; Xcode hasn't extracted them yet).
        "Scan a label",
        "Close scanner",
        "Point at the medication name or its barcode",
        "Point at a barcode or label, then tap a highlighted area",
        "Resolving…",
        "Add to Log",
        "Scan Again",
        "No match",
        "Point the camera at the printed drug name.",
        "Camera Access Needed",
        "Scanning Unavailable",
        "Enable camera access in Settings to scan medication labels.",
        "Label scanning isn't available on this device.",
        # The 2026-08-04 sweep's two strings the extractor didn't pick up.
        "Estimates from primary literature.",
        "Suppresses the enzyme that makes serotonin, so recovery takes weeks.",
        "%@ acts through %@ — the pharmacology below is %@'s.",
        "Off-Target Effects",
        "Significant",
        "Limited",
        "Minor",
        "Real but bounded",
        "Not clinically dominant",
        "How Long It Stays",
        "Elimination half-life — not how long you feel it.",
        "Metabolite of the above",
        "Drug Class",
        "The rest of the family",
        "Selective serotonin reuptake inhibitor",
        "Serotonin–noradrenaline reuptake inhibitor",
        "Noradrenaline–dopamine reuptake inhibitor",
        "Tricyclic antidepressant",
        "Monoamine oxidase inhibitor",
        "Serotonin antagonist and reuptake inhibitor",
        "Noradrenergic and specific serotonergic antidepressant",
        "Blocks the serotonin transporter and little else, which is why its effects and its side effects are both mostly serotonergic.",
        "Blocks serotonin and noradrenaline reuptake together. The noradrenaline share grows with dose, so a low dose can behave much like an SSRI.",
        "Blocks noradrenaline and dopamine reuptake, leaving serotonin alone — the activating end of the family.",
        "Blocks serotonin and noradrenaline reuptake like an SNRI, and also histamine, muscarinic and α₁ receptors. That extra binding is the sedation, the dry mouth, and the narrow margin in overdose.",
        "Blocks the enzyme that breaks monoamines down, rather than the transporters that recycle them, so all three rise. The tyramine restriction and the long interaction list both follow from that.",
        "Blocks 5-HT₂A while weakly inhibiting serotonin reuptake. The receptor block dominates at low doses, which is why trazodone reached far more people as a sleep drug than as an antidepressant.",
        "Raises noradrenaline and serotonin release by blocking the α₂ autoreceptors that normally brake it, instead of blocking reuptake. The H₁ block alongside it is the sedation and the appetite.",
        "Log this",
        "Approved uses",
        "Boxed warning",
        "Fewer",
        "Dose sources",
        "In use",
        "About metabolites",
        "Compare all %lld sources",
        "%@ · %lld sources",
        "Every bar is drawn on the same scale. Piru shows the source you rank highest.",
        "%@ · %@ · %lld sources",
        "Buccal",
        "More actions",
        "Computed from the molecular structure (PubChem, NPS-DataHub) rather than measured in a lab.",
        "Recreational doses — not a prescribed amount",
        "%lld studies",
        "No effect timeline for this substance and route.",
        "%@ stays active in your body long after %@ itself is gone.",
        "About %@× %@'s activity at the %@.",
        "About %@× %@'s activity, by one measurement.",
        "About %@× as strong as %@, dose for dose.",
        "About as strong as %@ at the %@.",
        "Also measured at %@× %@'s %@ at the %@ — a lab measurement, not clinical potency.",
        "Also measured at %@× %@'s %@ — a lab measurement, not clinical potency.",
        "Effects can outlast the duration above — %@ clears much more slowly than %@.",
        "Measured at %@× %@'s %@ at the %@ — a lab measurement, not clinical potency.",
        "Measured at %@× %@'s %@ — a lab measurement, not clinical potency.",
        "Molecule for molecule, %@ is about %@× as strong as %@ — but how much of a dose converts isn't recorded here.",
        "Molecule for molecule, %@ is about %@× as strong as %@ — but only about %@%% of a dose becomes it.",
        "Molecule for molecule, %@ is about as strong as %@.",
        "Molecule for molecule, about %@× as strong as %@.",
        "What your body makes from this dose. Not a measured level.",
        "Your body turns %@ into %@, which is active too.",
        "Also Active",
        "Made by",
        "Share of dose",
        "Effects can outlast the duration above — %1$@ clears much more slowly than %2$@.",
        "About as strong as %@, dose for dose.",
        "About %1$@× as strong as %2$@, dose for dose.",
        "%1$@ stays active in your body long after %2$@ itself is gone.",
        "Molecule for molecule, %1$@ is about %2$@× as strong as %3$@ — but how much of a dose converts isn't recorded here.",
        "Molecule for molecule, %1$@ is about %2$@× as strong as %3$@ — but only about %4$@% of a dose becomes it.",
        "Molecule for molecule, %1$@ is about as strong as %2$@.",
        "Molecule for molecule, about %1$@× as strong as %2$@.",
        "How much of this you make is partly genetic — the same dose produces noticeably more in some people than others.",
        "About as strong as %1$@ at the %2$@.",
        "About %1$@× %2$@'s activity at the %3$@.",
        "About %1$@× %2$@'s activity, by one measurement.",
        "Acts differently from %@ — not simply stronger or weaker.",
        "Your body turns %1$@ into %2$@, which is active too.",
        "A binding-affinity measurement, not clinical potency.",
        "A lab measurement, not clinical potency.",
        "How strong it is compared to %@ hasn't been established.",
        "binding affinity",
        "activity",
        "Measured at %1$@× %2$@'s %3$@ — a lab measurement, not clinical potency.",
        "Also measured at %1$@× %2$@'s %3$@ — a lab measurement, not clinical potency.",
        "Measured at %1$@× %2$@'s %3$@ at the %4$@ — a lab measurement, not clinical potency.",
        "Also measured at %1$@× %2$@'s %3$@ at the %4$@ — a lab measurement, not clinical potency.",
        "Opens this substance in the library.",
        "%@ days",
        "µ-opioid receptor",
        "\u03ba-opioid receptor",
        "\u03b4-opioid receptor",
        "serotonin transporter",
        "norepinephrine transporter",
        "dopamine transporter",
        "GABA-A receptor",
        "NMDA receptor",
        "nicotinic receptor",
        "The file is missing a required field: %@.",
        "The file has an empty value for a required field: %@.",
        "The file isn't valid JSON.",
        "The file has an unexpected value at: %@.",
        "Active Now",
        "Dose options",
        "Opens full size",
        "Calibrated",
        "%lld min later",
        "%lld h later",
        "%lld h %lld m later",
        "Weakest input",
        "Releaser",
        "Reference dose",
        "Species",
        "µ-opioid drive",
        "GABA-A drive",
        "What the simulation is actually computing, and why rate matters more than amount.",
        "A releaser's output is limited by the vesicular dopamine still in store, and is suppressed further if a reuptake blocker is also on board. A blocker is not store-limited — it raises dopamine by slowing clearance rather than by pushing transmitter out. The two are handled by different code paths, not by one shared knob.",
        "What you feel is a gap, not a level",
        "No body weight, bioavailability or volume of distribution. Concentration here is dimensionless and relative to a reference dose, not a measured blood level.",
        # Detail level (UserProfile).
        "Detail Level",
        "How much pharmacology is shown by default on substance pages and in the Tolerance tool.",
        "Plain names, pharmacology folded away until you open it.",
        "Mechanism and pharmacokinetics open on the page, receptor names in the Tolerance tool.",
        # Check-in times (CheckInOfferBanner, CheckInScheduleEditor).
        "Use the suggested times",
        "Reset to the suggested times",
        "Adjust these times",
        # Insights cards.
        "Modeled Levels",
        "scheduled",
        # Skins store (SkinWardrobe, OnboardingSkinsStep).
        "substance.wiki",
        "Black, paper and signal cyan, from the effects index",
        "In partnership with substance.wiki ↗",
        "Skins",
        "Make it yours",
        "Skins pay for Piru's development. The journal, the library, and every tool are free.",
        "Free",
        "Paid",
        "Wearing This Skin",
        "Use This Skin",
        "Unlock %@ · %@",
        "Everything, Forever",
        "Every skin there is and every skin still to come.",
        "Restore Purchases",
        "Waiting for Approval",
        "Nothing to Restore",
        "Purchase Not Completed",
        "The skin unlocks as soon as the purchase is approved.",
        "This Apple Account has no Piru purchases.",
        "Nothing was charged. You can try again.",
        # What CYP2D6 does to a substance (CYP2D6NoteSection).
        "Activated by CYP2D6",
        "Cleared by CYP2D6",
        "CYP2D6 converts %@ into an active metabolite.",
        "CYP2D6 is the main enzyme clearing %@ from the body.",
        # Isomer picker racemic-parent label (CLI-added).
        "Regular",
        # QuickLog "Form" pill accessibility label (CLI-added).
        "Formulation",
        # QuickLog brand picker (CLI-added).
        "Extended-release",
        "More…",
        # Usage insights: common-dose ranking + trends metric (CLI-added).
        "Ranked by how often, or by total common-dose units",
        "Common doses",
        "Entries/wk",
        "Common doses/wk",
        "No common dose defined for these substances",
        "No common dose defined",
        "Common-dose units count each dose as a multiple of its common dose. %lld of %lld substances have one.",
        "%@ common-dose units across %lld entries",
        "Common doses per week, 7-day rolling average",
        "Common doses per week, 4-week rolling average",
        "Entries/day",
        "Common doses/day",
        "Common doses per day",
        "Which weekdays you log on most",
        "Common-dose units by weekday, most on %@",
        "Which days and hours, by common-dose units",
        "%@ common-dose units",
        "%@ common-dose units, busiest around %@",
        "%@ rising to %@ per day",
        "%@ falling to %@ per day",
        "%@ steady at %@ per day",
        # Configurable dose-time presets (Settings › Journal › Quick Times).
        "Add Preset",
        "Quick Times",
        "Reset to Defaults",
        "That preset already exists.",
        "Choose at least one minute.",
        "Adds “%@”.",
        "Minutes",
        # Benzo effect ladder + occupancy / withdrawal (CLI-added; Xcode hasn't extracted them yet).
        "Faded",
        "Unchanged",
        "strong evidence",
        "moderate evidence",
        "low evidence",
        "%lld%% left",
        "%lld percent left",
        "%lld days",
        "Muscle relaxation",
        "Coordination",
        "Fades near-completely in ~2 weeks",
        "The sleep effect tolerizes",
        "No decline detected",
        "Fades slowly and partially, over months",
        "Develops; rate not quantified",
        "No tolerance detected",
        "About %lld%% of your recent peak GABA-A load right now, summed across everything active.",
        "Combined load across your active GABAergics, relative to your recent peak.",
        "Combined load across your active GABAergics, relative to your recent peak. Alcohol is included; it loads the receptor at a different site.",
        "GABA-A receptor load over time",
        "Combined load relative to your recent peak, currently about %lld percent, clearing over the following days.",
        'Three things people call "withdrawal" that behave differently, and roughly when each starts for drugs like the ones you\'ve logged.',
        "A model of your dose log, not medical advice. Stopping a benzodiazepine abruptly after regular use can cause seizures.",
        "under a day",
        "Your modeled GABA-A load is still about %lld%% of your recent peak — the drug is still clearing, so withdrawal hasn't started yet.",
        "Your modeled GABA-A load is still about %lld%% of your recent peak — the drug is still clearing, so withdrawal hasn't started. On your current clearance it drops into the onset range in about %@.",
        "Research findings, not medical advice. Benzodiazepine discontinuation can be medically dangerous.",
        "Effect-selective tolerance",
        "Some effects fade, others don't",
        "For most drugs every effect tolerizes together. Benzodiazepines are the exception: sedation fades almost completely in about two weeks, while the anxiety relief, memory impairment and loss of coordination barely change. That's why the benzodiazepine card shows an effect ladder instead of one bar.",
        "Why — the receptor comes in subtypes",
        "GABA-A is built from several α-subtypes that adapt at different rates. α1 carries sedation and desensitizes (it uncouples, then the receptors are pulled from the synapse); α5 is required for that sedative tolerance to develop at all; α2 and α3, which carry the anxiety relief, don't adapt. So the dose that no longer makes you sleepy impairs your memory and coordination exactly as much as it did on day one — which is how tolerance quietly drives the dose up.",
        "Benzodiazepine effect kinetics: Vinkers & Olivier 2012; Piot & Jovanovic 2026. These are directions from the literature, graded low — not fitted numbers.",
        "Why these effects differ",
        "Prediction",
        "Prediction from a model",
        # Steady State tool (CLI-added; Xcode hasn't extracted them yet).
        "Values are body content in the dose's units, not a plasma concentration. Real accumulation varies with metabolism, dosing gaps, and metabolites.",
        "Uses the same one-compartment oral model, assuming a regular schedule and linear kinetics. Values are body content in the dose's units, not a plasma concentration. Real accumulation varies with metabolism, dosing gaps, and active metabolites.",
        "Steady State",
        "Where a repeated dose settles, and when",
        "Where a med taken every day settles",
        "Dose each time",
        "Taken every",
        "Every 4 hours",
        "Every 6 hours",
        "Every 8 hours",
        "Every 12 hours",
        "Once daily",
        "Twice daily",
        "Barely accumulates",
        "Accumulates modestly",
        "Accumulates substantially",
        "Each dose has mostly cleared before the next, so the level tracks a single dose.",
        "The level settles around %@ a single dose, reaching steady state in about %@.",
        "Doses stack faster than they clear — the level climbs to roughly %@ a single dose and takes about %@ to get there.",
        "Level over time — climbing to plateau",
        "Estimated amount in your body, in %@. The shaded band is the steady-state range once the level stops climbing; the dashed line is a single dose.",
        "At steady state",
        "Steady state by",
        "fully settled in %@",
        "Accumulation",
        "at the peak, vs. one dose",
        "Plateau range",
        "%@ · trough to peak",
        "Fluctuation",
        "smooth",
        "moderate swing",
        "spiky",
        "Time to steady state depends only on the half-life — not the dose or how often you take it. A bigger dose or shorter gap raises the plateau; it doesn't arrive sooner.",
        "This projects a perfectly regular schedule onto the same one-compartment oral model the Half-Life Calculator uses, assuming dose-proportional (linear) kinetics. Amounts are body content in the dose's units — not a plasma concentration, which would need an individual volume of distribution. Real accumulation varies with metabolism, missed or extra doses, active metabolites, and saturable elimination. A model of the pharmacology, not a dosing plan — it says what a level does, never what a dose should be. Not medical advice.",
        "%@ peak",
        "%@ trough",
        "Climbs from one dose to a steady-state range of %@ to %@ %@, reached in about %lld days",
        "Taking this daily? See where the level settles",
        "Where a med taken on a schedule settles",
        "Half-life data not available for %@.",
        # Bupropion enzyme modulator (A1)
        "Bupropion",
        "Bupropion's reductive metabolites strongly inhibit CYP2D6, raising the levels of drugs cleared by it. For prodrugs activated by CYP2D6 (tramadol, codeine), it blocks the activation pathway instead.",
        # b45 feedback — metabolizer variation chart (C1)
        "Fast metabolizer",
        "Slow metabolizer",
        "Genetic variation in %@ formation",
        "Same dose, different conversion — the effect varies by genotype.",
        # b45 feedback — insight group previews (D6)
        "substance modeled",
        "substances modeled",
        "Add regular meds to project steady state",
        "regular med",
        "regular meds",
        # b45 feedback — receptor load zoom (E2)
        "Wide",
        "Medium",
        "Close",
        "Zoom",
        # import file errors (2026-09-18)
        "The file is empty. Nothing was saved into it, so export again and wait for the save to finish before importing.",
        "This file isn't a Piru export or a PsychonautWiki journal.",
        "This is an encrypted Piru backup. Use Restore Encrypted Backup and enter its passphrase.",
        "This file uses export format %lld, which this version of Piru can't read yet. Update Piru, then import it.",
        "%@ The file was written by %@.",
        # b53 feedback batches (2026-09-17)
        "Open Injection Levels",
        "Entry",
        "Count × strength",
        "Added at this strength, in the item's unit.",
        "Counted in %@. A dose logged in mg is taken off at this strength.",
        "Due at %@",
        "Your Body",
        "Splits a busy session's overlapping curves into one lane per substance.",
        "How many substances a session needs before it splits into lanes.",
        "Adds a per-dose grapefruit toggle for substances whose breakdown grapefruit slows (CYP3A4), so the entry records it.",
        "Shows acetaldehyde buildup on alcohol entries. The ALDH2 variant slows its clearance, causing flushing.",
        # LegacyHandoff notices
        "Piru has moved",
        "Piru now lives in a new app. Install it on this device and the first time you open it, your journal, meds and settings come across on their own. Nothing here is deleted.",
        "Your journal has moved",
        "The new Piru app already has your journal. Entries you add here stay in this app and won't follow, so the new one is the place to log from now on.",
        "Open in TestFlight",
        "Your journal came with you",
        "Everything from the old Piru app is here: your journal, meds and settings. Once you've looked it over, you can delete the old app.",
    }

    print("--- Piru main app catalog ---")
    n, added, missing = apply_translations(
        project_root / "Piru/Localizable.xcstrings",
        T,
        insert_keys=NEW_KEYS,
        extra_languages=EXTRA_LANGUAGES,
    )
    print(f"Translated: {n}  (inserted {len(added)} new key(s))")
    for a in added:
        print(f"  + {a!r}")
    print(f"Missing: {len(missing)}")
    for m in missing[:30]:
        print(f"  - {m!r}")

    print()
    print("--- Widget catalog ---")
    # Widget reuses many Shared model strings (RouteOfAdministration, DoseFrequency, etc.)
    # Keep the widget's insert set to just the handful of strings the widget target
    # actually shows, so it stays a small subset.
    WIDGET_NEW_KEYS: set[str] = set()
    widget_dict = {**T, **WT}
    n, added, missing = apply_translations(
        project_root / "PiruWidget/Localizable.xcstrings",
        widget_dict,
        insert_keys=WIDGET_NEW_KEYS,
        extra_languages=EXTRA_LANGUAGES,
    )
    print(f"Translated: {n}  (inserted {len(added)} new key(s))")
    for a in added:
        print(f"  + {a!r}")
    print(f"Missing: {len(missing)}")
    for m in missing:
        print(f"  - {m!r}")

    print()
    print("--- Live Activity catalog ---")
    # The Live Activity target has its own catalog and, like the widget, reuses
    # Shared strings. It went unhandled until 2026-08-03, when the heavy-tier
    # threshold band put target-specific strings there and they came back
    # untranslated: the export/import round-trip cross-fills from project-wide
    # translations, but only for keys Xcode already resolves elsewhere, so a
    # string that lives *only* in this catalog was never reached. Same empty
    # insert set as the widget — the keys are extracted by the build; this pass
    # only fills them.
    ACTIVITY_NEW_KEYS: set[str] = set()
    n, added, missing = apply_translations(
        project_root / "PiruLiveActivityExtension/Localizable.xcstrings",
        {**T, **WT},
        insert_keys=ACTIVITY_NEW_KEYS,
        extra_languages=EXTRA_LANGUAGES,
    )
    print(f"Translated: {n}  (inserted {len(added)} new key(s))")
    for a in added:
        print(f"  + {a!r}")
    print(f"Missing: {len(missing)}")
    for m in missing:
        print(f"  - {m!r}")

    print()
    print("--- Watch catalog ---")
    n, added, missing = apply_translations(
        project_root / "PiruWatch Watch App/Localizable.xcstrings",
        WATCH_T,
        insert_keys=set(WATCH_T),
        extra_languages=EXTRA_LANGUAGES,
    )
    print(f"Translated: {n}  (inserted {len(added)} new key(s))")
    for a in added:
        print(f"  + {a!r}")

    # Hand all three catalogs back to Xcode so it re-collates every key into its
    # canonical order — this is what stops the IDE from churning the file on the
    # next build. Done last, after all translations are filled, so the export
    # captures the freshly-inserted keys. Skipped gracefully if xcodebuild is
    # unavailable (the Python serialization above is still valid, just unsorted).
    print()
    print("--- Canonicalizing key order via Xcode (export/import round-trip) ---")
    if canonicalize_catalogs(project_root / "Piru.xcodeproj"):
        print("Done — catalogs rewritten in Xcode's canonical order.")
